File Nos. 333-174627
811-22564
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
ON SEPTEMBER 15, 2011
 
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM N-1A
     
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
  o
      Pre-Effective Amendment No. 2
  þ
      Post-Effective Amendment No. __
  o
 
   
and
 
   
REGISTRATION STATEMENT UNDER THE INVESTMENT COMPANY ACT OF 1940
  o
      Amendment No. 2
  þ
GMO SERIES T RUST
(Exact Name of Registrant as Specified in Charter)
40 Rowes Wharf, Boston, Massachusetts 02110
(Address of principal executive offices)
617-330-7500
(Registrant’s telephone number, including area code)
with a copy to:
     
J.B. Kittredge, Esq.
GMO Trust
40 Rowes Wharf
Boston, Massachusetts 02110
  Thomas R. Hiller, Esq.
Ropes & Gray LLP
Prudential Tower
800 Boylston Street
Boston, Massachusetts 02199
(Name and address of agents for service)
Approximate date of proposed public offering: As soon as practicable after the effective date of this registration statement.
It is proposed that this filing will become effective:
o immediately upon filing pursuant to paragraph (b)
o on (date), pursuant to paragraph (b)
o 60 days after filing pursuant to paragraph (a)(1)
o on (date), pursuant to paragraph (a)(1)
o 75 days after filing pursuant to paragraph (a)(2)
o on (date) pursuant to paragraph (a)(2) of Rule 485
If appropriate, check the following box:
      o This post-effective amendment designates a new effective date for a previously filed post-effective amendment.
Pursuant to the provisions of Rule 24f-2 under the Investment Company Act of 1940, Registrant declares that an indefinite number of its shares of common stock are being registered under the Securities Act of 1933 by this registration statement.
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH THE PROVISIONS OF SECTION 8(a) OF THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SECTION 8(a), MAY DETERMINE.
 
 


 

GMO Series Trust
Prospectus
October 1, 2011
§ GMO U.S. Core Equity Series Fund
Class R1: —
                                                              
§ Shares of the Fund described in
this Prospectus may not be available
for purchase in all states. This
Prospectus does not offer shares in
any state where they may not lawfully
be offered.
Grantham, Mayo, Van Otterloo & Co. LLC
40 Rowes Wharf Boston, Massachusetts 02110
The Securities and Exchange Commission has not approved or disapproved these securities or passed upon the adequacy of this Prospectus. Any representation to the contrary is a criminal offense.

 


 

TABLE OF CONTENTS
         
    Page  
    2  
 
       
    7  
 
       
    8  
 
       
    14  
 
       
    16  
 
       
    18  
 
       
    18  
 
       
    19  
 
       
    21  
 
       
    22  
 
       
    22  
 
       
  back cover  
 
       
  back cover  
 
       
  back cover  

i


 

GMO U.S. Core Equity Series Fund
FUND SUMMARY
Investment Objective
          High total return (including both capital appreciation and income).
Fees and Expenses
          The table below describes the fees and expenses that you may pay if you buy and hold shares of GMO U.S. Core Equity Series Fund (the “Fund”).
Annual Fund Operating Expenses 1
(expenses that you pay each year as a percentage of the value of your investment)
         
    Class R1
Management fee
    0.31 % 2
Distribution (12b-1) fee
  None
Other expenses
       
Administration fee
    0.05 %
Other expenses
    0.82 %
Total other expenses
    0.87 %
Total annual fund operating expenses
    1.23 %
Expense reimbursement
    (0.62 %) 3
Total annual operating expenses after reimbursement
    0.61 %
 
1   The amounts represent an annualized estimate of the Fund’s operating expenses for its initial fiscal year. The information in this table and in the Example below reflect the expenses of both the Fund and GMO U.S. Core Equity Fund (“USCEF”), the underlying fund in which the Fund invests.
 
2   The amount reflects the management fee paid by USCEF. The Fund does not charge a management fee, but indirectly bears the management fee paid by USCEF.
 
3   Subject to certain exclusions (“Excluded Fund Fees and Expenses”), Grantham, Mayo, Van Otterloo & Co. LLC (the “Manager” or “GMO”) has contractually agreed to reimburse the Fund to the extent the Fund’s total annual operating expenses exceed 0.00% of the Fund’s average daily net assets. Excluded Fund Fees and Expenses include administration fees, expenses incurred indirectly by investment in USCEF and any other underlying funds, independent Trustee expenses, certain legal costs, investment-related costs (e.g., brokerage commissions, securities lending fees, interest expense), hedging transaction fees, and extraordinary expenses, as described under “Expenses” in this Prospectus. This expense limitation will continue through at least October 1, 2012, and may not be terminated prior to this date without the consent of the Fund’s Board of Trustees.
Example
          This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated, regardless of whether or not you redeem your shares at the end of such periods. The example also assumes that your investment has a 5% return each year and that the Fund’s operating expenses remain the same as those shown in the table. The one year amounts shown reflect expense reimbursements and both amounts shown include the expenses of both USCEF and the Fund.

-2-


 

          Although your actual costs may be higher or lower, based on these assumptions your costs would be:
                 
    1 Year*   3 Years
Class R1
  $ 62     $ 329  
 
*   After reimbursement
Portfolio Turnover
          The Fund pays transaction costs when it buys and sells securities. A higher portfolio turnover rate may indicate higher transaction costs. These costs, which are not reflected in Annual Fund Operating Expenses or in the Example, affect the Fund’s performance. Because the Fund commenced operations on or following the date of this Prospectus, the Fund’s portfolio turnover rate is not available.
Principal Investment Strategies
          The Fund invests substantially all of its assets in GMO U.S. Core Equity Fund (“USCEF”), which invests directly in securities and other instruments. The Fund’s investment objective and principal investment strategies, therefore, are substantially similar to those of USCEF. References to the Fund may refer to actions undertaken by the Fund or USCEF. The Fund’s investment adviser, GMO, is also the investment adviser to USCEF.
          The Manager seeks to achieve the Fund’s investment objective by investing in equities or groups of equities that the Manager believes will provide higher returns than the S&P 500 Index.
          The Manager uses active investment management methods, which means that equities are bought and sold according to the Manager’s evaluation of companies’ published financial information, securities’ prices, equity and bond markets, and the overall economy.
          In selecting equities for the Fund, the Manager may use a combination of quantitative and qualitative investment methods to identify equities that the Manager believes present positive return potential relative to other equities. Some of these methods evaluate individual equities or groups of equities (e.g. equities of companies in a particular industry) based on the ratio of their price to historical financial information, including book value, cash flow and earnings, and forecasted financial information provided by industry analysts. The Manager may compare these ratios to industry or market averages in assessing the relative attractiveness of an equity or group of equities. Other methods used by the Manager focus on evaluating patterns of price movement or volatility of an equity or group of equities relative to the Fund’s investment universe. The Manager also may adjust the Fund’s portfolio for factors such as position size, industry and sector exposure, and market capitalization. The Manager may invest in companies of any market capitalization.
          As a substitute for direct investments in equities, the Manager may use exchange-traded and over-the-counter (“OTC”) derivatives. The Manager also may use derivatives: (i) in an attempt to reduce investment exposures (which may result in a reduction below zero); (ii) in an attempt to adjust elements of the Fund’s investment exposure; and (iii) to effect transactions intended as substitutes for securities lending. Derivatives used may include futures, options and swap contracts. In addition, the Fund may lend its portfolio securities.
          Under normal circumstances, the Fund invests directly and indirectly (e.g., through underlying funds or derivatives) at least 80% of its assets in equity investments tied economically to the U.S. The

-3-


 

terms “equities” and “equity investments” refer to direct and indirect investments in common stocks and other stock-related securities, such as preferred stocks, convertible securities and depositary receipts.
          For cash management purposes, the Fund may invest in GMO U.S. Treasury Fund, another fund managed by GMO and offered through a separate prospectus, and unaffiliated money market funds.
          The Fund may hold cash, cash equivalents, and/or U.S. government securities to manage cash inflows and outflows as a result of shareholder purchases and redemptions.
Principal Risks of Investing in the Fund
          The value of the Fund’s shares changes with the value of the Fund’s investments, principally in USCEF shares. Many factors can affect this value, and you may lose money by investing in the Fund. Because the Fund invests substantially all of its assets in USCEF, the most significant risks of investing in the Fund are the risks to which the Fund is exposed through USCEF, which include those outlined in the following brief summary of principal risks. In addition to the risks the Fund is exposed to through its investment in USCEF, the Fund is subject to the risk that cash flows in or out of the Fund will cause its performance to differ from that of USCEF.
  Market Risk — Equity Securities — The market value of equity investments may decline due to factors affecting the issuing companies, their industries, or the economy and equity markets generally. If the Fund purchases equity investments at a discount from their value as determined by the Manager, the Fund runs the risk that the market prices of these investments will not increase to that value for a variety of reasons, one of which may be the Manager’s overestimation of the value of those investments. The Fund also may purchase equity investments that typically trade at higher multiples of current earnings than other securities, and the market values of these investments often are more sensitive to changes in future earnings expectations than those other securities. Because the Fund normally does not take temporary defensive positions, declines in stock market prices generally are likely to reduce the net asset value of the Fund’s shares.
  Management and Operational Risk — The Fund relies on GMO’s ability to achieve its investment objective by effectively implementing its investment approach. The Fund runs the risk that GMO’s proprietary investment techniques will fail to produce the desired results. The Fund’s portfolio managers may use quantitative analyses and/or models and any imperfections or limitations in such analyses and/or models could affect the ability of the portfolio managers to implement strategies. By necessity, these analyses and models make simplifying assumptions that limit their efficacy. Models that appear to explain prior market data can fail to predict future market events. Further, the data used in models may be inaccurate and/or it may not include the most recent information about a company or a security. The Fund is also subject to the risk that deficiencies in the Manager’s or another service provider’s internal systems or controls will cause losses for the Fund or impair operations.
  Derivatives Risk — The use of derivatives involves the risk that their value may not move as expected relative to the value of the relevant underlying assets, rates or indices. Derivatives also present other Fund risks, including market risk, liquidity risk and counterparty risk.
  Counterparty Risk — The Fund runs the risk that the counterparty to an OTC derivatives contract or a borrower of the Fund’s securities will be unable or unwilling to make timely settlement payments or otherwise honor its obligations.
  Leveraging Risk — The Fund’s use of derivatives and securities lending may cause its portfolio to be leveraged. Leverage increases the Fund’s portfolio losses when the value of its investments decline.

-4-


 

  Smaller Company Risk — Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, or may lack managers with experience or depend on a few key employees. The securities of small- and mid-cap companies often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations.
  Focused Investment Risk — Focusing investments in sectors or companies or in industries with high positive correlations to one another creates additional risk.
  Market Disruption and Geopolitical Risk — Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events as well as other changes in foreign and domestic economic and political conditions could adversely affect the value of the Fund’s investments.
  Large Shareholder Risk — To the extent that shares of the Fund are held by large shareholders (e.g., institutional investors, financial intermediaries, asset allocation funds, or other funds managed by GMO (“GMO Funds”)), the Fund is subject to the risk that these shareholders will disrupt operations by purchasing or redeeming shares in large amounts and/or on a frequent basis.
  Fund of Funds Risk — The Fund is indirectly exposed to all of the risks of an investment in USCEF, including the risk that USCEF will not perform as expected.
Performance
          The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in USCEF’s annual total returns from year to year for the periods indicated and by comparing USCEF’s average annual total returns for different calendar periods with those of a broad-based index. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-deferred arrangements (such as a 401(k) plan or individual retirement account). Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns/Class III Shares *
Years Ending December 31
(BAR GRAPH)
Highest Quarter: 16.38% (2Q2003)
Lowest Quarter: -17.31% (3Q2002)
Year-to-Date (as of 08/15/2011): -0.25%

-5-


 

Average Annual Total Returns*
Periods Ending December 31, 2010
                                 
    1 Year   5 Years   10 Years   Inception
Class III
                            9/18/85  
Return Before Taxes
    7.99 %     -0.31 %     0.11 %     10.19 %
Return After Taxes on Distributions
    7.72 %     -1.07 %     -0.48 %     7.39 %
Return After Taxes on Distributions and Sale of Fund Shares
    5.22 %     -0.46 %     -0.15 %     7.57 %
S&P 500 Index (reflects no deduction for fees, expenses, or taxes)
    15.06 %     2.29 %     1.41 %     10.52 %
 
*   The Fund invests substantially all of its assets in USCEF, a series of GMO Trust that has an investment objective and policies and restrictions substantially identical to those of the Fund. Performance of the Fund is that of USCEF (Class III shares) and its predecessor fund, adjusted to reflect the gross expenses (on a percentage basis) that are expected to be borne by shareholders of Class R1 shares of the Fund, as reflected in the Annual Fund Operating Expenses table.
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Division and Senior Members of GMO responsible for day-to-day management of the Fund:
         
    Senior Members    
Investment Division   (Length of Service)   Title
Quantitative Equity
  Thomas Hancock
(since the Fund’s inception)
  Co-Director, Quantitative Equity Division, GMO.
 
       
Quantitative Equity
  Sam Wilderman
(since the Fund’s inception)
  Co-Director, Quantitative Equity Division, GMO.
Purchase and Sale of Fund Shares
          Class R1 shares of the Fund may be purchased by eligible retirement plans. There are no minimum initial or subsequent investment requirements for Class R1 shares of the Fund.
          In general, retirement plan participants may redeem shares of the Fund on any day when the New York Stock Exchange (“NYSE”) is open for business by contacting the retirement plan administrator.
Tax Information
          The Fund normally distributes net investment income and net realized capital gains, if any, to shareholders. By investing in the Fund through a tax-advantaged retirement account, you will not be subject to tax on these Fund distributions if your Fund shares remain in a tax-advantaged account. Depending on the type of retirement account, you may be taxed upon withdrawals from that account. You should consult with your tax advisor or the plan administrator or other financial intermediary through

-6-


 

which your investment in the Fund is made regarding the U.S. federal income tax consequences of your investment.
Financial Intermediary Compensation
          If you purchase shares of the Fund through a broker-dealer, agent or other financial intermediary (such as a bank), the Fund and its related companies may pay that party for the sale of Fund shares and related services. These payments may create a conflict of interest by influencing the broker-dealer or other intermediary and your salesperson to recommend the Fund over another investment. Ask your salesperson or visit your financial intermediary’s website for more information.
ADDITIONAL INFORMATION ABOUT THE FUND’S
INVESTMENT STRATEGIES, RISKS, AND EXPENSES
           Fund Summary. The preceding section contains a summary of the investment objective, fees and expenses, principal investment strategies, principal risks, management, and other important information for the Fund. The summary is not all-inclusive, and the Fund may make investments, employ strategies, and be exposed to risks that are not described in the summary. More information about the Fund’s investments and strategies is contained in the Statement of Additional Information (“SAI”). See the back cover of this Prospectus for information about how to receive the SAI. Information about USCEF is contained in a separate prospectus.
           Fundamental Investment Objective/Policies. The Board of Trustees (“Trustees”) of GMO Series Trust (the “Trust”) may change the Fund’s investment objective or policies without shareholder approval or prior notice unless an objective or policy is identified in this Prospectus or in the SAI as “fundamental.” Because the Fund invests substantially all of its assets in USCEF, its investment objective and policies will change to reflect any changes to USCEF’s investment objectives and policies. There is no guarantee that the Fund will be able to achieve its investment objective.
           Portfolio Turnover. Portfolio turnover is not a principal consideration when GMO makes investment decisions for the Fund, and the Fund has not placed any limit on the rate of portfolio turnover and portfolio securities may be sold without regard to the time they have been held. Based on its assessment of market conditions and purchase or redemption requests, GMO may cause the Fund to trade more frequently at some times than at others. High turnover rates may adversely affect the Fund’s performance by generating higher transaction costs.
           Certain Definitions. When used in this Prospectus, the term “invest” includes both direct investing and indirect investing and the term “investments” includes both direct investments and indirect investments. For example, the Fund may invest indirectly by investing in another Fund or by investing in derivatives and synthetic instruments. When used in this Prospectus, (i) the terms “equity investments” and “equities” refer to investments (as defined above) in common stocks and other stock-related securities, such as preferred stocks, convertible securities, and depositary receipts, and (ii) the term “total return” includes capital appreciation and income.
           Benchmark. The Fund’s benchmark, the S&P 500 Index, is an independently maintained and widely published index comprised of U.S. large capitalization stocks.
           Fee and Expense Information. The following paragraphs contain additional information about the fee and expense information included in the Fund Summary.

-7-


 

           Annual Fund Operating Expenses — Other Expenses. The amount listed under “Other expenses” in the “Annual Fund Operating Expenses” table included in the Fund Summary reflects an annualized estimate of direct expenses associated with an investment in the Fund and USCEF for the Fund’s initial fiscal year. USCEF may invest in certain other funds of GMO Trust and certain other pooled investment vehicles (“underlying funds”), and the indirect net expenses associated with USCEF’s investment in underlying funds are reflected in “Other expenses.” Actual indirect expenses will vary depending on the particular underlying funds in which USCEF invests.
           Fee and Expense Example. The expense example under “Example” included in the Fund Summary assumes that all dividends and distributions, if any, are reinvested.
           Temporary Defensive Positions. The Fund normally does not take temporary defensive positions. To the extent the Fund takes a temporary defensive position, it may not achieve its investment objective.
           Fund Codes. See “Fund Codes” on the inside back cover of this Prospectus for information regarding the Fund’s ticker, news-media symbol, and CUSIP number.
          This Prospectus does not offer shares in any state where they may not lawfully be offered.
DESCRIPTION OF PRINCIPAL RISKS
          Investing in mutual funds involves many risks, and factors that may affect the Fund’s portfolio as a whole, called “principal risks,” are discussed briefly in the Fund Summary and are discussed in additional detail in this section. The risks of investing in the Fund depend on the types of investments in its portfolio and the investment strategies the Manager employs on its behalf. This section describes the nature of these principal risks and some related risks, but does not describe every potential risk of investing in the Fund. The Fund could be subject to additional risks because of the types of investments it makes and market conditions, which may change over time. The SAI includes more information about the Fund and its investments.
          Because the Fund invests substantially all of its assets in USCEF, the most significant risks of investing in the Fund are the risks to which the Fund is exposed through USCEF, which include the principal risks summarized below. In addition to the risks the Fund is exposed to through its investment in USCEF, the Fund is subject to the risk that cash flows in or out of the Fund will cause its performance to differ from that USCEF. As indicated in the Fund Summary and in the “Additional Information About the Fund’s Investment Strategies, Risks, and Expenses” section of this Prospectus, references in this section to investments made by the Fund include those made by USCEF.
          The Fund, by itself, generally is not a complete investment program, but rather is intended to serve as part of a diversified portfolio of investments. An investment in the Fund is not a bank deposit and, therefore, is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.
    MARKET RISK—EQUITY SECURITIES
          The Fund runs the risk that the market value of its equity investments will decline. The market value of an equity investment may decline for reasons that directly relate to the issuing company, such as management performance, financial leverage and reduced demand for its goods or services. It also may decline due to factors that affect a particular industry, such as a decline in demand, labor or raw material shortages, increased production costs, regulation, or competitive industry conditions. In addition, market

-8-


 

value may decline as a result of general market conditions that are not specifically related to a company or industry, such as real or perceived adverse economic conditions, changes in the general outlook for corporate earnings, changes in interest or currency rates, or adverse investor sentiment generally. Equity investments generally have greater price volatility than fixed-income and other investments with a scheduled stream of payments, and the market price of equity investments is more susceptible to moving up or down in a rapid or unpredictable manner.
          The Fund invests a substantial portion of its assets in equities and, as described under “Additional Information About the Fund’s Investment Strategies, Risks, and Expenses — Temporary Defensive Positions,” generally does not take temporary defensive positions. As a result, declines in stock market prices generally are likely to reduce the net asset value of the Fund’s shares.
          If the Fund purchases equity investments at a discount from their value as determined by the Manager, the Fund runs the risk that the market prices of these investments will not increase to that value for a variety of reasons, one of which may be the Manager’s overestimation of the value of those investments.
          Equity investments trading at higher multiples of current earnings than other securities have market values that often are more sensitive to changes in future earnings expectations than other securities. At times when the market is concerned that these expectations may not be met, the market values of those securities typically fall.
    MANAGEMENT AND OPERATIONAL RISK
     The Fund is subject to management risk because it relies on the Manager’s ability to achieve their investment objectives. The Manager uses proprietary investment techniques in making investment decisions for the Fund, but that does not assure that the Manager will achieve the desired results and the Fund may incur significant losses. The Manager, for example, may fail to use derivatives effectively, choosing to hedge or not to hedge positions at disadvantageous times. As described in the Fund Summary, the Manager uses quantitative analyses and/or models. Any imperfections or limitations in such analyses and/or models could affect the ability of the portfolio managers to implement strategies. By necessity, these analyses and models make simplifying assumptions that limit their efficacy. Models that appear to explain prior market data can fail to predict future market events. Further, the data used in models may be inaccurate and/or it may not include the most recent information about a company or a security. There also can be no assurance that all of the Manager’s personnel will continue to be associated with the Manager for any length of time. The loss of the services of one or more employees of the Manager could have an adverse impact on the Fund’s ability to achieve its investment objectives.
     The Fund generally does not take temporary defensive positions. Instead it usually is fully invested in the asset class in which it is permitted to invest (e.g., equity investments tied economically to the U.S.). The Fund may buy securities not included in its benchmark, hold securities in very different proportions than its benchmark, and/or engage in other strategies that cause its performance to differ from (and/or be uncorrelated with or negatively correlated with) that of its benchmark. In those cases, the Fund’s performance will depend on the ability of the Manager to choose securities that perform better than securities that are included in the benchmark and/or to utilize those other strategies in a way that adds value relative to the benchmark.
     The Fund is also subject to the risk of loss and impairment of operations from operational risk as a result of the Manager’s and other service providers’ provision of investment management, administrative, accounting, tax, legal, shareholder, and other services to the Fund. Operational risk can result from inadequate procedures and controls, human error, and system failures by a service provider. For example,

-9-


 

trading delays or errors (both human and systematic) could prevent the Fund from purchasing or selling a security that the Manager expects will appreciate or decline in value, as the case may be, thus preventing the Fund from benefiting from potential investment gains or avoiding losses on the security. The Manager is not contractually liable to the Fund for losses associated with operational risk absent the Manager’s willful misfeasance, bad faith, gross negligence, or reckless disregard of its contractual obligations to provide services to the Fund. Other Fund service providers also have limitations on their liability to the Fund for losses resulting from their errors.
    DERIVATIVES RISK
          The Fund may invest in derivatives, which are financial contracts whose value depends on, or is derived from, the value of underlying assets, reference rates, or indices. Derivatives include futures, foreign currency contracts, swap contracts, reverse repurchase agreements, and other OTC contracts. Derivatives may relate to securities, interest rates, currencies or currency exchange rates, inflation rates, commodities, and indices. The SAI contains a description of the various types and uses of derivatives in the Fund’s investment strategies.
          The use of derivatives involves risks that are in addition to, and potentially greater than, the risks associated with investing directly in securities and other more traditional assets. In particular, the use of OTC derivatives exposes the Fund to the risk that the counterparty to a derivatives contract will be unable or unwilling to make timely settlement payments or otherwise honor its obligations. OTC derivatives contracts typically can be closed only with the other party to the contract. If the counterparty defaults, the Fund will have contractual remedies but may not be able to enforce them. Because the contract for each OTC derivative is individually negotiated, the counterparty may interpret contractual terms (e.g., the definition of default) differently than the Fund, and if that occurs, the Fund may decide not to pursue its claims against the counterparty in order to avoid incurring the cost and unpredictability of legal proceedings. The Fund, therefore, may be unable to obtain payments the Manager believes are owed under OTC derivatives contracts or those payments may be delayed or made only after the Fund has incurred the costs of litigation.
          The Fund may invest in derivatives that do not require the counterparty to post collateral (e.g., foreign currency forwards), that require collateral but that do not provide for the Fund’s security interest in it to be perfected, that require a significant upfront deposit by the Fund unrelated to the derivative’s intrinsic value, or that do not require the collateral to be regularly marked-to-market (e.g., certain OTC derivatives). Even when obligations are required by contract to be collateralized, there is usually a lag between the day the collateral is called for and the day the Fund receives it. When a counterparty’s obligations are not fully secured by collateral, the Fund is exposed to the risk of having limited recourse if the counterparty defaults. The Fund may invest in derivatives with a limited number of counterparties, and events affecting the creditworthiness of any of those counterparties may have a pronounced effect on the Fund. Derivatives risk is particularly acute in environments (like those experienced recently) in which financial services firms are exposed to systemic risks of the type evidenced by the insolvency of Lehman Brothers and subsequent market disruptions. During these periods of market disruptions, the Fund may have a greater need for cash to provide collateral for large swings in its mark-to-market obligations under the derivatives used by the Fund.
          Derivatives also present risks described elsewhere in this “Description of Principal Risks” section, including market risk and counterparty risk. Many derivatives, in particular OTC derivatives, are complex and their valuation often requires modeling and judgment, which increases the risk of mispricing or improper valuation. The pricing models used by the Fund or its pricing agents may not produce valuations that are consistent with the values realized when OTC derivatives are actually closed out or sold. This valuation risk is more pronounced when the Fund enters into OTC derivatives with specialized

-10-


 

terms because the value of those derivatives in some cases is determined only by reference to similar derivatives with more standardized terms. As a result, incorrect valuations may result in increased cash payments to counterparties, undercollateralization and/or errors in the calculation of the Fund’s net asset value.
          The Fund’s use of derivatives may not be effective or have the desired results. Moreover, suitable derivatives will not be available in all circumstances. For example, the economic costs of taking some derivative positions may be prohibitive, and if a counterparty or its affiliate is deemed to be an affiliate of the Fund, the Fund will not be permitted to trade with that counterparty. In addition, the Manager may decide not to use derivatives to hedge or otherwise reduce the Fund’s risk exposures, potentially resulting in losses for the Fund.
          Derivatives also involve the risk that changes in their value may not move as expected relative to the value of the assets, rates, or indices they are designed to track.
          Swap contracts and other OTC derivatives are highly susceptible to counterparty risk (see “Counterparty Risk” below), and are subject to documentation risks. Because many derivatives have a leverage component (i.e., a notional value in excess of the assets needed to establish and/or maintain the derivative position), adverse changes in the value or level of the underlying asset, rate or index may result in a loss substantially greater than the amount invested in the derivative itself.
          The U.S. government recently enacted legislation that provides for new regulation of the derivatives market, including clearing, margin, reporting and registration requirements. Because the legislation leaves much to rule making, its ultimate impact remains unclear. New regulations could, among other things, restrict the Fund’s ability to engage in derivatives transactions (for example, by making certain types of derivatives transactions no longer available to the Fund) and/or increase the costs of such derivatives transactions (for example, by increasing margin or capital requirements), and the Fund may be unable to execute its investment strategy as a result. It is unclear how the regulatory changes will affect counterparty risk.
    COUNTERPARTY RISK
          This is the risk that the counterparty to a repurchase agreement or reverse repurchase agreement or other OTC derivatives contract or a borrower of the Fund’s securities will be unable or unwilling to make timely settlement payments or otherwise honor its obligations. If a counterparty fails to meet its contractual obligations, goes bankrupt, or otherwise experiences a business interruption, the Fund could miss investment opportunities or otherwise hold investments it would prefer to sell, resulting in losses for the Fund. Counterparty risk is pronounced during unusually adverse market conditions and is particularly acute in environments (like those experienced recently) in which financial services firms are exposed to systemic risks of the type evidenced by the insolvency of Lehman Brothers in 2008 and subsequent market disruptions.
          Participants in OTC derivatives markets typically are not subject to the same level of credit evaluation and regulatory oversight as are members of exchange-based markets and, therefore, OTC derivatives generally expose the Fund to greater counterparty risk than exchange-traded derivatives. The Fund is subject to the risk that a counterparty will not settle a transaction in accordance with its terms and conditions because of a dispute over the terms of the contract (whether or not bona fide) or because of a credit or liquidity problem, thus causing the Fund to suffer a loss. If a counterparty’s obligation to the Fund is not collateralized, then the Fund is essentially an unsecured creditor of the counterparty. If the counterparty defaults, the Fund will have contractual remedies, but the Fund may be unable to enforce them. Counterparty risk is greater for derivatives with longer maturities where events may intervene to

-11-


 

prevent settlement. Counterparty risk is also greater when the Fund has concentrated its derivatives with a single or small group of counterparties as it sometimes does as a result of its use of swaps and other OTC derivatives. To the extent the Fund has significant exposure to a single counterparty, this risk will be particularly pronounced. The Fund is subject, in particular, to the creditworthiness of the contracts’ counterparties because some types of swap contracts used by the Fund have durations longer than six months (and, in some cases, a number of decades). The creditworthiness of a counterparty may be adversely affected by greater than average volatility in the markets, even if the counterparty’s net market exposure is small relative to its capital. Counterparty risk still exists even if a counterparty’s obligations are secured by collateral because the Fund’s interest in collateral may not be perfected or additional collateral may not be promptly posted as required.
          The Fund is also subject to counterparty risk because it executes its securities transactions through brokers and dealers. If a broker or dealer fails to meet its contractual obligations, goes bankrupt, or otherwise experiences a business interruption, the Fund could miss investment opportunities or be unable to dispose of investments it would prefer to sell, resulting in losses for the Fund.
          Counterparty risk with respect to OTC derivatives may be further complicated by recently enacted U.S. financial reform legislation. See “Derivatives Risk” above for more information.
    LEVERAGING RISK
          The Fund’s use of reverse repurchase agreements and other derivatives and securities lending may cause its portfolio to be leveraged (i.e., the Fund’s exposure to underlying securities, assets or currencies exceeds its net asset value). Leverage increases the Fund’s portfolio losses when the value of its investments declines. Because many derivatives have a leverage component (i.e., a notional value in excess of the assets needed to establish and/or maintain the derivative position), adverse changes in the value or level of the underlying asset, rate or index may result in a loss substantially greater than the amount invested in the derivative itself. In the case of swaps, the risk of loss generally is related to a notional principal amount, even if the parties have not made any initial investment. Some derivatives have the potential for unlimited loss, regardless of the size of the initial investment. The Fund’s use of reverse repurchase agreements also subjects the Fund to interest costs based on the difference between the sale and repurchase price of a security involved in such a transaction. The Fund’s portfolio also will be leveraged if it borrows money to meet redemption requests or settle investment transactions or if it avails itself of the right to delay payment on a redemption.
          The Fund may manage some of its derivative positions by offsetting derivative positions against one another or against other assets. To the extent offsetting positions do not behave in relation to one another as expected, the Fund may perform as if it were leveraged.
    SMALLER COMPANY RISK
          Market risk and liquidity risk are particularly pronounced for securities of companies with smaller market capitalizations, including small- and mid-cap companies. These companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, or may lack managers with experience or depend on a few key employees. In addition, their securities often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations.

-12-


 

    FOCUSED INVESTMENT RISK
          A fund whose investments are focused in particular countries, regions, sectors or companies or in industries with high positive correlations to one another (e.g., different industries within broad sectors, such as technology or financial services) is subject to greater overall risk than a fund whose investments are more diversified. A fund that invests in the securities of a limited number of issuers is particularly exposed to adverse developments affecting those issuers, and a decline in the market value of a particular security held by a Fund may affect a Fund’s performance more than if the Fund invested in the securities of a larger number of issuers.
          Because the Fund typically invests a significant portion of its assets in equity investments tied economically to the U.S., it is vulnerable to events affecting those equity investments. Investments that share common characteristics are often subject to similar business risks and regulatory burdens, and often react similarly to specific economic, market, political or other developments.
    MARKET DISRUPTION AND GEOPOLITICAL RISK
          The Fund is subject to the risk that geopolitical and other events will disrupt securities markets and adversely affect global economies and markets. The wars in Iraq and Afghanistan have had a substantial effect on the economies and securities markets of the U.S. and other countries. Terrorism in the U.S. and around the world has had a similar global impact and has increased geopolitical risk. The terrorist attacks on September 11, 2001 resulted in the closure of some U.S. securities markets for four days, and similar attacks are possible in the future. War, terrorism, and related geopolitical events have led, and in the future may lead, to increased short-term market volatility and may have adverse long-term effects on U.S. and world economies and markets generally. Likewise, natural and environmental disasters, such as the earthquake and tsunami in Japan in early 2011, and systemic market dislocations of the kind surrounding the insolvency of Lehman Brothers in 2008, if repeated, would be highly disruptive to economies and markets. Those events as well as other changes in foreign and domestic economic and political conditions also could adversely affect individual issuers or related groups of issuers, securities markets, interest rates, credit ratings, inflation, investor sentiment and other factors affecting the value of the Fund’s investments. During such market disruptions, the Fund’s exposure to the risks described elsewhere in this “Description of Principal Risks” section, including market risk and counterparty risk likely will increase. Market disruptions can also prevent the Fund from implementing its investment program for a period of time and achieving its investment objective. For example, a disruption may cause the Fund’s derivatives counterparties to discontinue offering derivatives on some underlying commodities, securities, reference rates or indices, or to offer such products on a more limited basis, or the current global economic crisis may strain the U.S. Treasury’s ability to satisfy its obligations.
    LARGE SHAREHOLDER RISK
          To the extent that shares of the Fund are held by large shareholders (e.g., institutional investors, financial intermediaries or other GMO Funds), the Fund is subject to the risk that these shareholders will purchase or redeem shares in large amounts and/or on a frequent basis. In addition, GMO Funds and other accounts over which GMO has investment discretion that invest in the Fund are not subject to restrictions on the frequency of trading of shares. These transactions could adversely affect the Fund if the Fund sells portfolio securities to raise the cash to satisfy shareholder redemption requests or purchase portfolio securities to invest cash. This risk is particularly pronounced when one shareholder owns a substantial portion of the Fund. A substantial percentage of the Fund may be held by other GMO Funds and/or separate accounts managed by the Manager for its clients. Asset allocation decisions by the Manager may result in substantial redemptions from (or investments into) the Fund. These transactions may adversely affect the Fund’s performance to the extent that the Fund is required to sell investments (or invest cash) at

-13-


 

times when it would not otherwise do so. These transactions also may increase transaction costs. In addition, to the extent the Fund invests in other GMO Funds having large shareholders, the Fund is indirectly subject to this risk.
    FUND OF FUNDS RISK
          Because the Fund invest in substantially all of its assets in USCEF, which may invest in shares of other investment companies, including other GMO Funds and money market funds (for purposes of this risk disclosure, “underlying Funds”), the Fund is exposed to the risk that USCEF or the underlying Funds do not perform as expected.
          Because the Fund bears the fees and expenses of USCEF, and USCEF bears the fees and expense of the underlying Funds in which it invests (absent reimbursement of those expenses), the Fund and USCEF will incur additional expenses when investing in underlying Funds. In addition, total Fund expenses will increase if USCEF or its successor increases its fees or incurs additional expenses, or when USCEF makes a new investment in underlying Funds with higher fees or expenses than those of the underlying Funds in which USCEF has already invested. The fees and expenses associated with an investment in these underlying Funds can be less predictable and potentially higher than fees of other funds with similar investment programs.
          The Fund is also indirectly exposed to all of the risks applicable to an investment in the underlying Funds. In addition, since the Fund and USCEF invest in shares of other GMO Funds, they are also likely subject to Large Shareholder Risk because underlying GMO Funds are more likely to have large shareholders (e.g., other GMO Funds). See “Large Shareholder Risk” above.
MANAGEMENT OF THE FUND
          GMO, 40 Rowes Wharf, Boston, Massachusetts 02110, provides investment management and shareholder services to the Fund, USCEF and other GMO Funds. GMO is a private company, founded in 1977. As of December 31, 2011, GMO managed on a worldwide basis more than $100 billion of assets for the GMO Funds and other investors, such as pension plans, endowments, and foundations.
          Subject to the approval of the Trustees, the Manager establishes and modifies when it deems appropriate the investment strategies of the Fund. In addition to its management of the Fund’s investment portfolio and the shareholder services it provides to the Fund, the Manager administers the Fund’s business affairs.
          The Fund invests substantially all of its assets in an underlying fund, USCEF. The Trustees may unanimously determine to change the underlying fund in which the Fund invests, and will provide the Fund’s shareholders at least 60 days’ notice prior to implementing such a change.
          The Fund does not pay the management a fee for investment management services, but, as a shareholder of USCEF, it bears a pro rata portion of USCEF’s expenses. USCEF paid the Manager, as compensation for investment management services, an annual fee equal to 0.28% of USCEF’s average daily net assets for each class of shares during its fiscal year ended February 28, 2011.
          Class R1 shares of the Fund pay the Manager an administration fee, which is used by the Manager to defray its expenses (or the expenses of a third party) in providing administration and record keeping services to investors purchasing Class R1 shares of the Fund through eligible retirement plans.

-14-


 

          A discussion of the basis for the Trustees’ approval of the Fund’s initial investment management contract will be included in the Fund’s first shareholder report.
          GMO’s Quantitative Equity Division is responsible for day-to-day investment management of the Fund and USCEF. The Division’s investment professionals work collaboratively to manage the Fund’s and USCEF’s portfolio, and no one person is primarily responsible for day-to-day management of the Fund and USCEF.
          The following table identifies the senior members of GMO’s Quantitative Equity Division who are responsible for providing investment management services to the Fund and USCEF and each senior member’s length of service as a senior member, title, and business experience during the past five years. The senior members manage or allocate responsibility for portions of the portfolios to members of their Division, oversee the implementation of trades, review the overall composition of the portfolios, including compliance with stated investment objectives and strategies, and monitor cash.
         
    Senior Members   Title;
Investment Division   (Length of Service)   Business Experience During Past 5 Years
Quantitative Equity
  Thomas Hancock
(since the Fund’s inception)
  Co-Director, Quantitative Equity Division, GMO. Dr. Hancock has been responsible for overseeing the portfolio management of GMO’s international developed market and global quantitative equity portfolios since 1998.
 
       
Quantitative Equity
  Sam Wilderman
(since the Fund’s inception)
  Co-Director, Quantitative Equity Division, GMO. Mr. Wilderman has been responsible for overseeing the portfolio management of GMO’s U.S. quantitative equity portfolios since 2005. Previously, Mr. Wilderman was responsible for portfolio management of and research for GMO’s emerging equity portfolios since 1996.
          The SAI contains information about how GMO determines the compensation of the senior members, other accounts they manage and related conflicts, and their ownership of the Fund and other GMO Funds for which they have responsibility.
Custodian and Fund Accounting Agent
          State Street Bank and Trust Company (“State Street Bank”), One Lincoln Street, Boston, Massachusetts 02111, serves as the Trust’s custodian and fund accounting agent on behalf of the Fund.
Transfer Agent
          State Street Bank serves as the Trust’s transfer agent on behalf of the Fund.
Expenses
          There are two types of expenses related to mutual funds — expenses that a shareholder pays directly (called a sales charge) and expenses that are deducted from Fund assets.
          Class R1 shareholders do not pay any expenses directly as Class R1 shares of the Fund are sold without an initial sales charge or a contingent deferred sales charge upon redemption.

-15-


 

          The costs of managing, administering, and operating the Fund are spread among each class of shares, including Class R1 shares. These costs cover such things as the Fund’s pro rata share of the expenses of USCEF, shareholder servicing, custody, auditing, administrative and transfer agency expenses, and fees and expenses of the Trustees and are reflected in the Fund’s “Annual Fund Operating Expenses” table under the caption “Fees and Expenses” in the Fund Summary.
          As more fully described in the Fund’s fee table, the Manager has contractually agreed to reimburse the Fund for the portion of the Fund’s total annual operating expenses that exceed 0.00% of the Fund’s average daily net assets (the “Expense Reimbursement Amount”) exclusive of “Excluded Fund Fees and Expenses.” As used in this Prospectus, “Excluded Fund Fees and Expenses” means administration fees, expenses incurred indirectly by investment in USCEF and any other GMO Funds, fees and expenses of the independent Trustees of the Trust and their independent counsel, fees and expenses for legal services the Manager for the Trust has not undertaken to pay, compensation and expenses of Trust officers and agents who are not affiliated with GMO, brokerage commissions, securities lending fees and expenses, interest expense, transfer taxes, and other investment-related costs (including expenses associated with investments in any company that is an investment company (including an exchange-traded fund) or would be an investment company under the 1940 Act, but for the exceptions to the definition of investment company provided in Sections 3(c)(1) and 3(c)(7) of the 1940 Act), hedging transaction fees, extraordinary, non-recurring and certain other unusual expenses (including taxes).
          The Fund’s contractual expense limitations will continue through at least October 1, 2012, and may not be terminated prior to this date without the consent of the Fund’s Board of Trustees.
DETERMINATION OF NET ASSET VALUE
          The net asset value or “NAV” of the Fund is determined as of the close of regular trading on the NYSE, generally at 4:00 p.m. Boston time. The NAV per share of Class R1 shares of the Fund is determined by dividing the total value of the Fund’s portfolio investments and other assets, less any liabilities, allocated to that share class by the total number of outstanding shares of that class. NAV is not determined on any days when the NYSE is closed for business. The Fund also may elect not to determine NAV on days during which no share is tendered for redemption and no order to purchase or sell a share is received by the Fund. U.S. generally accepted accounting principles (“GAAP”) may require the Fund to accrue for certain taxes that may or may not ultimately be paid. The amounts of such accruals will be determined by the Manager in its sole discretion.
          Because the Fund invests substantially all of its assets in USCEF, the Fund’s net asset value is calculated based upon the net asset value of USCEF. Like the Fund, USCEF’s NAV is determined as of the close of regular trading on the NYSE. Following is a description of how the value of USCEF’s investments and any investments by the Fund in addition to its investments in USCEF are generally determined:
Exchange-listed securities (other than Exchange-listed options)
    Last sale price or
 
    Official closing price or
 
    Most recent quoted price published by the exchange (if no reported last sale or official closing price) or

-16-


 

    Quoted price provided by a pricing source (if the private market is more reliable in determining market value than the exchange)
    (Also, see discussion in “Fair Value Pricing” below regarding foreign equity securities.)
Exchange-listed options
    Exchange-listed options are valued at the last sale price, provided that price is between the closing bid and ask prices. If the last sale price is not within this range, then they will be valued at the closing bid price for long positions and the closing ask price for short positions
Unlisted securities (if market quotations are readily available)
    Most recent quoted price
Note: There can be no assurance that quoted prices will be available. If reliable quotes are not available, the Fund or USCEF may seek alternative valuation methodologies (e.g., valuing the relevant assets at “fair value” as described below).
Non-emerging market debt obligations (having sixty days or less to final maturity)
    Amortized cost (unless circumstances dictate otherwise; for example, if the issuer’s creditworthiness has become impaired)
All other fixed income securities (includes bonds, asset-backed securities, loans, structured notes)
    Most recent quoted price supplied by a single pricing source chosen by the Manager
Shares of other GMO Funds and other open-end registered investment companies
    Most recent NAV
“Fair Value” Pricing
          For all other assets and securities, including derivatives, and in cases where market prices are not readily available or circumstances make an existing methodology or procedure unreliable, the Fund’s and USCEF’s investments are valued at “fair value,” as determined in good faith by the Trustees or pursuant to procedures approved by the Trustees.
          The value of assets that are “fair valued” is determined by the Trustees or persons acting at their direction pursuant to procedures approved by the Trustees. Factors that may be considered in determining “fair value” include, among others, the value of other financial instruments traded on other markets, trading volumes, changes in interest rates, observations from financial institutions, significant events (which may be considered to include changes in the value of U.S. securities or securities indices) that occur after the close of the relevant market and before the Fund’s or USCEF’s net asset value is calculated, other news events, and significant unobservable inputs (including the Fund’s or USCEF’s own assumptions in determining the fair value of investments). Although the goal of fair valuation is to determine the amount the owner of the securities might reasonably expect to receive upon their current sale, because of the uncertainty inherent in fair value pricing, the fair value determined for a particular security may be materially different from the value realized upon its sale.

-17-


 

          Quoted prices are typically the “bid price” for securities held long and the “ask price” for securities sold short. If the pricing convention for the applicable security does not involve a bid or an ask, the quoted price is the quotation provided by a third party pricing source in accordance with the convention for that security.
          The Manager evaluates pricing sources on an ongoing basis and may change a pricing source at any time. The Manager normally does not evaluate the prices supplied by pricing sources on a day-to-day basis. The Manager monitors erratic or unusual movements (including unusual inactivity) in the prices supplied for a security and has discretion to override a price supplied by a source (e.g., by taking a price supplied by another) when it believes that the price supplied is not reliable. In addition, although alternative prices often are available for many securities held by the Fund or USCEF, the existence of those alternative sources does not necessarily provide greater certainty about the prices used by the Fund or USCEF. In addition, because the Fund or USCEF may hold portfolio securities listed on foreign exchanges that trade on days on which the NYSE or the U.S. bond markets are closed, the net asset value of the Fund’s or USCEF’s shares may change significantly on days when shares cannot be redeemed.
NAME POLICY
          To comply with Securities and Exchange Commission (“SEC”) rules regarding the use of descriptive words in a fund’s name, the Fund has adopted a policy of investing at least 80% of its assets, through USCEF, in equity investments tied economically to the U.S. (the “Name Policy”). The Name Policy is described in the “Principal investment strategies” section of the Fund Summary.
          The Fund will not change its Name Policy without providing its shareholders at least 60 days’ prior written notice. When used in connection with the Fund’s Name Policy, “assets” include the Fund’s net assets plus any borrowings made for investment purposes. For purposes of this Prospectus, an investment is “tied economically” to the U.S. if: (i) it is an investment in an issuer that is organized under the laws of the U.S. or in an issuer that maintains its principal place of business in the U.S.; (ii) it is traded principally in the U.S.; or (iii) it is an investment in an issuer that derived at least 50% of its revenues or profits from goods produced or sold, investments made, or services performed in the U.S., or has at least 50% of its assets in the U.S. USCEF may invest directly in securities of companies in the U.S. or indirectly, for example, through investments in another GMO Fund, derivatives, or synthetic instruments with underlying assets that have economic characteristics similar to investments tied economically to the U.S.
DISCLOSURE OF PORTFOLIO HOLDINGS
          The Fund has established a policy with respect to disclosure of its portfolio holdings. That policy is described in the SAI. The largest fifteen portfolio holdings of the Fund and USCEF are posted monthly on GMO’s website. In addition, from time to time, position attribution information regarding the Fund and USCEF may be posted to GMO’s website (e.g., best/worst performing positions in the Fund over a specified time period). Such information is available without a confidentiality agreement to registered users on GMO’s website. Additional information regarding the Fund’s and USCEF’s portfolio holdings as of each month’s end is made available to shareholders of the Trust, qualified potential shareholders as determined by GMO (“potential shareholders”), and their consultants or agents through a secured link on GMO’s website approximately five days after month end. Periodically, in response to heightened market interest in specific issuers, the Fund’s and USCEF’s holdings in one or more issuers may be made available on a more frequent basis to shareholders of the Trust, potential shareholders, and their consultants or agents through a secured link on GMO’s website. This information may be posted as soon as the business day following the date to which the information relates.

-18-


 

          To access this information on GMO’s website (http://www.gmo.com/america/strategies), shareholders, potential shareholders, and their consultants and agents (“permitted recipients”) must contact GMO to obtain a password and user name (to the extent they do not already have them) and generally must enter into a confidentiality agreement with GMO and the Trust. GMO also may provide permitted recipients with information regarding underlying direct holdings of the Fund, and a confidentiality agreement is not required to view this information. GMO may make portfolio holdings information available in alternate formats and under additional circumstances under the conditions described in the SAI. Beneficial owners of shares of the Fund who have invested in the Fund through a broker or agent should contact that broker or agent for information on how to obtain access to information on the website regarding the Fund’s portfolio holdings.
          The Fund, USCEF, or GMO may suspend the posting of portfolio holdings, and the Fund may modify the disclosure policy, without notice to shareholders. Once posted, the Fund’s and USCEF’s portfolio holdings will remain available on the website at least until the Fund files a Form N-CSR (annual/semiannual report) or Form N-Q (quarterly schedule of portfolio holdings) for the period that includes the date of those holdings.
HOW TO PURCHASE SHARES
          Class R1 shares of the Fund may be purchased by eligible retirement plans (e.g., 401(k) plans, 457 plans, employer-sponsored 403(b) plans, profit-sharing and money purchase pension plans, and qualified deferred compensation plans) whose accounts are maintained by the Fund at an omnibus level.
          Under ordinary circumstances, you may purchase the Fund’s shares on days when the NYSE is open for business. Retirement plan participants may establish an account and add shares to an account by contacting the plan administrator (or another financial intermediary designated by the Fund or the plan administrator). The plan administrator or designated financial intermediary will conduct the transaction, or provide plan participants with the means to conduct the transaction themselves. Retirement plan participants should contact the plan administrator or designated financial intermediary for instructions on purchasing shares.
          There are no minimum initial or subsequent investment requirements for Class R1 shares of the fund. The plan administrator or other financial intermediary may impose transaction fees and/or other restrictions (in addition to those described in this Prospectus) for purchasing Fund shares through them.
           Funding Your Investment. You may purchase shares:
  4   By wire. Instruct your bank to wire the amount of your investment to:
State Street Bank and Trust Company, Boston, Massachusetts
ABA#: 011000028
Attn: Transfer Agent
Credit: GMO Series Fund Deposit Account 10111003
Further credit: GMO U.S. Core Equity Series Fund
           Purchase Policies. The plan administrator or other financial intermediary is responsible for transmitting a purchase request in good order to the Trust or its designated agent to avoid having it rejected by the Trust or its designated agent. If the purchase request is received in good order by the Trust or its designated agent, together with the U.S. dollar amount of the shares to be purchased (when federal funds, a wire, a check or Automated Clearing House (ACH) transaction are received), prior to the close of regular trading on the NYSE (generally 4:00 p.m. Boston time), the purchase price for the Fund

-19-


 

shares to be purchased is the net asset value per share determined on that day. If the request and payment are received after the close of regular trading on the NYSE, the purchase price for the Fund shares to be purchased is the net asset value per share determined on the next business day that the NYSE is open. The specific requirements for good order depend on the type of account and transaction and the method of purchase; contact your financial intermediary. The Fund and its agents reserve the right to reject any purchase request.
          To help the U.S. government fight the funding of terrorism and money laundering activities, federal law requires the Trust to verify identifying information provided by each investor that opens an account. Additional identifying documentation also may be required. If the Trust is unable to verify the information shortly after your account is opened, the account may be closed and your shares redeemed at their net asset value at the time of the redemption.
          The Fund in its sole discretion and without notice may temporarily or permanently suspend sales of its shares to new investors and/or existing shareholders, change the categories of investors eligible to purchase Class R1 shares of the Fund, and change the minimum initial or subsequent investment requirements for Class R1 shares of the Fund.
           Frequent Trading Activity. As a matter of policy, the Trust will not honor requests for purchases or exchanges by shareholders identified as engaging in frequent trading strategies, including market timing, that GMO determines could be harmful to the Fund and its shareholders. Frequent trading strategies are generally strategies that involve repeated exchanges and/or purchases and redemptions (or redemptions and purchases) within a short period of time. Frequent trading strategies may be disruptive to the efficient management of the Fund, materially increase portfolio transaction costs and taxes, dilute the value of shares held by long-term investors, or otherwise be harmful to the Fund and its shareholders.
          The Trustees have adopted procedures designed to detect and prevent frequent trading activity that is harmful to the Fund and its shareholders (the “Procedures”). The Procedures include the fair valuation of foreign securities, periodic surveillance of trading in shareholder accounts and inquiry as to the nature of trading activity. If GMO determines that an account is engaging in frequent trading that has the potential to be harmful to the Fund or its shareholders, the Procedures permit GMO to adopt various prevention measures, including suspension of the account’s exchange and purchase privileges. There is no assurance that the Procedures will be effective in all instances. The Fund will not automatically redeem shares that are the subject of a rejected exchange request. The Fund reserves the right to reject any order or terminate the sale of Fund shares at any time.
          Class R1 shares of the Fund are distributed through financial intermediaries that submit aggregate or net purchase and redemption orders through omnibus accounts. These omnibus accounts often by nature engage in frequent transactions due to the daily trading activity of their underlying investors. Because transactions by omnibus accounts often take place on a net basis, GMO’s ability to detect and prevent frequent trading strategies within those accounts is limited. GMO ordinarily seeks the agreement of a financial intermediary to monitor for and/or restrict frequent trading in accordance with the Procedures. In addition, the Fund may rely on a financial intermediary to monitor for and/or restrict frequent trading in accordance with the intermediary’s policies and procedures in lieu of the Procedures if GMO believes that the financial intermediary’s policies and procedures are reasonably designed to detect and prevent frequent trading activity that GMO considers to be potentially harmful to the Fund and its shareholders. Shareholders who own Fund shares through an intermediary should consult with that intermediary regarding its frequent trading policies.

-20-


 

HOW TO REDEEM SHARES
          Under ordinary circumstances, you may redeem the Fund’s shares on days when the NYSE is open for business. Retirement plan participants may sell shares of the Fund by contacting the plan administrator (or another financial intermediary designated by the Fund or the plan administrator). The plan administrator or designated financial intermediary will conduct the transaction for retirement plan participants, or provide retirement plan participants with the means to conduct the transaction themselves. Financial intermediaries, including your plan administrator, may impose transaction fees and/or other restrictions (in addition to those described in this Prospectus) for redeeming Fund shares through them.
           Redemption Policies. The plan administrator or other financial intermediary is responsible for submitting a redemption request in good order to avoid having it rejected by the Trust or its designated agent. If the redemption request is received in good order by the Trust or its designated agent prior to the close of regular trading on the NYSE (generally 4:00 p.m. Boston time), the redemption price for the Fund shares to be redeemed is the net asset value per share determined on that day. If the request is received after the close of regular trading on the NYSE, the redemption price for the Fund shares to be redeemed is the net asset value per share determined on the next business day that the NYSE is open. The specific requirements for good order depend on the type of account and transaction and the method of redemption; contact your financial intermediary. In the event of a disaster affecting Boston, Massachusetts, plan administrators and other financial intermediaries should contact GMO to confirm that your redemption request was received and is in good order.
          Failure to provide the Trust with a properly authorized redemption request or otherwise satisfy the Trust as to the validity of any change to the wire instructions or registration address may result in a delay in processing a redemption request, delay in remittance of redemption proceeds, or a rejection of the redemption request.
          In its sole discretion, GMO may determine to have the Fund pay redemption proceeds wholly or partly in securities (selected by GMO) instead of cash. In particular, if market conditions deteriorate and the Manager believes the Fund’s redemption fee (if any) is not fair compensation for transaction costs, the Fund may limit cash redemptions (honoring redemptions with portfolio securities) to protect the interests of all Fund shareholders. In the event that the Fund makes a redemption in kind, you should expect to incur brokerage and other transaction charges when converting the securities to cash, and the securities will likely increase or decrease in value before you sell them.
          Redemption proceeds for investors who invest through eligible retirement plans or other financial intermediaries will be sent directly to the plan administrator or other financial intermediary. The Fund may take up to seven days to remit proceeds to the plan administrator or other financial intermediary.
          The Fund may suspend the right of redemption and may postpone payment for more than seven days:
    if the NYSE and/or the Federal Reserve Bank are closed on days other than weekends or holidays
 
    during periods when trading on the NYSE is restricted
 
    during an emergency that makes it impracticable for the Fund to dispose of its securities or to fairly determine the net asset value of the Fund
 
    during any other period permitted by the SEC for your protection.

-21-


 

          Pursuant to the Trust’s Agreement and Declaration of Trust, the Trust has the unilateral right to redeem Fund shares held by a shareholder at any time.
DISTRIBUTIONS AND TAXES
          The Fund’s policy is to declare and pay distributions of its net investment income, if any, at least annually. The Fund also intends to distribute net realized capital gains, whether from the sale of securities held by the Fund for not more than one year (net short-term capital gains) or from the sale of securities held by the Fund for more than one year (net long-term capital gains), if any, at least annually. In addition, the Fund may, from time to time and at its discretion, make unscheduled distributions in advance of large redemptions by shareholders or as otherwise deemed appropriate by the Fund. From time to time, distributions by the Fund could constitute, for U.S. federal income tax purposes, a return of capital to shareholders. Shareholders should read the description below for information regarding the tax character of distributions from the Fund to shareholders.
          All dividends and capital gain distributions paid to shareholders will be reinvested automatically, unless a shareholder elects to receive cash.
          The Fund is treated as a separate taxable entity for U.S. federal income tax purposes and intends to qualify each year as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). A RIC generally is not subject to tax at the fund level on income and gains from investments that are timely distributed to shareholders. However, the Fund’s failure to qualify as a RIC would result in Fund-level taxation, and consequently, a reduction in the value of the Fund, as well as in the income available for distribution to its shareholders.
          Shares of the Fund are offered primarily to certain eligible retirement plans, as well as through certain other tax-advantaged accounts (see “How to Purchase Shares” above). Shareholders that are retirement plans that qualify for tax-exempt treatment under U.S. federal income tax laws generally are not subject to U.S. federal income tax on distributions from the Fund or on redemptions of Fund shares. Special tax rules apply to investments through such plans. Plan participants whose retirement plan invests in the Fund generally are not subject to U.S. federal income tax on Fund distributions received by the plan or on redemptions of Fund shares by the plan. However, distributions to plan participants from a retirement plan generally are taxable to plan participants as ordinary income, with certain exceptions (for example, distributions to participants from a Roth 401(k) plan generally are not taxable to those participants).
          This prospectus does not address tax considerations that may be relevant to participants in “nonqualified” retirement plans, or to other investors. You should consult with your own tax advisor or the plan administrator or other financial intermediary through which your investment in the Fund is made to determine the suitability of the Fund as an investment through your retirement plan or other tax-advantaged account and the specific U.S. federal income, as well as any possible state, local, foreign or other, tax consequences to you of investing in the Fund through your plan or other account. See “Taxes” in the SAI for more information.
FUND CODES
The following chart identifies the ticker, news-media symbol, and CUSIP number for each share class of the Fund currently being offered (if any).
             
    Ticker   Symbol   CUSIP
Class R1
     

-22-


 

GMO SERIES TRUST
ADDITIONAL INFORMATION
          The Fund’s annual and semiannual reports to shareholders (when available) will contain additional information about the Fund’s investments. The Fund’s annual report (when available) will contain a discussion of the market conditions and investment strategies that significantly affected the Fund’s performance during its initial fiscal year. The Fund’s annual and semiannual reports (when available) will be, and the Fund’s SAI is, available free of charge by writing to Shareholder Services at GMO, 40 Rowes Wharf, Boston, Massachusetts 02110 or by calling collect at 1-617-346-7646. The SAI contains more detailed information about the Fund and is incorporated by reference into this Prospectus, which means that it is legally considered to be part of this Prospectus.
          You can review and copy the Prospectus, SAI, and reports (when available) at the SEC’s Public Reference Room in Washington, D.C. Information regarding the operation of the Public Reference Room may be obtained by calling the SEC at 1-202-551-8090. Reports and other information about the Fund are available on the EDGAR database on the SEC’s Internet site at http://www.sec.gov. Copies of this information may be obtained, upon payment of a duplicating fee, by electronic request at the following e-mail address: publicinfo@sec.gov, or by writing the Public Reference Section of the SEC, Washington, D.C. 20549-1520.
          Shareholders who wish to communicate with the Trustees must do so by mailing a written communication, addressed as follows: To the Attention of the Board of Trustees, c/o GMO Trust Chief Compliance Officer, 40 Rowes Wharf, Boston, MA 02110. The shareholder communication must (i) be in writing and be signed by the shareholder, (ii) identify the Fund, and (iii) identify the class and number of shares held beneficially or of record by the shareholder.
SHAREHOLDER INQUIRIES
Plan administrators and financial
intermediaries may request additional
information from and direct inquiries to:
Shareholder Services at
Grantham, Mayo, Van Otterloo & Co. LLC
40 Rowes Wharf, Boston, MA 02110
1-617-346-7646 (call collect)
1-617-439-4192 (fax)
SHS@GMO.com
website: http://www.gmo.com
Plan participants should contact their plan administrator
or other financial intermediary for information.
DISTRIBUTOR
Funds Distributor, LLC
10 High Street
Suite 302
Boston, Massachusetts 02110
Investment Company Act File No. 811-22564

 


 

GMO SERIES TRUST
STATEMENT OF ADDITIONAL INFORMATION
October 1, 2011
GMO U.S. Core Equity Series Fund
Class R1: —
This Statement of Additional Information is not a prospectus. It relates to the Prospectus for GMO U.S. Core Equity Series Fund (the “Fund”) dated October 1, 2011, as amended and revised from time to time thereafter (the “Prospectus”), and should be read in conjunction therewith. Information from the Prospectus is, and (when available) information from the annual report to shareholders of the Fund will be, incorporated by reference into this Statement of Additional Information. The Prospectus and the annual report to shareholders (when available) of the Fund may be obtained free of charge from GMO Series Trust (the “Trust”), 40 Rowes Wharf, Boston, Massachusetts 02110, or by calling the Trust collect at 1-617-346-7646.

 


 

Table of Contents
         
    Page  
    2  
    2  
    3  
    31  
    33  
    36  
    37  
    37  
    45  
    53  
    56  
    58  
    59  
    62  
    63  
    63  
    64  
    64  
    A-1  
    B-1  
-i-

 


 

INVESTMENT OBJECTIVES AND POLICIES
The investment objective and principal strategies of, and risks of investing in, the Fund are described in the Prospectus. The Fund invests substantially all of its assets in GMO U.S. Core Equity Fund (“USCEF”), which invests directly in securities and other instruments. References to the Fund in this Statement of Additional Information may refer to actions undertaken by the Fund or USCEF. Unless otherwise indicated in the Prospectus or this Statement of Additional Information, the investment objective and policies of the Fund may be changed without shareholder approval.
FUND INVESTMENTS
The following list indicates the types of investments that the Fund (through USCEF) is generally permitted (but not required) to make. The Fund may, however, make other types of investments, provided the investments are consistent with the Fund’s investment objective and policies and the Fund’s investment restrictions do not expressly prohibit it from so doing.
Investors should note that, when used in this Statement of Additional Information, the term “invest” includes both direct investing and indirect investing and the term “investments” includes both direct investments and indirect investments. For instance, the Fund may invest indirectly or make indirect investments by investing in another investment company or in derivatives and synthetic instruments with economic characteristics similar to the underlying asset. Accordingly, the following list indicates the types of investments that the Fund (through USCEF) is directly or indirectly permitted to make.
  U.S. Equity Securities 1
 
  Foreign Investments—Foreign Issuers 2
 
  Foreign Investments—Foreign Issuers (Traded on U.S. Exchanges) 2
 
  Securities Lending
 
  Depositary Receipts
 
  Convertible Securities
 
  Preferred Stocks
 
  Warrants and Rights
 
  Options and Futures
 
  Swap Contracts and Other Two-Party Contracts
 
  Foreign Currency Transactions
  Repurchase Agreements
 
  Debt and Other Fixed Income Securities
 
  Debt and Other Fixed Income Securities—Long and Medium Term Corporate & Government Bonds 3
 
  Debt and Other Fixed Income Securities—Short-Term Corporate & Government Bonds 3
 
  Cash and Other High Quality Investments
 
  U.S. Government Securities and Foreign Government Securities
 
  Real Estate Investment Trusts and other Real Estate-Related Investments

2


 

  Reverse Repurchase Agreements and Dollar Roll Agreements
 
  Illiquid Securities, Private Placements, Restricted Securities, and IPOs and Other Limited Opportunities
 
  Investments in Other Investment Companies or Other Pooled Investments
 
  Investments in Other Investment Companies—Shares of Other GMO Trust Funds
Footnotes to Fund Investments List
     
1   For more information, see, among other sections, “Description of Principal Risks—Market Risk—Equity Securities Risk” in the Prospectus.
 
2   For more information, see, among other sections, “Descriptions and Risks of Fund Investments—Risks of Foreign Investments” herein.
 
3   For more information, see, among other sections, “Descriptions and Risks of Fund Investments—U.S. Government Securities and Foreign Government Securities” herein.
( Note : Some of the footnotes to the above list refer investors to various risks described in the “Description of Principal Risks” section of the Prospectus for more information relating to a particular type of investment listed in the charts. The presence of such a risk cross reference for a particular Fund investment is not intended to indicate that such risk is a principal risk of the Fund, and instead is intended to provide more information regarding the risks associated with the particular investment. Please refer to the “Fund Summary” and “Description of Principal Risks” sections of the Prospectus for a description of the Fund’s principal risks.)
DESCRIPTIONS AND RISKS OF FUND INVESTMENTS
The following is a description of investment practices in which the Fund (through USCEF) may engage and the risks associated with their use. Because the Fund invests substantially all of its assets in USCEF, the Fund is exposed to the investment practices of USCEF. USCEF, and therefore the Fund, is also indirectly exposed to the investment practices of the GMO Funds or other investment companies in which USCEF invests (the “underlying funds”), and USCEF and the Fund are therefore subject to all risks associated with the practices of the underlying funds. UNLESS OTHERWISE NOTED HEREIN, THE INVESTMENT PRACTICES AND ASSOCIATED RISKS DETAILED BELOW ALSO INCLUDE THOSE TO WHICH USCEF AND THE FUND MAY BE EXPOSED THROUGH USCEF’S INVESTMENT IN UNDERLYING FUNDS. ANY REFERENCES TO INVESTMENTS MADE BY THE FUND INCLUDE THOSE THAT MAY BE MADE BOTH DIRECTLY BY THE FUND AND USCEF, AND INDIRECTLY BY USCEF (E.G., THROUGH USCEF’S INVESTMENTS IN UNDERLYING FUNDS OR THROUGH INVESTMENTS IN DERIVATIVES OR SYNTHETIC INSTRUMENTS).
Portfolio Turnover
Based on the Manager’s assessment of market conditions, it may trade the Fund’s investments more frequently at some times than at others, resulting in a higher portfolio turnover rate. Increased portfolio turnover involves correspondingly greater brokerage commissions and other transaction costs, which will be borne directly by the Fund, and which may adversely affect the Fund’s performance. It also may give rise to additional taxable income for its shareholders, including through the realization of capital gains or other types of income that are taxable to Fund shareholders when distributed by the Fund to them, unless those shareholders are

3


 

themselves exempt from taxation or otherwise investing in the Fund through a tax-advantaged account. If portfolio turnover results in the recognition of short-term capital gains, those gains, when distributed to shareholders, typically are taxed to shareholders at ordinary income tax rates. The after-tax impact of portfolio turnover is not considered when making investment decisions for the Fund. See “Distributions and Taxes” in the Prospectus and “Distributions” and “Taxes” in this Statement of Additional Information for more information.
Diversified Portfolios
The Fund is a “diversified” fund required to satisfy the diversified fund requirements under the Investment Company Act of 1940, as amended (the “1940 Act”). At least 75% of the value of a diversified fund’s total assets must be represented by cash and cash items (including receivables), government securities, securities of other investment companies, and other securities that for the purposes of this calculation are limited in respect of any one issuer to not greater than 5% of the value of the fund’s total assets and not more than 10% of the outstanding voting securities of any single issuer.
The Fund also must meet diversification standards to qualify as a “regulated investment company” under the Internal Revenue Code of 1986, as amended (the “Code”). See “Taxes” below for a description of these diversification standards.
Accelerated Transactions
For the Fund to take advantage of certain available investment opportunities, the Manager may need to make investment decisions on an expedited basis. In such cases, the information available to the Manager at the time of an investment decision may be limited. The Manager may not, therefore, have access to the detailed information necessary for a full analysis and evaluation of the investment opportunity.
Risks of Foreign Investments
General. Investment in foreign issuers or securities principally traded outside the United States may involve special risks due to foreign economic, political, and legal developments, including favorable or unfavorable changes in currency exchange rates, exchange control regulations (including currency blockage), expropriation, nationalization or confiscatory taxation of assets, and possible difficulty in obtaining and enforcing judgments against foreign entities. The Fund may be subject to foreign taxation on realized capital gains, dividends or interest payable on foreign securities, on transactions in those securities and on the repatriation of proceeds generated from those securities. Transaction-based charges are generally calculated as a percentage of the transaction amount and are paid upon the sale or transfer of portfolio securities subject to such taxes. Any taxes or other charges paid or incurred by the Fund in respect of its foreign securities will reduce its yield. See “Taxes” below for more information about these and other special tax considerations applicable to investments in securities of foreign issuers and securities principally traded outside the United States.
In addition, the tax laws of some foreign jurisdictions in which the Fund may invest are unclear and interpretations of such laws can change over time. As a result, in order to comply with guidance related to the accounting and disclosure of uncertain tax positions under U.S. generally

4


 

accepted accounting principles (“GAAP”), the Fund may be required to accrue for book purposes certain foreign taxes in respect of its foreign securities or other foreign investments that it may or may not ultimately pay. Such tax accruals will reduce the Fund’s net asset value at the time accrued, even though, in some cases, the Fund ultimately will not pay the related tax liabilities. Conversely, the Fund’s net asset value will be increased by any tax accruals that are ultimately reversed.
Issuers of foreign securities are subject to different, often less comprehensive, accounting, custody, reporting, and disclosure requirements than U.S. issuers. The securities of some foreign governments, companies, and securities markets are less liquid, and at times more volatile, than comparable U.S. securities and securities markets. Foreign brokerage commissions and related fees also are generally higher than in the United States. The Fund also may be affected by different custody and/or settlement practices or delayed settlements in some foreign markets. The laws of some foreign countries may limit the Fund’s ability to invest in securities of certain issuers located in those countries.
Foreign countries may have reporting requirements with respect to the ownership of securities, and those reporting requirements may be subject to interpretation or change without prior notice to investors. While the Fund makes reasonable efforts to stay informed of foreign reporting requirements relating to the Fund’s foreign portfolio securities ( e.g. , through the Fund’s brokerage contacts, publications of the Investment Company Institute, which is the national association of U.S. investment companies, the Fund’s custodial network, and, to the extent deemed appropriate by the Fund under the circumstances, local counsel in the relevant foreign country), no assurance can be given that the Fund will satisfy applicable foreign reporting requirements at all times.
Securities Lending
The Fund may make secured loans of its portfolio securities amounting to not more than one-third of its total assets. For these purposes, total assets include the proceeds of such loans. The risks in lending portfolio securities, as with other extensions of credit, consist of possible delay in recovery of the securities or possible loss of rights in the collateral should the borrower fail financially, including possible impairment of the Fund’s ability to vote the securities. However, securities loans will be made to broker-dealers that the Manager believes to be of relatively high credit standing pursuant to agreements requiring that the loans be collateralized by cash, liquid securities, or shares of other investment companies with a value at least equal to the market value of the loaned securities (marked to market daily). If a loan is collateralized by U.S. government or other securities, the Fund receives a fee from the borrower. If a loan is collateralized by cash, the Fund typically invests the cash collateral for its own account in one or more money market funds (in which case the Fund will bear its pro rata share of such money market fund’s fees and expenses), or directly in interest-bearing, short-term securities, and typically pays a fee to the borrower that normally represents a portion of the Fund’s earnings on the collateral. As with other extensions of credit, the Fund bears the risk of delay in the recovery of loaned securities and of loss of rights in the collateral should the borrower fail financially. The Fund also bears the risk that the value of investments made with collateral may decline. The Fund bears the risk of total loss with respect to the investment of collateral.

5


 

Voting rights or rights to consent with respect to the loaned securities pass to the borrower. The Fund has the right to call loans at any time on reasonable notice and will do so if both (i) the Manager receives adequate notice of a proposal upon which shareholders are being asked to vote, and (ii) the Manager believes that the benefits to the Fund of voting on such proposal outweigh the benefits to the Fund of having the security remain out on loan. However, the Fund bears the risk of delay in the return of the security, impairing the Fund’s ability to vote on such matters. The Manager has retained lending agents on behalf of the Fund that are compensated based on a percentage of the Fund’s return on its securities lending. The Fund may also pay various fees in connection with securities loans, including shipping fees and custodian fees.
Depositary Receipts
The Fund may invest in American Depositary Receipts (“ADRs”), Global Depositary Receipts (“GDRs”), and European Depositary Receipts (“EDRs”) or other similar securities representing ownership of foreign securities (collectively, “Depositary Receipts”) if issues of such Depositary Receipts are available that are consistent with the Fund’s investment objective. Depositary Receipts generally evidence an ownership interest in a corresponding foreign security on deposit with a financial institution. Transactions in Depositary Receipts usually do not settle in the same currency as the underlying foreign securities are denominated or traded. Generally, ADRs are designed for use in the U.S. securities markets and EDRs are designed for use in European securities markets. GDRs may be traded in any public or private securities market and may represent securities held by institutions located anywhere in the world. GDRs and other types of Depositary Receipts are typically issued by foreign banks or trust companies, although they may be issued by U.S. financial institutions, and evidence ownership interests in a security or pool of securities issued by either a foreign or a domestic corporation.
Because the value of a Depositary Receipt is dependent upon the market price of an underlying foreign security, Depositary Receipts are subject to most of the risks associated with investing in foreign securities directly. Depositary Receipts may be issued as sponsored or unsponsored programs. See “Descriptions and Risks of Fund Investments—Risks of Foreign Investments.” Depositary Receipts also may be subject to liquidity risk.
Convertible Securities
A convertible security is a security (a bond or preferred stock) that may be converted at a stated price within a specified period into a specified number of shares of common stock of the same or a different issuer. Convertible securities are senior to common stock in a corporation’s capital structure, but are usually subordinated to senior debt obligations of the issuer. Convertible securities provide holders, through their conversion feature, an opportunity to participate in increases in the market price of their underlying securities. The price of a convertible security is influenced by the market price of the underlying security, and tends to increase as the market price rises and decrease as the market price declines. The Manager regards convertible securities as a form of equity security.
The value of a convertible security is a function of its “investment value” (determined by its yield in comparison with the yields of other securities of comparable maturity and quality that do not have a conversion privilege) and its “conversion value” (the security’s worth, at market

6


 

value, if converted into the underlying common stock). The investment value of a convertible security is influenced by changes in interest rates, with investment value declining as interest rates increase and increasing as interest rates decline. The credit standing of the issuer and other factors may also have an effect on the convertible security’s investment value. The conversion value of a convertible security is determined by the market price of the underlying common stock. If the conversion value is low relative to the investment value, as in the case of “broken” or “busted” convertibles, the price of the convertible security is governed principally by its investment value. To the extent the market price of the underlying common stock approaches or exceeds the conversion price, the price of the convertible security will be increasingly influenced by its conversion value. A convertible security generally will sell at a premium over its conversion value by the extent to which investors place value on the right to acquire the underlying common stock while holding a fixed income security. Generally, the amount of the premium decreases as the convertible security approaches maturity.
A convertible security may be subject to redemption at the option of the issuer at a price established in the convertible security’s governing instrument. If a convertible security held by the Fund is called for redemption, the Fund will be required to permit the issuer to redeem the security, convert it into the underlying common stock or sell it to a third-party.
Preferred Stocks
Preferred stocks include convertible and non-convertible preferred and preference stocks that are senior to common stock. Preferred stocks are equity securities that are senior to common stock with respect to the right to receive dividends and a fixed share of the proceeds resulting from the issuer’s liquidation. Some preferred stocks also entitle their holders to receive additional liquidation proceeds on the same basis as holders of the issuer’s common stock, and thus represent an ownership interest in the issuer. Depending on the features of the particular security, holders of preferred stock may bear the risks disclosed in the Prospectus or this Statement of Additional Information regarding equity or fixed income securities.
Investment in preferred stocks involves certain risks. Certain preferred stocks contain provisions that allow an issuer under certain conditions to skip or defer distributions. If the Fund owns a preferred stock that is deferring its distribution, it may be required to report income for tax purposes despite the fact that it is not receiving current income on this position. Preferred stocks often are subject to legal provisions that allow for redemption in the event of certain tax or legal changes or at the issuer’s call. In the event of redemption, the Fund may not be able to reinvest the proceeds at comparable rates of return. Preferred stocks are subordinated to bonds and other debt securities in an issuer’s capital structure in terms of priority for corporate income and liquidation payments, and therefore will be subject to greater credit risk than those debt securities. Preferred stocks may trade less frequently and in a more limited volume and may be subject to more abrupt or erratic price movements than many other securities, such as common stocks, corporate debt securities and U.S. government securities.
Warrants and Rights
The Fund may purchase or otherwise receive warrants or rights. Warrants and rights generally give the holder the right to receive, upon exercise, a security of the issuer at a stated price. The

7


 

Fund typically uses warrants and rights in a manner similar to its use of options on securities, as described in “Options and Futures” below. Risks associated with the use of warrants and rights are generally similar to risks associated with the use of options. Unlike most options, however, warrants and rights are issued in specific amounts, and warrants generally have longer terms than options. Warrants and rights are not likely to be as liquid as exchange-traded options backed by a recognized clearing agency. In addition, the terms of warrants or rights may limit the Fund’s ability to exercise the warrants or rights at such time, or in such quantities, as the Fund would otherwise wish.
Options and Futures
The Fund uses options and futures for various purposes, including for investment purposes and as a means to hedge other investments. (See “Uses of Derivatives” below for more information regarding the various derivatives strategies the Fund may employ using options and futures.) The use of options contracts, futures contracts, and options on futures contracts involves risk. Thus, while the Fund may benefit from the use of options, futures, and options on futures, unanticipated changes in interest rates, securities prices, currency exchange rates, or other underlying assets or reference rates may adversely affect the Fund’s performance.
Options on Securities and Indices. The Fund may purchase and sell put and call options on equity, fixed income or other securities or indices in standardized exchange-traded contracts. An option on a security or index is a contract that gives the holder of the option, in return for a premium, the right (but not the obligation) to buy from (in the case of a call) or sell to (in the case of a put) the writer of the option the security underlying the option (or the cash value of the index underlying the option) at a specified price. Upon exercise, the writer of an option on a security has the obligation to deliver the underlying security upon payment of the exercise price or to pay the exercise price upon delivery of the underlying security. Upon exercise, the writer of an option on an index is required to pay the difference between the cash value of the index and the exercise price multiplied by the specified multiplier for the index option.
Purchasing Options on Securities and Indices. Among other reasons, the Fund may purchase a put option to hedge against a decline in the value of a portfolio security. If such a decline occurs, the put option will permit the Fund to sell the security at the higher exercise price or to close out the option at a profit. By using put options in this manner, the Fund will reduce any profit it might otherwise have realized in the underlying security by the amount of the premium paid for the put option and by its transaction costs. In order for a put option purchased by the Fund to be profitable, the market price of the underlying security must decline sufficiently below the exercise price to cover the premium paid by the Fund and transaction costs.
Among other reasons, the Fund may purchase call options to hedge against an increase in the price of securities the Fund anticipates purchasing in the future. If such a price increase occurs, a call option will permit the Fund to purchase the securities at the exercise price or to close out the option at a profit. The premium paid for the call option, plus any transaction costs, will reduce the benefit, if any, that the Fund realizes upon exercise of the option and, unless the price of the underlying security rises sufficiently, the option may expire worthless to the Fund. Thus, for a call option purchased by the Fund to be profitable, the market price of the underlying security

8


 

must rise sufficiently above the exercise price to cover the premium paid by the Fund to the writer and transaction costs.
In the case of both call and put options, the purchaser of an option risks losing the premium paid for the option plus related transaction costs if the option expires worthless.
Writing Options on Securities and Indices. Because the Fund receives a premium for writing a put or call option, the Fund may seek to increase its return by writing call or put options on securities or indices. The premium the Fund receives for writing an option will increase the Fund’s return in the event the option expires unexercised or is closed out at a profit. The size of the premium the Fund receives reflects, among other things, the relationship of the market price and volatility of the underlying security or index to the exercise price of the option, the remaining term of the option, supply and demand, and interest rates.
The Fund may write a call option on a security or other instrument held by the Fund (commonly known as “writing a covered call option”). In such case, the Fund limits its opportunity to profit from an increase in the market price of the underlying security above the exercise price of the option. Alternatively, the Fund may write a call option on securities in which it may invest but that are not currently held by the Fund (commonly known as “writing a naked call option”). During periods of declining securities prices or when prices are stable, writing these types of call options can be a profitable strategy to increase the Fund’s income with minimal capital risk. However, when securities prices increase, the Fund is exposed to an increased risk of loss, because if the price of the underlying security or instrument exceeds the option’s exercise price, the Fund will suffer a loss equal to the amount by which the market price exceeds the exercise price at the time the call option is exercised, minus the premium received. Calls written on securities that the Fund does not own are riskier than calls written on securities owned by the Fund because there is no underlying security held by the Fund that can act as a partial hedge. When such a call is exercised, the Fund must purchase the underlying security to meet its call obligation or make a payment equal to the value of its obligation in order to close out the option. Calls written on securities that the Fund does not own have speculative characteristics and the potential for loss is unlimited. There is also a risk, especially with less liquid preferred and debt securities, that the securities may not be available for purchase.
The Fund also may write a put option on a security. In so doing, the Fund assumes the risk that it may be required to purchase the underlying security for an exercise price higher than its then-current market price, resulting in a loss on exercise equal to the amount by which the market price of the security is below the exercise price minus the premium received.
OTC Options . The Fund may also invest in over-the-counter (“OTC”) options. OTC options differ from exchange-traded options in that they are two-party contracts, with price and other terms negotiated between the buyer and seller, and generally do not have as much market liquidity as exchange-traded options.
Closing Options Transactions . The holder of an option may terminate its position in a put or call option it has purchased by allowing it to expire or by exercising the option. If an option is

9


 

American style, it may be exercised on any day up to its expiration date. In contrast, a European style option may be exercised only on its expiration date.
In addition, a holder of an option may terminate its obligation prior to the option’s expiration by effecting an offsetting closing transaction. In the case of exchange-traded options, the Fund, as a holder of an option, may effect an offsetting closing sale transaction by selling an option of the same series as the option previously purchased. The Fund realizes a loss from a closing sale transaction if the premium received from the sale of the option is less than the premium paid to purchase the option (plus transaction costs). Similarly, if the Fund has written an option, it may effect an offsetting closing purchase transaction by buying an option of the same series as the option previously written. The Fund realizes a loss from a closing purchase transaction if the cost of the closing purchase transaction (option premium plus transaction costs) is greater than the premium received from writing the option. If the Fund desires to sell a security on which it has written a call option, it will effect a closing purchase prior to or concurrently with the sale of the security. There can be no assurance, however, that a closing purchase or sale can be effected when the Fund desires to do so.
An OTC option may be closed only with the counterparty, although either party may engage in an offsetting transaction that puts that party in the same economic position as if it had closed out the option with the counterparty.
No guarantee exists that the Fund will be able to effect a closing purchase or a closing sale with respect to a specific option at any particular time.
Risk Factors in Options Transactions. There are various risks associated with transactions in exchange-traded and OTC options. The value of options written by the Fund will be affected by many factors, including changes in the value of underlying securities or indices, changes in the dividend rates of underlying securities (or in the case of indices, the securities comprising such indices), changes in interest rates, changes in the actual or perceived volatility of the stock market and underlying securities, and the remaining time to an option’s expiration. The value of an option also may be adversely affected if the market for the option is reduced or becomes less liquid. In addition, since an American style option allows the holder to exercise its rights any time prior to expiration of the option, the writer of an American style option has no control over the time when it may be required to fulfill its obligations as a writer of the option. This risk is not present when writing a European style option since the holder may only exercise the option on its expiration date.
The Fund’s ability to use options as part of its investment programs depends on the liquidity of the markets in those instruments. In addition, there can be no assurance that a liquid market will exist when the Fund seeks to close out an option position. If the Fund were unable to close out an option that it had purchased on a security, it would have to exercise the option in order to realize any profit or the option may expire worthless. As the writer of a call option on a portfolio security, during the option’s life, the Fund foregoes the opportunity to profit from increases in the market value of the security underlying the call option above the sum of the premium and the strike price of the call, but retains the risk of loss (net of premiums received) should the price of the underlying security decline. Similarly, as the writer of a call option on a securities index, the

10


 

Fund foregoes the opportunity to profit from increases in the index over the strike price of the option, though it retains the risk of loss (net of premiums received) should the price of the Fund’s portfolio securities decline. If the Fund writes a call option and does not hold the underlying security or instrument, the amount of the Fund’s potential loss is theoretically unlimited.
An exchange-traded option may be closed out by means of an offsetting transaction only on a national securities exchange (“Exchange”), which provides a secondary market for an option of the same series. If a liquid secondary market for an exchange-traded option does not exist, the Fund might not be able to effect an offsetting closing transaction for a particular option. Reasons for the absence of a liquid secondary market on an Exchange include the following: (i) insufficient trading interest in some options; (ii) restrictions by an Exchange on opening or closing transactions, or both; (iii) trading halts, suspensions, or other restrictions on particular classes or series of options or underlying securities; (iv) unusual or unforeseen interruptions in normal operations on an Exchange; (v) inability to handle current trading volume; or (vi) discontinuance of options trading (or trading in a particular class or series of options) (although outstanding options on an Exchange that were issued by the Options Clearing Corporation should continue to be exercisable in accordance with their terms). In addition, the hours of trading for options on an Exchange may not conform to the hours during which the securities held by the Fund are traded. To the extent that the options markets close before the markets for the underlying securities, significant price and rate movements can take place in the underlying markets that may not be reflected in the options markets.
The Exchanges generally have established limits on the maximum number of options an investor or group of investors acting in concert may write. The Fund, the Manager, and other clients of the Manager may constitute such a group. These limits could restrict the Fund’s ability to purchase or sell options on a particular security.
An OTC option may be closed only with the counterparty, although either party may engage in an offsetting transaction that puts that party in the same economic position as if it had closed out the option with the counterparty; however, the exposure to counterparty risk may differ. See “Swap Contracts and Other Two-Party Contracts—Risk Factors in Swap Contracts, OTC Options, and Other Two-Party Contracts” below for a discussion of counterparty risk and other risks associated with investing in OTC options.
The Fund’s ability to engage in options transactions may be limited by tax considerations.
Currency Options. The Fund may purchase and sell options on currencies. Options on currencies possess many of the same characteristics as options on securities and generally operate in a similar manner.
Futures. To the extent consistent with applicable law and its investment restrictions, the Fund may invest in futures contracts on, among other things, financial instruments (such as a U.S. government security or other fixed income security), individual equity securities (“single stock futures”), securities indices, interest rates, and currencies. Futures contracts on securities indices are referred to herein as “Index Futures.” The purchase of futures contracts can serve as a long

11


 

hedge, and the sale of futures contracts can serve as a limited short hedge. The purchase and sale of futures contracts also may be used for speculative purposes.
Certain futures contracts are physically settled (i.e. , involve the making and taking of delivery of a specified amount of an underlying security or other asset). For instance, the sale of futures contracts on foreign currencies or financial instruments creates an obligation of the seller to deliver a specified quantity of an underlying foreign currency or financial instrument called for in the contract for a stated price at a specified time. Conversely, the purchase of such futures contracts creates an obligation of the purchaser to pay for and take delivery of the underlying foreign currency or financial instrument called for in the contract for a stated price at a specified time. In some cases, the specific instruments delivered or taken, respectively, on the settlement date are not determined until on or near that date. That determination is made in accordance with the rules of the exchange on which the sale or purchase was made. Some futures contracts are cash settled (rather than physically settled), which means that the purchase price is subtracted from the current market value of the instrument and the net amount, if positive, is paid to the purchaser by the seller of the futures contract and, if negative, is paid by the purchaser to the seller of the futures contract. In particular, Index Futures are agreements pursuant to which two parties agree to take or make delivery of an amount of cash equal to the difference between the value of a securities index at the close of the last trading day of the contract and the price at which the index contract was originally written. Although the value of a securities index might be a function of the value of certain specified securities, no physical delivery of these securities is made.
The purchase or sale of a futures contract differs from the purchase or sale of a security or option in that no price or premium is paid or received. Instead, an amount of cash, U.S. government securities, or other liquid assets equal in value to a percentage of the face amount of the futures contract must be deposited with the broker. This amount is known as initial margin. The amount of the initial margin is generally set by the market on which the contract is traded (margin requirements on foreign exchanges may be different than those on U.S. exchanges). Subsequent payments to and from the broker, known as variation margin, are made on a daily basis as the price of the underlying futures contract fluctuates, making the long and short positions in the futures contract more or less valuable, a process known as “marking to the market.” For futures contracts which are cash settled, the Fund may designate or segregate liquid assets in an amount equal to the Fund’s daily marked-to-market value of such contract. Prior to the settlement date of the futures contract, the position may be closed by taking an opposite position. A final determination of variation margin is then made, additional cash is required to be paid to or released by the broker, and the purchaser realizes a loss or gain. In addition, a commission is paid to the broker on each completed purchase and sale.
Although some futures contracts call for making or taking delivery of the underlying securities, currencies or other underlying instrument, in most cases, futures contracts are closed before the settlement date without the making or taking of delivery by offsetting purchases or sales of matching futures contracts (i.e., with the same exchange, underlying financial instrument, currency, or index, and delivery month). If the price of the initial sale exceeds the price of the offsetting purchase, the seller is paid the difference and realizes a gain. Conversely, if the price of the offsetting purchase exceeds the price of the initial sale, the seller realizes a loss. Similarly,

12


 

a purchase of a futures contract is closed out by selling a corresponding futures contract. If the offsetting sale price exceeds the original purchase price, the purchaser realizes a gain, and, if the original purchase price exceeds the offsetting sale price, the purchaser realizes a loss. Any transaction costs must also be included in these calculations.
In the United States, futures contracts are traded only on commodity exchanges or boards of trade — known as “contract markets” — approved by the Commodity Futures Trading Commission (“CFTC”), and must be executed through a futures commission merchant or brokerage firm that is a member of the relevant market. The Fund may also purchase futures contracts on foreign exchanges or similar entities, which are not regulated by the CFTC and may not be subject to the same degree of regulation as the U.S. contract markets. (See “Additional Risks of Options on Securities, Futures Contracts, and Options on Futures Contracts Traded on Foreign Exchanges” below.)
Index Futures. The Fund’s purchase and sale of Index Futures is limited to contracts and exchanges approved by the CFTC. The Fund may close open positions on an exchange on which Index Futures are traded at any time up to and including the expiration day. In general, all positions that remain open at the close of business on that day must be settled on the next business day (based on the value of the relevant index on the expiration day). Additional or different margin requirements as well as settlement procedures may apply to foreign stock Index Futures.
Interest Rate Futures. The Fund may engage in transactions involving the use of futures on interest rates. These transactions may be in connection with investments in U.S. government securities and other fixed income securities.
Currency Futures. The Fund may buy and sell futures contracts on currencies.
Options on Futures Contracts. Options on futures contracts give the purchaser the right in return for the premium paid to assume a long position (in the case of a call option) or a short position (in the case of a put option) in a futures contract at the option exercise price at any time during the period of the option (in the case of an American style option) or on the expiration date (in the case of European style option). Upon exercise of a call option, the holder acquires a long position in the futures contract and the writer is assigned the opposite short position. In the case of a put option, the holder acquires a short position and the writer is assigned the opposite long position in the futures contract. Accordingly, in the event that an option is exercised, the parties will be subject to all the risks associated with the trading of futures contracts, such as payment of initial and variation margin deposits.
The Fund may use options on futures contracts in lieu of writing or buying options directly on the underlying securities or purchasing and selling the underlying futures contracts. For example, to hedge against a possible decrease in the value of its portfolio securities, the Fund may purchase put options or write call options on futures contracts rather than selling futures contracts. Similarly, the Fund may hedge against a possible increase in the price of securities the Fund expects to purchase by purchasing call options or writing put options on futures contracts rather than purchasing futures contracts. In addition, the Fund may purchase and sell interest

13


 

rate options on U.S. Treasury or Eurodollar futures to take a long or short position on interest rate fluctuations. Options on futures contracts generally operate in the same manner as options purchased or written directly on the underlying investments.
The Fund also is required to deposit and maintain margin with respect to put and call options on futures contracts written by it. Such margin deposits may vary depending on the nature of the underlying futures contract (and the related initial margin requirements), the current market value of the option, and other futures positions held by the Fund.
A position in an option on a futures contract may be terminated by the purchaser or seller prior to expiration by effecting a closing purchase or sale transaction, subject to the availability of a liquid secondary market, which is the purchase or sale of an option of the same type (i.e., the same exercise price and expiration date) as the option previously purchased or sold. The difference between the premiums paid and received represents the Fund’s profit or loss on the transaction.
Risk Factors in Futures and Futures Options Transactions . Investment in futures contracts involves risk. A purchase or sale of futures contracts may result in losses in excess of the amount invested in the futures contract. If a futures contract is used for hedging, an imperfect correlation between movements in the price of the futures contract and the price of the security, currency, or other investment being hedged creates risk. Correlation is higher when the investment being hedged underlies the futures contract. Correlation is lower when the investment being hedged is different than the security, currency, or other investment underlying the futures contract, such as when a futures contract on an index of securities is used to hedge a single security, a futures contract on one security (e.g., U.S. Treasury bonds) is used to hedge a different security, or when a futures contract in one currency is used to hedge a security denominated in another currency. In the case of Index Futures and futures on commodity indices, changes in the price of those futures contracts may not correlate perfectly with price movements in the relevant index due to market distortions. In the event of an imperfect correlation between a futures position and the portfolio position (or anticipated position) intended to be hedged, the Fund may realize a loss on the futures contract at the same time the Fund is realizing a loss on the portfolio position intended to be hedged. To compensate for imperfect correlations, the Fund may purchase or sell futures contracts in a greater amount than the hedged investments if the volatility of the price of the hedged investments is historically greater than the volatility of the futures contracts. Conversely, the Fund may purchase or sell fewer futures contracts if the volatility of the price of the hedged investments is historically less than that of the futures contract. The successful use of transactions in futures and related options for hedging also depends on the direction and extent of exchange rate, interest rate and asset price movements within a given time frame. For example, to the extent equity prices remain stable during the period in which a futures contract or option is held by the Fund investing in equity securities (or such prices move in a direction opposite to that anticipated), the Fund may realize a loss on the futures transaction, which is not fully or partially offset by an increase in the value of its portfolio securities. As a result, the Fund’s total return for such period may be less than if it had not engaged in the hedging transaction.

14


 

All participants in the futures market are subject to margin deposit and maintenance requirements. Instead of meeting margin calls, investors may close futures contracts through offsetting transactions, which could distort normal correlations. The margin deposit requirements in the futures market are less onerous than margin requirements in the securities market, allowing for more speculators who may cause temporary price distortions. Trading hours for foreign stock Index Futures may not correspond perfectly to the trading hours of the foreign exchange to which a particular foreign stock Index Future relates. As a result, the lack of continuous arbitrage may cause a disparity between the price of foreign stock Index Futures and the value of the relevant index.
The Fund may purchase futures contracts (or options on them) as an anticipatory hedge against a possible increase in the price of a currency in which securities the Fund anticipates purchasing is denominated. In such instances, the currency may instead decline. If the Fund does not then invest in those securities, the Fund may realize a loss on the futures contract that is not offset by a reduction in the price of the securities purchased.
The Fund’s ability to engage in the futures and options on futures strategies described above depends on the liquidity of the markets in those instruments. Trading interest in various types of futures and options on futures cannot be predicted. Therefore, no assurance can be given that the Fund will be able to utilize these instruments at all or that their use will be effective. In addition, there can be no assurance that a liquid market will exist at a time when the Fund seeks to close out a futures or option on a futures contract position, and that Fund would remain obligated to meet margin requirements until the position is closed. The liquidity of a secondary market in a futures contract may be adversely affected by “daily price fluctuation limits” established by commodity exchanges to limit the amount of fluctuation in a futures contract price during a single trading day. Once the daily limit has been reached, no trades of the contract may be entered at a price beyond the limit, thus preventing the liquidation of open futures positions. In the past, prices have exceeded the daily limit on several consecutive trading days. Short (and long) positions in Index Futures may be closed only by purchasing (or selling) a futures contract on the exchange on which the Index Futures are traded.
As discussed above, if the Fund purchases or sells a futures contract, it is only required to deposit initial and variation margin as required by relevant CFTC regulations and the rules of the contract market. The Fund’s net asset value will generally fluctuate with the value of the security or other instrument underlying a futures contract as if it were already in the Fund’s portfolio. Futures transactions can have the effect of investment leverage. Furthermore, if the Fund combines short and long positions, in addition to possible declines in the values of its investment securities, the Fund will incur losses if the index underlying the long futures position underperforms the index underlying the short futures position.
In addition, if the Fund’s futures brokers become bankrupt or insolvent, or otherwise default on their obligations to the Fund, the Fund may not receive all amounts owing to it in respect of its trading, despite the futures clearinghouse fully discharging all of its obligations. Furthermore, in the event of the bankruptcy of a futures broker, the Fund could be limited to recovering only a pro rata share of all available funds segregated on behalf of the futures broker’s combined customer accounts, even though certain property specifically traceable to the Fund was held by

15


 

the futures broker.
The Fund’s ability to engage in futures and options on futures transactions may be limited by tax considerations.
Additional Risks of Options on Securities, Futures Contracts, and Options on Futures Contracts Traded on Foreign Exchanges. Options on securities, futures contracts, options on futures contracts, and options on currencies may be traded on foreign exchanges. Such transactions may not be regulated as effectively as similar transactions in the United States (which are regulated by the CFTC) and may be subject to greater risks than trading on domestic exchanges. For example, some foreign exchanges may be principal markets so that no common clearing facility exists and a trader may look only to the broker for performance of the contract. The lack of a common clearing facility creates counterparty risk. If a counterparty defaults, the Fund normally will have contractual remedies against that counterparty, but may be unsuccessful in enforcing those remedies. When seeking to enforce a contractual remedy, the Fund also is subject to the risk that the parties may interpret contractual terms (e.g., the definition of default) differently. Counterparty risk is greater for derivatives with longer maturities where events may intervene to prevent settlement. Counterparty risk is also greater when the Fund has concentrated its derivatives with a single or small group of counterparties as it sometimes does as a result of its use of swaps and other OTC derivatives. To the extent the Fund has significant exposure to a single counterparty, this risk will be particularly pronounced for the Fund. If a dispute occurs, the cost and unpredictability of the legal proceedings required for the Fund to enforce its contractual rights may lead the Fund to decide not to pursue its claims against the counterparty. The Fund thus assumes the risk that it may be unable to obtain payments owed under foreign futures contracts or that those payments may be delayed or made only after the Fund has incurred the costs of litigation. In addition, unless the Fund hedges against fluctuations in the exchange rate between the currencies in which trading is done on foreign exchanges and other currencies, any profits that the Fund might realize in trading could be offset (or worse) by adverse changes in the exchange rate. The value of foreign options and futures may also be adversely affected by other factors unique to foreign investing (see “Risks of Foreign Investments” above).
Swap Contracts and Other Two-Party Contracts
The Fund uses swap contracts (or “swaps”) and other two-party contracts for the same or similar purposes as options and futures. (See “Uses of Derivatives” below for more information regarding the various derivatives strategies the Fund may employ using swap contracts and other two-party contracts.)
Swap Contracts. The Fund may directly or indirectly use various different types of swaps, such as swaps on securities and securities indices, total return swaps, interest rate swaps, currency swaps, credit default swaps, variance swaps, inflation swaps, and other types of available swap agreements. Swap contracts are two-party contracts entered into primarily by institutional investors for periods ranging from a few weeks to a number of years. Under a typical swap, one party may agree to pay a fixed rate or a floating rate determined by reference to a specified instrument, rate, or index, multiplied in each case by a specified amount (“notional amount”),

16


 

while the other party agrees to pay an amount equal to a different floating rate multiplied by the same notional amount. On each payment date, the parties’ obligations are netted, with only the net amount paid by one party to the other.
Swap contracts are typically individually negotiated and structured to provide exposure to a variety of different types of investments or market factors. Swap contracts may be entered into for hedging or non-hedging purposes and therefore may increase or decrease the Fund’s exposure to the underlying instrument, rate, asset or index. Swaps can take many different forms and are known by a variety of names. The Fund is not limited to any particular form or variety of swap agreement if the Manager determines it is consistent with the Fund’s investment objective and policies.
The Fund may enter into swaps on securities, baskets of securities or securities indices. For example, the parties to a swap contract may agree to exchange returns calculated on a notional amount of a security, basket of securities, or securities index (e.g., S&P 500 Index). Additionally, the Fund may use total return swaps, which typically involve commitments to pay amounts computed in the same manner as interest in exchange for a market-linked return, both based on notional amounts. The Fund may use such swaps to gain investment exposure to the underlying security or securities where direct ownership is either not legally possible or is economically unattractive. To the extent the total return of the security, basket of securities, or index underlying the transaction exceeds or falls short of the offsetting interest rate obligation, the Fund will receive a payment from or make a payment to the counterparty, respectively.
In addition, the Fund may enter into an interest rate swap in order to protect against declines in the value of fixed income securities held by the Fund. In such an instance, the Fund may agree with a counterparty to pay a fixed rate (multiplied by a notional amount) and the counterparty pay a floating rate multiplied by the same notional amount. If interest rates rise, resulting in a diminution in the value of the Fund’s portfolio, the Fund would receive payments under the swap that would offset, in whole or in part, such diminution in value. The Fund may also enter into swaps to modify its exposure to particular currencies using currency swaps. For instance, the Fund may enter into a currency swap between the U.S. dollar and the Japanese Yen in order to increase or decrease its exposure to each such currency.
The Fund may use inflation swaps, which involve commitments to pay a regular stream of inflation indexed cash payments in exchange for receiving a stream of nominal interest payments (or vice versa), where both payment streams are based on a notional amount. The nominal interest payments may be based on either a fixed interest rate or variable interest rate, such as LIBOR. Inflation swaps may be used to hedge the inflation risk in nominal bonds (i.e., non-inflation indexed bonds), thereby creating synthetic inflation indexed bonds, or combined with U.S. Treasury futures contracts to create synthetic inflation indexed bonds issued by the U.S. Treasury.
In addition, the Fund may directly or indirectly use credit default swaps to take an active long or short position with respect to the likelihood of default by a corporate or sovereign issuer of fixed income securities (including asset-backed securities). In a credit default swap, one party pays, in effect, an insurance premium through a stream of payments to another party in exchange for the

17


 

right to receive a specified return in the event of default (or similar events) by one or more third parties on their obligations. For example, in purchasing a credit default swap, the Fund may pay a premium in return for the right to put specified bonds or loans to the counterparty, such as a U.S. or foreign issuer or basket of such issuers, upon issuer default (or similar events) at their par (or other agreed-upon) value. The Fund, as the purchaser in a credit default swap, bears the risk that the investment might expire worthless. It also would be subject to counterparty risk — the risk that the counterparty may fail to satisfy its payment obligations to the Fund in the event of a default (or similar event) (see “Risk Factors in Swap Contracts, OTC Options, and Other Two-Party Contracts” below). In addition, as a purchaser in a credit default swap, the Fund’s investment would only generate income in the event of an actual default (or similar event) by the issuer of the underlying obligation. The Fund may also invest in credit default indices, which are indices that reflect the performance of a basket of credit default swaps.
The Fund also may use credit default swaps for investment purposes by selling a credit default swap, in which case the Fund will receive a premium from its counterparty in return for the Fund’s taking on the obligation to pay the par (or other agreed-upon) value to the counterparty upon issuer default (or similar events). As the seller in a credit default swap, the Fund effectively adds economic leverage to its portfolio because, in addition to its total net assets, the Fund is subject to investment exposure on the notional amount of the swap. If no event of default (or similar event) occurs, the Fund would keep the premium received from the counterparty and would have no payment obligations. For credit default swap agreements on asset-backed securities, an event of default may result from various events, which may include an issuer’s failure to pay interest or principal, a breach of a material representation or covenant, an agreement by the holders of an asset-backed security to a maturity extension, or a write-down on the collateral underlying the security. For credit default swap agreements on corporate or sovereign issuers, an event of default may result from such events as the issuer’s bankruptcy, failure to pay interest or principal, repudiation/moratorium or restructuring.
The Fund may use variance swap agreements, which involve an agreement by two parties to exchange cash flows based on the measured variance (or square of volatility) of a specified underlying asset. One party agrees to exchange a “fixed rate” or strike price payment for the “floating rate” or realized price variance on the underlying asset with respect to the notional amount. At inception, the strike price chosen is generally fixed at a level such that the fair value of the swap is zero. As a result, no money changes hands at the initiation of the contract. At the expiration date, the amount paid by one party to the other is the difference between the realized price variance of the underlying asset and the strike price multiplied by the notional amount. A receiver of the realized price variance would receive a payment when the realized price variance of the underlying asset is greater than the strike price and would make a payment when that variance is less than the strike price. A payer of the realized price variance would make a payment when the realized price variance of the underlying asset is greater than the strike price and would receive a payment when that variance is less than the strike price. This type of agreement is essentially a forward contract on the future realized price variance of the underlying asset.
Contracts for Differences. Contracts for differences are swap arrangements in which the parties agree that their return (or loss) will be based on the relative performance of two different groups

18


 

or baskets of securities. Often, one or both baskets will be an established securities index. The Fund’s return will be based on changes in value of theoretical long futures positions in the securities comprising one basket (with an aggregate face value equal to the notional amount of the contract for differences) and theoretical short futures positions in the securities comprising the other basket. The Fund also may use actual long and short futures positions and achieve similar market exposure by netting the payment obligations of the two contracts. The Fund will only enter into contracts for differences (and analogous futures positions) when the Manager believes that the basket of securities constituting the long position will outperform the basket constituting the short position. If the short basket outperforms the long basket, the Fund will realize a loss — even in circumstances when the securities in both the long and short baskets appreciate in value.
Interest Rate Caps, Floors, and Collars. The Fund uses interest rate caps, floors, and collars for the same or similar purposes as it uses interest rate futures contracts and related options and, as a result, will be subject to similar risks. See “Options and Futures—Risk Factors in Options Transactions” and “—Risk Factors in Futures and Futures Options Transactions” above. Like interest rate swap contracts, interest rate caps, floors, and collars are two-party agreements in which the parties agree to pay or receive interest on a notional principal amount and are generally individually negotiated with a specific counterparty. The purchaser of an interest rate cap receives interest payments from the seller to the extent that the return on a specified index exceeds a specified interest rate. The purchaser of an interest rate floor receives interest payments from the seller to the extent that the return on a specified index falls below a specified interest rate. The purchaser of an interest rate collar receives interest payments from the seller to the extent that the return on a specified index falls outside the range of two specified interest rates.
Swaptions . An option on a swap agreement, also called a “swaption,” is an OTC option that gives the buyer the right, but not the obligation, to enter into a swap on a specified future date in exchange for paying a market-based premium. A receiver swaption gives the owner the right to receive the total return of a specified asset, reference rate, or index (such as a call option on a bond). A payer swaption gives the owner the right to pay the total return of a specified asset, reference rate, or index (such as a put option on a bond). Swaptions also include options that allow one of the counterparties to terminate or extend an existing swap.
Risk Factors in Swap Contracts, OTC Options, and Other Two-Party Contracts . The Fund may only close out a swap, contract for differences, cap, floor, collar, or OTC option (including swaption) with its particular counterparty, and may only transfer a position with the consent of that counterparty. If a counterparty fails to meet its contractual obligations, goes bankrupt, or otherwise experiences a business interruption, the Fund could miss investment opportunities or otherwise hold investments it would prefer to sell, resulting in losses for the Fund. If the counterparty defaults, the Fund will have contractual remedies, but there can be no assurance that the counterparty will be able to meet its contractual obligations or that the Fund will be able to enforce its rights. For example, because the contract for each OTC derivatives transaction is individually negotiated with a specific counterparty, the Fund is subject to the risk that a counterparty may interpret contractual terms (e.g., the definition of default) differently than the Fund. The cost and unpredictability of the legal proceedings required for the Fund to enforce its

19


 

contractual rights may lead it to decide not to pursue its claims against the counterparty. Counterparty risk is greater with longer maturities where events may intervene to prevent settlement. Counterparty risk is also greater when the Fund has concentrated its derivatives with a single or small group of counterparties as it sometimes does as a result of its use of swaps and other OTC derivatives. To the extent the Fund has significant exposure to a single counterparty, this risk will be particularly pronounced for the Fund. The Fund, therefore, assumes the risk that it may be unable to obtain payments the Manager believes are owed under an OTC derivatives contract or that those payments may be delayed or made only after the Fund has incurred the costs of litigation. In addition, counterparty risk is pronounced during unusually adverse market conditions and is particularly acute in environments (like those experienced recently) in which financial services firms are exposed to systemic risks of the type evidenced by the insolvency of Lehman Brothers in 2008 and subsequent market disruptions.
The credit rating of a counterparty may be adversely affected by greater-than-average volatility in the markets, even if the counterparty’s net market exposure is small relative to its capital.
Counterparty risk with respect to OTC derivatives may be further complicated by recently enacted U.S. financial reform legislation. See “Legal and Regulatory Risk” below for more information.
The Fund’s ability to enter into these transactions may be affected by tax considerations.
Additional Risk Factors in OTC Derivatives Transactions. Participants in OTC derivatives markets typically are not subject to the same level of credit evaluation and regulatory oversight as are members of exchange-based markets and, therefore, OTC derivatives generally expose the Fund to greater counterparty risk than exchange-traded derivatives.
Among other trading agreements, the Fund is party to International Swaps and Derivatives Association, Inc. Master Agreements (“ISDA Agreements”) or other similar types of agreements with select counterparties that generally govern over-the-counter derivative transactions entered into by the Fund. The ISDA Agreements typically include representations and warranties as well as contractual terms related to collateral, events of default, termination events, and other provisions. Termination events may include the decline in the net assets of the Fund below a certain level over a specified period of time and entitle a counterparty to elect to terminate early with respect to some or all the transactions under the ISDA Agreement with that counterparty. Such an election by one or more of the counterparties could have a material adverse impact on the Fund’s operations.
Use of Futures and Related Options, Interest Rate Floors, Caps and Collars, Certain Types of Swap Contracts and Related Instruments—Commodity Pool Operator Status . The Fund has claimed an exclusion from the definition of “commodity pool operator” under the Commodity Exchange Act and, therefore, is not subject to registration or regulation as a commodity pool operator under that Act.

20


 

Foreign Currency Transactions
Currency exchange rates may fluctuate significantly over short periods of time. They generally are determined by the forces of supply and demand in the currency exchange markets, trade balances, the relative merits of investments in different countries, actual or perceived changes in interest rates, differences in relative values of similar assets in different currencies, long-term opportunities for investment and capital appreciation, and other complex factors. Currency exchange rates also can be affected unpredictably as a result of intervention (or the failure to intervene) by the U.S. or foreign governments, central banks, or supranational agencies such as the International Monetary Fund, or by currency or exchange controls or political and economic developments in the U.S. or abroad. Currencies in which the Fund’s assets are denominated, or in which the Fund has taken a long position, may be devalued against other currencies, resulting in a loss to the Fund. Similarly, currencies in which the Fund has taken a short position may increase in value relative to other currencies, resulting in a loss to the Fund.
In addition, some currencies are illiquid (e.g., emerging country currencies), and the Fund may not be able to covert these currencies into U.S. dollars, in which case the Manager may decide to purchase U.S. dollars in a parallel market where the exchange rate is materially and adversely different. Exchange rates for many currencies (e.g., emerging country currencies) are particularly affected by exchange control regulations.
The Fund may buy or sell foreign currencies or deal in forward foreign currency contracts, currency futures contracts and related options, and options on currencies. The Fund may use such currency instruments for hedging, investment, and/or currency risk management. Currency risk management may include taking overweighted or underweighted currency positions relative to both the securities portfolio of the Fund and the Fund’s performance benchmark or index. The Fund also may purchase forward foreign exchange contracts in conjunction with U.S. dollar-denominated securities in order to create a synthetic foreign currency-denominated security that approximates desired risk and return characteristics when the non-synthetic securities either are not available in foreign markets or possess undesirable characteristics.
Forward foreign currency contracts are contracts between two parties to purchase and sell a specified quantity of a particular currency at a specified price, with delivery and settlement to take place on a specified future date. A forward foreign currency contract can reduce the Fund’s exposure to changes in the value of the currency it will deliver and can increase its exposure to changes in the value of the currency it will receive for the duration of the contract. The effect on the value of the Fund is similar to the effect of selling securities denominated in one currency and purchasing securities denominated in another currency. Contracts to sell a particular foreign currency would limit any potential gain that might be realized by the Fund if the value of the hedged currency increases. In addition, it is not always possible to hedge fully or perfectly against currency fluctuations affecting the value of the securities denominated in foreign currencies because the value of such securities also is likely to fluctuate because of independent factors not related to currency fluctuations. If a forward foreign currency contract is used for hedging, an imperfect correlation between movements in the price of the forward foreign currency contract and the price of the currency or other investment being hedged creates risk.

21


 

Forward foreign currency contracts involve a number of the same characteristics and risks as currency futures contracts (discussed below) but there also are several differences. Forward foreign currency contracts are not market traded, and are not necessarily marked to market on a daily basis. They settle only at the pre-determined settlement date. This can result in deviations between forward foreign currency prices and currency futures prices, especially in circumstances where interest rates and currency futures prices are positively correlated. Second, in the absence of exchange trading and involvement of clearing houses, there are no standardized terms for forward currency contracts. Accordingly, the parties are free to establish such settlement times and underlying amounts of a currency as desirable, which may vary from the standardized provisions available through any currency futures contract. Finally, forward foreign currency contracts, as two party obligations for which there is no secondary market, involve counterparty risk not present with currency futures contracts, discussed below.
The Fund also may purchase or sell currency futures contracts and related options. Currency futures contracts are contracts to buy or sell a standard quantity of a particular currency at a specified future date and price. However, currency futures can be and often are closed out prior to delivery and settlement. In addition, the Fund may use options on currency futures contracts, which give their holders the right, but not the obligation, to buy (in the case of a call option) or sell (in the case of a put option) a specified currency futures contract at a fixed price during a specified period. (See “Options and Futures—Futures” above for more information on futures contracts and options on futures contracts.)
The Fund also may purchase or sell options on currencies. These give their holders the right, but not the obligation, to buy (in the case of a call option) or sell (in the case of a put option) a specified quantity of a particular currency at a fixed price during a specified period. Options on currencies possess many of the same characteristics as options on securities and generally operate in a similar manner. They may be traded on an exchange or in the OTC markets. Options on currencies traded on U.S. or other exchanges may be subject to position limits, which may limit the ability of the Fund to reduce foreign currency risk using options. (See “Options and Futures—Currency Options” above for more information on currency options.)
Repurchase Agreements
The Fund may enter into repurchase agreements with banks and broker-dealers. A repurchase agreement is a contract under which the Fund acquires a security (usually an obligation of the government in the jurisdiction where the transaction is initiated or in whose currency the agreement is denominated) for a relatively short period (usually less than a week) for cash and subject to the commitment of the seller to repurchase the security for an agreed-upon price on a specified date. The repurchase price exceeds the acquisition price and reflects an agreed-upon market rate unrelated to the coupon rate on the purchased security. Repurchase agreements afford the Fund the opportunity to earn a return on temporarily available cash without market risk, although the Fund bears the risk of a seller’s failure to meet its obligation to pay the repurchase price when it is required to do so. Such a default may subject the Fund to expenses, delays, and risks of loss including: (i) possible declines in the value of the underlying security while the Fund seeks to enforce its rights thereto, (ii) possible reduced levels of income and lack of access to income during this period, and (iii) the inability to enforce its rights and the expenses involved in attempted enforcement. Entering into repurchase agreements entails certain risks,

22


 

which include the risk that the counterparty to the repurchase agreement may not be able to fulfill its obligations, as discussed above, that the parties may disagree as to the meaning or application of contractual terms, or that the instrument may not perform as expected. See “Description of Principal Risks—Counterparty Risk” in the Prospectus.
Debt and Other Fixed Income Securities Generally
Debt and other fixed income securities include fixed and floating rate securities of any maturity. Fixed rate securities pay a specified rate of interest or dividends. Floating rate securities pay a rate that is adjusted periodically by reference to a specified index or market rate. Fixed and floating rate securities include securities issued by federal, state, local, and foreign governments and related agencies, and by a wide range of private issuers, and generally are referred to in this Statement of Additional Information as “fixed income securities.” Indexed bonds are a type of fixed income security whose principal value and/or interest rate is adjusted periodically according to a specified instrument, index, or other statistic (e.g., another security, inflation index or currency). In addition, the Fund may create “synthetic” bonds which approximate desired risk and return profiles. This may be done where a “non-synthetic” security having the desired risk/return profile either is unavailable (e.g., short-term securities of certain foreign governments) or possesses undesirable characteristics (e.g., interest payments on the security would be subject to foreign withholding taxes).
Holders of fixed income securities are exposed to both market and credit risk. Market risk (or “interest rate risk”) relates to changes in a security’s value as a result of changes in interest rates. In general, the values of fixed income securities increase when interest rates fall and decrease when interest rates rise. Credit risk relates to the ability of an issuer to make payments of principal and interest. Obligations of issuers are subject to bankruptcy, insolvency and other laws that affect the rights and remedies of creditors. Fixed income securities denominated in foreign currencies also are subject to the risk of a decline in the value of the denominating currency.
Because interest rates vary, the future income of the Fund cannot be predicted with certainty. To the extent the Fund invests in indexed securities, the future income of the Fund also will be affected by changes in those securities’ indices over time (e.g., changes in inflation rates or currency rates).
Cash and Other High Quality Investments
The Fund may temporarily invest a portion of its assets in cash or cash items pending other investments or to maintain liquid assets required in connection with some of the Fund’s investments. These cash items and other high quality debt securities may include money market instruments, such as securities issued by the United States Government and its agencies, bankers’ acceptances, commercial paper, and bank certificates of deposit. If a custodian holds cash on behalf of the Fund, the Fund may be an unsecured creditor in the event of the insolvency of the custodian. In addition, the Fund will be subject to credit risk with respect to such a custodian, which may be heightened to the extent the Fund takes a temporary defensive position.

23


 

U.S. Government Securities and Foreign Government Securities
U.S. government securities include securities issued or guaranteed by the U.S. government or its authorities, agencies, or instrumentalities. Foreign government securities include securities issued or guaranteed by foreign governments (including political subdivisions) or their authorities, agencies, or instrumentalities or by supra-national agencies. Different kinds of U.S. government securities and foreign government securities have different kinds of government support. For example, some U.S. government securities (e.g., U.S. Treasury bonds) are supported by the full faith and credit of the United States. Other U.S. government securities are issued or guaranteed by federal agencies or government-chartered or -sponsored enterprises but are neither guaranteed nor insured by the U.S. government (e.g., debt securities issued by the Federal Home Loan Mortgage Corporation (“Freddie Mac”), Federal National Mortgage Association (“Fannie Mae”), and Federal Home Loan Banks (“FHLBs”)). Similarly, some foreign government securities are supported by the full faith and credit of a foreign national government or political subdivision and some are not. Foreign government securities of some countries may involve varying degrees of credit risk as a result of financial or political instability in those countries or the possible inability of the Fund to enforce its rights against the foreign government. As with issuers of other fixed income securities, sovereign issuers may be unable or unwilling to satisfy their obligations to pay principal or interest payments.
Supra-national agencies are agencies whose member nations make capital contributions to support the agencies’ activities. Examples include the International Bank for Reconstruction and Development (the World Bank), the Asian Development Bank, and the Inter-American Development Bank.
As with other fixed income securities, U.S. government securities and foreign government securities expose their holders to market risk because their values typically change as interest rates fluctuate. For example, the value of U.S. government securities or foreign government securities may fall during times of rising interest rates. Yields on U.S. government securities and foreign government securities tend to be lower than those of corporate securities of comparable maturities. Generally, when interest rates on short term U.S. Treasury obligations equal or approach zero, a fund that invests a substantial portion of its assets in U.S. Treasury obligations will have a negative return unless the Manager waives or reduces its management fees.
In addition to investing directly in U.S. government securities and foreign government securities, the Fund may purchase certificates of accrual or similar instruments evidencing undivided ownership interests in interest payments and/or principal payments of U.S. government securities and foreign government securities. The Fund may also invest in Separately Traded Registered Interest and Principal Securities (“STRIPS”), which are interests in separately traded interest and principal component parts of U.S. Treasury obligations that represent future interest payments, principal payments, or both, are direct obligations of the U.S. government, and are transferable through the federal reserve book-entry system. Certificates of accrual and similar instruments may be more volatile than other government securities.

24


 

Real Estate Investment Trusts and other Real Estate-Related Investments
The Fund may invest in pooled real estate investment vehicles (so-called “real estate investment trusts” or “REITs”) and other real estate-related investments such as securities of companies principally engaged in the real estate industry. In addition to REITs, companies in the real estate industry and real estate-related investments may include, for example, entities that either own properties or make construction or mortgage loans, real estate developers, and companies with substantial real estate holdings. Each of these types of investments is subject to risks similar to those associated with direct ownership of real estate. Factors affecting real estate values include the supply of real property in particular markets, overbuilding, changes in zoning laws, casualty or condemnation losses, delays in completion of construction, changes in real estate values, changes in operations costs and property taxes, levels of occupancy, adequacy of rent to cover operating expenses, possible environmental liabilities, regulatory limitations on rent, fluctuations in rental income, increased competition and other risks related to local and regional market conditions. The value of real-estate related investments also may be affected by changes in interest rates, macroeconomic developments, and social and economic trends. For instance, during periods of declining interest rates, certain mortgage REITs may hold mortgages that the mortgagors elect to prepay, which prepayment may diminish the yield on securities issued by those REITs. Some REITs have relatively small market capitalizations, which can tend to increase the volatility of the market price of their securities.
REITs are pooled investment vehicles that invest in real estate or real estate-related companies. The Fund may invest in different types of REITs, including equity REITs, which own real estate directly; mortgage REITs, which make construction, development, or long-term mortgage loans; and hybrid REITs, which share characteristics of equity REITs and mortgage REITs. In general, the value of a REIT’s shares changes in light of factors affecting the real estate industry. REITs are also subject to the risk of fluctuations in income from underlying real estate assets, poor performance by the REIT’s manager and the manager’s inability to manage cash flows generated by the REIT’s assets, prepayments and defaults by borrowers, self-liquidation, adverse changes in the tax laws, and, with regard to U.S. REITs (as defined in “Taxes” below), the risk of failing to qualify for tax-free pass-through of income under the Code and/or to maintain exempt status under the 1940 Act. See “Taxes” below for a discussion of special tax considerations relating to the Fund’s investment in U.S. REITs.
By investing in REITs indirectly through a Fund, investors will bear not only their proportionate share of the expenses of the Fund, but also, indirectly, similar expenses of REITs. In addition, REITs depend generally on their ability to generate cash flow to make distributions to investors. Investments in REITs are subject to risks associated with the direct ownership of real estate.
Reverse Repurchase Agreements and Dollar Roll Agreements
The Fund may enter into reverse repurchase agreements and dollar roll agreements with banks and brokers to enhance return. Reverse repurchase agreements involve sales by the Fund of portfolio securities concurrently with an agreement by the Fund to repurchase the same securities at a later date at a fixed price. During the reverse repurchase agreement period, the Fund continues to receive principal and interest payments on the securities and also has the

25


 

opportunity to earn a return on the collateral furnished by the counterparty to secure its obligation to redeliver the securities.
Dollar rolls are transactions in which the Fund sells securities for delivery in the current month and simultaneously contracts to repurchase substantially similar (same type and coupon) securities on a specified future date. During the roll period, the Fund foregoes principal and interest paid on the securities. The Fund is compensated by the difference between the current sales price and the forward price for the future purchase (often referred to as the “drop”) as well as by the interest earned on the cash proceeds of the initial sale.
If the Fund enters into reverse repurchase agreements and dollar roll agreements, it will maintain cash, U.S. government securities, or other liquid assets equal in value to its obligations under those agreements. If the buyer in a reverse repurchase agreement or dollar roll agreement files for bankruptcy or becomes insolvent, the Fund’s use of proceeds from the sale of its securities may be restricted while the other party or its trustee or receiver determines whether to honor the Fund’s right to repurchase the securities. Furthermore, in that situation the Fund may be unable to recover the securities it sold in connection with a reverse repurchase agreement and as a result would realize a loss equal to the difference between the value of the securities and the payment it received for them. This loss would be greater to the extent the buyer paid less than the value of the securities the Fund sold to it (e.g., a buyer may only be willing to pay $95 for a bond with a market value of $100). The Fund’s use of reverse repurchase agreements also subjects the Fund to interest costs based on the difference between the sale and repurchase price of a security involved in such a transaction. Additionally, reverse repurchase agreements entail the same risks as over-the-counter derivatives. These include the risk that the counterparty to the reverse repurchase agreement may not be able to fulfill its obligations, as discussed above, that the parties may disagree as to the meaning or application of contractual terms, or that the instrument may not perform as expected. See “Description of Principal Risks—Derivatives Risk” and “—Counterparty Risk” in the Prospectus and “Uses of Derivatives” below. Reverse repurchase agreements and dollar rolls are not considered borrowings by the Fund for purposes of the Fund’s fundamental investment restriction on borrowings.
Illiquid Securities, Private Placements, Restricted Securities, and IPOs and Other Limited Opportunities
The Fund may invest up to 15% of its net assets in illiquid securities. For this purpose, “illiquid securities” are securities that the Fund may not sell or dispose of within seven days in the ordinary course of business at approximately the amount at which the Fund has valued the securities.
A repurchase agreement maturing in more than seven days is considered illiquid, unless it can be terminated after a notice period of seven days or less.
The Manager also may deem certain securities to be illiquid as a result of the Manager’s receipt from time to time of material, non-public information about an issuer, which may limit the Manager’s ability to trade such securities for the account of any of its clients, including the Fund. In some instances, these trading restrictions could continue in effect for a substantial period of time.

26


 

Private Placements and Restricted Investments. Illiquid securities include securities of private issuers, securities traded in unregulated or shallow markets, securities issued by entities deemed to be affiliates of the Fund, and securities that are purchased in private placements and are subject to legal or contractual restrictions on resale. Because relatively few purchasers of these securities may exist, especially in the event of adverse economic and liquidity conditions or adverse changes in the issuer’s financial condition, the Fund may not be able to initiate a transaction or liquidate a position in such investments at a desirable price. Disposing of illiquid securities may involve time-consuming negotiation and legal expenses, and selling them promptly at an acceptable price may be difficult or impossible.
While private placements may offer attractive opportunities not otherwise available in the open market, the securities purchased are usually “restricted securities” or are “not readily marketable.” Restricted securities cannot be sold without being registered under the Securities Act of 1933, as amended (the “1933 Act”), unless they are sold pursuant to an exemption from registration (such as Rules 144 or 144A). Securities that are not readily marketable are subject to other legal or contractual restrictions on resale. The Fund may have to bear the expense of registering restricted securities for resale and the risk of substantial delay in effecting registration. The Fund selling its securities in a registered offering may be deemed to be an “underwriter” for purposes of Section 11 of the 1933 Act. In such event, the Fund may be liable to purchasers of the securities under Section 11 if the registration statement prepared by the issuer, or the prospectus forming a part of it, is materially inaccurate or misleading, although the Fund may have a due diligence defense.
At times, the inability to sell illiquid securities can make it more difficult to determine their fair value for purposes of computing the Fund’s net asset value. The judgment of the Manager normally plays a greater role in valuing these securities than in valuing publicly traded securities.
IPOs and Other Limited Opportunities . The Fund may purchase securities of companies that are offered pursuant to an initial public offering (“IPO”) or other similar limited opportunities. Although companies can be any age or size at the time of their IPO, they are often smaller and have a limited operating history, which involves a greater potential for the value of their securities to be impaired following the IPO. The price of a company’s securities may be highly unstable at the time of its IPO and for a period thereafter due to factors such as market psychology prevailing at the time of the IPO, the absence of a prior public market, the small number of shares available, and limited availability of investor information. Securities purchased in IPOs have a tendency to fluctuate in value significantly shortly after the IPO relative to the price at which they were purchased. These fluctuations could impact the net asset value and return earned on the Fund’s shares. Investors in IPOs can be adversely affected by substantial dilution in the value of their shares, by sales of additional shares, and by concentration of control in existing management and principal shareholders. In addition, all of the factors that affect the performance of an economy or equity markets may have a greater impact on the shares of IPO companies. IPO securities tend to involve greater risk due, in part, to public perception and the lack of publicly available information and trading history.

27


 

Investments in Other Investment Companies or Other Pooled Investments
Subject to applicable regulatory requirements, the Fund may invest in shares of both open- and closed-end investment companies (including other GMO Funds, money market funds, and exchange-traded funds (“ETFs”)). Investing in another investment company exposes the Fund to all the risks of that investment company and, in general, subjects it to a pro rata portion of the other investment company’s fees and expenses. The Fund also may invest in private investment funds, vehicles, or structures.
ETFs are hybrid investment companies that are registered as open-end investment companies or unit investment trusts (“UITs”) but possess some of the characteristics of closed-end funds. ETFs in which the Fund may invest typically hold a portfolio of common stocks that is intended to track the price and dividend performance of a particular index. The Fund may also invest in actively managed ETFs. Common examples of ETFs include S&P Depositary Receipts (“SPDRs”), Vanguard ETFs, and iShares, which may be purchased from the UIT or investment company issuing the securities or in the secondary market (SPDRs, Vanguard ETFs, and iShares are predominantly listed on the NYSE Arca). The market price for ETF shares may be higher or lower than the ETF’s net asset value. The sale and redemption prices of ETF shares purchased from the issuer are based on the issuer’s net asset value.
Because ETFs are investment companies, investments in ETFs would, absent exemptive relief, be limited under applicable statutory limitations. Those limitations restrict the Fund’s investment in the shares of an ETF or other investment company to up to 5% of the Fund’s assets (which may represent no more than 3% of the securities of such ETF or other investment company) and limit aggregate investments in all ETFs and other investment companies to 10% of the Fund’s assets.
Short Sales
The Fund may seek to hedge investments or realize additional gains through short sales. The Fund may make short sales “against the box,” meaning the Fund may make short sales where the Fund owns, or has the right to acquire at no added cost, securities or currencies identical to those sold short. If the Fund makes a short sale against the box, the Fund will not immediately deliver the securities or currencies sold and will not immediately receive the proceeds from the sale. However, with respect to securities, the Fund is required to hold securities equivalent in kind and amount to the securities sold short (or securities convertible or exchangeable into such securities) while the short sale is outstanding. Once the Fund closes out its short position by delivering the securities or currencies sold short, it will receive the proceeds of the sale. The Fund will incur transaction costs, including interest, in connection with opening, maintaining, and closing short sales against the box.
A Fund will incur a loss as a result of a short sale if the price of the security or index or currency increases between the date of the short sale and the date on which the Fund replaces the borrowed security or currency. A Fund will realize a gain if the price of the security or currency declines between those dates. The amount of any gain will be decreased, and the amount of any loss increased, by the amount of the premium, dividends or interest a Fund may be required to pay in connection with a short sale. A Fund may also take short positions in securities through

28


 

various derivative products. These derivative products will typically expose the Fund to economic risks similar to those associated with shorting securities directly.
Lack of Correlation Risk
There can be no assurance that the short positions that a Fund holds will act as an effective hedge against its long positions. Any decrease in negative correlation or increase in positive correlation between the positions the Manager anticipated would be offsetting (such as short and long positions in securities or currencies held by a Fund) could result in significant losses for the Fund.
Legal and Regulatory Risk
Legal, tax and regulatory changes could occur during the term of the Fund that may adversely affect the Fund. New (or revised) laws or regulations may be imposed by the CFTC, the SEC, the U.S. Federal Reserve or other banking regulators, other governmental regulatory authorities or self-regulatory organizations that supervise the financial markets that could adversely affect the Fund. In particular, these agencies are empowered to promulgate a variety of new rules pursuant to recently enacted financial reform legislation in the United States. The Fund also may be adversely affected by changes in the enforcement or interpretation of existing statutes and rules by these governmental regulatory authorities or self-regulatory organizations. In addition, the securities and futures markets are subject to comprehensive statutes, regulations and margin requirements. The CFTC, the SEC, the Federal Deposit Insurance Corporation, other regulators and self-regulatory organizations and exchanges are authorized to take extraordinary actions in the event of market emergencies. The regulation of derivatives transactions and funds that engage in such transactions is an evolving area of law and is subject to modification by government and judicial action.
The U.S. government recently enacted legislation that provides for new regulation of the derivatives market, including clearing, margin, reporting and registration requirements. Because the legislation leaves much to rule making, its ultimate impact remains unclear. New regulations could, among other things, restrict the Fund’s ability to engage in derivatives transactions (for example, by making certain types of derivatives transactions no longer available to the Fund) and/or increase the costs of such derivatives transactions (for example, by increasing margin or capital requirements), and the Fund may be unable to execute its investment strategy as a result. It is unclear how the regulatory changes will affect counterparty risk.
The CFTC and certain futures exchanges have established limits, referred to as “position limits,” on the maximum net long or net short positions which any person may hold or control in particular options and futures contracts. All positions owned or controlled by the same person or entity, even if in different accounts, may be aggregated for purposes of determining whether the applicable position limits have been exceeded. Thus, even if the Fund does not intend to exceed applicable position limits, it is possible that different clients managed by the Manager and its affiliates may be aggregated for this purpose. Although it is possible that the trading decisions of the Manager may have to be modified and that positions held by the Fund may have to be liquidated in order to avoid exceeding such limits, the Manager believes that this is unlikely.

29


 

The modification of investment decisions or the elimination of open positions, if it occurs, may adversely affect the profitability of the Fund.
The SEC in the past has adopted interim rules requiring reporting of all short positions above a certain de minimis threshold and is expected to adopt rules requiring monthly public disclosure in the future. In addition, other non-U.S. jurisdictions where the Fund may trade have adopted reporting requirements. If the Fund’s short positions or its strategy become generally known, it could have a significant effect on the Manager’s ability to implement its investment strategy. In particular, it would make it more likely that other investors could cause a “short squeeze” in the securities held short by a Fund forcing the Fund to cover its positions at a loss. Such reporting requirements may also limit the Manager’s ability to access management and other personnel at certain companies where the Manager seeks to take a short position. In addition, if other investors engage in copycat behavior by taking positions in the same issuers as the Fund, the cost of borrowing securities to sell short could increase drastically and the availability of such securities to the Fund could decrease drastically. Such events could make a Fund unable to execute its investment strategy. In addition, the SEC recently proposed additional restrictions on short sales. If the SEC were to adopt additional restrictions regarding short sales, they could restrict a Fund’s ability to engage in short sales in certain circumstances, and the Fund may be unable to execute its investment strategy as a result.
The SEC and regulatory authorities in other jurisdictions may adopt (and in certain cases, have adopted) bans on short sales of certain securities in response to market events. Bans on short selling may make it impossible for the Fund to execute certain investment strategies and may have a material adverse effect on the Fund’s ability to generate returns.
Pending federal legislation would require the adoption of regulations that would require any creditor that makes a loan and any securitizer of a loan to retain at least 5% of the credit risk on any loan that is transferred, sold or conveyed by such creditor or securitizer. It is currently unclear how these requirements would apply to loan participations, syndicated loans, and loan assignments. Funds that invest in loans could be adversely affected by the regulation. The effect of any future regulatory change on the Fund could be substantial and adverse.
Lack of Operating History
As of the date of this SAI, the Fund has no operating history. The past performance of other investment funds managed by the Manager cannot be relied upon as an indicator of the Fund’s success, in part because of the unique nature of such Fund’s investment strategy. An investor in each Fund must rely upon the ability of the Manager in identifying and implementing investments. There can be no assurance that such personnel will be successful in identifying and implementing investment opportunities for such Fund.

30


 

USES OF DERIVATIVES
Introduction and Overview
Derivatives are financial contracts whose value depends on, or is derived from, the value of underlying assets, reference rates, or indices, to increase, decrease or adjust elements of the investment exposures of the Fund’s portfolio. Derivatives may relate to securities, interest rates, currencies, currency exchange rates, inflation rates, and indices, and include foreign currency contracts, swap contracts, reverse repurchase agreements, and other exchange-traded and OTC contracts.
This overview outlines various ways in which the Fund (through USCEF) may use different types of exchange-traded and OTC derivatives in implementing its investment programs. It is intended to supplement the information included in the Prospectus, including the risks associated with derivatives described under “Description of Principal Risks” in the Prospectus, and the information provided in the “Fund Investments” and “Descriptions and Risks of Fund Investments” sections of this Statement of Additional Information. This overview, however, is not intended to be exhaustive and the Fund may use types of derivatives and/or employ derivatives strategies not otherwise described in this Statement of Additional Information or the Prospectus.
In addition, the Fund may decide not to employ any of the strategies described below, and no assurance can be given that any strategy used will succeed. Also, suitable derivatives transactions may not be available in all circumstances and there can be no assurance that the Fund will be able to identify or employ a desirable derivatives transaction at any time or from time to time, or that any such transactions will be successful.
The Fund may take advantage of instruments and any security or synthetic or derivative instruments which are not presently contemplated for use by the Fund or which are not currently available, but which may be developed, to the extent such opportunities are both consistent with the Fund’s investment objective and legally permissible for the Fund. The Fund may become a party to various other customized derivative instruments entitling the counterparty to certain payments on the gain or loss on the value of an underlying or referenced instrument.
Note : Unless otherwise noted below in this section, the uses of derivatives discussed herein with respect to the Fund only refer to the Fund’s (through USCEF’s) direct use of such derivatives. As indicated in the Prospectus and in the “Fund Investments” section of this Statement of Additional Information, the USCEF may invest in other Funds of the Trust, which, in turn, may use types of derivatives and/or employ derivatives strategies that differ from those described in this Statement of Additional Information or the Prospectus.
Function of Derivatives in the Fund. The types of derivatives used and derivatives strategies employed by the Fund and the extent the Fund uses derivatives may vary. In addition, specific market conditions may influence the Manager’s choice of derivatives and derivatives strategies for the Fund, in some cases to a significant extent.

31


 

Legal and Regulatory Risk Relating to Derivatives. As described above under “Descriptions and Risks of Fund Investments—Legal and Regulatory Risk,” the U.S. government recently enacted legislation which includes provisions for new regulation of the derivatives market, including clearing, margin, reporting and registration requirements. Because the legislation leaves much to rule making, its ultimate impact remains unclear. The regulatory changes could, among other things, restrict the Fund’s ability to engage in derivatives transactions (including because certain types of derivatives transactions may no longer be available to the Fund) and/or increase the costs of such derivatives transactions (including through increased margin or capital requirements), and the Fund may be unable to execute its investment strategy as a result. It is unclear how the regulatory changes will affect counterparty risk.
Use of Derivatives by the Fund
Types of Derivatives That May Be Used by the Fund
    Options, futures contracts, and related options on securities indices
 
    Long swap contracts in which the Fund pays a fixed rate plus the negative performance, if any, and receives the positive performance, if any, of an index, a single equity security, or a basket of equity securities
 
    Short swap contracts in which the Fund receives a fixed rate plus the negative performance, if any, and pays the positive performance of an index, a single equity security, or a basket of equity securities
 
    Contracts for differences, i.e. , swaps on an index, a single equity security, or a basket of equity securities that contain both long and short equity components
 
    Warrants and rights
 
    Reverse repurchase agreements
Foreign Currency Derivative Transactions That May Be Employed by the Fund
    Buying and selling spot currencies
Uses of Derivatives by the Fund
The Fund primarily uses derivatives as a substitute for direct investment in securities or other assets. For example, the Fund may use derivatives instead of investing directly in equity securities, including using equity derivatives to maintain equity exposure when it holds cash by “equitizing” its cash balances using futures contracts or other types of derivatives.
The Fund also may use derivatives in an attempt to reduce its investment exposures (which may result in a reduction below zero).
In addition, the Fund may use derivatives in an attempt to adjust elements of its investment exposures to various securities, sectors and markets without actually having to sell existing investments or make new direct investments. For example, if the Fund holds a large proportion of stocks of companies in a particular sector and the Manager believes that stocks of companies

32


 

in another sector will outperform those stocks, the Fund might use a short futures contract on an appropriate index (to synthetically “sell” a portion of the Fund’s portfolio) in combination with a long futures contract on another index (to synthetically “buy” exposure to that index).
The Fund may use derivatives to effect transactions intended as substitutes for securities lending.
The Fund does not employ leverage as a principal investment strategy, but the Fund may have net long exposure in excess of its net assets.
INVESTMENT RESTRICTIONS
Fundamental Restrictions:
The following are Fundamental Investment Restrictions of the Fund, which may not be changed without shareholder approval. The Fund has adopted the same Fundamental Investment Restrictions as USCEF.
(1) The Fund may not borrow money except under the following circumstances: (i) The Fund may borrow money from banks so long as after such a transaction, the total assets (including the amount borrowed) less liabilities other than debt obligations, represent at least 300% of outstanding debt obligations; (ii) The Fund may also borrow amounts equal to an additional 5% of its total assets without regard to the foregoing limitation for temporary purposes, such as for the clearance and settlement of portfolio transactions and to meet shareholder redemption requests; and (iii) The Fund may enter into transactions that are technically borrowings under the 1940 Act because they involve the sale of a security coupled with an agreement to repurchase that security (e.g . , reverse repurchase agreements, dollar rolls, and other similar investment techniques) without regard to the asset coverage restriction described in (i) above, so long as and to the extent that the Fund’s custodian earmarks and maintains cash and/or high-grade debt securities equal in value to its obligations in respect of these transactions.
Under current pronouncements of the Securities and Exchange Commission (“SEC”) staff, the above types of transactions are not treated as involving senior securities so long as and to the extent that the Fund maintains liquid assets equal in value to its obligations in respect of these transactions.
(2) The Fund may not purchase securities on margin, except such short-term credits as may be necessary for the clearance of purchases and sales of securities. (For this purpose, the deposit or payment of initial or variation margin in connection with futures contracts or related options transactions is not considered the purchase of a security on margin.)
(3) The Fund may not make short sales of securities or maintain a short position for the Fund’s account unless at all times when a short position is open the Fund owns an equal amount of such securities or owns securities which, without payment of any further consideration, are convertible into or exchangeable for securities of the same issue as, and equal in amount to, the securities sold short.

33


 

This restriction does not prohibit the payment of an amount to exercise the right to acquire the identical securities, provided that the Fund maintains segregated liquid assets in an amount sufficient to exercise such right.
(4) The Fund may not underwrite securities issued by other persons except to the extent that, in connection with the disposition of its portfolio investments, it may be deemed to be an underwriter under federal securities laws.
(5) The Fund may not purchase or sell real estate, although it may purchase securities of issuers which deal in real estate, including securities of real estate investment trusts, and may purchase securities which are secured by interests in real estate.
(6) The Fund may not make loans, except by purchase of debt obligations or by entering into repurchase agreements or through the lending of the Fund’s portfolio securities. Loans of portfolio securities may be made with respect to up to 33 1/3% of the Fund’s total assets.
(7) The Fund may not concentrate more than 25% of the value of its total assets in any one industry.
For purposes of this Fundamental Restriction (7), an industry shall not be considered to include the U.S. government or its agencies or instrumentalities.
(8) The Fund may not purchase or sell commodities or commodity contracts, except that the Fund may purchase and sell financial futures contracts and options thereon.
(9) The Fund may not issue senior securities, as defined in the 1940 Act and as amplified by rules, regulations and pronouncements of the SEC.
The SEC has concluded that even though reverse repurchase agreements, firm commitment agreements, and standby commitment agreements fall within the functional meaning of the term “evidence of indebtedness,” the issue of compliance with Section 18 of the 1940 Act will not be raised with the SEC by the Division of Investment Management if the Fund covers such obligations or maintains liquid assets equal in value to its obligations with respect to these transactions. Similarly, so long as such assets are maintained, the issue of compliance with Section 18 will not be raised with respect to any of the following: any swap contract or contract for differences; any pledge or encumbrance of assets permitted by Non-Fundamental Restriction (4) below; any borrowing permitted by Fundamental Restriction (1) above; any collateral arrangements with respect to initial and variation margin permitted by Non-Fundamental Restriction (4) below; and the purchase or sale of options, forward contracts, futures contracts or options on futures contracts.

34


 

(10) The Fund may not cause less than 75% of the value of the Fund’s total assets to be represented by cash and cash items (including receivables), Government securities, securities of other investment companies, and other securities for the purposes of this calculation limited in respect of any one issuer to an amount not greater than 5% of the value of the Fund’s total assets and to not more than 10% of the outstanding voting securities of any single issuer.
Non-Fundamental Restrictions:
The following are Non-Fundamental Investment Restrictions of the Fund, which may be changed by the Trustees without shareholder approval:
(1) The Fund may not buy or sell oil, gas, or other mineral leases, rights or royalty contracts, although it may purchase securities of issuers that deal in oil, gas, or other mineral leases, rights or royalty contracts, including securities of royalty trusts, and may purchase securities which are secured by, or otherwise hold or represent interests in, oil, gas, or other mineral leases, rights or royalty contracts.
(2) The Fund may not make investments for the purpose of gaining control of a company’s management.
(3) The Fund may not invest more than 15% of its net assets in illiquid securities.
(4) The Fund may not pledge, hypothecate, mortgage, or otherwise encumber its assets in excess of 33 1/3% of the Fund’s total assets (taken at cost). (For the purposes of this restriction, collateral arrangements with respect to swap agreements, the writing of options, stock index, interest rate, currency or other futures, options on futures contracts and collateral arrangements with respect to initial and variation margin are not deemed to be a pledge or other encumbrance of assets. The deposit of securities or cash or cash equivalents in escrow in connection with the writing of covered call or put options, respectively, is not deemed to be a pledge or encumbrance.)
(5) The Fund may not change its Name Policy as set forth under the Fund’s “Principal investment strategies” in the Prospectus without providing the Fund’s shareholders with a notice meeting the requirement of Rule 35d-1(c) at least 60 days prior to such change.
For purposes of the Name Policy, the Fund considers the term “invest” to include both direct investing and indirect investing and the term “investments” to include both direct investments and indirect investments (for instance, the Fund may invest indirectly or make indirect investments by investing in another GMO Fund or in derivatives and synthetic instruments with economic characteristics similar to the underlying asset), and the Fund may achieve exposure to a particular investment, industry, country, or geographic region through direct investing or indirect investing and/or direct investments or indirect investments. The terms “equity investments” and “equities” refer to direct and indirect investments (described above) in common stocks and other stock-related securities, such as preferred stocks, convertible securities and depositary receipts. These investments also include exchange-traded equity REITs and equity income trusts.

35


 

When used in connection with the Fund’s Name Policy, the Manager uses the terms “assets” and “tied economically” as defined in the Prospectus.
Except as indicated above in Fundamental Restriction (1), all percentage limitations on investments set forth herein and in the Prospectus will apply at the time of the making of an investment and shall not be considered violated unless an excess or deficiency occurs or exists immediately after and as a result of such investment.
The phrase “shareholder approval,” as used in the Prospectus and in this Statement of Additional Information, and the phrases “vote of a majority of the outstanding voting securities” and “the approval of shareholders,” as used herein with respect to the Fund, mean the affirmative vote of the lesser of (1) more than 50% of the outstanding shares of the Fund, or (2) 67% or more of the shares of the Fund present at a meeting if more than 50% of the outstanding shares are represented at the meeting in person or by proxy. Except for policies and restrictions that are explicitly described as fundamental in the Prospectus or this Statement of Additional Information, the investment policies and restrictions of the Fund may be changed by the Trust’s Trustees without the approval of shareholders of the Fund. Policies and restrictions of the Fund that are explicitly described as fundamental in the Prospectus or this Statement of Additional Information cannot be changed without the approval of shareholders of the Fund.
DETERMINATION OF NET ASSET VALUE
The net asset value or “NAV” of each class of shares of the Fund is determined as of the close of regular trading on the New York Stock Exchange (“NYSE”), generally at 4:00 p.m. Boston time. The NAV per share of a class of shares of the Fund is determined by dividing the total value of the Fund’s portfolio investments and other assets, less any liabilities, allocated to that share class by the total number of outstanding shares of that class. NAV is not determined on any days when the NYSE is closed for business. The Fund also may elect not to determine NAV on days during which no share is tendered for redemption and no order to purchase or sell a share is received by the Fund. Because the Fund invests substantially all of its assets in USCEF, the Fund’s net asset value is calculated based upon the net asset value of USCEF. Please refer to “Determination of Net Asset Value” in the Prospectus for additional information.
The Manager evaluates pricing sources on an ongoing basis and may change a pricing source at any time. The Manager normally does not evaluate the prices supplied by pricing sources on a day-to-day basis. The Manager monitors erratic or unusual movements (including unusual inactivity) in the prices supplied for a security and has discretion to override a price supplied by a source (e.g., by taking a price supplied by another) when it believes that the price supplied is not reliable. In addition, although alternative prices may be available for securities held by the Fund, those alternative sources are not typically part of the valuation process and do not necessarily provide greater certainty about the prices used by the Fund. In addition, because the

36


 

Fund may hold portfolio securities listed on foreign exchanges that trade on days on which the NYSE or the U.S. bond markets are closed, the net asset value of the Fund’s shares may change significantly on days when shares cannot be redeemed.
DISTRIBUTIONS
The Prospectus describes the distribution policies of the Fund under the heading “Distributions and Taxes.” The Fund generally maintains a policy to pay its shareholders, as dividends, substantially all net investment income, if any, and all net realized capital gains, if any, after offsetting any available capital loss carryovers. The Fund, from time to time and at the Fund’s discretion, also may make unscheduled distributions of net investment income, short-term capital gains, and/or long-term capital gains prior to large redemptions by shareholders from the Fund or as otherwise deemed appropriate by the Fund (see discussion in “Taxes” below).
TAXES
The following discussion of U.S. federal income tax consequences of investment in the Fund is based on the Internal Revenue Code of 1986, as amended (“the Code”), U.S. Treasury regulations, and other applicable authority, as of the date of this SAI. These authorities are subject to change by legislative or administrative action, possibly with retroactive effect. This discussion does not purport to be complete or to deal with all aspects of U.S. federal income taxation of an investment in the Fund. Further, the discussion below is based on the assumption that the shares of the Fund are held solely by certain eligible retirement plans, as well as through certain other tax-advantaged accounts, and only certain tax aspects of an investment in the Fund relevant to such shareholders are described herein. The discussion below does not address tax considerations that may be relevant to participants in “nonqualified” retirement plans, or to other investors. Prospective investors are urged to consult the plan sponsor or other intermediary through which their investment is made, as well as their own tax advisors and financial planners, regarding the U.S. federal income tax consequences to them of an investment in the Fund, the application of state, local, or foreign laws, and the effect of any possible changes in applicable tax laws on an investment in the Fund.
Tax Status and Taxation of the Fund
The Fund is treated as a separate taxable entity for U.S. federal income tax purposes. The Fund intends to qualify each year as a regulated investment company (“RIC”) under Subchapter M of the Code. In order to qualify for the special tax treatment accorded RICs and their shareholders, the Fund must, among other things:
(a)   derive at least 90% of its gross income for each taxable year from (i) dividends, interest, payments with respect to certain securities loans, and gains from the sale or other disposition of stock, securities, or foreign currencies, or other income (including but not limited to gains from options, futures, or forward contracts) derived with respect to its business of investing in such stock, securities, or currencies and (ii) net income derived from interests in “qualified publicly traded partnerships” (as defined below);
 
(b)   diversify its holdings so that, at the end of each quarter of the Fund’s taxable year, (i) at least 50% of the market value of the Fund’s total assets consists of cash and cash items, U.S.

37


 

    government securities, securities of other RICs, and other securities limited in respect of any one issuer to a value not greater than 5% of the value of the Fund’s total assets and not more than 10% of the outstanding voting securities of such issuer, and (ii) not more than 25% of the value of the Fund’s total assets is invested in the securities (other than those of the U.S. government or RICs) of any one issuer or of two or more issuers which the Fund controls and which are engaged in the same, similar, or related trades or businesses, or in the securities of one or more qualified publicly traded partnerships (as defined below); and
 
(c)   distribute with respect to each taxable year at least 90% of the sum of its investment company taxable income (as that term is defined in the Code without regard to the deduction for dividends paid—generally, taxable ordinary income and the excess, if any, of net short-term capital gains over net long-term capital losses) and any net tax-exempt interest income for such year.
In general, for purposes of the 90% gross income requirement described in paragraph (a) above, income derived from a partnership will be treated as qualifying income only to the extent such income is attributable to items of income of the partnership which would be qualifying income if realized directly by the RIC. However, 100% of the net income derived from an interest in a qualified publicly traded partnership (defined generally as a partnership (i) the interests in which are traded on an established securities market or are readily tradable on a secondary market or the substantial equivalent thereof, (ii) that derives at least 90% of its income from passive income sources defined in Section 7704(d) of the Code, and (iii) that derives less than 90% of its income from the qualifying income described in paragraph (a)(i) above) will be treated as qualifying income. In addition, although in general the passive loss rules of the Code do not apply to RICs, such rules do apply to a RIC with respect to items attributable to an interest in a qualified publicly traded partnership. Further, for the purposes of the diversification test in paragraph (b) above: (i) the term “outstanding voting securities of such issuer” will include the equity securities of a qualified publicly traded partnership, and (ii) identification of the issuer (or, in some cases, issuers) of a particular Fund investment can depend on the terms and conditions of that investment. In some cases, identification of the issuer (or issuers) is uncertain under current law, and an adverse determination or future guidance by the Internal Revenue Service (“IRS”) with respect to issuer identification for a particular type of investment may adversely affect the Fund’s ability to meet the diversification test in (b) above.
If the Fund qualifies as a RIC that is accorded special tax treatment, the Fund will not be subject to U.S. federal income tax on income distributed in a timely manner to its shareholders in the form of dividends (including Capital Gain Dividends, as defined below).
As described above, the Fund intends generally to distribute at least annually to its shareholders substantially all of its net investment income (including any net tax-exempt interest income) and all of its net realized capital gains (including both net short-term and long-term capital gains). Any net taxable investment income or net short-term capital gains (as reduced by any net long-term capital losses) retained by the Fund will be subject to tax at the Fund level at regular corporate rates. Although the Fund intends generally to distribute all of its net capital gain (i.e., the excess of any net long-term capital gains over net short-term capital losses) each year, the Fund reserves the right to retain for investment all or a portion of its net capital gain. If the Fund

38


 

retains any net capital gain, it will be subject to tax at the Fund level at regular corporate rates on the amount retained.
Amounts not distributed on a timely basis by RICs in accordance with a calendar-year distribution requirement are subject to a nondeductible 4% excise tax at the Fund level. This excise tax, however, is inapplicable to any RIC whose sole shareholders are certain qualified retirement or pension plans, separate accounts of life insurance companies funding variable contracts, Section 529 qualified tuition programs or certain other permitted tax-exempt investors, or other RICs that are also exempt from the excise tax. In determining whether these investors are the sole shareholders of a RIC for purposes of this exception to the excise tax, shares attributable to an investment in the RIC (not exceeding $250,000) made in connection with the organization of the RIC are not taken into account.
If the Fund is subject to the excise tax and fails to distribute in a calendar year at least an amount generally equal to the sum of 98% of its ordinary income for such year and 98.2% of its capital gain net income for the one-year period ending October 31 within that year, plus any such retained amounts from the prior year, the Fund would be subject to a nondeductible 4% excise tax on the undistributed amounts. If the Fund is subject to the excise tax, the Fund intends generally to make distributions sufficient to avoid imposition of the 4% excise tax, although the Fund reserves the right to pay an excise tax rather than make an additional distribution when circumstances warrant (e.g., the payment of the excise tax amount is deemed by the Fund to be de minimis ). For purposes of the required excise tax distribution, the Fund’s ordinary gains and losses from the sale, exchange, or other taxable disposition of property that would otherwise be taken into account after October 31 of a calendar year generally are treated as arising on January 1 of the following calendar year.
Realized capital losses in excess of realized capital gains (“Net Capital Losses”) are not permitted to be deducted against net investment income. Instead, potentially subject to the limitations described below, the Fund will carry Net Capital Losses forward from any taxable year to subsequent taxable years to offset capital gains, if any, realized during such subsequent taxable year. Distributions from capital gains are generally made after applying any available capital loss carryforwards. Capital loss carryforwards are reduced to the extent they offset current-year net realized capital gains, whether the Fund retains or distributes such gains.
Any Net Capital Losses will be carried forward to one or more subsequent taxable years without expiration. Any such carryforward losses will retain their character as short-term or long-term and will be applied first against gains of the same character before offsetting gains of a different character (e.g., Net Capital Losses that are long-term will first offset any long-term capital gain with any remaining amounts available to offset any short-term capital gain). The Fund’s available capital loss carryforwards, if any, will be set forth in its annual shareholder report for each fiscal year.
In addition, the Fund’s ability to use Net Capital Losses may be limited following the occurrence of certain (i) acquisitive reorganizations and (ii) shifts in the ownership of the Fund by a shareholder owning or treated as owning 5% or more of the shares of the Fund (each, an “ownership change”). The Code may similarly limit the Fund’s ability to use any of its other

39


 

capital losses, or ordinary losses, that have accrued but have not been recognized (i.e., “built-in” losses) at the time of an ownership change to the extent they are realized within the five-year period following the ownership change.
Taxation of Fund Distributions and Redemptions
As noted above, shares of the Fund will be held solely by certain eligible retirement plans, as well as through certain other tax-advantaged accounts. Shareholders that are retirement plans that qualify for tax-exempt treatment under U.S. federal income tax laws generally are not subject to U.S. federal income tax on distributions from the Fund or on redemptions of Fund shares. Special tax rules apply to investments through such plans. Plan participants whose retirement plan invests in the Fund generally are not subject to U.S. federal income tax on Fund distributions received by the plan or on redemptions of Fund shares by the plan. However, distributions to plan participants from a retirement plan generally are taxable to plan participants as ordinary income, with certain exceptions (for example, distributions to participants from a Roth 401(k) plan generally are not taxable to those participants).
As noted above, this discussion does not address tax considerations that may be relevant to participants in “nonqualified” retirement plans, or to other investors. All investors should consult with their own tax advisors or the plan administrator or other financial intermediary through which their investment in the Fund is made to determine the suitability of the Fund as an investment through their retirement plan or other tax-advantaged account and the specific U.S. federal income, as well as any possible state, local, foreign, or other tax consequences to them of investing in the Fund through their plan or other account.
Backup Withholding
The Fund (or in the case of shares held through an intermediary, the intermediary) generally is required to withhold and remit to the U.S. Treasury a percentage of the taxable distributions and redemption proceeds paid to any individual shareholder who fails to properly furnish the Fund (or the intermediary) with a correct taxpayer identification number, who has under-reported dividend or interest income, or who fails to certify that he or she is not subject to such withholding. The backup withholding tax rate is 28% for amounts paid through 2012. This rate will expire and the backup withholding rate will be 31% for amounts paid after December 31, 2012, unless Congress enacts tax legislation providing otherwise. Any tax withheld as a result of backup withholding does not constitute an additional tax imposed on the record owner of the account, and may be claimed as a credit on the record owner’s U.S. federal income tax return, provided the appropriate information is furnished to the IRS.
Shareholder Reporting Obligations With Respect to Foreign Bank and Financial Accounts and Other Foreign Financial Assets
Certain individuals (and, if provided in future guidance, certain domestic entities) must disclose annually their interests in “specified foreign financial assets” on IRS Form 8938, which must be attached to their U.S. federal income tax returns for taxable years beginning after March 18, 2010 The IRS has not yet released a copy of the Form 8938 and has suspended the requirement to attach Form 8938 for any taxable year for which an income tax return is filed before the release

40


 

of Form 8938. Following Form 8938’s release, individuals will be required to attach to their next income tax return required to be filed with the IRS a Form 8938 for each taxable year for which the filing of Form 8938 was suspended. Until the IRS provides more details regarding this reporting requirement, including in Form 8938 itself and related Treasury regulations, it remains unclear under what circumstances, if any, a shareholder’s (indirect) interest in the Fund’s “specified foreign financial assets,” if any, will be required to be reported on this Form 8938. In addition, shareholders that are U.S. persons and own, directly or indirectly, more than 50% of a Fund could be required to report annually their “financial interest” in the Fund’s “foreign financial accounts,” if any, on Treasury Department Form TD F 90-22.1, Report of Foreign Bank and Financial Accounts (FBAR). Shareholders should consult their plan sponsor or other intermediary through which a Fund investment is made (if applicable), as well as a tax advisor, regarding the applicability to them of both of these reporting requirements.
Other Reporting and Withholding Requirements
Rules enacted in March 2010 under the HIRE Act require the reporting to the IRS of direct and indirect ownership of foreign financial accounts and foreign entities by U.S. persons. Failure to provide this required information can result in a 30% withholding tax on certain payments (“withholdable payments”), beginning in 2014 or 2015, depending on the type of payment. Specifically, withholdable payments subject to this 30% withholding tax include payments of U.S.-source interest and dividends, including certain payments with respect to derivative instruments that are treated as “dividend equivalents,” in each case made on or after January 1, 2014, and payments of gross proceeds from the sale or other disposal of property that can produce U.S.-source interest or dividends made on or after January 1, 2015.
The IRS has issued only preliminary guidance with respect to these rules; their scope remains unclear and potentially subject to material change. Very generally, it is possible that all or a portion of distributions made by the Fund on or after the dates noted above (or such later dates as may be provided in future guidance) to a shareholder will be subject to the 30% withholding requirement. Payments to a foreign shareholder that is a “foreign financial institution” will generally be subject to withholding, unless such shareholder enters into a timely agreement with the IRS. Payments to shareholders that are U.S. persons or foreign individuals will generally not be subject to withholding, so long as such shareholders provide the Fund with such certifications or other documentation, including, to the extent required, with regard to their direct and indirect owners, as the Fund requires to comply with these rules. Persons investing in the Fund through an intermediary should contact their intermediary regarding the application of this reporting and withholding regime to their investments in the Fund.
Shareholders are urged to consult a tax advisor regarding this reporting and withholding regime, in light of their particular circumstances.
The Fund and its shareholders may be subject to certain other tax reporting requirements as a result of the investment strategies and activities of the Fund. Certain U.S. federal, state, local and foreign tax reporting requirements may require the Fund to provide certain information about its shareholders to the IRS and other similar authorities responsible for tax matters in other jurisdictions (e.g., foreign countries).

41


 

Tax Implications of Certain Investments
As discussed in the Fund’s Prospectus, the Fund invests substantially all of its assets in shares of USCEF. Therefore, unless otherwise specified, the following section discusses certain U.S. federal income tax consequences of investments made by USCEF.
USCEF may make extensive use of various types of derivative financial instruments to the extent consistent with its investment policies and restrictions. The tax treatment of certain derivative instruments may require USCEF to accrue and distribute income not yet received. To generate sufficient cash to make the requisite distributions, USCEF may be required to sell securities in its portfolio (including when it is not advantageous to do so) that it otherwise would have continued to hold.
The tax rules applicable to derivative financial instruments are in some cases uncertain under current law, including under Subchapter M of the Code. Accordingly, while USCEF intends to account for such transactions in a manner it deems to be appropriate, an adverse determination or future guidance by the IRS with respect to one or more of these rules (which determination or guidance could be retroactive) may adversely affect USCEF’s ability to meet one or more of the relevant requirements to maintain its qualification as a RIC, as well as to avoid the Fund-level tax. See “Loss of RIC Status” below.
Certain investments made and investment practices engaged in by USCEF can produce a difference between its book income and its taxable income. These can include, but are not limited to, certain hedging activities, as well as Section 1256 contracts, passive foreign investment companies (as defined below), and debt obligations with discount or purchased at a premium.
Any investment by USCEF in equity securities of a real estate investment trust (as defined in Section 856 of the Code) qualifying for special tax treatment under Subchapter M of the Code (“U.S. REIT”) may result in the Fund’s receipt of cash in excess of the U.S. REIT’s earnings; if the Fund distributes these amounts, these distributions could constitute a return of capital to Fund shareholders for U.S. federal income tax purposes. Investments in U.S. REIT equity securities may also require the Fund to accrue and distribute income not yet received. To generate sufficient cash to make the requisite distributions, the Fund may be required to sell securities in its portfolio (including when it is not advantageous to do so) that it otherwise would have continued to hold.
Under a notice issued by the IRS in October 2006 and Treasury regulations that have not yet been issued, but may apply retroactively, a portion of the Fund’s income (including income allocated to the Fund from USCEF with respect to USCEF’s investment in a U.S. REIT or other pass-through entity) that is attributable to a residual interest in a real estate mortgage investment conduit (“REMIC”) or an equity interest in a taxable mortgage pool (“TMP”) (referred to in the Code as an “excess inclusion”) will be subject to U.S. federal income tax in all events. This notice also provides and the regulations are expected to provide that excess inclusion income of RICs, such as USCEF and the Fund, will be allocated to shareholders of RICs in proportion to the dividends received by such shareholders, with the same consequences as if the shareholders held the related interest directly. As a result, to the extent the Fund invests in any such interests

42


 

through USCEF, it may not be a suitable investment for certain tax-exempt investors, as noted below.
In general, excess inclusion income allocated to shareholders (i) cannot be offset by net operating losses (subject to a limited exception for certain thrift institutions), and (ii) will constitute unrelated business taxable income (“UBTI”) to entities (including a qualified pension plan, an individual retirement account, a 401(k) plan, a Keogh plan, or other tax-exempt entity) subject to tax on UBTI, thereby potentially requiring such an entity that is allocated excess inclusion income, and otherwise might not be required to file a tax return, to file a tax return and pay tax on such income.
Under current law, income of the Fund that would be treated as UBTI if earned directly by a tax-exempt entity generally will not be attributed and taxed as UBTI when distributed to tax-exempt shareholders (that is, the Fund “blocks” this income with respect to such shareholders). Notwithstanding this “blocking” effect, a tax-exempt shareholder could realize UBTI by virtue of its investment in the Fund if shares in the Fund constitute debt-financed property in the hands of the tax-exempt shareholder within the meaning of Section 514(b) of the Code. A tax-exempt shareholder may also recognize UBTI if the Fund recognizes excess inclusion income derived from direct or indirect investments in residual interests in REMICs or equity interests in TMPs as described above, if the amount of such income recognized by the Fund exceeds the Fund’s investment company taxable income (after taking into account deductions for dividends paid by the Fund).
Some debt obligations with a fixed maturity date of more than one year from the date of issuance (and zero-coupon debt obligations with a fixed maturity date of more than one year from the date of issuance) that are acquired by USCEF or the Fund will be treated as debt obligations that are issued originally at a discount. Generally, the amount of the OID is treated as interest income and is included in USCEF’s or the Fund’s taxable income (and required to be distributed by USCEF or the Fund) over the term of the debt security, even though payment of that amount is not received until a later time, usually upon partial or full repayment or disposition of the debt security. In addition, payment-in-kind securities will give rise to income which is required to be distributed and is taxable even though USCEF or the Fund, as a holder of the security, receives no interest payment in cash on the security during the year.
If USCEF or the Fund holds certain debt obligations that are treated as issued or purchased at a discount, it may be required to pay out as an income distribution each year an amount which is greater than the total amount of cash interest USCEF or the Fund actually received in respect of such obligations. To generate a sufficient amount of cash to make the requisite distributions, USCEF or the Fund may be required to sell securities in its portfolio (including when it is not advantageous to do so) that it otherwise would have continued to hold.
USCEF’s investments in foreign securities (if any) may be subject to foreign withholding and other taxes on dividends, interest, or capital gains, which can decrease the Fund’s yield. USCEF may otherwise be subject to foreign taxation on repatriation proceeds generated from those securities or to other transaction-based foreign taxes on those securities, which can also decrease the Fund’s yield. Such foreign withholding taxes and other taxes may be reduced or eliminated under income tax treaties between the United States and certain foreign jurisdictions. Depending

43


 

on the number of foreign shareholders in USCEF, however, such reduced foreign withholding and other tax rates may not be available for investments in certain jurisdictions.
In addition, any transactions by USCEF in foreign currencies, foreign currency-denominated debt obligations, or certain foreign currency options, futures contracts, or forward contracts (or similar instruments) may give rise to ordinary income or loss to the extent such income or loss results from fluctuations in the value of the foreign currency concerned and can give rise to differences in USCEF’s book and taxable income. USCEF may be required to sell securities in its portfolio (including when it is not advantageous to do so) in order to generate sufficient cash to make the requisite distributions of such income. Any net ordinary losses so created cannot be carried forward by USCEF to offset income or gains earned in subsequent taxable years.
USCEF’s investments in certain passive foreign investment companies (“PFICs”), as defined below, could subject USCEF to U.S. federal income tax (including interest charges) on distributions received from a PFIC or on proceeds received from the disposition of shares in a PFIC, which tax cannot be eliminated by making distributions to USCEF shareholders, including the Fund. However, USCEF may make certain elections to avoid the imposition of that tax. For example, USCEF may elect to treat a PFIC as a “qualified electing fund” (“QEF”) (i.e., make a “QEF election”), in which case USCEF will be required to include its share of the PFIC’s income and net capital gain annually, regardless of whether it receives any distribution from the PFIC. Alternately, USCEF may make an election to mark the gains (and to a limited extent the losses) in such holdings “to the market” as though it had sold (and, solely for purposes of this mark-to-market election, repurchased) its holdings in those PFICs on the last day of USCEF’s taxable year. Such gains and losses are treated as ordinary income and loss. The QEF and mark-to-market elections may have the effect of accelerating the recognition of income (without the receipt of cash) and increasing the amount required to be distributed for USCEF to avoid taxation. Making either of these elections therefore may require USCEF to liquidate other investments (including when it is not advantageous to do so) to meet its distribution requirement, which also may affect the Fund’s total return. In addition, there is a risk that USCEF may not realize that a foreign corporation in which it invests is a PFIC for U.S. federal tax purposes and thus fail to timely make a QEF or mark-to-market election in respect of that corporation, in which event USCEF could be subject to the U.S. federal income taxes and interest charges described above.
A PFIC is any foreign corporation in which (i) 75% or more of the gross income for the taxable year is passive income, or (ii) the average percentage of the assets (generally by value, but by adjusted tax basis in certain cases) that produce, or are held for the production of, passive income is at least 50%. Generally, passive income for this purpose means dividends, interest (including income equivalent to interest), royalties, rents, annuities, the excess of gains over losses from certain property transactions and commodities transactions, income from certain notional principal contracts, and foreign currency gains. Passive income for this purpose does not include rents and royalties received by the foreign corporation from active business and certain income received from related persons.

44


 

Loss of RIC Status
If the Fund were to fail to meet the income or diversification test described in “Tax Status and Taxation of the Fund” above, the Fund could in some cases cure such failure, including by paying a Fund-level tax and, in the case of a diversification test failure, disposing of certain assets. If the Fund were ineligible to or otherwise did not cure such failure for any year, or if the Fund were otherwise to not qualify for taxation as a RIC for such year, the Fund would be taxed as an ordinary corporation on its taxable income for that year without being able to deduct the distributions it makes to its shareholders, thereby reducing the value of a shareholder’s investment in the Fund, and depending on when the Fund discovered its qualification failure for a particular taxable year, the Fund may be subject to penalties and interest on any late payments of its Fund-level taxes for such year. In addition, in the event of any such loss of RIC status, all distributions from the Fund’s earnings and profits, including any distributions of net tax-exempt income and net long-term capital gains, would be taxable to Fund shareholders as ordinary income. In order to re-qualify for taxation as a RIC that is accorded special tax treatment, the Fund may be required to recognize unrealized gains, pay substantial taxes and interest on such gains, and make certain substantial distributions.
Tax Shelter Reporting Regulations
Under Treasury regulations, if a shareholder recognizes a loss on disposition of the Fund’s shares of $2 million or more for an individual shareholder or $10 million or more for a corporate shareholder, the shareholder must file with the IRS a disclosure statement on Form 8886. Direct shareholders of portfolio securities are in many cases excepted from this reporting requirement, but under current guidance, shareholders of a RIC are not excepted. Future guidance may extend the current exception from this reporting requirement to shareholders of most or all RICs. The fact that a loss is reportable under these regulations does not affect the legal determination of whether the taxpayer’s treatment of the loss is proper. Shareholders should consult their tax advisors to determine the applicability of these regulations in light of their individual circumstances.
MANAGEMENT OF THE TRUST
The following tables present information regarding each Trustee and officer of the Trust as of the date of this Statement of Additional Information. Each Trustee’s and officer’s date of birth (“DOB”) is set forth after his or her name. Unless otherwise noted, (i) each Trustee and officer has engaged in the principal occupation(s) noted in the table for at least the most recent five years, although not necessarily in the same capacity, and (ii) the address of each Trustee and officer is c/o GMO Series Trust, 40 Rowes Wharf, Boston, MA 02110. Each Trustee serves in office for a term of eight years or, if sooner, until the Trustee dies, resigns or is removed or until the election and qualification of the Trustee’s successor. Each officer serves in office until his or her successor is elected and determined to be qualified to carry out the duties and responsibilities of the office, or until the officer resigns or is removed from office.

45


 

                                         
                Number of    
                Portfolios in    
    Position(s)           Fund   Other
Name and Date   Held   Length of   Principal Occupation(s)   Complex 1   Directorships
of Birth   with the Trust   Time Served   During Past 5 Years   Overseen   Held
INDEPENDENT TRUSTEE                    
 
                       
Maria D. Furman
DOB: 02/03/1954
  Trustee   Since August 2011.   Retired.     1     Trustee of MassMutual Premier Funds and MML Series Investment Fund II (32 portfolios).
 
                       
INTERESTED TRUSTEE AND OFFICER                    
 
                       
Joseph B. Kittredge, Jr. 2
DOB: 08/22/1954
  Trustee;
President and
Chief Executive
Officer of the Trust
  Since May 2011.   General Counsel, Grantham, Mayo, Van Otterloo & Co. LLC (October 2005-present); President and Chief Executive Officer of GMO Trust since March 2009.     67     None.
 
1   The Fund Complex consists of the funds of GMO Series Trust and GMO Trust.
 
2   Mr. Kittredge is an “interested person” of the Trust, as such term is used in the 1940 Act (an “Interested Trustee”), by virtue of his positions with GMO indicated in the table above.

46


 

Information About Each Trustee’s Experience, Qualifications, Attributes, or Skills for Board Membership. The Board of Trustees has determined that each Trustee should serve as such based on identifying and evaluating the skill sets and qualifications of potential candidates. The Board of Trustees generally considered the educational, business and professional experience of each Trustee in determining his or her qualifications to serve as a Trustee of the Fund. The Board of Trustees focuses on the complementary skills and experience of the Trustees as a group, as well as on those of any particular Trustee. The Board of Trustees noted that both Trustees had considerable experience in overseeing investment management activities and/or related operations and in serving on the boards of other companies. In addition, the Board of Trustees also considered, among other factors, the particular attributes described below with respect to the individual Trustees:
Maria D. Furman — Ms. Furman’s experience serving on the boards and committees of other organizations, her professional training and her qualification as a chartered financial analyst, and her experience in the management of a leading investment management firm.
Joseph B. Kittredge, Jr. — Mr. Kittredge’s experience serving as President of GMO Trust and General Counsel and a Member of GMO, his professional training and his experience as a lawyer representing mutual funds and investment management firms, including as a partner at a leading law firm, and his perspective on Board matters as a senior executive of GMO.
Information relating to the experience, qualifications, attributes and skills of the Trustees is required by the registration form adopted by the SEC, does not constitute holding out the Board or any Trustee as having any special expertise or experience, and does not impose any greater responsibility or liability on any such person or on the Board as a whole than would otherwise be the case.
Officers
             
    Position(s)        
Name and Date of   Held   Length   Principal Occupation(s)
Birth   with the Trust   of Time Served   During Past 5 Years
Joseph B. Kittredge, Jr.
DOB: 08/22/1954
  Trustee;
President and Chief Executive Officer
  Since May 2011.   General Counsel, Grantham, Mayo, Van Otterloo & Co. LLC (October 2005-present); President and Chief Executive Officer, GMO Trust (March 2009- present).
 
           
Sheppard N. Burnett
DOB: 10/24/1968
  Treasurer and Chief Financial Officer   Since May 2011   Head of Fund Administration (December 2006-present), Fund Administration Staff (June 2004-November 2006), Grantham, Mayo, Van Otterloo & Co. LLC; Chief Financial Officer (March 2007-present), Treasurer (November 2006-March 2007), and Assistant Treasurer (September 2004- November 2006), GMO Trust. 1

47


 

             
    Position(s)        
Name and Date of   Held   Length   Principal Occupation(s)
Birth   with the Trust   of Time Served   During Past 5 Years
John McGinty
DOB: 08/11/1962
  Chief Compliance
Officer
  Since August 2011.   Chief Compliance Officer, Grantham, Mayo, Van Otterloo & Co. LLC (July 2009-present); Chief Compliance Officer, GMO Trust (February 2011-present); Senior Vice President and Deputy General Counsel (January 2007-July 2009), Vice President and Associate General Counsel (February 2006-December 2006), Fidelity Investments.
 
           
Jason B. Harrison
DOB: 01/29/1977
  Clerk and Chief Legal Officer   Clerk since May 2011; Chief Legal Officer since September 2011.   Legal Counsel, Grantham, Mayo, Van Otterloo & Co. LLC (since February 2006); Chief Legal Officer and Vice President-Law (October 2010-present), Vice President (November 2006-October 2010).
 
1   Mr. Burnett also serves as an officer of certain other pooled investment vehicles of which GMO or an affiliate of GMO serves as the investment adviser.
Trustees’ Responsibilities. Under the provisions of the GMO Series Trust Declaration of Trust, the Trustees manage the business of the Trust, an open-end management investment company. The Trustees have all powers necessary or convenient to carry out that responsibility, including the power to engage in transactions of all kinds on behalf of the Trust. Except as provided in the Declaration of Trust, the exercise by the Trustees of their powers shall be valid if, but only if, the exercise is approved by a majority of the Trustees then in office, so long as: (i) at least one Independent Trustee votes for or abstains from such exercise, and (ii) at least one Interested Trustee votes for or abstains from such exercise; and further provided that if there is only one Trustee, such Trustee is permitted to exercise any power on his own. Without limiting the foregoing, the Trustees shall have the power to amend the Declaration of Trust; select the investment companies, including series of GMO Trust, in which a series of the Trust shall invest; adopt, amend or repeal By-Laws not inconsistent with the Declaration of Trust providing for the regulation and management of the affairs of the Trust; elect and remove officers and appoint and terminate agents; fix the number of Trustees and, subject to the provisions of the Declaration of Trust, fill any vacancies on the Board; remove a Trustee; extend a Trustee’s term for one or more successive eight (or fewer)-year periods; designate one or more committees of the Trustees with such powers and authority as the Trustees determine; employ one or more custodians of the assets of the Trust and to authorize such custodians to employ subcustodians and to deposit all or any part of such assets in a system or systems for the central handling of securities or with a Federal Reserve Bank; retain a transfer agent or a shareholder servicing agent, or both, to provide for the distribution of shares by the Trust, through one or more principal underwriters or otherwise, and make rules for the transfer of shares of each series and class and similar matters; establish or change a record date for determining shareholders who are entitled to receive payment of any dividend or other distribution and close the register or transfer books of a series or class of the Trust prior to the payment of a distribution; and they may in general delegate such authority as they consider desirable to any officer of the Trust, to any committee of the Trustees, and to any agent or employee of the Trust or to any such custodian or underwriter.

48


 

Board Leadership Structure and Risk Oversight. The Board of Trustees is responsible for the general oversight of the Fund’s affairs and for assuring that the Fund is managed in the best interests of its shareholders. The Board regularly reviews the Fund’s investment performance as well as the quality of services provided to the Fund and its shareholders by GMO and its affiliates, including shareholder servicing. At least annually, the Board reviews and evaluates the fees and operating expenses paid by the Fund for these services and negotiates changes that it deems appropriate. In carrying out these responsibilities, the Board is assisted by the Fund’s auditors, independent counsel to the Independent Trustees and other persons as appropriate, who are selected by and responsible to the Board. In addition, the Fund’s Chief Compliance Officer reports directly to the Board.
Currently, one of the Trustees is an Independent Trustee. The Independent Trustee must vote separately to approve all financial arrangements and other agreements with the Fund’s investment adviser, GMO, and other affiliated parties. The role of the Independent Trustee has been characterized as that of a “watchdog” charged with oversight of protecting shareholders’ interests against overreaching and abuse by those who are in a position to control or influence a fund.
The Board of Trustees focuses on the oversight of risk as part of its broader oversight of the Fund’s affairs. While risk management is primarily the responsibility of the Fund’s investment adviser, GMO, the Board regularly receives reports, including reports from GMO and the Fund’s Chief Compliance Officer, regarding investment risks, compliance risks, and certain other risks applicable to the Fund. The Audit Committee, which is discussed in more detail below, focuses on different aspects of these risks within the scope of the committee’s authority and their potential impact on the Fund, and discusses with GMO the ways in which GMO monitors and controls such risks.
The Board recognizes that not all risks that may affect the Fund can be identified, that it may not be practical or cost-effective to eliminate or mitigate certain risks, that it may be necessary to bear certain risks (such as investment-related risks) to achieve the Fund’s goals, that reports received by the Trustees with respect to risk management matters are typically summaries of the relevant information, and that the processes, procedures and controls employed to address risks may be limited in their effectiveness. As a result of the foregoing and other factors, risk management oversight by the Board and by the Committee is subject to substantial limitations.
Committees
The Board of Trustees has the authority to establish committees, which may exercise the power

49


 

and authority of the Trustees to the extent the Board determines. The committees assist the Board of Trustees in performing its functions and duties under the 1940 Act and Massachusetts law.
The Board of Trustees currently has established one standing committee: the Audit Committee. As of the date of this SAI, the Audit Committee has held 1 meeting.
Audit Committee. The Audit Committee (i) oversees the Trust’s accounting and financial reporting policies and practices and internal controls over financial reporting; (ii) oversees the quality and objectivity of the Trust’s financial statements and the independent audit of those statements; (iii) appoints, determines the independence and compensation of, and oversees the work performed by the Trust’s independent auditors in preparing or issuing an audit report or related work; (iv) approves all audit and permissible non-audit services provided to the Trust, and certain other persons by the Trust’s independent auditors; and (v) acts as a liaison between the Trust’s independent auditors and the Board of Trustees. Ms. Furman is the sole member of the Audit Committee.
The Audit Committee may utilize the resources of the Fund’s counsel and auditors as well as other persons. The Committee meets from time to time, either in conjunction with regular meetings of the Board or otherwise. The Board appoints the members of the Committee and has appointed the sole Independent Trustee to the Committee.
Trustee Fund Ownership
The following table sets forth ranges of the current Trustees’ direct beneficial share ownership in the Fund and the aggregate dollar ranges of their direct beneficial share ownership in the funds of GMO Series Trust and GMO Trust (the “Family of Investment Companies”) as of December 31, 2010.
                   
        Aggregate Dollar Range of Shares
        Directly Owned in all
        Registered Investment Companies
    Dollar Range of   (whether or not offered in the
    Shares Directly Owned in   Prospectus) Overseen by Trustee in
Name   the Fund*   Family of Investment Companies
Maria D. Furman
  None   None
 
       
Joseph B. Kittredge, Jr.
  None   $50,001- $100,000
 
*   The Fund will commence operations on or following the date of this SAI, and, therefore, has not yet offered any shares for sale as of this date.
The following table sets forth ranges of Mr. Kittredge’s indirect beneficial share ownership in the Fund and the aggregate dollar range of his indirect beneficial share ownership in the Family of Investment Companies as of December 31, 2010.

50


 

                 
        Aggregate Dollar Range of Shares
        Indirectly Owned in all
        Registered Investment Companies
    Dollar Range of   (whether or not offered in the
    Shares Directly Owned in   Prospectus) Overseen by Trustee in
Name   the Fund*   Family of Investment Companies
Joseph B. Kittredge, Jr.
  None   $50,001 - $100,000
 
*   The Fund will commence operations on or following the date of this SAI, and, therefore, has not yet offered any shares for sale as of this date.
Trustee Ownership of Securities Issued by the Manager or Principal Underwriter
None.
Trustee Ownership of Related Companies
There were no securities owned by the current Independent Trustee and her family members, as of December 31, 2010, in the Manager, Funds Distributor, LLC, the Fund’s principal underwriter, or entities directly or indirectly controlling, controlled by, or under common control with the Manager or Funds Distributor, LLC.
Remuneration. The Trust has adopted a compensation policy for its Trustees. Ms. Furman, the Trust’s Independent Trustee, receives an annual retainer from the Trust for her services. Ms. Furman also is paid a fee for participating in in-person and telephone meetings of the Board of Trustees and its committee, and a fee for consideration of actions proposed to be taken by written consent. The Trust pays no additional compensation for travel time to meetings, attendance at director’s educational seminars or conferences, service on industry or association committees, participation as speakers at directors’ conferences, or service on special director task forces or subcommittees, although the Trust does reimburse Trustees for seminar or conference fees and for travel expenses incurred in connection with attendance at seminars or conferences. The Trustees do not receive any employee benefits such as pension or retirement benefits or health insurance.
Other than as set forth in the following table, no Trustee of the Trust received any direct compensation from the Fund or the Fund Complex for the fiscal year ended April 30, 2011:
         
Name of Person,   Maria D. Furman,  
Position:   Trustee  
Compensation from the Fund:
  $ 59,000 *
Pension or Retirement Benefits Accrued as Part of Fund Expenses:
    N/A  
Estimated Annual Benefits Upon Retirement:
    N/A  
Total Compensation from the Fund Complex:
  $ 59,000 *

51


 

 
*   Reflects an estimate of the direct compensation to be paid to the Trustee for the Fund’s initial fiscal year ending April 30, 2012. Actual direct compensation paid to the Trustee will vary depending on the net assets of the Fund throughout its initial fiscal year.
The Fund does not expect to pay any officer of the Trust aggregate compensation exceeding $60,000 for the Fund’s initial fiscal year ending April 30, 2012.
Mr. Kittredge does not receive any compensation from the Trust, but as a member of the Manager will benefit from management, shareholder servicing, administration, and any other fees paid to GMO and its affiliates by the Fund and various other GMO Funds not offered through the Prospectus. The officers of the Trust do not receive any employee benefits such as pension or retirement benefits or health insurance from the Trust.
The Fund will commence operations on or following the date of this Statement of Additional Information, and therefore, has not yet offered any shares for sale. Therefore, as of the date hereof, the Trustees and Officers of the Trust as a group owned less than 1% of the outstanding shares of each class of shares of the Fund.
Code of Ethics. The Trust and the Manager have each adopted a Code of Ethics pursuant to the requirements of the 1940 Act. Under each Code of Ethics, personnel are permitted to engage in personal securities transactions only in accordance with specified conditions relating to their position, the identity of the security, the timing of the transaction, and similar factors. Transactions in securities that may be purchased or held by the Fund are permitted, subject to compliance with each Code. Personal securities transactions must be reported quarterly and broker confirmations must be provided for review.
The non-interested Trustees of the Trust are subject to a separate Code of Ethics for the Independent Trustees pursuant to the requirements of the 1940 Act. Transactions by the Independent Trustees in securities, including securities that may be purchased or held by the Fund, are permitted, subject to compliance with the Code of Ethics. Pursuant to the Code of Ethics, an Independent Trustee ordinarily is not required to report his or her personal securities transactions or to identify his or her brokerage accounts to the Fund or its representatives, subject to certain limited exceptions specified in the Code of Ethics.
The Fund’s principal underwriter, which is not affiliated with the Fund or the Manager, also has adopted a Code of Ethics pursuant to the requirements of the 1940 Act. Transactions in securities effected by the principal underwriter’s personnel who are designated as Access Persons under the Code, including securities that may be purchased or held by the Fund, are permitted, subject to compliance with the Code. Currently, there are no Access Persons of the Distributor as it relates to the Fund.

52


 

INVESTMENT ADVISORY AND OTHER SERVICES
Management Contracts
As disclosed in the Prospectus under the heading “Management of the Trust,” under a Management Contract (the “Management Contract”) between the Trust, on behalf of the Fund, and the Manager, subject to such policies as the Trustees of the Trust may determine, the Manager furnishes continuously an investment or asset allocation program, as applicable, for the Fund, and makes investment decisions on behalf of the Fund and places all orders for the purchase and sale of portfolio securities. Subject to the control of the Trustees, the Manager also manages, supervises, and conducts the other affairs and business of the Trust, furnishes office space and equipment, provides bookkeeping and certain clerical services, and pays all salaries, fees, and expenses of officers and Trustees of the Trust who are affiliated with the Manager. As indicated under “Portfolio Transactions — Brokerage and Research Services,” the Trust’s portfolio transactions may be placed with broker-dealers who furnish the Manager, at no cost, research, statistical and quotation services of value to the Manager in advising the Trust or its other clients.
In addition, as disclosed in the Prospectus, the Manager has contractually agreed to waive and/or reimburse the Fund for specified Fund expenses through at least October 1, 2012.
The Management Contract provides that the Manager shall not be subject to any liability in connection with the performance of its services in the absence of willful misfeasance, bad faith, gross negligence, or reckless disregard of its obligations and duties.
The Management Contract will be approved by the Trustees of the Trust (including a majority of the Trustees who were not “interested persons” of the Manager) and by the Fund’s sole initial shareholder in connection with the organization of the Trust and the establishment of the Fund. Generally, the Management Contract continues in effect for a period of two years from the date of its execution and continuously thereafter so long as its continuance is approved at least annually by (i) the vote, cast in person at a meeting called for that purpose, of a majority of those Trustees who are not “interested persons” of the Manager or the Trust, and by (ii) the majority vote of either the full Board of Trustees or the vote of a majority of the outstanding shares of the Fund. The Management Contract automatically terminates on assignment, and is terminable on not more than 60 days’ notice by the Trust to the Manager. In addition, the Management Contract may be terminated on not more than 60 days’ written notice by the Manager to the Trust.
The Manager does not charge the Fund a Management Fee. The Fund, as a result of its investment in USCEF, indirectly bears the Management Fee paid by USCEF, which is calculated based on a fixed percentage of the Fund’s average daily net assets.
In the event that the Manager ceases to be the manager of the Fund, the right of the Trust to use the identifying name “GMO” may be withdrawn.

53


 

Portfolio Management
GMO’s Quantitative Equity Division is responsible for day-to-day investment management of the Fund. The division’s investment professionals work collaboratively to manage the Fund’s portfolio, and no one person is primarily responsible for day-to-day management of the Fund.
The following table sets forth information about accounts overseen or managed by the senior members of the Quantitative Equity Division as of June 30, 2011.
                                                 
    Registered investment companies        
    managed (including non-GMO        
Senior   mutual fund subadvisory   Other pooled investment   Separate accounts managed
Member   relationships)   vehicles managed (world-wide)   (world-wide)
    Number of           Number of           Number of    
    accounts 1   Total assets 1,2   accounts   Total assets   accounts   Total assets
Thomas Hancock
    22     $ 39,606,579,724.31       8     $ 3,771,131,608.57       43     $ 9,802,534,789.93  
 
                                               
Sam Wilderman
    22     $ 39,606,579,724.31       8     $ 3,771,131,608.57       43     $ 9,802,534,789.93  
                                                 
    Registered investment companies        
    managed for which GMO receives   Other pooled investment   Separate accounts managed
    a performance-based fee   vehicles managed (world-wide)   (world-wide) for which GMO
    (including non-GMO mutual fund   for which GMO receives a   receives a performance-based
    subadvisory relationships)   performance-based fee   fee
    Number of           Number of           Number of    
    accounts   Total assets   accounts   Total assets   accounts   Total assets
Thomas Hancock
    0       0       2     $ 1,923,426,551.41       8     $ 2,019,760,575.59  
 
                                               
Sam Wilderman
    0       0       2     $ 1,923,426,551.41       8     $ 2,019,760,575.59  
 
1   Includes GMO Funds (including GMO Funds not offered through the Prospectus) that had commenced operations on or before June 30, 2011.
 
2   For some senior members, “Total assets” includes assets invested by other GMO Funds.
Because the senior members manage other accounts, including accounts that pay higher fees or accounts that pay performance-based fees, potential conflicts of interest exist, including potential conflicts between the investment strategy of the Fund and the investment strategy of the other accounts managed by the senior members and potential conflicts in the allocation of investment opportunities between the Fund and the other accounts.
Senior members of the division are generally members (partners) of GMO. As of August 15, 2011, the compensation of the senior members consisted of a fixed annual base salary, a partnership interest in the firm’s profits and, possibly, an additional, discretionary, bonus related to the senior members’ contribution to GMO’s success. The compensation program does not disproportionately reward outperformance by higher fee/performance fee products. Base salary is determined by taking into account current industry norms and market data to ensure that GMO pays a competitive base salary. The level of partnership interest is determined by taking into

54


 

account the individual’s contribution to GMO and its mission statement. A discretionary bonus may also be paid to recognize specific business contributions and to ensure that the total level of compensation is competitive with the market. Because each person’s compensation is based on his or her individual performance, GMO does not have a typical percentage split among base salary, bonus and other compensation. A GMO membership interest is the primary incentive for persons to maintain employment with GMO. GMO believes this is the best incentive to maintain stability of portfolio management personnel.
Senior Member Fund Ownership. The Fund will commence operations on or following the date of this Statement of Additional Information, and therefore, has not yet offered any shares for sale. Therefore, as of the date hereof, neither Mr. Hancock nor Mr. Wilderman had any direct or indirect ownership of the Fund.
Custodial Arrangements and Fund Accounting Agents . As described in the Prospectus, State Street Bank and Trust Company (“State Street Bank”), One Lincoln Street, Boston, Massachusetts 02111, serves as the Trust’s custodian and fund accounting agent on behalf of the Fund. As such, State Street Bank holds in safekeeping certificated securities and cash belonging to the Fund and, in such capacity, is the registered owner of securities in book-entry form belonging to the Fund. Upon instruction, State Street Bank receives and delivers cash and securities of the Fund in connection with Fund transactions and collects all dividends and other distributions made with respect to Fund portfolio securities. State Street Bank also maintains certain accounts and records of the Trust and calculates the total net asset value, total net income and net asset value per share of the Fund on a daily basis.
Administration Arrangements . As disclosed in the Prospectus, pursuant to the terms of an Administration Agreement with the Fund, Class R1 shares of the Fund pay the Manager an administration fee, which is used by the Manager to defray its expenses (or the expenses of a third party) in providing administration and record keeping services to investors purchasing Class R1 shares of the Fund through eligible retirement plans. The Manager contracts with State Street Bank in connection with the provision of certain administrative services and pays State Street Bank a portion of its administration fee in connection therewith.
Independent Registered Public Accounting Firm . The Trust’s independent registered public accounting firm is PricewaterhouseCoopers LLP, 125 High Street, Boston, Massachusetts 02110. PricewaterhouseCoopers LLP conducts annual audits of the Trust’s financial statements, assists in the preparation of the Fund’s federal and state income tax returns, consults with the Trust as to matters of accounting and federal and state income taxation, and provides assistance in connection with the preparation of various SEC filings.
Distributor . Funds Distributor, LLC, 10 High Street, Suite 302, Boston, Massachusetts 02110, serves as the Trust’s distributor on behalf of the Fund.
Counsel . Ropes & Gray LLP, Prudential Tower, 800 Boylston Street, Boston, Massachusetts 02199, serves as counsel to the Trust.
Transfer Agent. State Street Bank serves as the Trust’s transfer agent on behalf of the Fund.

55


 

PORTFOLIO TRANSACTIONS
Decisions to buy and sell portfolio securities for the Fund and for each of its other investment advisory clients are made by the Manager with a view to achieving each client’s investment objectives taking into consideration other account-specific factors such as, without limitation, cash flows into or out of the account, current holdings, the account’s benchmark(s), applicable regulatory limitations, liquidity, cash restrictions, applicable transaction documentation requirements, market registration requirements and/or time constraints limiting the Manager’s ability to confirm adequate transaction documentation or seek interpretation of investment guideline ambiguities. Therefore, a particular security may be bought or sold only for certain clients of the Manager even though it could have been bought or sold for other clients at the same time. Also, a particular security may be bought/sold for one or more clients when one or more other clients are selling/buying the security or taking a short position in the security, including clients invested in the same investment strategy.
To the extent permitted by applicable law, the Manager’s compliance policies and procedures and a client’s investment guidelines, the Manager may engage in “cross trades” where, as investment manager to a client account, the Manager causes that client account to purchase a security directly from (or sell a security directly to) another client account.
In certain cases, the Manager may identify investment opportunities that are suitable for the Fund and one or more private investment companies for which the Manager or one of its affiliates serves as investment manager, general partner and/or managing member (“GMO Private Funds”). In most cases, the Manager receives greater compensation in respect of a GMO Private Fund (including incentive-based compensation) than it receives in respect of the Fund. In addition, senior members or other portfolio managers frequently have a personal investment in a GMO Private Fund that is greater than such person’s investment in the Fund (or, in some cases, may have no investment in the Fund). The Manager itself also makes investments in GMO Private Funds. To help manage these potential conflicts, the Manager has developed and reviewed with the Trust’s Board of Trustees trade allocation policies that establish a framework for allocating initial public offerings (“IPOs”) and other limited opportunities that take into account the needs and objectives of each Fund and the other GMO clients.
Transactions involving the issuance of Fund shares for securities or assets other than cash will be limited to a bona fide reorganization or statutory merger and to other acquisitions of portfolio securities that meet all of the following conditions: (i) such securities meet the investment objective and policies of the Fund; (ii) such securities are acquired for investment and not for resale; and (iii) such securities can be valued pursuant to the Trust’s pricing policies.
Brokerage and Research Services . In selecting brokers and dealers to effect portfolio transactions for the Fund, the Manager seeks best execution. Best execution is not based solely on the explicit commission charged by the broker/dealer and, consequently, a broker/dealer effecting a transaction may be paid a commission higher than that charged by another broker/dealer for the same transaction. Seeking best price and execution involves the weighing of qualitative as well as quantitative factors, and evaluations of best execution are, to a large extent, possible, if at all, only after multiple trades have been completed. The Manager does place trades with broker/dealers that provide investment ideas and other research services, even

56


 

if the relevant broker has not yet demonstrated an ability to effect best price and execution; however, trading with such a broker (as with any and all brokers) will typically be curtailed or suspended, in due course, if the Manager is not reasonably satisfied with the quality of particular trade executions, unless or until the broker has altered its execution capabilities in such a way that the Manager can reasonably conclude that the broker is capable of achieving best price and execution.
The determination of what may constitute best price and execution involves a number of considerations, including, without limitation, the overall net economic result to the Fund; the efficiency with which the transaction is effected; access to order flow; the ability of the executing broker/dealer to effect the transaction where a large block is involved; reliability (e.g., lack of failed trades); availability of the broker/dealer to stand ready to execute possibly difficult transactions in the future; technological capabilities of the broker/dealer; the broker/dealer’s inventory of securities sought; the financial strength and stability of the broker/dealer; and the relative weighting of opportunity costs (i.e., timeliness of execution) by different strategies. Additionally, regulations in certain markets, primarily emerging markets, require the Manager to identify and trade with one or a limited number of brokers on behalf of clients. In some instances, the Manager may utilize principal bids with consideration to such factors as reported broker flow, past bids and a firm’s ability and willingness to commit capital. Most of the foregoing are subjective considerations made in advance of the trade and are not always borne out by the actual execution.
The Manager’s broker/dealer selection may, in addition to the factors listed above, also be based on research services provided by the broker/dealer. In seeking best execution and in determining the overall reasonableness of brokerage commissions, the Manager may consider research services received by broker-dealers and therefore, may have an incentive to select or recommend a broker-dealer based on the Manager’s interest in receiving the research or other products or services, rather than on the lowest commission charged. The Manager may also direct trades to broker/dealers based in part on the broker/dealers’ history of providing, and capability to continue providing, pricing information for securities purchased. Best execution may be determined for investment strategies without regard to client specific limitations.
Generally, the Manager determines the overall reasonableness of brokerage commissions paid upon consideration of the relative merits of a number of factors, which may include: (i) the net economic effect to the Fund; (ii) historical and current commission rates; (iii) the kind and quality of the execution services rendered; (iv) the size and nature of the transactions effected; and (v) research services received. These factors are considered mostly over multiple transactions covering extended periods of time and are used to evaluate the relative performance of the brokers and other institutions used to effect transactions for accounts. In some instances, the Manager may evaluate best execution on principal bids based on the total commissions charged (the bid for handling a trade as a principal trade) because the trades were filled at the price set at an agreed upon time (e.g., previous night’s close). In those cases, any additional “impact” or cost is represented by the cents per share or basis points extra paid in addition to a typical commission rate.

57


 

Because the Manager will frequently use broker/dealers that provide research in all markets and that research is a factor in evaluating broker/dealers, the Manager relies on the statutory safe harbor in Section 28(e) of the Securities Exchange Act of 1934, as amended (the “1934 Act”). However, the Manager does not participate in any formal soft dollar arrangements involving third party research (i.e., research provided by someone other than the executing broker/dealer) or the payment of any of the Manager’s out-of-pocket expenses. In all cases, the research services received by the Manager are limited to the types of research contemplated by Section 28(e) of the 1934 Act. Research services provided by broker/dealers take various forms, including personal interviews with analysts, written reports, pricing services in respect of securities, and meetings arranged with various sources of information regarding particular issuers, industries, governmental policies, specific information about local markets and applicable regulations, economic trends, and other matters. To the extent that services of value are received by the Manager, the Manager may avoid expenses which might otherwise be incurred. Such services furnished to the Manager may be used in furnishing investment or other advice to all or some subset of the Manager’s clients, including the Fund, and services received from a broker/dealer that executed transactions for the Fund will not necessarily be used by the Manager specifically in servicing the Fund.
The Fund will commence operations on or following the date of this Statement of Additional Information and, therefore, has not yet paid any amounts in brokerage commissions or acquired securities of any brokers or dealers (as defined in the 1940 Act) or of their parents.
Due to restrictions under the 1940 Act, it is possible that, as the result of certain affiliations between a broker/dealer or its affiliates and the Fund, the Manager or the Fund’s distributor, the Fund may refrain, or be required to refrain, from engaging in principal trades with such broker/dealer. Additionally, the Fund may be restricted in its ability to purchase securities issued by affiliates of the Fund’s distributor.
PROXY VOTING POLICIES AND PROCEDURES
The Trust has adopted a proxy voting policy under which responsibility to vote proxies related to its portfolio securities has been delegated to the Manager. Because the Fund invests in USCEF in reliance on Section 12(d)(1)(E) of the 1940 Act, the Fund is obligated either to seek instructions from its security holders with regard to the voting of all proxies with respect to its interest in USCEF and to vote such proxies only in accordance with such instructions, or to vote the shares of USCEF held by it in the same proportion as the vote of all other holders of USCEF. The Board of Trustees of the Trust has reviewed and approved the proxy voting policies and procedures the Manager follows when voting proxies on behalf of USCEF.
The Manager’s proxy voting policies on a particular issue may or may not reflect the views of individual members of the Board of Trustees of the Trust, or a majority of the Board of Trustees.
Information regarding how the Fund voted proxies relating to portfolio securities during the most recent 12-month period ended June 30 will be available on the Trust’s website at www.gmo.com and on the Securities and Exchange Commission’s website at www.sec.gov no later than August 31 of each year.

58


 

DISCLOSURE OF PORTFOLIO HOLDINGS
The policy of the Trust is to protect the confidentiality of the Fund’s portfolio holdings and to prevent inappropriate selective disclosure of those holdings. The Board of Trustees has approved this policy and material amendments require its approval.
Registered investment companies that are sub-advised by GMO may be subject to different portfolio holdings disclosure policies, and neither GMO nor the Board of Trustees exercises control over those policies. In addition, separate account clients of GMO have access to their portfolio holdings and are not subject to the Fund’s portfolio holdings disclosure policies. Some of the funds that are sub-advised by GMO and some of the separate accounts managed by GMO have substantially similar investment objectives and strategies and, therefore, potentially similar portfolio holdings.
Neither GMO nor the Fund will receive any compensation or other consideration in connection with its disclosure of the Fund’s portfolio holdings.
GMO may disclose the Fund’s portfolio holdings (together with any other information from which the Fund’s portfolio holdings could reasonably be derived, as reasonably determined by GMO) (the “Portfolio Holdings Information”) to shareholders, qualified potential shareholders as determined by GMO, and their consultants and agents (collectively, “Permitted Recipients”) by means of the GMO website. The Fund’s Prospectus describes the type of information disclosed on GMO’s website, as well as the frequency with which it is disclosed and the lag between the date of the information and the date of its disclosure. The largest fifteen holdings of the Fund and USCEF are posted monthly on GMO’s website and typically are available to shareholders without a confidentiality agreement. In addition, from time to time position attribution information regarding the Fund and USCEF may be posted to GMO’s website (e.g., best/worst performing positions in the Fund or USCEF over a specified time period). In response to market interest in specific issuers, the Fund’s and USCEF’s holdings in one or more issuers may be made available on a more frequent basis as circumstances warrant. Typically, no confidentiality agreement is needed to access this information.
GMO also may make Portfolio Holdings Information available to Permitted Recipients by email, or by any other means in such scope and form and with such frequency as GMO may reasonably determine, no earlier than the day next following the day on which the Portfolio Holdings Information is posted on the GMO website (provided that the Fund’s Prospectus describes the nature and scope of the Portfolio Holdings Information that will be available on the GMO website, when the information will be available and the period for which the information will remain available, and the location on the Fund’s website where the information will be made available) or on the same day as a publicly available, routine filing with the SEC that includes the Portfolio Holdings Information. A confidentiality agreement is not required to access Portfolio Holdings Information filed with the SEC as described in the preceding sentence.
GMO also may disclose portfolio holdings information to all shareholders of the Fund and USCEF and their consultants and agents from time-to-time. Such disclosure may be made by email, written notice or any other means in such scope and form as GMO may reasonably

59


 

determine, and generally will not be subject to a confidentiality agreement and will not be required to be posted to GMO’s website in advance.
Except as otherwise noted, to receive Portfolio Holdings Information, Permitted Recipients must enter into a confidentiality agreement with GMO and the Trust that requires that the Portfolio Holdings Information be used solely for purposes determined by senior management of GMO to be in the best interest of the shareholders of the Fund.
In some cases, GMO may disclose to a third party Portfolio Holdings Information that has not been made available to Permitted Recipients on the GMO website or in a publicly available, routine filing with the SEC. That disclosure may only be made if senior management of GMO determines that it is in the best interests of the shareholders of the Fund. In addition, the third party receiving the Portfolio Holdings Information must enter into a confidentiality agreement with GMO and the Trust that requires that the Portfolio Holdings Information be used solely for purposes determined by GMO senior management to be in the best interest of the Fund’s shareholders.
If GMO becomes aware that a recipient has or is likely to violate the terms of a confidentiality agreement regarding Portfolio Holdings Information, GMO shall cease providing such information to such recipient.
The procedures pursuant to which GMO may disclose to a third party Portfolio Holdings Information that has not been made available to Permitted Recipients do not apply to Portfolio Holdings Information provided to entities who provide on-going services to the Fund in connection with its day-to-day operations and management, including GMO, GMO’s affiliates, the Fund’s custodian and auditors, the Fund’s pricing service vendors, broker-dealers when requesting bids for or price quotations on securities, brokers in the normal course of trading on the Fund’s behalf, and persons assisting the Fund in the voting of proxies. In addition, (i) when an investor indicates that it wants to purchase shares of the Fund in exchange for securities acceptable to GMO, GMO may make available a list of securities that it would be willing to accept for the Fund, and, from time to time, the securities on the list may overlap with securities currently held by the Fund; and (ii) when the Fund determines to pay redemption proceeds wholly or partly in-kind with securities, GMO may make available a list of securities it intends to deliver from the Fund.
No provision of this policy is intended to restrict or prevent the disclosure of Portfolio Holdings Information as may be required by applicable law, rules or regulations.
GMO’s General Counsel or Chief Compliance Officer may authorize exceptions to these procedures. Exceptions must be disclosed to the Chief Compliance Officer of the Trust.
If senior management of GMO identifies a potential conflict with respect to the disclosure of Portfolio Holdings Information between the interest of the Fund’s shareholders, on the one hand, and GMO or an affiliated person of GMO or the Fund, on the other, GMO is required to inform the Trust’s Chief Compliance Officer of the potential conflict, and the Trust’s Chief Compliance Officer has the power to decide whether, in light of the potential conflict, disclosure should be permitted under the circumstances. The Trust’s Chief Compliance Officer also is required to

60


 

report his decision to the Board of Trustees.
GMO periodically reports the following information to the Board of Trustees:
    Determinations made by senior management of GMO relating to the use of Portfolio Holdings Information by Permitted Recipients and third parties;
 
    The nature and scope of disclosure of Portfolio Holdings Information to third parties;
 
    Exceptions to the disclosure policy authorized by GMO’s General Counsel or Chief Compliance Officer; and
 
    Any other information the Trustees may request relating to the disclosure of Portfolio Holdings Information.
Ongoing Arrangements To Make Portfolio Holdings Available . Senior management of GMO has authorized disclosure of Portfolio Holdings Information on an on-going basis (generally, daily, except with respect to PricewaterhouseCoopers LLP, which receives holdings semi-annually and as necessary in connection with the services it provides to the Fund) to the following entities that provide on-going services to the Fund in connection with its day-to-day operations and management, provided that they agree or have a duty to maintain this information in confidence:
     
Name of Recipient   Purpose of Disclosure
State Street Bank and Trust Company
  Custodial services and compliance testing
 
   
Brown Brothers Harriman & Co.
  Compliance testing
 
   
Boston Global Advisors
  Securities lending services
 
   
PricewaterhouseCoopers LLP
  Independent registered public accounting firm
 
   
Institutional Shareholder Services Inc.
(formerly known as RiskMetrics Group, Inc.)
  Corporate actions services
 
   
FactSet
  Data service provider
Senior management of GMO has authorized disclosure of Portfolio Holdings Information on an on-going basis (daily) to the following recipients, provided that they agree or have a duty to maintain this information in confidence and are limited to using the information for the specific purpose for which it was provided:
     
Name of Recipient   Purpose of Disclosure
Epstein & Associates, Inc.
  Software provider for Code of Ethics monitoring system
 
   
Financial Models Company Inc.
  Recordkeeping system

61


 

DESCRIPTION OF THE TRUST AND OWNERSHIP OF SHARES
The Trust, an open-end management investment company, is organized as a Massachusetts business trust under the laws of Massachusetts by an Agreement and Declaration of Trust dated May 27, 2011, as amended and restated September 13, 2011, and as such Declaration of Trust may be amended from time to time. A copy of the Declaration of Trust is on file with the Secretary of The Commonwealth of Massachusetts. The Trust operates as a “series investment company” that consists of separate series of investment portfolios, each of which is represented by a separate series of shares of beneficial interest. The Fund is a series of the Trust. The fiscal year for the Fund ends on the last day of April.
Pursuant to the Declaration of Trust, the Trustees have currently authorized the issuance of an unlimited number of full and fractional shares of the Fund.
Interests in the Fund are represented by shares of the series. Each share of the series represents an equal proportionate interest, together with each other share, in the Fund. Upon liquidation of the Fund, shareholders of the series are entitled to share pro rata in the net assets of the Fund available for distribution to shareholders. The Declaration of Trust also permits the Trustees to charge shareholders directly for custodial, transfer agency, and servicing expenses, but the Trustees have no present intention to make such charges.
The Declaration of Trust also permits the Trustees, without shareholder approval, to subdivide the shares of any series into two or more classes of shares with such preferences and special or relative rights and privileges (including conversion rights, if any) as the Trustees may designate. This power is intended to allow the Trustees to provide for an equitable allocation of the effect of any future regulatory requirements that might affect various classes of shareholders differently. The Trustees have currently authorized the establishment and designation of one class of shares for the series: Class R1 Shares.
The Trustees may also, without shareholder approval, establish one or more additional separate portfolios for investments in the Trust or merge two or more existing portfolios (i.e., a new fund). Shareholders’ investments in such a portfolio would be evidenced by a separate series of shares.
The Declaration of Trust provides for the perpetual existence of the Trust. While the Declaration of Trust further provides that the Trustees, may terminate the Trust at any time, the 1940 Act requires that the Trust receive the authorization of a majority of its outstanding shares in order to change the nature of its business so as to cease to be an investment company.
Shareholders should be aware that to the extent a shareholder’s investment in a Fund exceeds certain threshold amounts or percentages, the investment may constitute a reportable acquisition under the Hart-Scott-Rodino Act (“HSR”) and the shareholder may be required to make a corresponding filing under HSR. HSR regulations are complex and shareholders should consult their legal advisers about the precise HSR filing consequences of an investment in the Fund.

62


 

VOTING RIGHTS
The Shareholders shall have power to vote only on matters that the Trustees consider necessary or desirable. Shareholders are entitled to one vote for each full share held (with fractional votes for fractional shares held) as to any matter on which it is entitled to vote.
Normally the Trust does not hold meetings of shareholders to elect Trustees except in accordance with the 1940 Act (i) the Trust will hold a shareholders’ meeting for the election of Trustees at such time as less than a majority of the Trustees holding office have been elected by shareholders, and (ii) if, as a result of a vacancy in the Board of Trustees, less than two-thirds of the Trustees holding office have been elected by the shareholders, that vacancy may only be filled by a vote of the shareholders.
The Trustees may modify the rights and preferences of any shares. Voting rights are not cumulative.
SHAREHOLDER AND TRUSTEE LIABILITY
Under Massachusetts law, shareholders could, under some circumstances, be held personally liable for the obligations of the Trust. However, the Declaration of Trust disclaims shareholder liability for acts or obligations of the Trust and requires that notice of that disclaimer be given in each agreement, obligation, or instrument entered into or executed by the Trust or the Trustees. The Declaration of Trust provides for indemnification out of all the property of the Fund for all loss and expense of any shareholder of the Fund held personally liable for the obligations of the Trust. Thus, the risk of a shareholder incurring financial loss on account of shareholder liability is limited to circumstances in which the disclaimer is inoperative and the Fund is unable to meet its obligations.
The Declaration of Trust further provides that the Trustees will not be liable for errors of judgment or mistakes of fact or law. However, nothing in the Declaration of Trust protects a Trustee against any liability to which the Trustee would otherwise be subject by reason of willful misfeasance, bad faith, gross negligence, or reckless disregard of the duties involved in the conduct of his office. The Declaration of Trust provides for indemnification by the Trust of the Trustees and the officers of the Trust except for any matter as to which any such person did not act in good faith in the reasonable belief that his action was in or not opposed to the best interests of the Trust. Trustees and officers may not be indemnified against any liability to the Trust or the Trust shareholders to which they would otherwise be subject by reason of willful

63


 

misfeasance, bad faith, gross negligence, or reckless disregard of the duties involved in the conduct of their office.
BENEFICIAL OWNERS OF 5% OR MORE OF THE FUND’S SHARES
The Fund will commence operations on or following the date of this Statement of Additional Information, and therefore, no shareholder owns beneficially more than 5% of the outstanding shares of the Fund as of the date of this Statement of Additional Information.
FINANCIAL STATEMENTS
The Fund’s initial audited financial statements are attached as Appendix B.

64


 

Appendix A
      COMMERCIAL PAPER AND CORPORATE DEBT RATINGS
Commercial Paper Ratings
Standard & Poor’s . Standard & Poor’s short-term ratings are generally assigned to those obligations considered short-term in the relevant market. In the U.S., for example, that means obligations with an original maturity of no more than 365 days — including commercial paper. The following are excerpts from Standard & Poor’s short-term issue credit ratings definitions:
A-1 — A short-term obligation rated “A-1” is rated in the highest category by Standard & Poor’s. The obligor’s capacity to meet its financial commitment on the obligation is strong. Within this category, certain obligations are designated with a plus sign (+). This indicates that the obligor’s capacity to meet its financial commitment on these obligations is extremely strong.
A-2 — A short-term obligation rated “A-2” is somewhat more susceptible to the adverse effects of changes in circumstances and economic conditions than obligations in higher rating categories. However, the obligor’s capacity to meet its financial commitment on the obligation is satisfactory.
A-3 — A short-term obligation rated “A-3” exhibits adequate protection parameters. However, adverse economic conditions or changing circumstances are more likely to lead to a weakened capacity of the obligor to meet its financial commitment on the obligation.
B — A short-term obligation rated “B” is regarded as having significant speculative characteristics. Ratings of “B-1”, “B-2”, and “B-3” may be assigned to indicate finer distinctions within the “B” category. The obligor currently has the capacity to meet its financial commitment on the obligation; however, it faces major ongoing uncertainties which could lead to the obligor’s inadequate capacity to meet its financial commitment on the obligation.
B-1 — A short-term obligation rated “B-1” is regarded as having significant speculative characteristics, but the obligor has a relatively stronger capacity to meet its financial commitments over the short-term compared to other speculative-grade obligors.
B-2 — A short-term obligation rated “B-2” is regarded as having significant speculative characteristics, and the obligor has an average speculative-grade capacity to meet its financial commitments over the short-term compared to other speculative-grade obligors.
B-3 — A short-term obligation rated “B-3” is regarded as having significant speculative characteristics, and the obligor has a relatively weaker capacity to meet its financial commitments over the short-term compared to other speculative-grade obligors.
C — A short-term obligation rated “C” is currently vulnerable to nonpayment and is dependent upon favorable business, financial, and economic conditions for the obligor to meet its financial commitment on the obligation.
D — A short-term obligation rated “D” is in payment default. The “D” rating category is used when payments on an obligation, including a regulatory capital instrument, are not made on the date due even if the applicable

A-1


 

Appendix A
grace period has not expired, unless Standard & Poor’s believes that such payments will be made during such grace period. The “D” rating also will be used upon the filing of a bankruptcy petition or the taking of a similar action if payments on an obligation are jeopardized.
Moody’s . Moody’s short-term ratings are opinions of the ability of issuers to honor short-term financial obligations. Ratings may be assigned to issuers, short-term programs, or to individual short-term debt instruments. Such obligations generally have an original maturity not exceeding thirteen months, unless explicitly noted. The following are excerpts from Moody’s short-term ratings definitions:
P-1 — Issuers (or supporting institutions) rated Prime-1 have a superior ability to repay short-term debt obligations.
P-2 — Issuers (or supporting institutions) rated Prime-2 have a strong ability to repay short-term debt obligations.
P-3 — Issuers (or supporting institutions) rated Prime-3 have an acceptable ability to repay short-term obligations.
NP — Issuers (or supporting institutions) rated Not Prime do not fall within any of the Prime rating categories.
Note: Canadian issuers rated P-1 or P-2 have their short-term ratings enhanced by the senior-most long-term rating of the issuer, its guarantor or support-provider.
Corporate Debt Ratings
Standard & Poor’s . A Standard & Poor’s issue credit rating is a forward-looking opinion about the creditworthiness of an obligor with respect to a specific financial obligation, a specific class of financial obligations, or a specific financial program. The following are excerpts from Standard & Poor’s long-term issue credit ratings definitions:
AAA — An obligation rated “AAA” has the highest rating assigned by Standard & Poor’s. The obligor’s capacity to meet its financial commitment on the obligation is extremely strong.
AA — An obligation rated “AA” differs from the highest-rated obligations only to a small degree. The obligor’s capacity to meet its financial commitment on the obligation is very strong.
A — An obligation rated “A” is somewhat more susceptible to the adverse effects of changes in circumstances and economic conditions than obligations in higher-rated categories. However, the obligor’s capacity to meet its financial commitment on the obligation is still strong.
BBB — An obligation rated “BBB” exhibits adequate protection parameters. However, adverse economic conditions or changing circumstances are more likely to lead to a weakened capacity of the obligor to meet its financial commitment on the obligation.
BB, B, CCC, CC, and C — Obligations rated “BB”, “B”, “CCC”, “CC”, and “C” are regarded as having significant speculative characteristics. BB indicates the least degree of speculation and “C” the highest. While

A-2


 

Appendix A
such obligations will likely have some quality and protective characteristics, these may be outweighed by large uncertainties or major exposures to adverse conditions.
BB — An obligation rated “BB” is less vulnerable to nonpayment than other speculative issues. However, it faces major ongoing uncertainties or exposure to adverse business, financial, or economic conditions, which could lead to the obligor’s inadequate capacity to meet its financial commitment on the obligation.
B — An obligation rated “B” is more vulnerable to nonpayment than obligations rated “BB”, but the obligor currently has the capacity to meet its financial commitment on the obligation. Adverse business, financial, or economic conditions will likely impair the obligor’s capacity or willingness to meet its financial commitment on the obligation.
CCC — An obligation rated “CCC” is currently vulnerable to nonpayment, and is dependent upon favorable business, financial, and economic conditions for the obligor to meet its financial commitment on the obligation. In the event of adverse business, financial, or economic conditions, the obligor is not likely to have the capacity to meet its financial commitment on the obligation.
CC — An obligation rated “CC” is currently highly vulnerable to nonpayment.
C — A “C” rating is assigned to obligations that are currently highly vulnerable to nonpayment, obligations that have payment arrearages allowed by the terms of the documents, or obligations of an issuer that is the subject of a bankruptcy petition or similar action which have not experienced a payment default. Among others, the “C” rating may be assigned to subordinated debt, preferred stock or other obligations on which cash payments have been suspended in accordance with the instrument’s terms or when preferred stock is the subject of a distressed exchange offer, whereby some or all of the issue is either repurchased for an amount of cash or replaced by other instruments having a total value that is less than par.
D — An obligation rated “D” is in payment default. The “D” rating category is used when payments on an obligation, including a regulatory capital instrument, are not made on the date due even if the applicable grace period has not expired, unless Standard & Poor’s believes that such payments will be made during such grace period. The “D” rating also will be used upon the filing of a bankruptcy petition or the taking of similar action if payments on an obligation are jeopardized. An obligation’s rating is lowered to “D” upon completion of a distressed exchange offer, whereby some or all of the issue is either repurchased for an amount of cash or replaced by other instruments having a total value that is less than par.
Plus (+) or Minus (-) — The ratings from “AA” to “CCC” may be modified by the addition of a plus (+) or minus (-) sign to show relative standing within the major rating categories.
NR — This indicates that no rating has been requested, that there is insufficient information on which to base a rating, or that Standard & Poor’s does not rate a particular obligation as a matter of policy.
Moody’s . Moody’s long-term ratings are opinions of the relative credit risk of financial obligations with an original maturity of one year or more. They address the possibility that a financial obligation will not be

A-3


 

Appendix A
honored as promised. Such ratings use Moody’s Global Scale and reflect both the likelihood of default and any financial loss suffered in the event of default. The following are excerpts from Moody’s long-term obligation ratings definitions:
Aaa — Obligations rated “Aaa” are judged to be of the highest quality, with minimal credit risk.
Aa — Obligations rated “Aa” are judged to be of high quality and are subject to very low credit risk.
A — Obligations rated “A” are considered upper-medium grade and are subject to low credit risk.
Baa — Obligations rated “Baa” are subject to moderate credit risk. They are considered medium-grade and as such may possess certain speculative characteristics.
Ba — Obligations rated “Ba” are judged to have speculative elements and are subject to substantial credit risk.
B — Obligations rated “B” are considered speculative and are subject to high credit risk.
Caa — Obligations rated “Caa” are judged to be of poor standing and are subject to very high credit risk.
Ca — Obligations rated “Ca” are highly speculative and are likely in, or very near, default, with some prospect of recovery of principal and interest.
C — Obligations rated “C” are the lowest rated class and are typically in default, with little prospect for recovery of principal or interest.
Note: Moody’s appends numerical modifiers 1, 2, and 3 to each generic rating classification from Aa through Caa. The modifier 1 indicates that the obligation ranks in the higher end of its generic rating category; the modifier 2 indicates a mid-range ranking; and the modifier 3 indicates a ranking in the lower end of that generic rating category.

A-4


 

Appendix B
Report of Independent Registered Public Accounting Firm
To the Board of Trustees of GMO Series Trust and Shareholder of GMO U.S. Core Equity Series Fund
In our opinion, the accompanying statement of assets and liabilities, presents fairly, in all material respects, the financial position of GMO U.S. Core Equity Series Fund (the “Fund”) at August 24, 2011, in conformity with accounting principles generally accepted in the United States of America. This financial statement is the responsibility of the Fund’s management; our responsibility is to express an opinion on this financial statement based on our audit. We conducted our audit of this financial statement in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statement is free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statement, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
/s/ PricewaterhouseCoopers LLP
September 7, 2011

B-1


 

Appendix B
FINANCIAL STATEMENTS
GMO U.S. Core Equity Series Fund
(A Series of GMO Series Trust)
         
Statement of Assets and Liabilities — August 24, 2011
Assets:
       
 
       
Cash
  $ 100,000  
 
       
Total assets
    100,000  
 
     
 
       
Liabilities:
    0  
 
       
Net assets
  $ 100,000  
 
     
 
       
Net assets consist of:
       
 
       
Paid-in capital
  $ 100,000  
 
       
Shares outstanding:
    5,000  
 
       
Net asset value per share:
  $ 20.00  
See accompanying notes to financial statement.

B-2


 

Appendix B
GMO U.S. CORE EQUITY SERIES FUND
(A SERIES OF GMO SERIES TRUST)
NOTES TO FINANCIAL STATEMENTS
August 24, 2011
  1.   Organization
 
      GMO Series Trust, a Massachusetts business trust, was formed on May 27, 2011 and is registered as a diversified, open-end management investment company under the Investment Company Act of 1940 (the “1940 Act”), as amended. The Trust currently consists of one series, GMO U.S. Core Equity Series Fund (the “Fund”).
 
      The Fund has had no operations to date other than matters relating to its organization and the sale and issuance of 5,000 shares of beneficial interest in the Fund to Grantham, Mayo , Van Otterloo & Co. LLC (the “Manager” or “GMO”), at a net asset value of $20.00 per share on August 24, 2011.
 
      Upon commencement of the Fund’s investment operations, it will invest substantially all of its assets in GMO U.S. Core Equity Fund (“USCEF”), which invests directly in securities and other instruments. The Fund’s investment objective and principal investment strategies, therefore, will be substantially similar to those of USCEF. References to the Fund may refer to actions undertaken by the Fund or USCEF. The Fund’s investment advisor, GMO, is also the investment advisor to USCEF.
 
  2.   Summary of Significant Accounting Policies
 
      Use of Estimates:
 
      The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts and disclosures in these financial statements. Actual results could differ from those estimates.
 
      Federal Income Tax:
 
      The Fund intends to qualify as a regulated investment company under Subchapter M of the Internal Revenue Code of 1986, as amended. The Fund intends to distribute substantially all of its net investment income and all of its net realized short-term and long-term capital gain, if any, after giving effect to any available capital loss carryovers. Therefore, no U.S. federal income or excise tax provisions are necessary.
 
      Organizational Expenses:
 
      All organizational and offering expenses of the Trust will be borne by GMO and will not be subject to future recoupment. As a result, organizational and offering expenses are not reflected in this financial statement.

B-3


 

Appendix B
      Concentration of Credit Risk:
 
      Cash at August 24, 2011, is on deposit at State Street Bank and Trust Company in a non-interest bearing account.
 
  3.   Agreements
 
      State Street Bank and Trust Company serves as the Fund’s custodian, fund accounting agent and transfer agent.
 
  4.   Related Parties
 
      Certain officers of the Trust are also employees of the Advisor.
 
  5.   Principal Risks of Investing in the Fund
 
      The value of the Fund’s shares changes with the value of the Fund’s investments, principally in USCEF shares. Many factors can affect this value, and you may lose money by investing in the Fund. Because the Fund invests substantially all of its assets in USCEF, the most significant risks of investing in the Fund are the risks to which the Fund is exposed through USCEF, which include those outlined in the following brief summary of principal risks. In addition to the risks the Fund is exposed to through its investment in USCEF, the Fund is subject to the risk that cash flows in or out of the Fund will cause its performance to differ from that of USCEF.
    Market Risk — Equity Securities — The market value of equity investments may decline due to factors affecting the issuing companies, their industries, or the economy and equity markets generally. If the Fund purchases equity investments at a discount from their value as determined by the Manager, the Fund runs the risk that the market prices of these investments will not increase to that value for a variety of reasons, one of which may be the Manager’s overestimation of the value of those investments. The Fund also may purchase equity investments that typically trade at higher multiples of current earnings than other securities, and the market values of these investments often are more sensitive to changes in future earnings expectations than those other securities. Because the Fund normally does not take temporary defensive positions, declines in stock market prices generally are likely to reduce the net asset value of the Fund’s shares.
 
    Management and Operational Risk — The Fund relies on GMO’s ability to achieve its investment objective by effectively implementing its investment approach. The Fund runs the risk that GMO’s proprietary investment techniques will fail to produce the desired results. The Fund’s portfolio managers may use quantitative analyses and/or models and any imperfections or limitations in such analyses and/or models could affect the ability of the portfolio managers to implement strategies. By necessity, these analyses and models make simplifying assumptions that limit their efficacy. Models that appear to explain prior market data can fail to predict future market events. Further, the data used in models may be inaccurate and/or it may not include the most recent information about a company or a security. The Fund is also subject to the risk that deficiencies in the Manager’s or another service provider’s internal systems or controls will cause losses for the Fund or impair operations.

B-4


 

Appendix B
    Derivatives Risk — The use of derivatives involves the risk that their value may not move as expected relative to the value of the relevant underlying assets, rates or indices. Derivatives also present other Fund risks, including market risk, liquidity risk and counterparty risk.
 
    Counterparty Risk — The Fund runs the risk that the counterparty to an OTC derivatives contract or a borrower of the Fund’s securities will be unable or unwilling to make timely settlement payments or otherwise honor its obligations.
 
    Leveraging Risk — The Fund’s use of derivatives and securities lending may cause its portfolio to be leveraged. Leverage increases the Fund’s portfolio losses when the value of its investments decline.
 
    Smaller Company Risk — Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, or may lack managers with experience or depend on a few key employees. The securities of small- and mid-cap companies often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations.
 
    Focused Investment Risk — Focusing investments in sectors or companies or in industries with high positive correlations to one another creates additional risk.
 
    Market Disruption and Geopolitical Risk — Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events as well as other changes in foreign and domestic economic and political conditions could adversely affect the value of the Fund’s investments.
 
    Large Shareholder Risk — To the extent that shares of the Fund are held by large shareholders (e.g., institutional investors, financial intermediaries, asset allocation funds, or other funds managed by GMO (“GMO Funds”)), the Fund is subject to the risk that these shareholders will disrupt operations by purchasing or redeeming             shares in large amounts and/or on a frequent basis.
 
    Fund of Funds Risk — The Fund is indirectly exposed to all of the risks of an investment in USCEF, including the risk that USCEF will not perform as expected.
  6.   Guarantees
 
      In the normal course of business the Fund enters into contracts with third-party service providers that contain a variety of representations and warranties that provide general indemnifications. The Fund’s maximum exposure under these arrangements is unknown, as it involves possible future claims that may or may not be made against the Fund. Based on experience, GMO is of the view that the risk of loss to the Fund in connection with the Fund’s indemnification obligations is remote; however, there can be no assurance that such obligations will not result in material liabilities that adversely affect the Fund.

B-5


 

GMO SERIES TRUST
PART C. OTHER INFORMATION
Item 28. Exhibits
  (a)   1.   Agreement and Declaration of Trust of GMO Series Trust (the “Trust” or “Registrant”), dated May 27, 2011 (the “Declaration of Trust”) — Previously filed with the SEC as part of the Initial Registration Statement of the Registrant on Form N-1A on May 31, 2011, and hereby incorporated by reference; and
          2.   Amended and Restated Declaration of Trust, dated September 13, 2011 — Exhibit (a)(2).
  (b)   None.
 
  (c)   Please refer to Article II (Shares) and Article V (Shareholders’ Voting Powers and Meetings) of the Amended and Restated Declaration of Trust, which is filed herewith as Exhibit (a)(2).
 
  (d)   Form of Management Contract between the Trust, on behalf of GMO U.S. Core Equity Series Fund, and Grantham, Mayo, Van Otterloo & Co. LLC (“GMO”) — Exhibit (d).
 
  (e)   Conforming Distribution Agreement, dated August 23, 2011, between the Trust and Funds Distributor, LLC — Exhibit (e).
 
  (f)   None.
 
  (g)   Conforming Custodian Agreement, dated August 23, 2011, between the Trust and State Street Bank and Trust Company (“State Street Bank”) — Exhibit (g).
  (h)   1.   Conforming Transfer Agency and Service Agreement, dated August 23, 2011, between the Trust and State Street Bank — Exhibit (h)(1).
        2.   Form of Administration Agreement between the Trust, on behalf of GMO U.S. Core Equity Series Fund, and GMO — Exhibit (h)(2).
 
        3.   Conforming Administration Agreement, dated August 23, 2011, between GMO and State Street Bank — Exhibit (h)(3).
 
          4.   Form of Notification of Undertaking to Reimburse Certain Fund Expenses by GMO to the Trust — Exhibit (h)(4).
  (i)   Opinion and Consent of Legal Counsel — Exhibit (i).

1


 

  (j)   Consent of Independent Registered Public Accounting Firm — Exhibit (j).
 
  (k)   Not applicable.
 
  (l)   Form of Initial Capital and Subscription Agreement — Exhibit (l).
 
  (m)   Not applicable.
 
  (n)   Not applicable.
 
  (o)   Reserved.
  (p)   1.   GMO Code of Ethics, dated May 20, 2011, adopted by GMO, GMO Australasia LLC, GMO Australia Ltd., GMO Singapore PTE Ltd., GMO Switzerland GMBH, GMO U.K. Ltd., GMO Woolley Ltd., GMO Renewable Resources LLC, GMO Renewable Resources (in New Zealand), and GMO Renewable Resources Uruguay, SRL — Exhibit (p)(1).
          2.   GMO Series Trust and GMO Trust Code of Ethics, dated September 5, 2008, as adopted by the Trust on August 23, 2011 — Exhibit (p)(2).
 
          3.   Code of Ethics for the Independent Trustee of GMO Series Trust, dated August 23, 2011, adopted by the Board of Trustees of the Trust — Exhibit (p)(3).
Item 29. Persons Controlled by or Under Common Control with the Fund
     None.
Item 30. Indemnification
     Please refer to Article VIII (Indemnification) of the Amended and Restated Declaration of Trust.
     In addition, the Trust will maintain a trustees and officers liability insurance policy under which the Trust and its trustees and officers will be named insureds. The Trust also has entered into agreements with each of its trustees pursuant to which each of the Funds has agreed to indemnify each Trustee to the maximum extent permitted by applicable law against any liability and expense incurred by the Trustee by reason of the Trustee being or having been a Trustee.
     Insofar as indemnification for liability arising under the Securities Act of 1933 (the “Securities Act”) may be permitted to trustees, officers and controlling persons of the Registrant pursuant to the Trust’s By-laws, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is

2


 

against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a trustee, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such trustee, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
Item 31. Business and Other Connections of Investment Adviser
     A description of the business of Grantham, Mayo, Van Otterloo & Co. LLC, the investment adviser of the Fund (the “Investment Adviser”), is set forth under the captions “Management of the Trust” in the prospectuses and “Investment Advisory and Other Services” in the statements of additional information, all forming part of this Registration Statement.
     Except as set forth below, the directors, officers, and members of the Investment Adviser, have been engaged during the past two fiscal years in no business, profession, vocation or employment of a substantial nature other than as directors, officers, or members of the Investment Adviser or certain of its affiliates. Certain directors, officers, and members of the Investment Adviser serve as officers or trustees of the Registrant as set forth under the caption “Management of the Trust” in the Registrant’s statements of additional information, forming part of this Registration Statement, and/or as officers and/or directors of certain private investment companies managed by the Investment Adviser or certain of its affiliates. The address of the Investment Adviser and the Registrant is 40 Rowes Wharf, Boston, Massachusetts 02110.
         
    Position with    
Name   Investment Adviser   Other Connections
Arjun Divecha
  Member, Chairman of the Board of Directors, and Investment Director   Board Member, Divecha Centre for Climate Change, Indian Institute of Science, Bengaluru, India; Director, Frog Hollow Fresh LLC, P.O. Box 872, Brentwood, CA 94513
 
       
R. Jeremy Grantham
  Founding Member, Member of the Board of Directors, and Chief Investment Strategist   Board Member, Divecha Centre for Climate Change, Indian Institute of Science, Bengaluru, India; CFA Institute — Investors’ Working Group (IWG) Member, 560 Ray C. Hunt Drive, Charlottesville, VA 22903; MSPCC Investment Committee, 555 Amory Street, Jamaica Plain, MA 02130; Board Member, Imperial College of London — Grantham Institute for Climate Change, London SW7 2AZ; Board Member, London School of Economics — Grantham Institute for Climate Change, Houghton Street, London, WC2A 2AE

3


 

         
    Position with    
Name   Investment Adviser   Other Connections
John Rosenblum
  Member and Vice Chairman of the Board of Directors   Trustee, Jamestown-Yorktown Foundation, Inc., P.O. Box 1607, Williamsburg, VA 23187-1607; American Civil War Center Foundation, 200 S. Third St., Richmond, VA 23219; Chair of the Board, The Apprenticeshop (f/k/a Atlantic Challenge), 643 Main St., Rockland, ME 04841; University Symphony Society, 112 Old Cabell Hall, Charlottesville, VA 22903; Treasurer and Board Member, Farnsworth Art Museum, 16 Museum Street, Rockland, Maine 04841; Board Member, Maine Media Workshops and Maine Media College, 70 Camden Street, Rockport, ME 04856
 
       
Eyk Van Otterloo
  Founding Member and Member of the Board of Directors   Chairman of the Board, Chemonics International, 1133 20th Street, NW, Suite 600, Washington, D.C. 20036; Board Member, CliniLabs, 423 W. 55th Street, 4th Floor, New York, NY 10019; Overseer, Peabody Essex Museum, East India Square, Salem, MA 01970; Member, Board of Commissioners, Groothandelsgebouw NV, 45 Stationsplein P.O. Box 29057, 3001GB Rotterdam, Netherlands
Item 32. Principal Underwriters
Item 32(a).   Funds Distributor, LLC (“FD”) serves as principal underwriter for the following investment companies registered under the Investment Company Act of 1940, as amended:
      GMO Series Trust
GMO Trust
Munder Series Trust II
Munder Series Trust
Mirae Asset Discovery Funds

4


 

Item 32(b). The following are officers and directors of FD, the Registrant’s principal underwriter. FD’s main business address is Three Canal Plaza, Suite 100, Portland, Maine 04101.
         
Director or Officer   Positions with FD   Positions with Registrant
Mark A. Fairbanks
  President and Manager   None
Richard J. Berthy
  Vice President, Treasurer and Manager   None
Jennifer E. Hoopes
  Secretary   None
Nanette K. Chern
  Vice President and Chief Compliance Officer   None
Lisa S. Clifford
  Vice President and Director of Compliance   None
Item 32(c). None.
Item 33. Location of Accounts and Records
     The accounts, books, and other documents required to be maintained by Section 31(a) and the rules thereunder will be maintained at the offices of the Registrant, 40 Rowes Wharf, Boston, MA 02110, and at the offices of the Registrant’s investment adviser, Grantham, Mayo, Van Otterloo & Co. LLC, 40 Rowes Wharf, Boston, MA 02110; the Registrant’s distributor, Funds Distributor, LLC, Three Canal Plaza, Suite 100, Portland, Maine 04101; and the Registrant’s custodian and transfer agent, State Street Bank and Trust Company, One Lincoln Street, Boston, MA 02111.
Item 34. Management Services
     Not applicable.
Item 35. Undertakings
     None.
Notice
A copy of the Declaration of Trust, together with all amendments thereto, is on file with the Secretary of the Commonwealth of Massachusetts and notice is hereby given that this instrument is executed on behalf of the Trust by an officer of the Trust as an officer and not individually and that the obligations of this instrument are not binding upon any of the Trustees or officers of the Trust or shareholders of any series of the Trust individually but are binding only upon the assets and property of the Trust or the respective series.

5


 

SIGNATURES
      Pursuant to the requirements of the Securities Act of 1933 (the “Securities Act”) and the Investment Company Act of 1940, each as amended, the Registrant, GMO Series Trust, has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston and The Commonwealth of Massachusetts, on the 15 th day of September, 2011.
         
  GMO Series Trust
 
 
  By:   J.B. KITTREDGE*    
    J.B. Kittredge   
  Title:   President, Chief Executive Officer and
Principal Executive Officer 
 
     Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the date indicated.
         
Signatures   Title   Date
 
J.B. KITTREDGE*
 
J.B. Kittredge
  Trustee; President; Chief Executive Officer; Principal Executive Officer   September 15, 2011
SHEPPARD N. BURNETT*
 
Sheppard N. Burnett
  Treasurer; Chief Financial Officer; Principal Financial and Accounting Officer   September 15, 2011
MARIA D. FURMAN*
 
Maria D. Furman
  Trustee   September 15, 2011
         
     
  *By:   /s/ Jason B. Harrison     
    Jason B. Harrison   
    Attorney-in-Fact**   
 
 
**   Pursuant to Powers of Attorney for each of J.B. Kittredge and Sheppard N. Burnett, filed with the SEC as part of the Initial Registration Statement of the Registrant on May 31, 2011, and pursuant to Power of Attorney for Maria D. Furman filed herewith as Exhibit 2.
GMO SERIES TRUST PRE-EFFECTIVE AMENDMENT NO. 2

6


 

EXHIBIT INDEX
GMO SERIES TRUST
     
Exhibit Ref.   Title of Exhibit
(a)(2)
  Amended and Restated Declaration of Trust, dated September 13, 2011.
 
   
(d)
  Form of Management Contract between the Trust, on behalf of GMO U.S. Core Equity Series Fund, and GMO.
 
   
(e)
  Conforming Distribution Agreement, dated August 23, 2011, between the Trust and Funds Distributor, LLC.
 
   
(g)
  Conforming Custodian Agreement, dated August 23, 2011, between the Trust and State Street Bank.
 
   
(h)(1)
  Conforming Transfer Agency and Service Agreement, dated August 23, 2011, between the Trust and State Street Bank.
 
   
(h)(2)
  Form of Administration Agreement between the Trust, on behalf of GMO U.S. Core Equity Series Fund, and GMO.
 
   
(h)(3)
  Conforming Administration Agreement, dated August 23, 2011, between GMO and State Street Bank.
 
   
(h)(4)
  Form of Notification of Undertaking to Reimburse Certain Fund Expenses by GMO to the Trust.
 
   
(i)
  Opinion and Consent of Legal Counsel.
 
   
(j)
  Consent of Independent Registered Public Accounting Firm.
 
   
(l)
  Form of Initial Capital and Subscription Agreement.
 
   
(p)(1)
  GMO Code of Ethics, dated May 20, 2011.
 
   
(p)(2)
  GMO Series Trust and GMO Trust Code of Ethics, dated September 5, 2008, as adopted by the Trust on August 23, 2011.
 
   
(p)(3)
  Code of Ethics for the Independent Trustee of GMO Series Trust, dated August 23, 2011, adopted by the Board of Trustees of the Trust.
 
   
Other.
   
 
   
1
  Certificate of Clerk of the Trust certifying action by written consent of the sole Trustee of the Trust required pursuant to Rule 483 under the Securities Act of 1933.
 
   
2
  Power of Attorney for Maria D. Furman.

7

Exhibit (a)(2)
AMENDED AND RESTATED
AGREEMENT AND DECLARATION OF TRUST
GMO SERIES TRUST
     THIS AMENDED AND RESTATED AGREEMENT AND DECLARATION OF TRUST made at Boston, Massachusetts this 13th day of September, 2011 hereby amends and restates in its entirety the Agreement and Declaration of Trust dated May 27, 2011 by the sole initial Trustee hereunder and by the holders of shares of beneficial interest to be issued hereunder as hereinafter provided.
     WITNESSETH that
     WHEREAS this Trust has been formed to carry on the business of an investment company;
     WHEREAS this Trust has registered as a registered investment company and plans to comply with the applicable requirements of the 1940 Act; and
     WHEREAS the Trustee has agreed to manage all property coming into his hands as a trustee of a Massachusetts business trust in accordance with the provisions hereinafter set forth.
     NOW, THEREFORE, the Trustee does hereby direct that this Amended and Restated Agreement and Declaration of Trust be filed with the Secretary of The Commonwealth of Massachusetts and with the City Clerk of the City of Boston and does hereby declare that he will hold all cash, securities and other assets, which he may from time to time acquire in any manner as a Trustee hereunder IN TRUST to manage and dispose of the same upon the following terms and conditions for the benefit of the holders from time to time of Shares in this Trust as hereinafter set forth.
ARTICLE I.
Name and Definitions
Section 1. This Trust shall be known as “GMO Series Trust” with its principal place of business at 40 Rowes Wharf, Boston, Massachusetts 02110, and the Trustees shall conduct the business of the Trust under that name or any other name as they may from time to time determine.
Section 2. Definitions . Whenever used herein, unless otherwise required by the context or specifically provided:

 


 

(a) “Trust” refers to the Massachusetts business trust established by this Agreement and Declaration of Trust, as amended from time to time;
(b) “Trustees” refers to the Trustees of the Trust named in Article IV hereof or elected or appointed in accordance with such Article;
(c) “Independent Trustees” refers to the Trustees who are not “interested persons” of the Trust, as defined in the 1940 Act.
(d) “Interested Trustees” refers to the Trustees who are “interested persons” of the Trust, as defined in the 1940 Act.
(d) “Shares” means the equal proportionate transferable units of interest into which the beneficial interest in the Trust shall be divided from time to time or, if more than one Series or Class of Shares is authorized by the Trustees, the equal proportionate transferable units into which each Series or Class of Shares shall be divided from time to time.
(e) “Shareholder” means a record owner of Shares;
(f) “1940 Act” refers to the Investment Company Act of 1940 and the Rules and Regulations thereunder, all as amended from time to time;
(g) The terms “Commission” and “principal underwriter” shall have the meanings given to them in the 1940 Act;
(h) “Declaration of Trust” shall mean this Agreement and Declaration of Trust, as amended or restated from time to time;
(i) “By-Laws” shall mean the By-Laws of the Trust as amended from time to time;
(j) “Series” or “Series of Shares” refers to the one or more separate investment portfolios of the Trust into which the assets and liabilities of the Trust may be divided and the Shares of the Trust representing the beneficial interest of Shareholders in such respective portfolios; and
(k) “Class” or “Class of Shares” refers to the division of Shares representing any Series into two or more Classes, as provided in Article III, Section 1.
ARTICLE II.
Purpose of Trust
     The purpose of the Trust is to provide investors a managed investment directly or indirectly primarily in securities (including options), debt instruments, commodities, commodity contracts and options thereon, notional and other over-the-counter contracts, and other investments of any kind.

-2-


 

ARTICLE III.
Shares
Section 1. Division of Beneficial Interest . The Shares of the Trust shall be issued in one or more Series as the Trustees may authorize. Each Series shall be preferred over all other Series in respect of the assets allocated to that Series within the meaning of the 1940 Act and shall represent a separate investment portfolio of the Trust. The beneficial interest in each Series shall at all times be divided into Shares, without par value, each of which shall, except as provided in the following sentence, represent an equal proportionate interest in the Series with each other Share of the same Series, none having priority or preference over another. The Trustees may divide the Shares of any Series into two or more Classes, with Shares of each such Class having such preferences and special or relative rights and privileges (including conversion rights, if any) as the Trustees may determine and as shall be set forth herein and/or in such other document as the Trustees determine. The number of Shares authorized shall be unlimited. The Trustees may from time to time divide or combine the Shares of any Series or Class into a greater or lesser number, classify or re-classify any issued or unissued Shares of any Series or Class into one or more Series or Classes, and take such other actions with respect to the Shares as the Trustees deem desirable.
Section 2. Ownership of Shares . The ownership of Shares shall be recorded on the books of the Trust or a transfer or similar agent for the Trust, which books shall be maintained separately for the Shares of each Series and Class. No certificates certifying the ownership of Shares shall be issued except as the Trustees may otherwise determine from time to time. The Trustees may make such rules as they consider appropriate for the transfer of Shares of each Series and Class and similar matters. The record books of the Trust as kept by the Trust or any transfer or similar agent, as the case may be, shall be conclusive as to who are the Shareholders of each Series and Class and as to the number of Shares of each Series and Class held from time to time by each.
Section 3. Investments in the Trust . The Trustees shall accept investments in the Trust from such persons and on such terms and for such consideration, including the payment of any purchase premium fixed by the Trustees, as they from time to time authorize.
Section 4. Status of Shares and Limitation of Personal Liability . Shares shall be deemed to be personal property giving only the rights provided in this instrument. Every Shareholder by virtue of having become a Shareholder shall be held to have expressly assented and agreed to the terms of this Declaration of Trust and the By-Laws (each as amended from time to time) and to have become a party thereto. The death of a Shareholder during the continuance of the Trust shall not operate to terminate the same nor entitle the representative of any deceased Shareholder to an accounting or to take any action in court or elsewhere against the Trust or the Trustees, but entitles such representative only to the rights of said deceased Shareholder under this Trust. Ownership of Shares shall not entitle the Shareholder to any title in or to the whole or any part of the Trust property or right to call for a partition or division of the same or for an accounting, nor shall the ownership of Shares constitute the Shareholders partners. Neither the Trust nor the Trustees, nor any officer, employee or agent of the Trust shall have any power to bind personally any Shareholders, nor except as specifically provided herein, to call upon any Shareholder for the

-3-


 

payment of any sum of money or assessment whatsoever other than such as the Shareholder may at any time personally agree to pay.
      Section 5. Power of Trustees to Change Provisions Relating to Shares . Notwithstanding any other provisions of this Declaration of Trust and without limiting the power of the Trustees to amend the Declaration of Trust as provided elsewhere herein, the Trustees shall have the power to amend this Declaration of Trust, at any time and from time to time, in such manner as the Trustees may determine in their sole discretion, without the need for Shareholder action, so as to add to, delete, replace or otherwise modify any provisions relating to the Shares contained in this Declaration of Trust. The establishment and designation of any Series or Class of Shares in addition to the Series and Classes established and designated in Section 6 of this Article III shall be effective upon the execution by the Trustees of an amendment to this Declaration of Trust, taking the form of a complete restatement or otherwise, setting forth such establishment and designation and the relative rights and preferences of such Series or Class, as the case may be, or as otherwise provided in such instrument, this Declaration of Trust, and/or in such other document as the Trustees determine.
     Without limiting the generality of the foregoing, the Trustees may amend the Declaration of Trust to:
(a) create one or more Series or Classes of Shares (in addition to any Series or Classes already existing or otherwise) with such rights and preferences and such eligibility requirements for investment therein as the Trustees shall determine and reclassify any or all outstanding Shares as shares of particular Series or Classes in accordance with such eligibility requirements;
(b) combine one or more Series or Classes of Shares into a single Series or Class on such terms and conditions as the Trustees shall determine;
(c) change or eliminate any eligibility requirements for investment in Shares of any Series or Class, including without limitation the power to provide for the issue of Shares of any Series or Class in connection with any merger or consolidation of the Trust with another trust or company or any acquisition by the Trust of part or all of the assets of another trust or company;
(d) change the designation of any Series or Class of Shares;
(e) change the method of allocating dividends among the various Series and Classes of Shares;
(f) allocate any specific assets or liabilities of the Trust or any specific items of income or expense of the Trust to one or more Series or Classes of Shares;
(g) specifically allocate assets to any or all Series or Classes of Shares or create one or more additional Series or Classes of Shares which are preferred over all other Series or Classes of Shares in respect of assets specifically allocated thereto or any dividends paid by the Trust with respect to any net income, however determined, earned from the investment and reinvestment of any assets so allocated or otherwise and provide for any special voting or other rights with respect to such Series or Classes; and

-4-


 

(h) amend any of the provisions set forth in paragraphs (a) through (g) of this Section 5.
Section 6. Establishment and Designation of Series . Without limiting the authority of the Trustees set forth in Section 5 of this Article III, inter alia , to establish and designate any further Series or Classes or to modify the rights and preferences of any Series, each Series set forth on Schedule 3.6A attached hereto shall be, and are hereby, established and designated. In addition, with respect to each such Series, the Classes of Shares set forth on Schedule 3.6B attached hereto shall be, and are hereby, established and designated, which Classes shall have the respective rights and preferences as set forth herein and/or in such other document as the Trustees determine.
Section 7. Rights and Preferences of Series and Classes . Shares of each Series (or Class, as the case may be) established in this Article III shall have the following relative rights and preferences:
(a) Assets belonging to Series . All consideration received by the Trust for the issue or sale of Shares of a particular Series, together with all assets in which such consideration is invested or reinvested, all income, earnings, profits, and proceeds thereof from whatever source derived, including, without limitation, any proceeds derived from the sale, exchange or liquidation of such assets, and any funds or payments derived from any reinvestment of such proceeds in whatever form the same may be, shall irrevocably belong to that Series for all purposes, subject only to the rights of creditors, and shall be so recorded upon the books of account of the Trust. Such consideration, assets, income, earnings, profits and proceeds thereof, from whatever source derived, including, without limitation, any proceeds derived from the sale, exchange or liquidation of such assets, and any funds or payments derived from any reinvestment of such proceeds, in whatever form the same may be, are herein referred to as “assets belonging to” that Series. In the event that there are any assets, income, earnings, profits and proceeds thereof, funds or payments which are not readily identifiable as belonging to any particular Series (collectively, “General Assets”), the Trustees shall allocate such General Assets to, between or among any one or more of the Series established and designated from time to time in such manner and on such basis as they, in their sole discretion, deem fair and equitable, and any General Asset so allocated to a particular Series shall belong to that Series. Each such allocation by the Trustees shall be conclusive and binding upon the Shareholders of all Series for all purposes.
(b) Liabilities Belonging to Series . The assets belonging to each particular Series shall be charged solely with the liabilities of the Trust in respect to that Series, expenses, costs, charges and reserves attributable to that Series, and any general liabilities of the Trust which are not readily identifiable as belonging to any particular Series but which are allocated and charged by the Trustees to and among any one or more of the Series established and designated from time to time in a manner and on such basis as the Trustees in their sole discretion deem fair and equitable. The liabilities, expenses, costs, charges, and reserves so charged to a Series are herein referred to as “liabilities belonging to” that Series. Each allocation of liabilities, expenses, costs, charges and reserves by the Trustees shall be conclusive and binding upon the holders of all Series for all purposes.

-5-


 

(c) Dividends, Distributions, Redemptions, and Repurchases . Notwithstanding any other provisions of this Declaration, including, without limitation, Article VI, no dividend or distribution (including, without limitation, any distribution paid upon termination of the Trust or of any Series or Class) with respect to, nor any redemption or repurchase of, the Shares of any Series shall be effected by the Trust other than from the assets belonging to such Series, nor shall any Shareholder of any particular Series otherwise have any right or claim against the assets belonging to any other Series except to the extent that such Shareholder has such a right or claim hereunder as a Shareholder of such other Series.
(d) Voting . Shareholders of any particular Series or Class shall not be entitled to vote on any matters as to which such Series or Class is not affected except as otherwise determined by the Trustees or required by the 1940 Act. On any matter submitted to a vote of Shareholders, all Shares of the Trust then entitled to vote shall be voted by individual Series, unless otherwise determined by the Trustees or required by the 1940 Act.
(e) Equality . All the Shares of each particular Class of a Series shall represent an equal proportionate interest in the assets allocable to that Class, and each Share of any particular Series shall be equal to each other Share of that Series (subject to the liabilities allocated to each Class of that Series).
(f) Fractions . Any fractional Share of a Series or Class shall carry proportionately all the rights and obligations of a whole share of that Series or Class, including rights with respect to voting, receipt of dividends and distributions, redemption of Shares and termination of the Trust.
(g) Exchange Privilege . The Trustees shall have the authority to provide that the holders of Shares of any Series or Class shall have the right to exchange said Shares for Shares of one or more other Series or Class of Shares in accordance with such requirements and procedures as may be established by the Trustees.
(h) Combination of Series or Classes . The Trustees shall have the authority to combine the assets and liabilities belonging to any two or more Series (or the assets allocable to any two or more Classes) into assets and liabilities belonging (or allocable) to a single Series or Class.
(i) Division of Series or Classes. The Trustees shall have the authority to divide the assets and liabilities belonging to any Series (or the assets allocable to any Class) into assets and liabilities belonging (or allocable) to two or more Series or Classes
(j) Elimination of Series or Classes . The Trustees shall have the authority to eliminate any particular Series or Class previously established and designated.
(k) Assets and Liabilities Allocable to a Class . To the extent necessary or appropriate to give effect to the preferences and special or relative rights and privileges of any Classes, the Trustees may, allocate assets and liabilities belonging to a Series to a particular Class of that Series or apportion the same among two or more Classes of that Series.
Section 8. No Preemptive Rights . Shareholders shall have no preemptive or other right to subscribe to any additional Shares or other securities issued by the Trust.

-6-


 

ARTICLE IV.
The Trustees
Section 1. Appointment and Tenure . The number of Trustees shall be fixed from time to time by the Trustees and may be fixed at one Trustee.
Each Trustee shall serve during the continued lifetime of the Trust for a term of eight years or, if sooner, until he dies, resigns or is removed, or until the election and qualification of his successor; provided, however, that the Trustees may extend a Trustee’s term for one or more successive eight (or fewer)-year periods. Any Trustee may resign at any time by written instrument signed by him and delivered to any officer of the Trust or at a meeting of the Trustees. Such resignation shall be effective upon receipt unless specified to be effective at some other time. Except to the extent expressly provided in a written agreement with the Trust, no Trustee resigning and no Trustee removed shall have any right to any compensation for any period following his resignation or removal, or any right to damages on account of such removal.
Section 2. Removal . The Trustees may remove a Trustee with or without cause.
Section 3. Effect of Death, Resignation, etc. of a Trustee . The death, declination, resignation, retirement, removal, or incapacity of the Trustees, or any of them, shall not operate to annul the Trust or to revoke any existing agency created pursuant to the terms of this Declaration of Trust. If at any time there is a sole Trustee, such Trustee may designate a successor Trustee in writing and such successor Trustee shall take office upon the death, declination, resignation, retirement, removal, or incapacity of the sole Trustee. The Trustees may fill any vacancies; provided, however, that no person may be appointed to serve as an Interested Trustee unless he has been nominated by at least one Interested Trustee (or, if there is no Interested Trustee, then by the most senior officer of the Trust who is an “interested person” of the Trust, as defined in the 1940 Act).
Section 4. Powers . Subject to the provisions of this Declaration of Trust, the business of the Trust shall be managed by the Trustees, and they shall have all powers necessary or convenient to carry out that responsibility (or incidental to the foregoing) including the power to engage in transactions of all kinds on behalf of the Trust. The exercise by the Trustees of their powers shall be valid if, but only if, the exercise is approved by a majority of the Trustees then in office, so long as: (i) at least one Independent Trustee votes for or abstains from such exercise, and (ii) except in the case of the appointment of or shareholder election of an Interested Trustee nominated in accordance with Section 3 above, at least one Interested Trustee votes for or abstains from such exercise; and further provided that if there is only one Trustee, such Trustee is permitted to exercise any power on his own. The Trustees are permitted to delegate any or all of their authority to the officers of the Trust. Except as otherwise provided herein, any action to be taken by the Trustees may be taken at a meeting of the Trustees (a quorum being present), within or without Massachusetts, including any meeting held by means of a conference telephone or other communications equipment by means of which all persons participating in the meeting

-7-


 

can hear each other at the same time and participation by such means shall constitute presence in person at a meeting, or by written consents of the Trustees.
     Without limiting the foregoing, the Trustees shall have the following powers and authority:
(a) to determine the name under which the Trust shall conduct business and to establish and designate any Series or Classes (and amend Schedules 3.6A and 3.6B of the Declaration of Trust accordingly);
(b) to amend this Declaration of Trust, including to add to, delete, replace or otherwise modify any provisions of this Declaration of Trust relating to the Shares;
(c) to divide the Shares of the Trust into Series and Classes and to divide the Shares of any Series into two or more Classes, and to divide or combine the Shares of any Series or Class into a greater or lesser number, classify or re-classify any issued or unissued Shares of any Series or Class into one or more Series or Classes, and take such other actions with respect to the Shares as the Trustees deem desirable;
(d) to determine the preferences and special or relative rights and privileges of each Series or Class of Shares;
(e) to adopt a plan pursuant to Rule 18f-3 under the 1940 Act (and amend such plan from time to time);
(f) to establish an exchange privilege for holders of Shares of any Series or Class and to establish any related requirements and procedures;
(g) to combine the assets and liabilities belonging to any two or more Series (or the assets allocable to any two or more Classes) into assets and liabilities belonging (or allocable) to a single Series or Class and to cause the Trust or any Series or Class thereof to be merged or reorganized into or consolidated with another trust or company (including another Series or Class of the Trust) or its shares exchanged under or pursuant to any state or federal statute, if any, or otherwise to the extent permitted by law;
(h) to terminate the Trust or any particular Series or Class previously established and designated;
(i) at any time when no Shares of a Series or Class are outstanding, to exercise all rights of Shareholders of that Series or Class with respect to matters affecting that Series or Class and take any action required to be taken by the Shareholders;
(j) to allocate assets and liabilities belonging to a Series to a particular Class of that Series or apportion the same among two or more Classes of that Series, to the extent necessary or appropriate to give effect to the preferences and special or relative rights and privileges of any Classes and to allocate General Assets (as defined in Article III, Section 7(a)) to, between or among any one or more of the Series;

-8-


 

(k) to select the investment companies, including series of GMO Trust, in which a Series shall invest;
(l) to adopt, amend or repeal By-Laws not inconsistent with this Declaration of Trust providing for the regulation and management of the affairs of the Trust;
(m) to elect and remove officers and appoint and terminate agents;
(n) to fix the number of Trustees and, subject to the provisions of Section 1 of this Article IV, to fill any vacancies on the Board;
(o) to remove a Trustee;
(p) to extend a Trustee’s term for one or more successive eight (or fewer)-year periods;
(q) to designate one or more committees of the Trustees with such powers and authority as the Trustees determine;
(r) to employ one or more custodians of the assets of the Trust and to authorize such custodians to employ subcustodians and to deposit all or any part of such assets in a system or systems for the central handling of securities or with a Federal Reserve Bank;
(s) to retain a transfer agent or a shareholder servicing agent, or both, to provide for the distribution of Shares by the Trust, through one or more principal underwriters or otherwise, and to make rules for the transfer of Shares of each Series and Class and similar matters;
(t) to retain legal counsel for the Trust or any Series;
(u) to call meetings of Shareholders, give notice of such meetings to Shareholders, designate the location of such meetings, establish a larger quorum for such meetings than the quorum required in Article V, Section 4, establish or change a record date for determining the Shareholders of any Series or Class having the right to notice of and to vote at such meeting and any adjournment thereof, and close the register or transfer books of a Series or Class prior to such meeting.
(v) to cause the Trust to issue certificates certifying ownership of Shares;
(w) to cause each Shareholder to pay expenses of the Trust;
(x) to establish or change a record date for determining Shareholders who are entitled to receive payment of any dividend or other distribution and close the register or transfer books of a Series or Class prior to the payment of a distribution;
(y) to determine whether to accept investments in the Trust and to establish the terms and consideration for such investments in the Trusts, including any purchase premium;

-9-


 

(z) to exercise the powers set forth in Article VI of this Declaration of Trust;
(aa) to invest and reinvest cash, and to hold cash uninvested;
(bb) to sell, exchange, lend, pledge, mortgage, hypothecate, lease, or write options with respect to or otherwise deal in any property rights relating to any or all of the assets of the Trust;
(cc) to vote or give assent, or exercise any rights of ownership, with respect to stock or other securities or property; and to execute and deliver proxies or powers of attorney to such person or persons as the Trustees shall deem proper, granting to such person or persons such power and discretion with relation to securities or property as the Trustees shall deem proper;
(dd) to exercise power and rights of subscription or otherwise which may in any manner arise out of the ownership of securities;
(ee) to hold any security or property in a form not indicating any trust, whether in bearer, unregistered or other negotiable form, or in its own name or in the name of a custodian or subcustodian or a nominee or nominees or otherwise;
(ff) to consent to or participate in any plan for the reorganization, consolidation or merger of any corporation or issuer of any security which is held in the Trust; to consent to any contract, lease, mortgage, purchase or sale of property by such corporation or issuer; and to pay calls or subscriptions with respect to any security held in the Trust;
(gg) to contract for advisory and/or management services for the Trust or for any Series;
(hh) to join with other security holders in acting through a committee, depositary, voting trustee or otherwise, and in that connection to deposit any security with, or transfer any security to, any such committee, depositary or trustee, and to delegate to them such power and authority with relation to any security (whether or not so deposited or transferred) as the Trustees shall deem proper and to agree to pay, and to pay, such portion of the expenses and compensation of such committee, depositary or trustee as the Trustees shall deem proper;
(ii) to compromise, arbitrate or otherwise adjust claims in favor of or against the Trust or any matter in controversy, including but not limited to claims for taxes;
(jj) to enter into joint ventures, general or limited partnerships and any other combinations or associations;
(kk) to borrow funds or other property;
(ll) to make or issue notes, bonds, contracts, instruments, certificates or other undertakings on behalf of the Trust;
(mm) to endorse or guarantee the payment of any notes or other obligations of any person; to make contracts of guaranty or suretyship, or otherwise assume liability for payment thereof; and to mortgage and pledge Trust property or any part thereof to secure any of or all such obligations;

-10-


 

(nn) to pay or cause to be paid, entirely out of Trust property, all expenses, fees, charges, taxes and liabilities incurred or arising in connection with the Trust including, but not limited to, the Trustees’ compensation;
(oo) to purchase and pay for, entirely out of Trust property, such insurance as they may deem necessary or appropriate for the conduct of the business, including without limitation, insurance policies insuring the assets of the Trust and payment of distributions and principal on its portfolio investments, and insurance policies insuring the Shareholders, Trustees, officers, employees, agents, investment advisers, principal underwriters, or independent contractors of the Trust individually against all claims and liabilities of every nature arising by reason of holding being or having held any such office or position, or by reason of any action alleged to have been taken or omitted by any such person as Shareholder, Trustee, officer, employee, agent, investment adviser, principal underwriter, or independent contractor, including any action taken or omitted that may be determined to constitute negligence, whether or not the Trust would have the power to indemnify such person against liability; and
(pp) to pay pensions as deemed appropriate by the Trustees and to adopt, establish and carry out pension, profit-sharing, share bonus, share purchase, savings, thrift and other retirement, incentive and benefit plans, trusts and provisions, including the purchasing of life insurance and annuity contracts as a means of providing such retirement and other benefits, for any or all of the Trustees, officers, employees and agents of the Trust.
     The Trustees shall not in any way be bound or limited by any present or future law or custom in regard to investments by Trustees. The Trustees shall not be required to obtain any court order to deal with any assets of the Trust or take any other action hereunder.
Section 5. Payment of Expenses by the Trust . The Trustees are authorized to pay or cause to be paid out of the principal or income of the Trust, or partly out of principal and partly out of income, as they deem fair, all expenses, fees, charges, taxes and liabilities incurred or arising in connection with the Trust, or in connection with the management thereof, including but not limited to, the Trustees’ compensation and such expenses and charges for the services of the Trust’s officers, employees, investment adviser or manager, principal underwriter, auditor, counsel, custodian, transfer agent, shareholder servicing agent, and such other agents or independent contractors and such other expenses and charges as the Trustees may deem necessary or proper to incur.
Section 6. Payment of Expenses by Shareholders . The Trustees shall have the power, as frequently as they may determine, to cause each Shareholder, or each Shareholder of any particular Series or Class, to pay directly, in advance or arrears, for charges of the Trust’s custodian or transfer, shareholder servicing or similar agent, an amount fixed from time to time by the Trustees, by setting off such charges due from such Shareholder from declared but unpaid dividends owed such Shareholder and/or by reducing the number of Shares in the account of such Shareholder by that number of full and/or fractional Shares which represents the outstanding amount of such charges due from such Shareholder.
Section 7. Ownership of Assets of the Trust . Title to all of the assets of the Trust shall at all times be considered as vested in the Trustees.

-11-


 

Section 8. Advisory, Management and Distribution Contracts; Other Service Providers . The Trustees may, at any time and from time to time, contract for exclusive or nonexclusive advisory and/or management services for the Trust or for any Series with Grantham, Mayo, Van Otterloo & Co. LLC or any other partnership, corporation, trust, association or other organization (the “Manager”); and any such contract may contain such other terms as the Trustees may determine, including, without limitation, authority for a Manager to determine from time to time without prior consultation with the Trustees what investments shall be purchased, held, sold or exchanged and what portion, if any, of the assets of the Trust shall be held uninvested and to make changes in the Trust’s investments. The Trustees may also, at any time and from time to time, contract with the Manager or any other partnership, corporation, trust, association or other organization, appointing it exclusive or nonexclusive distributor or principal underwriter for the Shares; and any such contract may contain such other terms as the Trustees may determine.
The fact that:
     (i) any of the Shareholders, Trustees or officers of the Trust is a shareholder, director, officer, partner, trustee, employee, manager, adviser, principal underwriter, distributor or affiliate or agent of or for any partnership, corporation, trust, association, or other organization, or of or for any parent or affiliate of any organization, with which an advisory or management contract, or principal underwriter’s or distributor’s contract, or transfer, shareholder servicing or other agency contract may have been or may hereafter be made, or that any such organization, or any parent or affiliate thereof, is a Shareholder or has an interest in the Trust, or that
     (ii) any corporation, trust, association or other organization with which an advisory or management contract or principal underwriter’s or distributor’s contract, or transfer, shareholder servicing or other agency contract may have been or may hereafter be made also has an advisory or management contract, or principal underwriter’s or distributor’s contract, or transfer, shareholder servicing or other agency contract with one or more other corporations, trusts, associations, or other organizations, or has other business or interests,
shall not affect the validity of any such contract or disqualify any Shareholder, Trustee or officer of the Trust from voting upon or executing the same or create any liability or accountability to the Trust or its Shareholders.
ARTICLE V.
Shareholders’ Voting Powers and Meetings
Section 1. Voting Powers . The Shareholders shall have power to vote only on matters that the Trustees consider necessary or desirable. Each whole Share shall be entitled to one vote as to any matter on which it is entitled to vote and each fractional Share shall be entitled to a proportionate fractional vote. There shall be no cumulative voting in the election of Trustees. Shares may be voted in person or by proxy. A proxy with respect to Shares held in the name of

-12-


 

two or more persons shall be valid if executed by any one of them unless at or prior to exercise of the proxy the Trust receives a specific written notice to the contrary from any one of them. A proxy purporting to be executed by or on behalf of a Shareholder shall be deemed valid unless challenged at its exercise and the burden of proving invalidity shall rest on the challenger. At any time when no Shares of a Series or Class are outstanding, the Trustees may exercise all rights of Shareholders of that Series or Class with respect to matters affecting that Series or Class and may, with respect to that Series or Class, take any action required to be taken by the Shareholders.
Section 2. Meetings . Meetings of the Shareholders may be called by the Trustees. A meeting of Shareholders may be held at any place designated by the Trustees.
Section 3. Derivative Actions . No Shareholder shall have the right to bring or maintain any court action, proceeding, or claim on behalf of the Trust. In addition, no Shareholder shall have the right to bring or maintain any court action, proceeding, or claim on behalf of the Trust without first making a written demand on the Trustees requesting the Trustees to bring or maintain such action, proceeding, or claim. Such demand shall be mailed to the Secretary of the Trust at the Trust’s principal office and shall set forth in reasonable detail the nature of the proposed court action, proceeding, or claim and the essential facts relied upon by the Shareholder to support the allegations made in the demand. In their sole discretion, the Trustees may act on any demand or may submit the matter to a vote of the Shareholders of the Trust, as appropriate.
Section 4. Quorum and Required Vote . Except when a larger quorum is established by the Trustees, 10% of the Shares entitled to vote shall constitute a quorum at a Shareholders’ meeting. When any one Series or Class is to vote separately from any other Shares which are to vote on the same matters as a separate Series or Class, 10% of the Shares of each such Series or Class entitled to vote shall constitute a quorum at a Shareholder’s meeting of that Series or Class. Any meeting of Shareholders may be adjourned from time to time, whether or not a quorum is present, and the meeting may be held as adjourned after the date set for the original meeting without further notice. The Trustees shall determine the vote of Shares necessary to decide any questions at a Shareholders’ meeting.
Section 5. Action by Written Consent . At the discretion of the Trustees, any action to be taken by Shareholders may be taken by written consent. Such consent shall be treated for all purposes as a vote taken at a meeting of Shareholders.
Section 6. Record Dates . For the purpose of determining the Shareholders of any Series or Class who are entitled to vote or act at any meeting or any adjournment thereof, the Trustees may from time to time fix a time as the record date for determining the Shareholders of such Series or Class having the right to notice of and to vote at such meeting and any adjournment thereof, and in such case only Shareholders of record on such record date shall have such right, notwithstanding any transfer of shares on the books of the Trust after the record date. For the purpose of determining the Shareholders of any Series or Class who are entitled to receive payment of any dividend or of any other distribution, the Trustees may from time to time fix a date, which shall be before the date for the payment of such dividend or such other payment, as the record date for determining the Shareholders of such Series or Class having the right to receive such dividend or distribution. Without fixing a record date, the Trustees may, for voting

-13-


 

and/or distribution purposes, close the register or transfer books for one or more Series or Classes for all or any part of the period between a record date and a meeting of shareholders or the payment of a distribution. Nothing in this section shall be construed as precluding the Trustees from setting different record dates for different Series or Classes.
Section 7. Additional Provisions . The By-Laws may include further provisions for Shareholders’ votes and meetings and related matters.
ARTICLE VI.
Net Income, Distributions, Allocations, and Redemptions and Repurchases
Section 1. Distributions . The Trustees shall each year, or more frequently if they so determine in their sole discretion, distribute to the Shareholders of each Series or Class, in shares of that Series or Class, cash or otherwise, an amount approximately equal to the net income attributable to the assets belonging to such Series (or the assets allocable to such Class) and may from time to time distribute to the Shareholders of each Series or Class, in shares of that Series, cash or otherwise, such additional amounts from sources including, without limitation, capital gains and/or paid in surplus, but only from the assets belonging to such Series (or allocable to that Class), as they may authorize; provided, however, that with respect to any Series for which it is determined, prior to the time that any Shares of such Series are outstanding, that the Series will elect to be treated as a partnership for tax purposes, the Trustees shall determine in their sole discretion the timing and amount of any distributions to Shareholders of such Series. All dividends and distributions on Shares of a particular Series or Class shall be distributed pro rata to the holders of that Series or Class in proportion to the number of Shares of that Series or Class held by such holders and recorded on the books of the Trust at the date and time of record established for that payment or such dividend or distributions.
     The manner of determining net income, income, asset values, capital gains, expenses, liabilities and reserves of any Series or Class may from time to time be altered as necessary or desirable in the judgment of the Trustees to conform such manner of determination to any other method prescribed or permitted by applicable law. Net income shall be determined by the Trustees or by such person as they may authorize at the times and in the manner provided in the By-Laws. Determinations of net income of any Series or Class and determination of income, asset value, capital gains, expenses, and liabilities made by the Trustees, or by such person as they may authorize, in good faith, shall be binding on all parties concerned. The foregoing sentence shall not be construed to protect any Trustee, officer or agent of the Trust against any liability to the Trust or its security holders to which he would otherwise be subject by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of his office.
     If, for any reason, the net income of any Series or Class determined at any time is a negative amount, the pro rata share of such negative amount allocable to each Shareholder of such Series or Class shall constitute a liability of such Shareholder to that Series or Class which shall be paid out of such Shareholder’s account at such times and in such manner as the Trustees

-14-


 

may from time to time determine (x) out of the accrued dividend account of such Shareholder, (y) by reducing the number of Shares of that Series or Class in the account of such Shareholder, or (z) otherwise.
Section 2. Allocations . In respect of any Series that is treated as a partnership for federal income tax purposes, the Trustees (or such other person designated by the Trustees as having responsibility for making tax determinations on behalf of the Series) shall have authority to make special allocations of income, gain, loss or deduction among Shareholders upon withdrawals or transfers of shares as necessary to avoid mandatory basis adjustments in the assets of the Series as required by Internal Revenue Code of 1986, as amended (the “Code”), section 743 or 734 that would otherwise apply as a result of amendments to such Code sections under The American Jobs Creation Act of 2004, enacted on October 22, 2004.
Section 3. Redemptions and Repurchases . The Trust shall purchase such Shares as are offered by any Shareholder for redemption, upon the presentation of a proper instrument of transfer together with a request directed to the Trust or a person designated by the Trust that the Trust purchase such Shares or in accordance with such other procedures for redemption as the Trustees may from time to time authorize; and the Trust will pay therefor the net asset value thereof, as determined in accordance with the By-Laws, next determined, less any applicable redemption fee as the Trustees may approve from time to time. The Board may approve a redemption fee from time to time applicable to Shares whether such Shares were outstanding at the time of the Board’s approval or issued after the time of the Board’s approval.
     Payment for said Shares shall be made by the Trust to the Shareholder within seven days after the date on which the request is made. The obligation set forth in this Section 3 is subject to the provision that in the event that any time the New York Stock Exchange is closed for other than weekends or holidays, or if permitted by the rules of the Commission during periods when trading on the Exchange is restricted or during any emergency which makes it impracticable for the Trust to dispose of the investments of the applicable Series or to determine fairly the value of the net assets belonging to such Series (or net assets allocable to such Class) or during any other period permitted by order of the Commission for the protection of investors, such obligations may be suspended or postponed by the Trustees. The Trust may also purchase or repurchase Shares at a price not exceeding the net asset value of such Shares in effect when the purchase or repurchase or any contract to purchase or repurchase is made.
     Payment for any redemption, purchase, or repurchase may be made in cash or in other property, or in any combination thereof. The composition of any such payment shall be determined by the Trust in its sole discretion, and the Trust shall have no obligation to effect a pro rata division of cash or other property in making any such payment. In no case shall the Trust be liable for any delay of any corporation or other person in transferring securities selected for delivery as all or part of any payment in kind.
Section 4. Redemptions at the Option of the Trust . The Trustees shall have the right, in their sole discretion, to cause the Trust at any time to redeem Shares of any Shareholder at the net asset value thereof as described in Section 3 of this Article VI, less any redemption fee as the Board may approve from time to time as applicable to Shares, whether such Shares were outstanding at the time of the Board’s approval or issued after the time of the Board’s approval.

-15-


 

ARTICLE VII.
Compensation and Limitation of Liability of Trustees
Section 1. Compensation . The Trustees as such shall be entitled to reasonable compensation from the Trust, which compensation shall be determined by the Trustees. Nothing herein shall in any way prevent the employment of any Trustee for advisory, management, legal, accounting, investment banking or other services and payment for the same by the Trust.
Section 2. Limitation of Liability . A Trustee shall be liable for his own willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of the office of Trustee, and for nothing else, and shall not be liable for errors of judgment or mistakes of fact or law. The Trustees may take advice of counsel or other experts with respect to the meaning and operation of this Declaration of Trust, and shall be under no liability for any act or omission in accordance with such advice or for failing to follow such advice. The Trustees shall not be responsible or liable in any event for any neglect or wrong-doing of any officer, agent, employee, Manager or principal underwriter of the Trust, nor shall any Trustee be responsible for the act or omission of any other Trustee, but, for so long as the Trust is registered as an investment company under the 1940 Act and as long required by Section 17(h) of the 1940 Act, nothing herein contained shall protect any Trustee against any liability to which he would otherwise be subject by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of his office.
Every note, bond, contract, instrument, certificate or undertaking and every other act or thing whatsoever issued, executed or done by or on behalf of the Trust or the Trustees or any of them in connection with the Trust shall be conclusively deemed to have been issued, executed or done only in or with respect to their or his capacity as Trustees or Trustee, and such Trustees or Trustee shall not be personally liable thereon.
ARTICLE VIII.
Indemnification
Section 1. Trustees, Officers, etc. The Trust shall, to the maximum extent permitted by applicable law, indemnify each of its Trustees and officers (including persons who serve at the Trust’s request as directors, officers or trustees of another organization in which the Trust has any interest as a shareholder, creditor or otherwise) (hereinafter referred to as a “Covered Person”) against all liabilities and expenses, including but not limited to amounts paid in satisfaction of judgments, in compromise or as fines and penalties, and counsel fees reasonably incurred by any Covered Person in connection with the defense or disposition of any action, suit or other proceedings, whether civil or criminal, before any court or administrative or legislative body, in which such Covered Person may be or may have been involved as a party or otherwise or with which such person may be or may have been threatened, while in office or thereafter, by reason of any alleged act or omission as a Trustee or officer or by reason of his being or having been such a Trustee or officer, except with respect to any matter as to which such Covered

-16-


 

Person shall have been finally adjudicated in any such action, suit or other proceeding not to have acted in good faith in the reasonable belief that such Covered Person’s action was in or not opposed to the best interest of the Trust and except that no Covered Person shall be indemnified against any liability to the Trust or its Shareholders to which such Covered Person would otherwise be subject by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of such Covered Person’s office. Expenses, including counsel fees so incurred by any such Covered Person (but excluding amounts paid in satisfaction of judgments, in compromise or as fines or penalties), shall be paid by the Trust in advance of the final disposition of any such action, suit or proceeding upon receipt of an undertaking by or on behalf of such Covered Person to repay amounts so paid to the Trust if it is ultimately determined that indemnification of such expenses is not authorized under this Article, provided, however, that (a) such Covered Person shall provide security for his or her undertaking, (b) the Trust shall be insured against losses arising by reason of such Covered Person’s failure to fulfill his or her undertaking, or (c) either a majority of the Trustees who are disinterested persons (as defined in Section 4 of this Article VIII) and who are not “interested persons” of the Trust, as defined in the 1940 Act (provided that a majority of such Trustees then in office act on the matter), or independent legal counsel in a written opinion, shall determine, based on a review of readily available facts (but not a full trial-type inquiry), that there is reason to believe such Covered Person ultimately will be entitled to indemnification.
Section 2. Compromise Payment . As to any matter disposed of (whether by a compromise payment, pursuant to a consent decree or otherwise) without an adjudication in a decision on the merits by a court, or by any other body before which the proceeding was brought, that such Covered Person either (a) did not act in good faith in the reasonable belief that such Covered Person’s action was in or not opposed to the best interests of the Trust or (b) is liable to the Trust or its Shareholders by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of such Covered Person’s office, indemnification shall be provided if (x) approved as in or not opposed to the best interests of the Trust, after notice that it involves such indemnification, by at least a majority of the Trustees who are disinterested persons and are not “interested persons” of the Trust, as defined in the 1940 Act (provided that a majority of such Trustees then in office act on the matter), upon a determination, based upon a review of readily available facts (but not a full trial-type inquiry) that such Covered Person is not liable to the Trust or its Shareholders by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of such Covered Person’s office, or (y) there has been obtained an opinion in writing of independent legal counsel, based upon a review of readily available facts (but not a full trial-type inquiry), to the effect that such indemnification would not protect such Covered Person against any liability to the Trust or its Shareholders to which such Covered Person would otherwise be subject by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of his or her office. Any approval pursuant to this Section 2 shall not prevent the recovery from any Covered Person of any amount paid to such Covered Person in accordance with this Section 2 as indemnification if such Covered Person is subsequently adjudicated by a court of competent jurisdiction not to have acted in good faith in the reasonable belief that such Covered Person’s action was in or not opposed to the best interests of the Trust or to have been liable to the Trust or its Shareholders by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of such Covered Person’s office.

-17-


 

Section 3. Rebuttable Presumption . For purposes of the determination or opinion referred to in clause (c) of Section 1 of this Article VIII or clauses (x) or (y) of Section 2 of this Article VIII, the disinterested Trustees acting on the matter or independent legal counsel, as the case may be, shall be entitled to rely upon a rebuttable presumption that the Covered Person has not engaged in willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of such Covered Person’s office.
Section 4. Indemnification Not Exclusive . The right of indemnification hereby provided shall not be exclusive of or affect any other rights to which any such Covered Person may be entitled, whether by contract or otherwise. As used in this Article VIII, the term “Covered Person” shall include such person’s heirs, executors and administrators; and a “disinterested Trustee” or “disinterested person” is a Trustee or a person against whom none of such actions, suits or other proceedings or another action, suit or other proceeding on the same or similar grounds is then or has been pending. Nothing contained in this Article VIII shall affect the power of the Trust to purchase and maintain liability insurance on behalf of any such person.
Section 5. Amendment . Notwithstanding any other provision of this Declaration of Trust relating to its amendment generally, any repeal or modification of this Article VIII shall not adversely affect any right or protection of a Trustee or officer of the Trust with respect to any acts or omissions of such Trustee or officer occurring prior to such repeal or modification.
Section 6 . Shareholders . In case any Shareholder or former Shareholder shall be held to be personally liable solely by reason of his or her being or having been a Shareholder and not because of his or her acts or omissions or for some other reason, the Shareholder or former Shareholder (or his or her heirs, executors, administrators or other legal representative or in the case of a corporation or other entity, its corporate or other general successor) shall be entitled to be held harmless from and indemnified against all loss and expense arising from such liability, but only out of the assets of the particular Series or Class of Shares of which he or she is or was a Shareholder.
ARTICLE IX.
Miscellaneous
Section 1. Trustees, Shareholders, etc. Not Personally Liable; Notice . All persons extending credit to, contracting with or having any claim against the Trust or any Series or Class of Shares shall look only to the assets of the Trust, or, to the extent that the liability of the Trust may have been expressly limited by contract to the assets of a particular Series (or the assets allocable to a particular Class), only to the assets belonging to the relevant Series (or allocable to the relevant Class), for payment under such credit, contract or claim; and neither the Shareholders nor the Trustees, nor any of the Trust’s officers, employees or agents, whether past, present or future, shall be personally liable therefor. Nothing in this Declaration of Trust shall protect any Trustee against any liability to which such Trustee would otherwise be subject by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of the office of Trustee.

-18-


 

     Every note, bond, contract, instrument, certificate or undertaking made or issued on behalf of the Trust by the Trustees, by any officers or officer or otherwise shall give notice that this Declaration of Trust is on file with the Secretary of The Commonwealth of Massachusetts and shall recite that the same was executed or made by or on behalf of the Trust or by them as Trustee or Trustees or as officers or officer or otherwise and not individually and that the obligations of such instrument are not binding upon any of them or the shareholders individually but are binding only upon the assets and property of the Trust or upon the assets belonging to the Series (or allocable to the Class) for the benefit of which the Trustees have caused the note, bond, contract, instrument, certificate or undertaking to be made, or issued, and may contain such further recital as he or they may deem appropriate, but the omission of any such recital shall not operate to bind any Trustee or Trustees or officers or officer or Shareholders or any other person individually.
Section 2. No Bond or Surety . The exercise by the Trustees of their powers and discretions hereunder shall be binding upon everyone interested. The Trustees shall not be required to give any bond as such, nor any surety if a bond is required.
Section 3. Liability of Third Persons Dealing with Trustees . No person dealing with the Trustees shall be bound to make any inquiry concerning the validity of any transaction made or to be made by the Trustees or to see to the application of any payments made or property transferred to the Trust or upon its order.
Section 4. Termination of Trust or Series or Class . Unless terminated as provided herein, the Trust shall continue without limitation of time. The Trust may be terminated at any time by the Trustees. Any Series may be terminated at any time by the Trustees. Any Class may be separately terminated at any time by the Trustees.
     Upon termination of the Trust (or any Series or Class, as the case may be), after paying or otherwise providing for all charges, taxes, expenses and liabilities belonging, severally, to each Series or allocable to each Class (or the applicable Series or Classes, as the case may be), whether due or accrued or anticipated as may be determined by the Trustees, the Trust shall in accordance with such procedures as the Trustees consider appropriate reduce the remaining assets belonging, severally, to each Series or allocable to each Class (or the applicable Series or Classes, as the case may be), to distributable form in cash or shares or other securities, or any combination thereof, and distribute the proceeds belonging to each Series or allocable to each Class (or the applicable Series or Classes, as the case may be), to the Shareholders of that Series or Class, as a Series or Class, ratably according to the number of Shares of that Series or Class held by the several Shareholders on the date of termination.
Section 5. Merger and Consolidation . The Trustees may cause the Trust or any Series or Class thereof to be merged or reorganized into or consolidated with another trust or company (including another Series or Class of the Trust) or its shares exchanged under or pursuant to any state or federal statute, if any, or otherwise to the extent permitted by law; provided that in all respects not governed by statute or applicable law, the Trustees shall have power to prescribe the procedure necessary or appropriate to accomplish a sale of assets, merger or consolidation.

-19-


 

Section 6. Initials “GMO” and the name “Grantham, Mayo, Van Otterloo & Co. LLC” . The Trust acknowledges that the initials “GMO” and the name “Grantham, Mayo, Van Otterloo & Co. LLC” and any derivatives thereof are owned by the Manager and that the Trust may use the initials “GMO,” the name “GMO Series Trust,” or any other name embodying the initials “GMO” or the name “Grantham, Mayo, Van Otterloo & Co. LLC” only with the consent of the Manager and subject to such conditions as the Manager may impose. The Trust acknowledges and agrees that as between the Manager and the Trust, the Manager has the exclusive right to use, or authorize others to use, said initials and name and the Trust agrees to take such action as may reasonably be requested by the Manager to give full effect to the provisions of this section (including, without limitation, consenting to use of said initials and name by others). The Trust agrees that if the Manager terminates its consent to the use by the Trust of the initials “GMO” or the name “Grantham, Mayo, Van Otterloo & Co. LLC” the Trust will, at the request of the Manager, use its best efforts to promptly change the name of the Trust (and, as applicable, each Series thereof) so as to eliminate all reference, if any, to the initials “GMO” or the name “Grantham, Mayo, Van Otterloo & Co. LLC” and will not thereafter transact any business in a name containing the initials “GMO” or the words “Grantham, Mayo, Van Otterloo & Co. LLC” in any form or combination whatsoever, or designate itself as the same entity as or successor to an entity of such name, or otherwise use the initials “GMO” or the name “Grantham, Mayo, Van Otterloo & Co. LLC” or any other reference to the Manager. Such covenants on the part of the Trust shall be binding upon it, its Trustees, officers, Shareholders, creditors and all other persons claiming under or through it.
Section 7. Filing of Copies, References, Headings . The original or a copy of this instrument and of each amendment hereto shall be kept at the office of the Trust. A copy of this instrument and of each amendment hereto shall be filed by the Trust with the Secretary of The Commonwealth of Massachusetts and with any other governmental office where such filing may from time to time be required. Anyone dealing with the Trust may rely on a certificate by an officer of the Trust as to whether or not any such amendments have been made and as to any matters in connection with the Trust hereunder; and, with the same effect as if it were the original, may rely on a copy certified by an officer of the Trust to be a copy of this instrument or of any such amendments. In this instrument and in any such amendment, references to this instrument, and all expressions like “herein,” “hereof,” and “hereunder” shall be deemed to refer to this instrument as amended or affected by any such amendments. Headings are placed herein for convenience of reference only and shall not be taken as a part hereof or control or affect the meaning, construction or effect of this instrument. This instrument may be executed in any number of counterparts each of which shall be deemed an original.
Section 8. Applicable Law . This Declaration of Trust is made in The Commonwealth of Massachusetts, and it is created under and is to be governed by and construed and administered according to the laws of said Commonwealth. The Trust shall be of the type commonly called a Massachusetts business trust, and without limiting the provisions hereof, the Trust may exercise all powers which are ordinarily exercised by such a trust. The Massachusetts Business Corporations Act and the regulations thereunder shall not apply to the operations of the Trust or this Declaration of Trust. Should any part of this Declaration of Trust be held or made invalid by a court decision, statute, rule or otherwise, the remainder of this Declaration of Trust shall not be affected thereby.

-20-


 

Section 9. Amendments . This Declaration of Trust may be amended, without Shareholder approval, at any time by the Trustees.

-21-


 

     IN WITNESS WHEREOF, the undersigned Trustee as aforesaid does hereto set his hand this 13 th day of September, 2011.
         
 
 
  /s/ J.B. Kittredge, Jr.
 
J.B. Kittredge, Jr.
   
 
  Trustee    

-22-


 

Schedule 3.6A to Declaration of Trust
Series
GMO U.S. Core Equity Series Fund
GMO Quality Series Fund
GMO U.S. Intrinsic Value Series Fund
GMO U.S. Growth Series Fund
GMO Foreign Series Fund
GMO International Core Equity Series Fund
GMO International Growth Equity Series Fund
GMO International Large/Mid Cap Value Series Fund
GMO Developed World Stock Series Fund
GMO Emerging Countries Series Fund
GMO Core Plus Bond Series Fund
GMO International Bond Series Fund
GMO Global Asset Allocation Series Fund
GMO Global Equity Allocation Series Fund
GMO International Equity Allocation Series Fund
GMO U.S. Equity Allocation Series Fund
GMO Benchmark-Free Allocation Series Fund
GMO Emerging Country Debt Series Fund

 


 

Schedule 3.6B to Declaration of Trust
Classes
Class R1
Class R2
Class R3
Class R4
Class R5
Class R6

 

Exhibit (d)
MANAGEMENT CONTRACT
     Management Contract executed as of                      , 2011 between GMO SERIES TRUST, a Massachusetts business trust (the “Trust”) on behalf of its GMO U.S. Core Equity Series Fund (the “Fund”), and GRANTHAM, MAYO, VAN OTTERLOO & CO. LLC, a Massachusetts limited liability company (the “Manager”).
W I T N E S S E T H:
     That in consideration of the mutual covenants herein contained, it is agreed as follows:
1.   SERVICES TO BE RENDERED BY MANAGER TO THE TRUST.
     (a) Subject always to the control of the Trustees of the Trust and to such policies as the Trustees may determine, the Manager will, at its expense, furnish continuously an investment program for the Fund and will make investment decisions on behalf of the Fund and place all orders for the purchase and sale of its portfolio securities. In the performance of its duties, the Manager will comply with the provisions of the Trust’s Agreement and Declaration of Trust and By-laws and the Fund’s stated investment objective, policies and restrictions.
     (b) In placing orders for the portfolio transactions of the Fund, the Manager will seek the best price and execution available, except to the extent it may be permitted to pay higher brokerage commissions for brokerage and research services as described below. In using its best efforts to obtain for the Fund the most favorable price and execution available, the Manager shall consider all factors it deems relevant, including, without limitation, the overall net economic result to the Fund (involving price paid or received and any commissions and other costs paid), the efficiency with which the transaction is effected, the ability to effect the transaction at all where a large block is involved, availability of the broker to stand ready to execute possibly difficult transactions in the future and financial strength and stability of the broker. Subject to such policies as the Trustees may determine, the Manager shall not be deemed to have acted unlawfully or to have breached any duty created by this Contract or otherwise solely by reason of its having caused a Fund to pay a broker or dealer that provides brokerage and research services to the Manager an amount of commission for effecting a portfolio investment transaction in excess of the amount of commission another broker or dealer would have charged for effecting that transaction, if the Manager determines in good faith that such amount of commission was reasonable in relation to the value of the brokerage and research services provided by such broker or dealer, viewed in terms of either that particular transaction or the Manager’s overall responsibilities with respect to the Trust and to other clients of the Manager as to which the Manager exercises investment discretion.
     (c) The Manager shall not be obligated under this agreement to pay any expenses of or for the Trust or of or for the Fund not expressly assumed by the Manager pursuant to this Section 1 other than as provided in Section 3.

 


 

2.   OTHER AGREEMENTS, ETC.
     It is understood that any of the shareholders, Trustees, officers and employees of the Trust may be a partner, shareholder, director, officer or employee of, or be otherwise interested in, the Manager, and in any person controlled by or under common control with the Manager, and that the Manager and any person controlled by or under common control with the Manager may have an interest in the Trust. It is also understood that the Manager and persons controlled by or under common control with the Manager have and may have advisory, management service, distribution or other contracts with other organizations and persons, and may have other interests and businesses.
3.   COMPENSATION TO BE PAID BY THE TRUST TO THE MANAGER.
     The Fund will pay no fee to the Manager for the Manager’s investment management services rendered hereunder.
4.   ASSIGNMENT TERMINATES THIS CONTRACT; AMENDMENTS OF THIS CONTRACT.
     This Contract shall automatically terminate, without the payment of any penalty, in the event of its assignment; and this Contract shall not be amended unless such amendment is approved at a meeting by the affirmative vote of a majority of the outstanding shares of the Fund, and by the vote, cast in person at a meeting called for the purpose of voting on such approval, of a majority of the Trustees of the Trust who are not interested persons of the Trust or of the Manager.
5.   EFFECTIVE PERIOD AND TERMINATION OF THIS CONTRACT.
     This Contract shall become effective upon its execution, and shall remain in full force and effect continuously thereafter (unless terminated automatically as set forth in Section 4) until terminated as follows:
     (a) Either party hereto may at any time terminate this Contract by not more than sixty days’ written notice delivered or mailed by registered mail, postage prepaid, to the other party, or
     (b) If (i) the Trustees of the Trust or the shareholders by the affirmative vote of a majority of the outstanding shares of the Fund, and (ii) a majority of the Trustees of the Trust who are not interested persons of the Trust or of the Manager, by vote cast in person at a meeting called for the purpose of voting on such approval, do not specifically approve at least annually after the second anniversary of its execution, the continuance of this Contract, then this Contract shall automatically terminate at the close of business on the second anniversary of its execution, or upon the expiration of one year from the effective date of the last such continuance, whichever is later; provided, however, that if the continuance of this Contract is submitted to the shareholders of the Fund for their approval and such shareholders fail to approve such continuance of this Contract as provided herein, the Manager may continue to serve hereunder in

2


 

a manner consistent with the Investment Company Act of 1940 and the rules and regulations thereunder.
     Action by the Trust under (a) above may be taken either (i) by vote of a majority of its Trustees, or (ii) by the affirmative vote of a majority of the outstanding shares of the Fund.
     Termination of this Contract pursuant to this Section 5 shall be without the payment of any penalty.
6.   CERTAIN DEFINITIONS.
     For the purposes of this Contract, the “affirmative vote of a majority of the outstanding shares” of the Fund means the affirmative vote, at a duly called and held meeting of shareholders, (a) of the holders of 67% or more of the shares of the Fund present (in person or by proxy) and entitled to vote at such meeting, if the holders of more than 50% of the outstanding shares of the Fund entitled to vote at such meeting are present in person or by proxy, or (b) of the holders of more than 50% of the outstanding shares of the Fund entitled to vote at such meeting, whichever is less.
     For the purposes of this Contract, the terms “affiliated person”, “control”, “interested person” and “assignment” shall have their respective meanings defined in the Investment Company Act of 1940 and the rules and regulations thereunder, subject, however, to such exemptions as may be granted by the Securities and Exchange Commission under said Act; and the phrase “specifically approve at least annually” shall be construed in a manner consistent with the Investment Company Act of 1940 and the rules and regulations thereunder.
7.   NONLIABILITY OF MANAGER.
     In the absence of willful misfeasance, bad faith or gross negligence on the part of the Manager, or reckless disregard of its obligations and duties hereunder, the Manager shall not be subject to any liability to the Trust, or to any shareholder of the Trust, for any act or omission in the course of, or connected with, rendering services hereunder.
8.   INITIALS “GMO” and the name “Grantham, Mayo, Van Otterloo & Co. LLC”.
     The Manager owns the initials “GMO” and the name “Grantham, Mayo, Van Otterloo & Co. LLC” which may be used by the Trust only with the consent of the Manager. The Manager consents to the use by the Trust of the name “GMO Series Trust” or any other name embodying the initials “GMO” or the name “Grantham, Mayo, Van Otterloo & Co. LLC”, in such forms as the Manager shall in writing approve, but only on condition and so long as (i) this Contract shall remain in full force and (ii) the Trust shall fully perform, fulfill and comply with all provisions of this Contract expressed herein to be performed, fulfilled or complied with by it. No such name shall be used by the Trust at any time or in any place or for any purposes or under any conditions except as in this section provided. The foregoing authorization by the Manager to the Trust to use said initials and name as part of a business or name is not exclusive of the right of the Manager itself to use, or to authorize others to use, the same; the Trust acknowledges and agrees that as between the Manager and the Trust, the Manager has the exclusive right so to authorize others to use the same; the Trust acknowledges and agrees that as between the Manager and the Trust, the Manager has the exclusive right so to use, or authorize others to use, said initials and name and the Trust agrees to take such action as may reasonably be requested by the Manager to

3


 

give full effect to the provisions of this section (including, without limitation, consenting to such use of said initials and name). Without limiting the generality of the foregoing, the Trust agrees that, upon any termination of this Contract by either party or upon the violation of any of its provisions by the Trust, the Trust will, at the request of the Manager made within six months after the Manager has knowledge of such termination or violation, use its best efforts to change the name of the Trust so as to eliminate all reference, if any, to the initials “GMO” or the name “Grantham, Mayo, Van Otterloo & Co. LLC” and will not thereafter transact any business in a name containing the initials “GMO” or the words “Grantham, Mayo, Van Otterloo & Co. LLC” in any form or combination whatsoever, or designate itself as the same entity as or successor to an entity of such name, or otherwise use the initials “GMO” or the name “Grantham, Mayo, Van Otterloo & Co. LLC” or any other reference to the Manager. Such covenants on the part of the Trust shall be binding upon it, its trustees, officers, stockholders, creditors and all other persons claiming under or through it.
9.   LIMITATION OF LIABILITY OF THE TRUSTEES AND SHAREHOLDERS.
     A copy of the Agreement and Declaration of Trust of the Trust is on file with the Secretary of The Commonwealth of Massachusetts, and notice is hereby given that this instrument is executed on behalf of the Trustees of the Trust as Trustees and not individually and that the obligations of this instrument are not binding upon any of the Trustees or shareholders individually but are binding only upon the assets and property of the Fund.

4


 

     IN WITNESS WHEREOF, GMO SERIES TRUST and GRANTHAM, MAYO, VAN OTTERLOO & CO. LLC have each caused this instrument to be signed in duplicate on its behalf by its duly authorized representative, all as of the day and year first above written.
         
  GMO SERIES TRUST
 
 
  By      
    Title:   
       
 
 
GRANTHAM, MAYO, VAN OTTERLOO
& CO. LLC
 
 
  By      
    Title:   
       
 

5

Exhibit (e)
CONFORMING DISTRIBUTION AGREEMENT
          Conforming Distribution Agreement (the “Conforming Agreement”), dated as of this 23 rd day of August 2011 by and between GMO Series Trust (the “Series Trust”), a business trust established under the laws of the Commonwealth of Massachusetts, and Funds Distributor, LLC (formerly known as Funds Distributor, Inc.) (the “Distributor”).
          WHEREAS, the series of GMO Trust (each a “Fund”, collectively, the “Funds”) and the Distributor are party to the Distribution Agreement dated March 31, 2009 and amended as of May 12, 2011 (the “Agreement”) pursuant to which the Distributor agreed to serve as the distributor for the Funds;
          WHEREAS, in connection with the creation of the Series Trust, the parties intend to apply the terms of the Agreement, as it may be amended from time to time, to the Series Trust;
          NOW, THEREFORE, in connection with the foregoing and in consideration of the mutual covenants herein set forth, the Series Trust and the Distributor agree as follows:
  1.   All capitalized terms used, but not defined herein, shall have the same meaning ascribed to them in the Agreement.
 
  2.   The terms of the Agreement shall apply, mutatis mutandis, to each series of the Series Trust as if each were a Fund.
 
  3.   A list of the series of the Series Trust is set forth in Schedule A, which shall be amended from time to time by written notice from the Series Trust.
 
  4.   A new Section 1.3(a) is added:
“The Distributor shall maintain membership with the NSCC and any other similar successor organization to sponsor a participant number for the Funds so as to enable the Shares to be traded through FundSERV.”
  5.   A new Section 4.7 is added:
“To the extent the Distributor receives, in connection with its activities under this Conforming Agreement and the Agreement, Nonpublic Personal Information as defined in SEC’s Regulation S-P or information considered Personal Information as defined in Massachusetts regulation 201 CMR 17.00 (the “Massachusetts Regulation”), it shall protect and maintain the confidentiality, security and integrity of such information in the manner

 


 

provided for under, and otherwise comply with applicable laws, regulations, rules and industry standards related to the handling of such information, including without limitation the Massachusetts Regulation. To the extent that the Distributor’s affiliates or other permitted agents or subcontractors have access to such information, the Distributor shall require that such entities comply with all terms and conditions of this provisionrelated to such information. At all times, the Distributor shall remain responsible and liable for such entities’ compliance with this provision.”
     IN WITNESS WHEREOF; the parties hereto have caused this Amendment to be duly executed as of the day and year first written above.
         
GMO SERIES TRUST*    
 
       
By:
  /s/ JB Kittredge    
 
       
Name:
  JB Kittredge    
Title:
  President and Chief Executive Officer    
 
*   GMO Series Trust is a Massachusetts business trust and a copy of the Agreement and Declaration of Trust of GMO Trust is on file with the Secretary of State of the Commonwealth of Massachusetts. Notice is hereby given that this Agreement is executed on behalf of the Trustees of the Series Trust as Trustees and not individually, and that the obligations of or arising out of this Agreement with respect to each series of the Series Trust are not binding upon any of the Trustees or shareholders individually or any other series, but are binding only upon the assets and property of that series.
         
FUNDS DISTRIBUTOR, LLC    
 
       
By:
  /s/ Mark Fairbanks    
 
       
Name:
  Mark Fairbanks    
Title:
  President    

 


 

SCHEDULE A
LIST OF GMO SERIES TRUST FUNDS
1
GMO U.S. Core Equity Series Fund
 
1   As of August 23, 2011

 


 

[This page intentionally left blank]

 


 

DISTRIBUTION AGREEMENT
          THIS DISTRIBUTION AGREEMENT is made as of the 31st day of March, 2009 by and between each series of GMO Trust (the “Trust”) listed on Schedule A hereto, as such schedule may be amended from time to time in accordance with Section 8.4 below, separately and not jointly (each, a “Fund”), and Funds Distributor, LLC, a Massachusetts limited liability company having a place of business at 10 High Street Boston, Massachusetts 02110 (“FDI”).
          WHEREAS, the shares of beneficial interest of each of the Funds correspond to a distinct portfolio of securities and many of the Funds are also divided into multiple classes of shares, all as set forth on Schedule A. For purposes of this Agreement, the term “Shares” shall mean the authorized shares of the relevant Fund and classes of shares of the Fund, if any, and otherwise shall mean the Fund’s authorized shares; and
          WHEREAS, FDI is registered as a broker-dealer with the Securities and Exchange Commission (the “SEC”) under the Securities Exchange Act of 1934 (the “1934 Act”) and is a member of the Financial Industry Regulatory Authority (“FINRA”); and
          WHEREAS, the Board of Trustees wishes to engage FDI to act as the distributor for each of the Funds and FDI is willing to render such service on the terms and conditions set forth herein;
          NOW, THEREFORE, in consideration of the foregoing and the mutual promises set forth below, the parties agree as follows:
1. Appointment
          The Trust hereby appoints FDI as its principal underwriter for the distribution of Shares of each of the Funds. FDI accepts such appointment and agrees to perform such services as are described in this Agreement.
2. Services
          2.1. FDI will act as agent of the Trust on behalf of each Fund for the distribution of Shares covered by, and in accordance with, the registration statement and prospectus then in effect under the Securities Act of 1933, as amended (the “1933 Act”), and will transmit promptly any orders received by FDI for purchase or redemption of Shares to the Transfer and Dividend Disbursing Agent for the Fund of which the Fund has notified FDI in writing. The Fund reserves the right to sell Shares in accordance with any current applicable prospectus relating to the Shares.
          2.2. FDI agrees to use its best efforts to perform its duties hereunder in the solicitation of orders for the sale of Shares. It is contemplated that FDI, at the request of the Trust, may enter into sales or servicing agreements with securities dealers, financial institutions and other industry professionals, such as investment advisers, accountants and estate planning firms (“Servicing Agents”) for the purpose of facilitating the offer, sale

 


 

and redemption of Shares. The Trust shall pre-approve the forms of agreements with Servicing Agents and shall have the right to approve any compensation set forth therein or any material changes from such pre-approved forms.
          2.3. FDI shall act as distributor of Shares in compliance with all applicable laws, rules and regulations, including, without limitations, the Investment Company Act of 1940, as amended (the “1940 Act”), the 1933 Act, the 1934 Act, the Rules of FINRA, the Trust’s Amended and Restated Agreement and Declaration of Trust, as amended from time to time, and Amended and Restated By-Laws, as amended from time to time. In the event there is a change in applicable federal and state securities law related to or affecting the services contemplated in this Agreement, FDI shall perform the services hereunder in accordance with such change, commencing on or prior to the date such change is effective or enforceable. If the services performed hereunder following such change are materially different or more burdensome than the current level of services, the parties shall agree to mutually acceptable policies and procedures for such services. FDI represents and warrants that it is a broker-dealer registered with the SEC and that it is registered with the relevant securities regulatory agencies in all fifty states, the District of Columbia and Puerto Rico. FDI also represents and warrants that it is a member of the FINRA.
          2.4. The Trust represents and warrants (A) the registration statement has been, and any amendment thereto will be, as the case may be, prepared in conformity with the requirements of the 1940 Act and the rules and regulations thereunder, and all material statements of fact contained or to be contained in the registration statement are or will be true and correct in all material respects at the time indicated or on the effective date, as the case may be; and the registration statement, when it shall become effective or be authorized for use, will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading to a purchaser of Shares and (b) it shall not file any amendment to the registration statement or prospectuses without giving FDI reasonable advance notice thereof; provided, however, that nothing contained in this Agreement shall in any way limit the Fund’s right to file at any time such amendments to any registration statement and/or supplements to any prospectus, of whatever character, as the Fund may deem advisable, such right being in all respects absolute and unconditional.
          2.5. Nothing contained herein shall be construed to require FDI to perform any service that could cause FDI to be deemed an investment adviser for purposes of the 1940 Act or the Investment Advisers Act of 1940, as amended.
          2.6. Neither FDI, nor any other person acting on behalf of FDI is authorized to give any information or to make any representations other than as is contained in a Fund’s prospectus, statement of additional information, or any advertising materials or sales literature specifically approved in writing by the Trust or its agents.
          2.7. FDI shall timely file Fund advertisements, sales literature and other marketing and sales related materials with the appropriate regulatory agencies and shall

-2-


 

obtain such approvals for their use as may be required by the SEC, FINRA and/or state securities administrators.
          2.8. The Fund reserves the right to refuse at any time or times to sell its Shares or the Shares of any class hereunder for any reason deemed adequate by the Board of Trustees of the Trust. The Fund shall promptly notify FDI of such a determination by the Board of Trustees.
          2.9. The Fund agrees to pay: (i) all costs and expenses in connection with the registration of Shares under the federal securities laws and securities laws of any state or other jurisdiction in which the Shares are sold; (ii) all expenses in connection with supplying information, prices, and other data to be furnished by the Fund hereunder; and (iii) all expenses in connection with the preparation and printing of the Fund’s prospectuses and statements of additional information for regulatory purposes and for distribution to shareholders; provided however, that the Fund shall not pay any of the costs of advertising or promotion for the sale of Shares, except as authorized by a plan adopted pursuant to Rule 12b-1 under the 1940 Act. FDI shall pay all expenses connected with its own qualification as a dealer under state or Federal laws and all expenses incurred in providing office space, equipment, and personnel as may be necessary or convenient to provide the services contemplated under this Agreement.
          2.10. Except as provided in this paragraph, FDI shall not be paid a fee by the Trust or the Fund for the services rendered by it hereunder. FDI may receive compensation from the Trust or Grantham, Mayo, Van Otterloo & Co. LLC (the “Adviser”), related to its services hereunder or for additional services as may be agreed to between the Trust, Adviser and FDI. FDI, in its capacity as the principal underwriter of the Fund’s Shares and for so long as it continues to serve in such capacity, shall be paid Rule 12b-1 fees pursuant to GMO Trust’s Amended and Restated Distribution and Service Plan (Class M) (the “Rule 12b-1 Plan”) in an amount equal to 0.25% of the Fund’s average daily net assets attributable to its Class M shares, if any (the “Service Fees”). Since FDI, in turn, has or will enter into servicing arrangements with investment platforms and other financial intermediaries under which FDI will be obligated to pay the Service Fees to such intermediaries, FDI hereby directs that the Service Fees be paid by the Fund for the account of FDI to such financial intermediaries that are agreed to from time to time by the Trust and FDI. FDI may enter into dealer agreements and other selling agreements with broker-dealers and other intermediaries; provided, however, that FDI shall have no obligation to make any payments to any third parties, whether as finder’s fees, compensation or otherwise, unless FDI has received a corresponding payment from the Fund pursuant to the Rule 12b-1 Plan, the Adviser, or from another source as may be permitted by applicable law, and such corresponding payment has been approved by the Trust’s Board of Trustees. To the extent that Rule 12b-1 fees are paid to FDI as default broker-dealer, such Rule 12b-1 fees shall continue to be paid to FDI after FDI ceases to act as distributor of a Fund for so long as FDI continues to serve as such default broker-dealer.
          2.11. The Fund agrees to execute documents and to furnish information and otherwise to take actions as shall from time to time be reasonably requested by FDI for

-3-


 

the purpose of qualifying and maintaining qualification of the Fund’s Shares for sale under the so-called Blue Sky Laws of any state. The Fund shall furnish FDI from time to time, for use in connection with the sale of Shares, such information with respect to the Fund and the Shares as FDI may reasonably request. The Fund also shall furnish FDI upon request with semi-annual reports and annual audited reports of the Fund’s books and accounts made by independent public accountants regularly retained by the Trust and such additional information regarding the Fund’s financial condition as FDI may reasonably request.
          2.12. FDI will facilitate and deliver such quarterly reports as may be reasonably requested by the Trustees, substantially in the form requested by the Trust. If requested by the Trust, one or more representatives of FDI will attend meetings of the Trustees.
          2.13. With respect to the subject matter of this Agreement, FDI may rely on advice or instruction that it receives and that it reasonably believes in good faith was transmitted by the Trust or an authorized representative of the Trust.
          2.14. The Fund authorizes FDI and any dealers with whom FDI has entered into dealer agreements to use any prospectus in the form furnished by the Fund in connection with the sale of Shares.
          2.15. The Fund agrees to indemnify, defend and hold FDI, its several officers and directors, employees, subsidiaries who provide services to the Fund, and any person who controls FDI within the meaning of Section 15 of the 1933 Act (the “FDI Indemnified Persons”) free and harmless from and against any and all claims, demands, liabilities and expenses (including the reasonable cost of investigating or defending such claims, demands or liabilities and any reasonable counsel fees incurred in connection therewith) which the FDI Indemnified Persons may incur under the 1933 Act, the 1940 Act, or common law or otherwise, arising out of or on the basis of (a) FDI acting as distributor of the Funds; (b) FDI or any subsidiary or affiliate of FDI acting as a member of the National Securities Clearing Corporation (or any successor or other entity performing similar functions) (“NSCC”) on behalf of the Fund; (c) FDI or any subsidiary or affiliate of FDI entering into selling agreements, dealer agreements, participation agreements, NSCC Trust SERV or Networking agreements or similar agreements with financial intermediaries on behalf of the Fund; or (d) any untrue statement, or alleged untrue statement, of a material fact required to be stated in either any registration statement or any prospectus or any statement of additional information or any Fund-related advertisement or sales literature, or arising out of or based upon any omission, or alleged omission, to state a material fact required to be stated in any registration statement, any prospectus or any statement of additional information or any Fund-related advertisement or sales literature or necessary to make the statements in any of them not misleading, except that the Fund’s agreement to indemnify the FDI Indemnified Persons will not be deemed to cover any such claim, demand, liability or expense to the extent that it arises out of or is based upon any such untrue statement, alleged untrue statement, omission or alleged omission made in any registration statement, any prospectus or any statement of additional information or any Fund-related advertisement or sales literature in reliance upon information furnished by an Indemnified Person to the Fund or its

-4-


 

representatives for use in the preparation thereof, and except that the Fund’s agreement to indemnify the FDI Indemnified Persons will not be deemed to cover any liability to the Fund or its shareholders to which the FDI Indemnified Persons would otherwise be subject by reason of willful misfeasance, bad faith or gross negligence in the performance of its duties, or by reason of its reckless disregard of its obligations and duties under this Agreement (“Disqualifying Conduct”). The Fund’s agreement to indemnify the FDI Indemnified Persons, as aforesaid, is expressly conditioned upon the Fund’s being notified of any action brought against the FDI Indemnified Persons, such notification to be given by letter, by facsimile or by telegram addressed to the Fund at its address set forth on Schedule A, attached hereto, within a reasonable period of time after the summons or other first legal process shall have been served. The failure so to notify the Fund of any such action shall not relieve the Fund from any liability which the Fund may have to the person against whom such action is brought by reason of any such untrue, or alleged untrue, statement or omission, or alleged omission, otherwise than on account of the Fund’s indemnity agreement contained in this Section 2.15. The Fund will be entitled to assume the defense of any suit brought to enforce any such claim, demand or liability, but, in such case, such defense shall be conducted by counsel of good standing chosen by the Fund and approved by FDI, which approval shall not be unreasonably withheld. In the event the Fund elects to assume the defense of any such suit and retain counsel of good standing approved by FDI, the defendant or defendants in such suit shall bear the fees and expenses of any additional counsel retained by any of them; but in case the Fund does not elect to assume the defense of any such suit, the Fund will reimburse the FDI Indemnified Persons named as defendant or defendants in such suit, for the reasonable fees and expenses of any counsel retained by FDI or them. If the Fund does not assume the defense, the FDI Indemnified Persons shall not consent to a settlement or any other disposition not involving a final adjudication without the prior consent of the Fund. The Fund’s indemnification agreement contained in this Section 2.15 shall remain operative and in full force and effect regardless of any investigation made by or on behalf of the FDI Indemnified Persons, and shall survive the delivery of any Shares. This agreement of indemnity will inure exclusively to the benefit of the FDI Indemnified Persons and, if the FDI Indemnified Persons are natural persons, their respective estates, and to the benefit of any controlling persons and their successors. The Fund agrees promptly to notify FDI of the commencement of any litigation or proceedings against the Fund or any of its officers or Trustees in connection with the issue and sale of Shares.
          2.16. FDI agrees to indemnify, defend and hold the Fund, its several officers and Trustees, and any person who controls the Fund within the meaning of Section 15 of the 1933 Act (the “Fund Indemnified Persons”) free and harmless from and against any and all claims, demands, liabilities and expenses (including the reasonable cost of investigating or defending such claims, demands or liabilities and any reasonable counsel fees incurred in connection therewith) which the Fund Indemnified Persons, may incur under the 1933 Act, the 1940 Act, or under common law or otherwise, but only to the extent that such liability or expense incurred by the Fund Indemnified Persons resulting from such claims or demands, (a) shall arise out of or be based upon any unauthorized sales literature, advertisements, information, statements or representations or any Disqualifying Conduct in connection with the offering and sale of any Shares, (b) shall arise out of or be based upon any untrue, or alleged untrue, statement of a material fact

-5-


 

contained in information furnished in writing by FDI to the Fund specifically for use in the Fund’s registration statement, or shall arise out of or be based upon any omission, or alleged omission, to state a material fact in connection with such information furnished in writing by FDI to the Fund and required to be stated in such answers or necessary to make such information not misleading or (c) any other liability to which the Fund becomes subject by reason of willful misfeasance, bad faith or gross negligence in the performance (or failure to perform) of FDI’s duties under the Agreement. FDI’s agreement to indemnify the Fund Indemnified Persons, as aforesaid, is expressly conditioned upon FDI being notified of any action brought against the Fund Indemnified Persons, such notification to be given by letter, by facsimile or by telegram addressed to FDI at its address set forth below within a reasonable period of time after the summons or other first legal process shall have been served. FDI shall have the right to control the defense of such action, with counsel of its own choosing, satisfactory to the Fund, if such action is based solely upon such alleged misstatement or omission on FDI’s part, and in any other event the Fund Indemnified Persons shall each have the right to participate in the defense or preparation of the defense of any such action. The failure so to notify FDI of any such action shall not relieve FDI from any liability which FDI may have to the Fund Indemnified Persons by reason of any such untrue, or alleged untrue, statement or omission, or alleged omission, otherwise than on account of FDI’s indemnity agreement contained in this Section 2.16. This agreement of indemnity will inure exclusively to the benefit of the Fund Indemnified Persons, and if the Fund Indemnified Persons are natural persons, their respective estates, and to the benefit of any controlling persons and their successors. FDI agrees promptly to notify the Fund of the commencement of any litigation or proceedings against FDI or any of its officers or directors in connection with the issue and sale of Shares.
          2.17. No Shares shall be offered by either FDI or the Fund under any of the provisions of this Agreement and no orders for the purchase or sale of such Shares hereunder shall be accepted by the Fund if and so long as the effectiveness of the registration statement then in effect or any necessary amendments thereto shall be suspended under any of the provisions of the 1933 Act or if and so long as a current prospectus as required by Section 10 of said Act, as amended, is not on file with the SEC; provided, however, that nothing contained in this Section 2.17 shall in any way restrict or have an application to or bearing upon a Fund’s obligation to repurchase any Shares from any shareholder in accordance with the provisions of the Fund’s prospectus or the Trust’s charter documents.
          2.18. Notwithstanding anything in this Agreement to the contrary, except as specifically set forth below: (A) neither party shall be liable for losses, delays, failure, errors, interruption or loss of data occurring directly or indirectly by reason of circumstances beyond its reasonable control, including, without limitation, acts of God; action or inaction of civil or military authority; public enemy; war; terrorism; riot; fire; flood; sabotage; epidemics; labor disputes; civil commotion; interruption, loss or malfunction of utilities, transportation, computer or communications capabilities; insurrection; or elements of nature; (B) neither party shall be liable for any consequential, special or indirect losses or damages suffered by the other party, whether or not the likelihood of such losses or damages was known by the party; (C) no affiliate, director,

-6-


 

officer, employee, manager, shareholder, partner, agent, counsel or consultant of either party shall be liable at law or in equity for the obligations of such party under this Agreement or for any damages suffered by the other party related to this Agreement; and (D) each party shall have a duty to mitigate damages for which the other party may become responsible; the assets and liabilities of each Fund are separate and distinct from the assets and liabilities of each other Fund, and no Fund shall be liable or shall be charged for any debt, obligation or liability of any other Fund, whether arising under this Agreement or otherwise; and in asserting any rights or claims under this Agreement, FDI shall look only to the assets and property of the Fund to which FDI’s rights or claims relate in settlement of such rights or claims.
          2.19. The Fund agrees to advise FDI promptly:
  (a)   in the event of the issuance by the SEC of any stop order suspending the effectiveness of the registration statement or prospectus then in effect or the initiation of any proceeding for that purpose; and
 
  (b)   of the happening of any event which makes untrue any statement of a material fact made in the registration statement or prospectus then in effect or which requires the making of a change in such registration statement or prospectus in order to make the statements therein not misleading.
          2.20. The Trust agrees to comply in all material respects with all applicable provisions of the 1940 Act, the 1933 Act, and all other federal and state laws governing the issuance and sale of Shares or otherwise applicable to the Trust.
3. Offering Price
          Shares of any class of a Fund offered for sale by FDI shall be offered at the net asset value per share (the “Offering Price”) plus any applicable purchase premium, as set forth in the then-current prospectus. In addition, Shares of any class of the Fund offered for sale by FDI may be subject to a redemption fee, as set forth in the Fund’s then-current prospectus. Purchase premiums and redemption fees are retained by the Fund.
4. Term
          This Agreement shall become effective with respect to the Fund as of the date hereof and will continue until August 1, 2009 and will continue thereafter so long as such continuance is specifically approved at least annually (i) by the Trust’s Board of Trustees or (ii) by a vote of a majority of the outstanding voting securities of the Fund, provided that in either event its continuance also is approved by a majority of the Board of Trustees who are not “interested persons” of any party to this Agreement, by vote cast in person at a meeting called for the purpose of voting on such approval. This Agreement is terminable with respect to a Fund, without penalty, on not less than sixty days’ notice to FDI, by the Trust’s Board of Trustees or by vote of a majority of the outstanding voting securities of such Fund. This Agreement may be terminated by FDI on ninety days’ written notice to the Fund. This Agreement will automatically and immediately terminate in the event of its “assignment.” (As used in this Agreement, the terms

-7-


 

“majority of the outstanding voting securities,” “interested person” and “assignment” shall have the same meanings as such terms have in the 1940 Act). FDI agrees to notify the Fund immediately upon the event of its expulsion, suspension or censure by FINRA. This Agreement will automatically and immediately terminate in the event of FDI’s expulsion or suspension by FINRA.
5. Confidentiality
          5.1. Each party (for purposes of this Section 5, a “Receiving Party”) agrees to keep confidential all information disclosed by the other party (for purposes of this Section 5, a “Disclosing Party”), including, without limitation all forms and types of financial, business, marketing, operations, technical, economic and engineering information of the Disclosing Party, whether tangible or intangible.
          5.2. Notwithstanding any provision of this Agreement to the contrary, the parties agree that the following information shall not be deemed confidential information: (i) information that was known to the receiving party before receipt thereof from or on behalf of the Disclosing Party; (ii) information that is disclosed to the Receiving Party by a third person who has a right to make such disclosure without any obligation of confidentiality to the party seeking to enforce its rights under this Section 5; (iii) information that is or becomes generally known in the trade without violation of this Agreement by the Receiving Party; or (iv) information that is independently developed by the Receiving Party or its employees or affiliates without reference to the Disclosing Party’s information.
          5.3. Notwithstanding any provision of this Agreement to the contrary, FDI may: (i) provide information to FDI’s counsel and to persons engaged by FDI or the Trust to provide services with respect to the Trust; (ii) identify the Trust as a client of FDI for FDI’s sales and marketing purposes; and (iii) provide information as approved by an authorized person of the Trust, provided, that (A) such approval shall not be unreasonably withheld or delayed, and (B) FDI may release information without approval of the Trust if FDI is advised by outside counsel to FDI or the Trust that failure to do so will result in liability to Trust; and provided, further, that, in such event FDI shall endeavor promptly to advise the Trust of such advice, to the extent practicable in advance of any actual release of information.
          5.4. FDI acknowledges that certain shareholder information made available by the Trust to FDI or otherwise maintained by FDI under this Agreement may be deemed nonpublic personal information under the Gramm-Leach-Bliley Act and other applicable privacy Laws (collectively, “Privacy Laws”). FDI agrees (i) not to disclose or use such information except as required to carry out its duties under the Agreement or as otherwise permitted by law in the ordinary course of business; (ii) to limit access to such information to authorized representatives of FDI and the Trust; (iii) to establish and maintain reasonable physical, electronic and procedural safeguards to protect such information; and (iv) to cooperate with the Trust and provide reasonable assistance in ensuring compliance with such Privacy Laws to the extent applicable to either or both of the parties.

-8-


 

6. Notice
          Any notice required or permitted to be given hereunder by either party to the other shall be deemed sufficiently given if in writing and personally delivered or sent by, facsimile or registered, certified or overnight mail, postage prepaid, addressed by the party giving such notice to the other party at the address furnished below unless and until changed by FDI or Trust, as the case may be. Notice shall be given to each party at the following addresses:
           If to FDI :
Funds Distributor, LLC
10 High Street, 3rd Floor
Boston, MA 02110
Attn: Senior Counsel
Fax: (857) 318-0345
           If to Trust :
GMO Trust
40 Rowes Wharf
Boston, MA 02110
Attn: J.B. Kittredge
Fax: (617) 310-4517
7. Anti-Money Laundering Compliance
          7.1. FDI hereby represents and warrants that it has implemented and enforces an anti-money laundering program (“AMLP”) that complies with laws, regulations and regulatory guidance applicable to FDI, and includes, at a minimum: (A) written policies, procedures, and controls to detect and prevent money laundering, as appropriate to the nature of FDI’s business; (B) a designated compliance officer with sufficient authority to oversee the AML Program; (C) an ongoing training program for relevant FDI employees and associated persons; and (D) scheduled independent testing of FDI’s AML Program.
          7.2. FDI agrees to furnish to the Trust the following documents: (A) copy of FDI’s AMLP as in effect on the date hereof, and any material amendment thereto promptly after the adoption of any such amendment; (B) a copy of any deficiency letter sent by federal examination authorities concerning FDI’s AMLP; and (C) periodically, upon request from the Trust, a report on FDI’s AMLP that includes a certification to the Trust concerning FDI’s implementation of, and ongoing compliance with, its AMLP and a copy of any audit report prepared with respect to FDI’s AMLP.
          7.3. FDI agrees to provide periodic reports concerning its compliance with FDI’s AMLP and/or the Trust’s AML Program at such times as may be reasonably requested by the Trust’s Board of Directors or AML Compliance Officer.

-9-


 

8. Miscellaneous
          8.1. As used in this Agreement the terms “registration statement” and “prospectus” shall mean any registration statement of the Trust and prospectus, including the statement of additional information incorporated by reference therein, filed with the SEC and any amendments and supplements thereto which at any time shall have been filed with said Commission.
          8.2. The Fund recognizes that, except to the extent otherwise agreed to by the parties hereto, FDI’s directors, officers and employees may from time to time serve as directors, trustees, officers and employees of corporations and business trusts (including other investment companies), and that FDI or FDI’s affiliates may enter into distribution or other agreements with other corporations and trusts. FDI will be an independent contractor, and neither FDI nor any of its officers or employees, as such, is or shall be an employee of the Fund. FDI is responsible for its own conduct and the employment, control, and conduct of its agents and employees and for injury to such agents or employees or to others through its agents or employees. FDI assumes full responsibility for its agents and employees under applicable law and agrees to pay all employer taxes thereunder. FDI will maintain at its own expense insurance against public liability in such an amount as required by the conduct rules or other rules or requirements of FINRA or other applicable law, rule, or regulation.
          8.3. No provision of this Agreement may be changed, waived, discharged or terminated orally, but only by an instrument in writing signed by the party against which an enforcement of the change, waiver, discharge or termination is sought.
          8.4. This Agreement and the Schedules forming a part hereof may be amended at any time by a writing signed by each of the parties hereto. In the event that the Trustees indicate by vote that any additional funds of the Trust are to be made parties to this Agreement, whether such funds were in existence at the time of the effective date of this Agreement or subsequently formed, Schedule A hereto shall be amended to reflect the addition of such new funds. In the event that any of the Funds listed on Schedule A terminates its registration as a management investment company, or otherwise ceases operations, Schedule A shall be amended to reflect the deletion of such Fund and its various classes, provided, that the Trust shall remain obligated to make any payments for obligations incurred through the date of termination respecting such Fund and its classes, including any obligations that specifically survive the termination of this Agreement with respect to such Fund or class.
          8.5. This Agreement is executed by the Board of Trustees of the Trust, not individually, but in their capacity as Trustees under the Agreement and Declaration of Trust made June 24, 1985, as amended. None of the shareholders, Trustees, officers, employees, or agents of the Trust shall be personally bound or liable under this Agreement, nor shall resort be had to their private property for the satisfaction of any obligation or claim hereunder but only to the property of the Trust and, if the obligation or claim relates to the property held by the Trust for the benefit of one or more but fewer than all Funds, then only to the property held for the benefit of the affected Fund.

-10-


 

          8.6. This Agreement shall be governed by the internal laws of The Commonwealth of Massachusetts without giving effect to principles of conflicts of laws.
          8.7. If any provision of this Agreement shall be held or made invalid by a court decision, statute, rule, or otherwise, the remainder of this Agreement shall not be affected thereby. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors.

-11-


 

          IN WITNESS WHEREOF, the parties have executed this Agreement by a duly authorized representative of the parties hereto.
         
  GMO TRUST, on behalf of each
of its series listed on Schedule A
 
 
  By:   /s/ Jason B. Harrison    
    Jason B. Harrison   
    Vice President   
 
  FUNDS DISTRIBUTOR, LLC
 
 
  By:   /s/ Richard J. Berthy    
    Richard J. Berthy   
    Vice President   
 

-12-


 

[This page intentionally left blank.]

 


 

May 12, 2011
Funds Distributor, LLC
10 High Street, 3rd Floor
Boston, MA 02110
Attn: Senior Counsel
Re:   Amendment to the Distribution Agreement, dated March 31, 2009, by and between GMO Trust, on behalf of certain of its series, and Funds Distributor, LLC
Ladies and Gentlemen:
     This letter agreement amends the Distribution Agreement (the “Agreement”), dated March 31, 2009, by and between GMO Trust (the “Trust”), on behalf of certain of its series, and Funds Distributor, LLC (“FDI”). Terms used and not defined herein have the meanings ascribed to them in the Agreement.
     Pursuant to Section 8.4 of the Agreement, for good and valuable consideration, the sufficiency of which is hereby acknowledged by the parties, the parties hereby agree that Section 2.10 of the Agreement is amended and restated in its entirety as follows:
     2.10. Except as provided in this paragraph, FDI shall not be paid a fee by the Trust or the Fund for the services rendered by it hereunder. FDI may receive compensation from the Trust or Grantham, Mayo, Van Otterloo & Co. LLC (the “Adviser”), related to its services hereunder or for additional services as may be agreed to between the Trust, Adviser and FDI. FDI, in its capacity as the principal underwriter of the Fund’s Shares and for so long as it continues to serve in such capacity, shall be paid Rule 12b-1 fees pursuant to GMO Trust’s Amended and Restated Distribution and Service Plan (Class M) (the “Rule 12b-1 Plan”) in an amount equal to 0.25% of the Fund’s average daily net assets attributable to its Class M shares, if any (the “Service Fees”). Since FDI or the Trust, in turn, has or will enter into servicing arrangements with investment platforms and other financial intermediaries under which FDI or the Trust will be obligated to pay the Service Fees to such intermediaries, FDI hereby directs that the Service Fees be paid by the Fund to such financial intermediaries that are agreed to from time to time by the Trust and FDI. FDI may enter into dealer agreements and other selling agreements with broker-dealers and other intermediaries; provided, however, that FDI shall have no obligation to make any payments to any third parties, whether as finder’s fees, compensation or otherwise, unless FDI has received a corresponding payment from the Fund pursuant to the Rule 12b-1 Plan, the Adviser, or from another source as may be permitted by applicable law, and such corresponding payment has been approved by the Trust’s Board of Trustees. To the extent that Rule 12b-1 fees are paid to FDI as default broker-dealer, such Rule 12b-1 fees shall continue to be paid to FDI after FDI ceases to act as distributor of a Fund for so long as FDI continues to serve as such default broker-dealer.

 


 

May 12, 2011   Page 2
     This letter agreement shall constitute an amendment to the Agreement and, as such, a binding agreement between the parties in accordance with its terms. Except as set specifically amended hereby, all the terms of the Agreement shall remain in full force and effect and shall not otherwise be affected, amended, or modified by this letter agreement.
Notice
     A copy of the Declaration of Trust, together with all amendments thereto, is on file with the Secretary of the Commonwealth of Massachusetts and notice is hereby given that this instrument is executed on behalf of the Trust by an officer of the Trust as an officer and not individually and that the obligations of this instrument are not binding upon any of the Trustees or officers of the Trust or shareholders of any series of the Trust individually but are binding only upon the assets and property of the Trust or the respective series.
* * * *
     This letter agreement may be executed in one or more counterparts, each of which will be deemed an original, but all of which together shall constitute one and the same instrument.
             
    Sincerely,    
 
           
    GMO TRUST, on behalf of each of its series
listed on Schedule A of the Agreement
   
 
           
 
  By:   /s/ Jason B. Harrison
 
   
 
  Name:   Jason B. Harrison    
 
  Title:   Vice President    
The foregoing is hereby accepted and agreed.
         
FUNDS DISTRIBUTOR, LLC    
 
       
By:
  /s/ Mark Fairbanks    
 
       
Name:
  Mark Fairbanks    
Title:
  President    

 

Exhibit (g)
CONFORMING CUSTODIAN AGREEMENT
     Conforming Custodian Agreement (the “Conforming Agreement”) made as of this 23 rd day of August, 2011 by and between GMO Series Trust (the “Series Trust), a business trust established under the laws of the Commonwealth of Massachusetts, and State Street Bank and Trust Company (as successor by merger to Investors Bank Trust Company) (“State Street”).
     WHEREAS, GMO Trust (the “Company”), Grantham, Mayo, Van Otterloo & Co. LLC (“GMO”) and State Street are party to the Custodian Agreement dated August 1, 1991, as amended, supplemented or otherwise modified from time to time (the “Agreement”), pursuant to which State Street agrees to provide certain services to the Company;
     WHEREAS, in connection with the creation of the Series Trust, the parties intend to apply the terms of the Agreement to the Series Trust, without modifying the terms of the Agreement with respect to the Company;
     NOW, THEREFORE, in connection with the foregoing and in consideration of the mutual covenants herein set forth, the Series Trust and State Street agree as follows:
  1.   The terms of the Agreement shall apply, mutatis mutandis , to the Series Trust as if it were the Company and to each series of the Series Trust as if it were a series of the Company, provided that all obligations of GMO in the Agreement shall be the obligations of the Series Trust.
 
  2.   A list of the series of the Series Trust is set forth in Schedule A, which shall be amended from time to time in writing by mutual agreement of the Series Trust and State Street.
 
  3.   For the avoidance of doubt, the Series Trust and State Street shall be liable to the other to the extent and under the circumstances described in the Agreement.
[signature page immediately follows]

1


 

     IN WITNESS WHEREOF; the parties hereto have caused this Conforming Agreement to be duly executed as of the day and year first written above.
         
  GMO SERIES TRUST*
 
 
  By:   /s/ JB Kittredge    
  Name:   JB Kittredge   
  Title:   President and Chief Executive Officer 
 
 
*   GMO Series Trust is a Massachusetts business trust and a copy of the Agreement and Declaration of Trust of GMO Series Trust is on file with the Secretary of State of the Commonwealth of Massachusetts. Notice is hereby given that this Agreement is executed on behalf of the Trustees of the Series Trust as Trustees and not individually, and that the obligations of or arising out of this Agreement with respect to each series of the Series Trust are not binding upon any of the Trustees or shareholders individually or any other series, but are binding only upon the assets and property of that series.
STATE STREET BANK AND TRUST COMPANY
         
  By:   /s/ Michael F. Rogers    
  Name:   Michael F. Rogers   
  Title:   Executive Vice President   

2


 

         
SCHEDULE A
LIST OF GMO SERIES TRUST FUNDS
1
GMO U.S. Core Equity Series Fund
 
1   As of August 23, 2011

3


 

[This page intentionally left blank.]

 


 

Custodian Agreement
Among
GMO trust
and
Grantham, Mayo, Van Otterloo & Co.
and
Investors Bank & Trust Company

 


 

TABLE OF CONTENTS
         
TOPIC   PAGE  
1. Bank appointed custodian
    1  
 
       
2. Definitions
    1  
2.1 Authorized Person
    1  
2.2 Security
    1  
2.3 Portfolio security
    2  
2.4 Officers’ Certificate
    2  
2.5 Book-Entry System
    2  
2.6 Depository
    2  
 
       
3. Proper Instructions
    2  
 
       
4. Separate Accounts
    2  
 
       
5. Certification as to Authorized Persons
    3  
 
       
6. Custody of Cash and Securities
    3  
6.1 Cash
    3  
(a) Purchase of Securities
    3  
(b) Redemptions
    3  
(c) Distributions and Expenses or Fund
    3  
(d) Payment in respect of Securities
    4  
(e) Repayment of loans
    4  
(f) Repayment of Cash
    4  
(g) Foreign Exchange Transactions
    4  
(h) Other Authorized payments
    4  
(i) Termination
    4  
6.2 Securities
    4  
(a) Book-Entry System
    5  
(b) Use of a Depository
    6  
(c) Use of Book-Entry System for Commercial Paper
    8  
(d) Use of Immobilization Programs
    8  
6.3 Options and Futures Transactions
    9  
(a)  Puts and Calls Traded on Securities Exchanges, NASDAQ or Over-the-Counter
    9  
(b)  Puts, Calls and Futures Traded on Commodities
    9  
(c)  Segregated Account
    10  
6.4 Segregated Account for ”when-issued”, ”forward commitment” and reverse repurchase agreement transactions
    10  
6.5 Interest Bearing Call or Time Deposits
    11  
 
       
7. Transfer of Securities
    11  
 
       
8. Redemptions
    12  

 


 

         
TOPIC   PAGE  
9. Merger, dissolution, etc. of Trust
    13  
 
       
10. Actions of Bank without prior Authorization
    13  
 
       
11. Maintenance of Records: Fund Evaluation: Accounting Services
    14  
 
       
12. Concerning the Bank
    15  
12.1 Performance of Duties
    15  
12.2 Fees and Expenses of Bank
    16  
12.3 Advances by Bank
    17  
 
       
13. Termination
    17  
 
       
14. Notices
    18  
 
       
15. Amendments
    19  
 
       
16. Parties
    19  
 
       
17. Governing Law
    19  
 
       
18. Limitation of Liability
    19  
 
       
Schedule A Custody of Foreign Securities
    21  

 


 

CUSTODIAN AGREEMENT
          AGREEMENT made this 1st day of August, 1991 by and among GMO Trust , a business trust established under the laws of the Commonwealth of Massachusetts (the “ Trust ”) on behalf of the GMO Core Fund, GMO SAF Core Fund, GMO Value Allocation Fund, GMO Growth Fund, GMO Short-Term Income Fund and any other series of the Trust, currently existing or hereafter created, as shall be mutually agreed to by the parties hereto to be subject to this Agreement (each such series referred to herein as the “ Fund ” and collectively as the “ Funds ”), Grantham, Mayo, Van Otterloo & Co. , a Massachusetts general partnership, (the “ Manage r”) and Investors Bank & Trust Company, a Massachusetts trust company (the “ Bank ”).
The Trust, an open-end management investment company, desires to place and maintain all of its portfolio securities and cash in the custody of the Bank. The Bank has at least the minimum qualifications required by Section 17(f)(1) of the Investment Company Act of 1940 to act as custodian of the portfolio securities and cash of the Trust, and has indicated its willingness to so act, subject to the terms and conditions of this Agreement.
NOW, THEREFORE, in consideration of the premises and of the mutual agreements contained herein, the parties hereto agree as follows:
           1. Bank appointed custodian . The Trust hereby appoints the Bank as custodian; of its portfolio securities and cash delivered to the Bank as hereinafter described and to perform such duties and provide such services as are set forth on any schedule hereto, and the Bank agrees to act as such upon the terms and conditions hereinafter set forth.
           2. Definitions . Whenever used herein, the terms listed below will have the following meaning:
          2.1 Authorized Person . Authorized Person will mean any of the persons duly authorized to give Proper Instructions or otherwise act on behalf of the Trust by appropriate resolution of the Trustees of the Trust.
          2.2 Security . The term security as used herein will have the same meaning as when such term is used in the Securities Act of 1933 as amended, including, without limitation, any note, stock, treasury stock, bond, debenture, evidence of indebtedness, certificate of interest or participation in any profit sharing agreement, collateral-trust certificate, preorganization certificate or subscription, transferable share, investment contract, voting-trust certificate, certificate of deposit for a security, fractional undivided interest in oil, gas, or other mineral rights, any put, call, straddle, option, or privilege on any security, certificate of deposit, or group or index of securities (including any interest therein or based on the value thereof), or any put, call, straddle, option, or privilege entered into on a national securities exchange relating to a foreign currency, or, in general, any interest or instrument commonly known as a “security”, or any certificate of interest or participation in, temporary or interim certificate for, receipt for, guarantee of, or warrant or right to subscribe to, or option contract to purchase or sell any of the foregoing and futures, forward contracts and options thereon.

Page 1


 

          2.3 Portfolio security . Portfolio security will mean any security owned by the Trust.
          2.4 Officers’ Certificate . Officers’ Certificate will mean unless otherwise indicated, any request, direction, instruction, or certification in writing signed by any two Authorized Persons of the Trust.
          2.5 Book-Entry System . Book-Entry System shall mean the Federal Reserve-Treasury Department Book Entry System for United States government, instrumentality and agency securities operated by the Federal Reserve Bank, its successor or successors and its nominee or nominees.
          2.6 Depository . Depository shall mean The Depository Trust Company (“ DTC ”), a clearing agency registered with the Securities and Exchange Commission under Section 17A of the Securities Exchange Act of 1934, its successor or successors and its nominee or nominees. The term “Depository” shall further mean and include any other person authorized to act as a depository under the Investment Company Act of 1940, its successor or successors and its nominee or nominees, specifically identified in a certified copy of a resolution of the Trustees of the Trust.
           3. Proper Instructions . Proper Instructions shall mean (i) instructions regarding the purchase or sale of securities for the portfolio of the Trust, and payments and deliveries in connection therewith, given by an Authorized Person as shall have been designated in an Officers’ Certificate, such instructions to be given in such form and manner as the Bank and the Trust shall agree upon from time to time, and (ii) instructions (which may be continuing instructions) regarding other matters signed or initialed by such one or more persons from time to time designated in an Officers’ Certificate as having been authorized by the Trustees of the Trust. Oral instructions will be considered Proper Instructions if the Bank reasonably believes them to have been given by a person authorized to give such instructions with respect to the transaction involved. The Trust shall cause all oral instructions to be promptly confirmed in writing. The Bank shall act upon and comply with any subsequent Proper Instruction which modifies a prior instruction and the sole obligation of the Bank with respect to any follow-up or confirmatory instruction shall be to make reasonable efforts to detect any discrepancy between the original instruction and such confirmation and to report such discrepancy to the Trust. The Trust shall be responsible, at the Trust’s expense, for taking any action, including any reprocessing, necessary to correct any such discrepancy or error, and to the extent such action requires the Bank to act the Trust shall give the Bank specific Proper Instructions as to the action required. Upon receipt of an Officers’ Certificate as to the authorization by the Trustees of the Trust accompanied by a detailed description of procedures approved by the Trust, Proper Instructions may include communication effected directly between electro-mechanical or electronic devices provided that the Trustees and the Bank are satisfied that such procedures afford adequate safeguards for the Trust’s assets.
           4. Separate Accounts . The Bank will establish a Separate Account for each Fund of the Trust, and deposit and maintain therein the assets of such Fund (and all investment earnings thereon). Any references in this Agreement to the Trust shall be deemed to be references to the separate Funds as appropriate.

Page 2


 

           5. Certification as to Authorized Persons . The Secretary or Assistant Secretary of the Trust will at all times maintain on file with the Bank his certification to the Bank, in such form as may be acceptable to the Bank, of (i) the names and signatures of the Authorized Persons and (ii) the names of the members of the Trustees of the Trust, it being understood that upon the occurrence of any change in the information set forth in the most recent certification on file (including without limitation any person named in the most recent certification who is no longer an Authorized Person as designated therein), the Secretary or Assistant Secretary of the Trust will sign a new or amended certification setting forth the change and the new, additional or omitted names or signatures. The Bank will be entitled to rely and act upon any Officers’ Certificate given to it by the Trust which has been signed by officers named in the most recent certification.
           6. Custody of Cash and Securities . Except as set forth on Schedule A hereto with respect to assets of the Trust held outside of the U.S., as custodian for the Trust, the Bank will keep safely all of the portfolio securities delivered to the Bank, and will deposit to the account of the Trust all of the cash of the Trust delivered to the Bank, as set forth below.
          6.1 Cash . The Bank will open and maintain a separate account or accounts in the name of the Trust or in the name of the Bank, as custodian of the Trust, subject only to draft or order by the Bank acting pursuant to the terms of this Agreement. The Bank will hold in such account or accounts as custodian, subject to the provisions hereof, all cash received by it, including borrowed funds, for the account of the Trust. Upon receipt by the Bank of Proper Instructions (which may be continuing instructions) or in the case of payments for redemptions and repurchases of outstanding shares of common stock of the Trust, notification from the Trust’s transfer agent as provided in Section 8, requesting such payment, designating the payee or the account or accounts to which the Bank will release funds for deposit, and stating that it is for a purpose permitted under the terms of this Section 6.1, specifying the applicable subsection, or describing such purpose with sufficient particularity to permit the Bank to ascertain the applicable subsection, the Bank will make payments of cash held for the accounts of the Trust, insofar as funds are available for that purpose, only as permitted in (a)-(i) below.
          (a) Purchase of Securities: upon the purchase of securities for the Trust, against contemporaneous receipt of such securities or, where appropriate, satisfactory evidence of title thereto by the Bank registered in the name of the Trust or in the name of, or properly endorsed and in form for transfer to, the Bank, or a nominee of the Bank, or receipt for the account of the Bank through use of (1) the Book-Entry System pursuant to Section 6.2(a)(3) below, (2) Depository pursuant to 6.2(b) below, or (3) Book Entry Paper pursuant to Section 62(c) below, each such payment to be made at the purchase price shown in the Proper Instructions received by the Bank before such payment is made;
          (b) Redemptions: in such amount as may be necessary for the repurchase or redemption of shares of beneficial interest of the Trust offered for repurchase or redemption in accordance with Section 8 of this Agreement;
          (c) Distributions and Expenses or Fund: for the payment on the account of the Trust of dividends or other distributions to shareholders as may from time to time be declared by the Trustees of the Trust, interest, taxes, management or supervisory fees,

Page 3


 

distribution fees, fees of the Bank for its services hereunder and reimbursement of the expenses and liabilities of the Bank as provided hereunder, fees of any transfer agent, fees for legal, accounting, and auditing services, or other operating expenses of the Trust;
          (d) Payment in respect of Securities: for payments in connection with the conversion, exchange or surrender of portfolio securities or securities subscribed to by the Trust held by or to be delivered to the Bank;
          (e) Repayment of loans: to repay loans of money made to the Trust, but, in the case of final payment, only upon redelivery to the Bank of any portfolio securities pledged or hypothecated therefor and upon surrender of documents evidencing the loan;
          (f) Repayment of Cash: to repay the cash delivered to the Trust for the purpose of collateralizing the obligation to return to the Trust certificates borrowed from the Trust representing portfolio securities, but only upon redelivery to the Bank of such borrowed certificates;
          (g) Foreign Exchange Transactions: for payments in connection with foreign exchange contracts or options to purchase and sell foreign currencies for spot and future delivery which may be entered into by the Bank on behalf of the Trust upon the receipt of Proper Instructions, such Proper Instructions to specify the currency broker or banking institution (which may be the Bank, or any other subcustodian or agent hereunder, acting as principal) with which the contract or option is made, and the Bank shall have no duty with respect to the selection of such currency brokers or banking institutions with which the Trust deals or for their failure to comply with the terms of any contract or option;
          (h) Other Authorized payments: for other authorized transactions of the Trust, or other obligations of the Trust incurred for proper Trust purposes; provided that before making any such payment the Bank will also receive a certified copy of a resolution of the Trustees signed by an Authorized Person of the Trust (other than the Person certifying such resolution) and certified by its Secretary or Assistant Secretary, naming the person or persons to whom such payment is to be made, and either describing the transaction for which payment is to be made and declaring it to be an authorized transaction of the Trust, or specifying the amount of the obligation for which payment is to be made, setting forth the purpose for which such obligation was incurred and declaring such purpose to be a proper corporate purpose; and
          (i) Termination: upon the termination of this Agreement as hereinafter set forth pursuant to Section 9 and Section 13 of this Agreement.
          The Bank is hereby authorized to endorse for collection and collect on behalf of and in the name of the Trust all checks, drafts, or other negotiable or transferable instruments or other orders for the payment of money received by it for the account of the Trust.
          6.2 Securities . Except as otherwise provided herein, the Bank as custodian, will receive and hold pursuant to the provisions hereof, in a separate account or accounts and physically segregated at all times from those of other persons, any and all portfolio securities which may now or hereafter be delivered to it by or for the account of the

Page 4


 

Trust. All such portfolio securities will be held or disposed of by the Bank for, and subject at all times to, the instructions of the Trust pursuant to the terms of this Agreement. Subject to the specific provisions herein relating to securities that are not physically held by the Bank, the Bank will register all portfolio securities (unless otherwise directed by Proper Instructions or an Officers’ Certificate), in the name of a registered nominee of the Bank as defined in the Internal Revenue Code and any Regulations of the Treasury Department issued thereunder, and will execute and deliver all such certificates in connection therewith as may be required by such laws or regulations or under the laws of any State. The Bank will use its best efforts to the end that the specific securities held by it hereunder will be at all times identifiable.
          The Bank will use the same care with respect to the safekeeping of portfolio securities and cash of the Trust held by it as it uses in respect of its own similar property but it need not maintain any special insurance for the benefit of the Trust.
          The Trust will from time to time furnish to the Bank appropriate instruments to enable it to hold or deliver in proper form for transfer, or to register in the name of its registered nominee, any securities which it may hold for the account of the Trust and which may from time to time be registered in the name of the Trust.
          Neither the Bank nor any nominee of the Bank will vote any of the portfolio securities held hereunder by or for the account of the Trust, except in accordance with Proper Instructions or an Officers’ Certificate.
          The Bank will execute and deliver, or cause to be executed and delivered, to the Trust all notices, proxies and proxy soliciting materials with respect to such securities, such proxies to be executed by the registered holder of such securities (if registered otherwise than in the name of the Trust), but without indicating the manner in which such proxies are to be voted.
          (a) Book-Entry System. Provided (i) the Bank has received a certified copy of a resolution of the Trustees of the Trust specifically approving deposits of Trust assets in the Book-Entry System, and (ii) for each year following such approval, the Trustees of the Trust have reviewed and approved the arrangement and have not delivered an Officer’s Certificate to the Bank indicating that the Trustees have withdrawn their approval:
               1. The Bank may keep Securities of the Trust in the Book-Entry System provided that such securities are represented in an account (“ Account ”) of the Bank (or its agent) in such System which shall not include any assets of the Bank (or such agent) other than assets held as a fiduciary, custodian, or otherwise for customers.
               2. The records of the Bank (and any such agent) with respect to the Trust’s participation in the Book-Entry System through the Bank (or any such agent) will identify by book entry securities belonging to the Trust which are included with other securities deposited in the Account and shall at all times during the regular business hours of the Bank (or such agent) be open for inspection by duly authorized officers, employees or agents of the Trust. Where securities are transferred to the Trust’s account, the Bank shall also, by book entry or otherwise, identify as belonging to the Trust a quantity of

Page 5


 

securities in fusible bulk of securities (i) registered in the name of the Bank or its nominee, or (ii) shown on the Bank’s account on the books of the Federal Reserve Bank
               3. The Bank (or its agent) shall pay for securities purchased for the account of the Trust or shall pay cash collateral against the return of securities loaned by the Trust upon (i) receipt of advice from the Book-Entry System that such Securities have been transferred to the Account, and (ii) the making of an entry on the records of the Bank (or its agent) to reflect such payment and transfer for the account of the Trust. The Bank (or its agent) shall transfer securities sold or loaned for the account of the Trust upon
          (i) receipt of advice from the Book-Entry System that payment for Securities sold or payment of the initial cash collateral against the delivery of securities loaned by the Trust has been transferred to the Account, and
          (ii) the making of an entry on the records of the Bank (or its agent) to reflect such transfer and payment for the account of the Trust. Copies of all advices from the Book-Entry System of transfers of Securities for the account of the Trust shall identify the Trust, be maintained for the Trust by the Bank and shall be provided to the Trust at its request. The Bank shall send the Trust a confirmation, as defined by Rule 17f-4, under the Investment Company Act of 1940, of any transfers to or from the account of the Trust.
               4. The Bank will promptly provide the Trust with any report obtained by the Bank or its agent on the Book-Entry System’s accounting system, internal accounting control and procedures for safeguarding securities deposited in the Book-Entry System. The Bank will provide the Trust and cause any such agent to provide, at such times as the Trust may reasonably require, with reports by independent public accountants on the accounting system, internal accounting control and procedures for safeguarding securities, including Securities deposited in the Book-Entry System, relating to the services provided by the Bank or such agent under the Agreement.
               5. Anything to the contrary in the Agreement notwithstanding, the Bank shall be liable to the Trust for any loss or damage to the Trust resulting from use of the Book-Entry System by reason of any negligence, willful misfeasance or bad faith of the Bank or any of its agents or of any of its or their employees or from any reckless disregard by the Bank or any such agent of its duty to enforce effectively such rights as it may have against the Book-Entry System; at the election of the Trust, it shall be entitled to be subrogated for the Bank in any claim against the Book-Entry System or any other person which the Bank or its agent may have as a consequence of any such loss or damage if and to the extent that the Trust has not been made whole for any loss or damage.
          (b) Use of a Depository. Provided (i) the Bank has received a certified copy of a resolution of the Trustees of the Trust specifically approving deposits in DTC or other such Depository and (ii) for each year following such approval, the Trustees of the Trust have reviewed and approved the arrangement and have not delivered an Officer’s Certificate to the Bank indicating that the Trustees have withdrawn their approval:

Page 6


 

          1. The Bank may use a Depository to hold, receive, exchange, release, lend, deliver and otherwise deal with the securities owned by the Trust, including stock dividends, rights and other items of like nature, and to receive and remit to the Bank on behalf of the Trust all income and other payments thereon and to take all steps necessary and proper in connection with the collection thereof.
          2. Registration of the Trust’s securities may be made in the name of any nominee or nominees used by such Depository.
          3. Payment for securities purchased and sold may be made through the clearing medium employed by such Depository for transactions of participants acting through it. Upon any purchase of securities for the account of the Trust, payment will be made only upon delivery of the securities to or for the account of the Trust and the Trust shall pay cash collateral against the return of securities loaned by the Trust only upon delivery of the securities to or for the account of the Trust; and upon any sale of securities for the account of the Trust, delivery of the securities will be made only against payment thereof or, in the event securities are loaned, delivery of securities will be made only against receipt of the initial cash collateral to or for the account of the Trust.
          4. The Bank shall be subject to the same liability and duty to the Trust and its shareholders with respect to all securities of the Trust, and all cash, stock dividends, rights and items of like nature to which the Trust is entitled, held or received by a central securities system as agent for the Bank, pursuant to the foregoing authorization, as if the same were held or received by the Bank at its own offices. In this connection, with respect to the use of the Depository by the Bank but without limiting the foregoing duty or liability, the Bank, without cost to the Trust, shall ensure that:
          (i) The Depository obtains replacement of any certificated security deposited with it in the event such security is lost, destroyed, wrongfully taken or otherwise not available to be returned to the Bank upon its request;
          (ii) Any proxy materials received by Depository with respect to securities of the Trust deposited with such Depository are forwarded immediately to the Bank for prompt transmittal to the Trust;
          (iii) Such Depository immediately forwards to the Bank confirmation of any purchase or sale of securities for the account of the Trust and of the appropriate book entry made by such Depository to the Trust’s account;
          (iv) Such Depository prepares and delivers to the Bank such records with respect to the performance of the Bank’s obligations and duties hereunder as may be necessary for the Trust to comply with the recordkeeping requirements of Section 31(a) of the Investment Company Act of 1940 and Rules 31a-1 and 31a-2 thereunder; and
          (v) Such Depository delivers to the Bank and the Trust all internal accounting control reports, whether or not audited by an independent public

Page 7


 

accountant, as well as such other reports as the Trust may reasonably request in order to verify the Trust’s securities held by such Depository.
          (c) Use of Book-Entry System for Commercial Paper. Provided (i) the Bank has received a certified copy of a resolution of the Trustees of the Trust specifically approving participation in a system maintained by the Bank for the holding of commercial paper in book-entry form (“ Book Entry Paper ”) and (ii) for each year following such approval the Trustees of the Trust have received and approved the arrangements, upon receipt of Proper Instructions and upon receipt of confirmation from an Issuer (as defined below) that the Trust has purchased such Issuer’s Book Entry Paper, the Bank shall issue and hold in book-entry form, on behalf of the Trust, commercial paper issued by issuers with whom the Bank has entered into a book-entry agreement (the “ Issuers ”). In maintaining its Book Entry Paper System, the Bank agrees that:
          1. the Bank will maintain all Book Entry Paper held by the Trust in an account of the Bank that includes only assets held by it for customers;
          2. the records of the Bank with respect to the Trust’s purchase of Book Entry Paper through the Bank will identify, by book entry, Commercial Paper belonging to the Trust which is included in the Book Entry Paper System and shall at all times during the regular business hours of the Bank be open for inspection by duly authorized officers, employees or agents of the Trust.
          3. (a) The Bank shall pay for Book Entry Paper purchased for the account of the Trust upon contemporaneous (i) receipt of advice from the Issuer that such sale of Book Entry Paper has been effected, and (ii) the making of an entry on the records of the Bank to reflect such payment and transfer for the account of the Trust.
                    (b) The Bank shall cancel such Book Entry Paper obligation upon the maturity thereof upon contemporaneous (i) receipt of advice that payment for such Book Entry Paper has been transferred to the Trust, and (ii) the making of an entry on the records of the Bank to reflect such payment for the account of the Trust;
          4. the Bank shall transmit to the Trust a transaction journal confirming each transaction in Book Entry Paper for the account of the Trust on the next business day following the transactions; and
          5. the Bank will send to the Trust such reports on its system of internal accounting control as the Trust may reasonably request from time to time.
          (d) Use of Immobilization Programs. Provided (i) the Bank has received a certified copy of a resolution of the Trustees of the Trust specifically approving the maintenance of portfolio securities in an immobilization program operated by a bank which meets the requirements of Section 26(a)(1) of the Investment Company Act of 1940, and (ii) for each year following such approval the Trustees of the Trust have reviewed and approved the arrangement and have not delivered an Officer’s Certificate to the Bank indicating that the Trustees have withdrawn their approval, the Bank shall enter into such immobilization program with such bank acting as a subcustodian hereunder.

Page 8


 

          6.3 Options and Futures Transactions .
          (a) Puts and Calls Traded on Securities Exchanges, NASDAQ or Over-the-Counter .
          1. The Bank shall take action as to put options (“ puts ”) and call options (“ calls ”) purchased or sold (written) by the Trust regarding escrow or other arrangements (i) in accordance with the provisions of any agreement entered into upon receipt of Proper Instructions between the Bank, any broker-dealer registered under the Securities Exchange Act of 1934 and a member of the National Association of Securities Dealers, Inc., and, if necessary, the Trust relating to the compliance with the rules of the Options Clearing Corporation and of any registered national securities exchange, or of any similar organization or organizations.
          2. Unless another agreement requires it to do so, the Bank shall be under no duly or obligation to see that the Trust has deposited or is maintaining adequate margin, if required, with any broker in connection with any option, nor shall the Bank be under duty or obligation to present such option to the broker for exercise unless it receives Proper Instructions from the Trust. The Bank shall have no responsibility for the legality of any put or call purchased or sold on behalf of the Trust, the property of any such purchase or sale, or the adequacy of any collateral delivered to a broker in connection with an option or deposited to or withdrawn from a Segregated Account as described in subparagraph c of this Section 6.3. The Bank specifically, but not by way of limitation, shall not be under any duty or obligation to: (i) periodically check or notify the Trust that the amount of such collateral held by a broker or held in a Segregated Account as described in subparagraph (c) of this Section 6.3 is sufficient to protect such broker of the Trust against any loss; (ii) effect the return of any collateral delivered to a broker, or (iii) advise the Trust that any option it holds, has or is about to expire. Such duties or obligations shall be the sole responsibility of the Trust.
          (b) Puts, Calls and Futures Traded on Commodities .
          1. The Bank shall take action as to puts, calls and futures contracts (“ Futures ”) purchased or sold by the Trust in accordance with the provisions of any agreement among the Trust, the Bank and a Futures Commission Merchant registered under the Commodity Exchange Act, relating to compliance with the rules of the Commodity Futures Trading Commission and/or any Contract Market, or any similar organization or organizations, regarding account deposits in connection with transactions by the Trust.
          2. The responsibilities and liabilities of the Bank as to Futures, puts and calls traded on commodities exchanges, any Futures Commission Merchant account and the Segregated Amount shall be limited as set forth in subparagraph (a)(2) of this Section 6.3 as if such

Page 9


 

subparagraph referred to Futures Commission Merchants rather than brokers, and Futures and puts and calls thereon instead of options.
          (c) Segregated Account . The Bank shall upon receipt of Proper Instructions establish and maintain a Segregated Account or Accounts for and on behalf of the Trust, into which Account or Accounts may be transferred cash and/or securities including securities maintained in an Account by the Bank pursuant to Section 6.2 hereof, (i) in accordance with the provisions of any agreement among the Trust, the Bank and a broker/dealer registered under the Exchange Act and a member of the NASD or any Futures Commission Merchant registered under the Commodity Exchange Act, relating to compliance with the rules of the Options Clearing Corporation and of any registered national securities exchange or the Commodity Futures Trading Commission or any registered Contract Market, or of any similar organization or organizations regarding escrow or other arrangements in connection with transactions by the Trust, and (ii) for the purpose of segregating cash or securities in connection with options purchased, or written by the Trust or commodity futures purchased or written by the Trust, and (iii) for the purposes of compliance by the Trust with the procedures required by Investment Company Act Release No. 10666, or any subsequent release or releases of the Securities and Exchange Commission relating to the maintenance of Segregated Accounts by registered investment companies and (iv) for other proper corporate purposes, but only, in the case of clause (iv), upon receipt of, in addition to Proper Instructions, a certified copy of a resolution of the Trustees of the Trust, or of the Executive Committee signed by an officer of the Trust and certified by the Secretary or an Assistant Secretary, setting forth the purpose or purposes of such Segregated Account and declaring such purposes to be proper corporate purposes.
          6.4 Segregated Account for “when-issued”, “forward commitment” and reverse repurchase agreement transactions . Notwithstanding any other provisions hereof, the Bank will maintain a segregated account (the “ Segregated Account ”) in the name of the Trust (i) for the deposit of liquid assets, such as cash, U.S. Government securities or other high grade debt obligations, having a market value (marked to the market on a daily basis) at all times equal to not less than the aggregate purchase price due on the settlement dates of all the Trust’s then outstanding forward commitment or “when-issued” agreements relating to the purchase of portfolio securities and all the Trust’s then outstanding commitments under reverse repurchase agreements entered into with broker-dealer firms, and (ii) for the deposit of any portfolio securities which the Trust has agreed to sell on a forward commitment basis, all in accordance with Investment Company Act Release No. 10666. No assets shall be deposited in the Segregated Account except pursuant to Proper Instructions.
          Assets may be withdrawn from the Segregated Account pursuant to Proper Instructions only (a) for sale or delivery to meet the Trust’s obligations under outstanding firm commitment or when-issued agreements for the purchase of portfolio securities and under reverse repurchase agreements, (b) for exchange for other liquid assets of equal or greater value deposited in the Segregated Account, (c) to the extent that the Trust’s outstanding forward commitment or when-issued agreements for the purchase of portfolio securities or reverse repurchase agreements are sold to other parties or the

Page 10


 

Trust’s obligations thereunder are met from assets of the Trust other than those in the Segregated Account, or (d) for delivery upon settlement of a forward commitment agreement for the sale of portfolio securities.
          6.5 Interest Bearing Call or Time Deposits . The Bank shall, upon receipt of Proper Instructions relating to the purchase by the Trust of interest bearing fixed term and call deposits, transfer cash, by wire or otherwise, in such amounts and to such bank or banks as shall be indicated in such Proper Instructions. The Bank shall include in its records with respect to the assets of the Trust appropriate notation as to the amount of each such deposit, the banking institution with which such deposit is made (the “ Deposit Bank ”), and shall retain such forms of advice or receipt evidencing the deposit, if any, as may be forwarded to the Bank by the Deposit Bank. Such deposits shall be deemed portfolio securities of the Trust and the responsibility of the Bank therefore shall be the same as and no greater than the Bank’s responsibility in respect of other portfolio securities of the Trust.
           7. Transfer of Securities . The Bank will transfer, exchange, deliver or release portfolio securities held by it hereunder, insofar as such securities are available for such purpose, provided that before making any transfer, exchange, delivery or release under this Section the Bank will receive Proper Instructions requesting such transfer, exchange or delivery stating that it is for a purpose permitted under the terms of this Section 7, specifying the applicable subsection, or describing the purpose of the transaction with sufficient particularity to permit the Bank to ascertain the applicable subsection, only
          (a) upon sales of portfolio securities for the account of the Trust, against contemporaneous receipt by the Bank of payment therefor in full, each such payment to be in the amount of the sale price set forth in the Proper Instructions received by the Bank before such payment is made;
          (b) in exchange for or upon conversion into other securities alone or other securities and cash pursuant to any plan of merger, consolidation, reorganization, share split-up, change in par value, recapitalization or readjustment or otherwise, upon exercise of subscription, purchase or sale or other similar rights represented by such portfolio securities, or for the purpose of tendering shares in the event of a tender offer therefor, provided however that in the event of an offer of exchange, tender offer, or other exercise of rights requiring the physical tender or delivery of portfolio securities, the Bank shall have no liability for failure to so tender in a timely manner unless such Proper Instructions are received by the Bank at least two business days prior to the date required for tender, and unless the Bank (or its agent or subcustodian hereunder) has actual possession of such security at least two business days prior to the date of tender;
          (c) upon conversion of portfolio securities pursuant to their terms into other securities;
          (d) for the purpose of redeeming in kind shares of the trust upon authorization from the Trust;
          (e) in the case of option contracts owned by the Trust, for presentation to the endorsing broker;

Page 11


 

          (f) when such portfolio securities are called, redeemed or retired or otherwise become payable;
          (g) for the purpose of effectuating the pledge of portfolio securities held by the Bank pursuant to this Agreement in order to collateralize loans made to the Trust by any bank, including the Bank; provided, however, that such portfolio securities will be released only upon payment to the Bank for the account of the Trust of the monies borrowed, except that in cases where additional collateral is required to secure a borrowing already made, and such fact is made to appear in the Proper Instructions, further portfolio securities may be released for that purpose without any such payment. In the event that any such pledged portfolio securities are held by the Bank, they will be so held for the account of the lender, and after notice to the Trust from the lender in accordance with the normal procedures of the lender, that an event of deficiency or default on the loan has occurred, the Bank may deliver such pledged portfolio securities to or for the account of the lender;
          (h) for the purpose of releasing certificates representing portfolio securities of the Trust, against contemporaneous receipt by the Bank of the fair market value of such security, as set forth in Proper Instructions received by the Bank before such payment is made;
          (i) for the purpose of delivering securities lent by the Trust to a bank or broker dealer, but only against receipt in accordance with street delivery custom except as otherwise provided in Subsections 6.2(a) and (b) hereof, of adequate collateral as agreed upon from time to time by the Trust and the Bank, and upon receipt of payment in connection with any repurchase agreement relating to such securities entered into by the Trust;
          (j) for other authorized transactions of the Trust or for other proper corporate purposes; provided that before making such transfer, the Bank will also receive a certified copy of resolutions of the Trustees of the Trust, signed by an authorized officer of the Trust (other than the officer certifying such resolution) and certified by its Secretary or Assistant Secretary, specifying the portfolio securities to be delivered, setting forth the transaction in or purpose for which such delivery is to be made, declaring such transaction to be an authorized transaction of the Trust or such purpose to be a proper corporate purpose, and naming the person or persons to whom delivery of such securities shall be made; and
          (k) upon termination of this Agreement as hereinafter set forth pursuant to Section 9 and Section 13 of this Agreement.
          As to any deliveries made by the Bank pursuant to subsections (a), (b), (c), (e), (f), (g), (h) and (i) securities or cash receivable in exchange therefor shall be delivered to the Bank.
           8. Redemptions . In the case of payment of assets of the Trust held by the Bank in connection with redemptions and repurchases by the Trust of outstanding shares of beneficial interest, the Bank will rely on notification by the Trust’s transfer agent of receipt of a request for redemption and certificates, if issued, in proper form for redemption before such payment is

Page 12


 

made. Payment shall be made in accordance with the Declaration of Trust of the Trust, from assets available for said purpose.
           9. Merger, dissolution, etc. of Trust . In the case of the following transactions, not in the ordinary course of business, namely, the merger of the Trust into or the consolidation of the Trust with another investment company, the sale by the Trust of all, or substantially all, of its assets to another investment company, or the liquidation or dissolution of the Trust and distribution of its assets, the Bank will deliver the portfolio securities held by it under this Agreement and disburse cash only upon the order of the Trust set forth in an Officers’ Certificate, accompanied by a certified copy of a resolution of the Trustees of the Trust authorizing any of the foregoing transactions. Upon completion of such delivery and disbursement and the payment of the fees, disbursements and expenses of the Bank, this Agreement will terminate.
           10. Actions of Bank without prior Authorization . Notwithstanding anything herein to the contrary, unless and until the Bank receives an Officers’ Certificate to the contrary, it will without prior authorization or instruction of the Trust or the transfer agent:
          10.1 Receive and hold for the account of the Trust hereunder and deposit in the account or accounts referred to in Section 6 hereof, all income, dividends, interest and other payments or distribution of cash with respect to the portfolio securities held thereunder;
          10.2 Present for payment all coupons and other income items held by it for the account of the Trust which call for payment upon presentation and hold the cash received by it upon such payment for the account of the Trust account or accounts referred to in Section 6 hereof;
          10.3 Receive and hold for the account of the Trust hereunder and deposit in the account or accounts referred to in Section 6 hereof all securities received as a distribution on portfolio securities as a result of a stock dividend, share split-up, reorganization, recapitalization, merger, consolidation, readjustment, distribution of rights and similar securities issued with respect to any portfolio securities held by it hereunder;
          10.4 Execute as agent on behalf of the Trust all necessary ownership and other certificates and affidavits required by the Internal Revenue Code or the regulations of the Treasury Department issued thereunder, or by the laws of any state, now or hereafter in effect, inserting the Trust’s name on such certificates as the owner of the securities covered thereby, to the extent it may lawfully do so and as may be required to obtain payment in respect thereof. The Bank will execute and deliver such certificates in connection with portfolio securities delivered to it or by it under this Agreement as may be required under the provisions of the Internal Revenue Code and any Regulations of the Treasury Department issued thereunder, or under the laws of any State;
          10.5 Present for payment all portfolio securities which are called, redeemed, retired or otherwise become payable, and hold cash received by it upon payment for the account of the Trust in the account or accounts referred to in Section 6 hereof; and
          10.6 Exchange interim receipts or temporary securities for definitive securities.

Page 13


 

          The Bank will use all reasonable effort to collect any funds which may to its knowledge become collectible arising from such securities, including dividends, interest and other income, and to transmit to the Trust notice actually received by it of any call for redemption, offer of exchange, right of subscription, reorganization or other proceedings affecting such securities.
          If portfolio securities upon which such income is payable are in default or payment is refused after due demand or presentation, the Bank will notify the Trust in writing of any default or refusal to pay within two business days from the day on which it receives knowledge of such default or refusal. In addition, the Bank will send the Trust a written report once each month showing any income on any portfolio security held by it which is more than ten days overdue on the date of such report and which has not previously been reported.
           11. Maintenance of Records: Fund Evaluation: Accounting Services . The Bank will maintain records with respect to transactions for which the Bank is responsible pursuant to the terms and conditions of this Agreement, and in compliance with the applicable rules and regulations of the Investment Company Act of 1940, as amended, or any other applicable laws or rules, and will furnish the Trust daily with a statement of condition of the Trust. The Bank will furnish to the Trust at the end of every month, the close of each quarter of the Trust’s fiscal year, and at any other time upon receipt of reasonable notice, a list of the portfolio securities and the aggregate amount of cash held by it for the Trust. The books and records of the Bank pertaining to its actions under this Agreement and reports by the Bank or its independent accountants concerning its accounting system, procedures for safeguarding securities and internal amounting controls will be open to inspection and audit at reasonable times by officers of or auditors employed by the Trust and will be preserved by the Bank in the manner and in accordance With the applicable rules and regulations under the Investment Company Act of 1940 and any other applicable laws or rules.
          As custodian the Bank shall have and perform the following powers and duties:
          11.1 To keep the books of account and render statements or copies from time to time as reasonably requested by the Treasurer or any executive officer of the Trust.
          11.2 To compute and, unless otherwise directed by the Trustees of the Trust, determine as of the close of business on the New York Stock Exchange on each day on which said Exchange is open for unrestricted trading and as of such other hours, if any, as may be authorized by said Trustees the net asset value and the public offering price of a share of capital stock of the Trust, such determination to be made in accordance with the provisions of the Declaration of Trust of the Trust and Prospectus and Statement of Additional Information relating to the Trust, as they may from time to time be amended, and any applicable resolutions of the Trustees of the Trust at the time in force and applicable; and promptly to notify the Trust, or such other persons as the Trust may request of the results of such computation and determination. In computing the net asset value hereunder, the Bank may rely in good faith upon information furnished to it by any Authorized Person in respect of (i) the manner of accrual of the liabilities of the Trust and in respect of liabilities of the Trust not appearing on its books of account kept by the Bank, (ii) reserves, if any, authorized by the Trustees or that no such reserves have been authorized, (iii) the source of the quotations to be used in computing the net asset value, (iv) the value to be assigned to any security for which no price quotations are available, and (v) the method of computation of the public offering price on the basis of the net

Page 14


 

asset value of the shares, and the Bank shall not be responsible for any loss occasioned by such reliance or for any good faith reliance on any quotations received from a source pursuant to (iii) above.
          11.3 To assist generally in the preparation of reports to shareholders and others, audits of accounts, and other ministerial matters of like nature.
           12. Concerning the Bank .
          12.1 Performance of Duties . In performing its duties hereunder and any other duties listed on any Schedule hereto, if any, the Bank will be entitled to receive and act upon the advice of independent counsel of its own selection, which may be counsel for the Trust, and will be without liability for any action taken or thing done or omitted to be done in accordance with this Agreement in good faith in conformity with such advice. In the performance of its duties hereunder, the Bank will be protected and not be liable, and will be indemnified and saved harmless, by the Manager, for any action taken or omitted to be taken by it in good faith reliance upon the terms of this Agreement, any Officers’ Certificate, Proper Instructions, resolution of the Trustees, telegram, notice, request, certificate or other instrument reasonably believed by the Bank to be genuine and for any other loss to the Bank or the Trust except in the case of the Bank’s negligence, willful misfeasance or bad faith in the performance of its duties or reckless disregard of its obligations and duties hereunder. Notwithstanding anything herein to the contrary, in the event that the Bank is entitled to indemnification from the Manager pursuant to the terms hereof and the Bank is not promptly or fully indemnified, the Trust agrees that the Trust shall indemnify the Bank in accordance with the provisions hereof, and all references to the Manager in this Section 12.1 shall be deemed to refer to the Trust.
          The Bank may employ agents in the performance of its duties hereunder, including, upon receipt of Proper Instructions, subcustodians, provided that any such subcustodian meets at least the minimum qualifications required by Section 17(f)(1) of the Investment Company Act of 1940 to act as a custodian of the Trust’s assets; and provided further that the Bank shall have no more or less responsibility or liability to the Trust on account of any actions or omissions of any subcustodian so employed than any such subcustodian has to the Bank, and the Bank shall indemnify the Trust for any loss to the Trust resulting from the acts or omissions of any subcustodian to the extent that the Bank is so indemnified by the subcustodian.
          In order that the indemnification provision contained in this section 12.1 shall apply, however, it is understood that if in any case the Manager or the Trust may be asked to indemnify or save the Bank harmless, the Manager and Trust shall be fully and promptly advised of all pertinent facts concerning the situation in question, and it is further understood that the Bank will use all reasonable care to identify and notify the Manager and Trust promptly concerning any situation which presents or appears likely to present the probability of such claim for indemnification. The Manager or the Trust, as the case may be, shall have the option to defend the Bank against any claim which may be the subject of this indemnification, and in the event that the Manager or the Trust so elects it will so notify the Bank and thereupon the Manager or the Trust, as the case may be, shall take over the complete defense of the claim, and the Bank shall in such situations incur no further legal or other expenses in connection with such claim, provided however, if the defendants in any such action include both (i) the Manager or the Trust and (ii) the Bank, and the Bank shall have reasonably concluded that there may be legal defenses

Page 15


 

available to it which are different from or additional to those available to the Manager or the Trust, as the case may be, the Bank shall have the right to select separate counsel to assert such legal defenses and to otherwise participate in the defense of such action on behalf of the Bank with such cost to be borne by the party hereto ultimately liable with respect to such claim. The Bank shall in no case confess any claim or make any compromise in any case in which the Manager or the Trust will be asked to indemnify the Bank except with the prior written consent of the Manager or the Trust, as the case may be, which consent shall not be unreasonably withheld. The Manager or the Trust, as the case may be, shall not settle any claim without the Bank’s prior written consent, provided however that the Bank shall not unreasonably withhold its consent.
          The Trust shall pay all fees and expenses of any subcustodian.
          The Bank will be under no duty or obligation to inquire into and will not be liable for:
          (a) the validity of the issue of any portfolio securities purchased by or for the Trust, the legality of the purchases thereof or the propriety of the price incurred therefor;
          (b) the legality of any sale of any portfolio securities by or for the Trust or the propriety of the amount for which the same are sold;
          (c) the legality of an issue or sale of any shares of beneficial interest of the Trust or the sufficiency of the amount to be received therefor;
          (d) the legality of the repurchase of any shares of beneficial interest of the Trust or the propriety of the amount to be paid therefore except as specifically set forth on any Schedule hereto;
          (e) the legality of the declaration of any dividend by the Trust or the legality of the distribution of any portfolio securities as payment in kind of such dividend; or
          (f) any property or moneys of the Trust unless and until received by it, and any such property or moneys delivered or paid by it pursuant to the terms hereof.
          Moreover, the Bank will not be under any duty or obligation to ascertain whether any portfolio securities at any time delivered to or held by it for the account of the Trust are such as may properly be held by the Trust under the provisions of its Declaration of Trust, any federal or state statutes or any rule or regulation of any governmental agency.
          12.2 Fees and Expenses of Bank . The Manager will pay or reimburse the Bank from time to time for any transfer taxes payable upon transfer of portfolio securities made hereunder, and for all necessary proper disbursements, expenses and charges made or incurred by the Bank in the performance of this Agreement (including any duties listed on any Schedule hereto, if any) including any indemnities for any loss, liabilities or expense to the Bank as provided above. For the services rendered by the Bank hereunder, the Manager will pay to the Bank such compensation or fees at such rate and at such times as shall be agreed upon in writing by the parties from time to time. The Bank will also be entitled to reimbursement by the Manager for all reasonable expenses incurred in conjunction with termination of this Agreement by the Trust. To the extent the Manager is not obligated pursuant to an agreement with the Trust to pay the fees and

Page 16


 

expenses of the Bank hereunder, the Trust shall be responsible for such obligations of the Manager set forth in this section 12.2.
          12.3 Advances by Bank . The Bank may, in its sole discretion, advance funds on behalf of any Fund to make any payment permitted by this Agreement upon receipt of any proper authorization required by this Agreement for such payments by the Fund. Should such a payment or payments, with advanced funds, result in an overdraft (due to insufficiencies of the Fund’s account with the Bank, or for any other reason) this Agreement deems any such or related indebtedness, a loan made by the Bank to such Fund payable on demand and bearing interest at the current rate charged by the Bank for such loans unless the Trust shall provide the Bank with agreed upon compensating balances. Provided, however, that any such payment or payments by the Bank shall only be deemed a loan made by the Bank to a Fund to the extent such payment or payments do not exceed 10% of the value (taken at the lower of cost or current value) of such Fund’s total assets (not including the amount borrowed) at the time such payment or payments are made, and are made to facilitate the meeting of redemption requests which might otherwise require the untimely disposition of portfolio investments or for extraordinary or emergency purposes. To secure any such payments deemed to be loans in accordance with the foregoing, the Trust hereby grants to the Bank a security interest in and pledges to the Bank securities held by the Bank on behalf of the Fund on whose behalf such payments were made, in an amount not to exceed the lesser of the dollar amount deemed to constitute a loan or ten percent of such Fund’s total assets (taken at cost), the specific securities to be designated in writing from time to time by the Trust or the Manager; and provided, further, that (1) if from time to time neither the Trust nor the Manager shall have designated in writing specific securities in an amount at least equal to the lesser of the dollar amount deemed to constitute a loan or ten percent of the particular Fund’s total assets, or (2) if as a result of the delivery by the Bank out of its custody, pursuant to Proper Instructions, of any securities previously so designated, the remaining amount of securities so designated shall be less than the lesser of the dollar amount deemed to constitute a loan or ten percent of such Fund’s total assets, then the Bank shall have a security interest in the securities of such Fund, in an amount that, taken together with amounts of securities from time to time designated in writing by the Trust or the Manager that have not been delivered out of the custody of the Bank pursuant to Proper Instructions, does not exceed the lesser of the dollar amount deemed to constitute a loan or ten percent of such Fund’s total assets. Should the Trust fail to repay promptly any such advances, the Bank shall be entitled to use available cash and to dispose of pledged securities and property as is necessary to repay any such advances.
           13. Termination .
          13.1 This Agreement may be terminated at any time without penalty upon sixty days written notice delivered by either party to the other by means of registered mail, and upon the expiration of such sixty days this Agreement will terminate; provided, however, that the effective date of such termination may be postponed to a date not more than ninety days from the date of delivery of such notice (i) by the Bank in order to prepare for the transfer by the Bank of all of the assets of the Trust held hereunder, and (ii) by the Trust in order to give the Trust an opportunity to make suitable arrangements for a successor custodian. At any time after the termination of this Agreement, the Trust will,

Page 17


 

at its request, have access to the records of the Bank relating to the performance of its duties as custodian.
          13.2 In the event of the termination of this Agreement, the Bank will immediately upon receipt or transmittal, as the case may be, of notice of termination, commence and prosecute diligently to completion the transfer of all cash and the delivery of all portfolio securities duly endorsed and all records maintained under Section 11 to the successor custodian when appointed by the Trust. The obligation of the Bank to deliver and transfer over the assets of the Trust held by it directly to such successor custodian will commence as soon as such successor is appointed and will continue until completed as aforesaid. If the Trust does not select a successor custodian within ninety (90) days from the date of delivery of notice of termination the Bank may, subject to the provisions of subsection 13.3 of this Section, deliver the portfolio securities and cash of the Trust held by the Bank to a bank or trust company of its own selection which meets the requirements of Section 17(f)(1) of the Investment Company Act of 1940 and has a reported capital, surplus and undivided profits aggregating not less than $25,000,000, to be held as the property of the Trust under terms similar to those on which they were held by the Bank, whereupon such bank or trust company so selected by the Bank will become the successor custodian of such assets of the Trust with the same effect as though selected by the Trustees of the Trust.
          13.3 Prior to the expiration of ninety (90) days after notice of termination has been given, the Trust may furnish the Bank with an order of the Trust advising that a successor custodian cannot be found willing and able to act upon reasonable and customary terms and that there has been submitted to the shareholders of the Trust the question of whether the Trust will be liquidated or will function without a custodian for the assets of the Trust held by the Bank. In that event the Bank will deliver the portfolio securities and cash of the Trust held by it, subject as aforesaid, in accordance with one of such alternatives which may be approved by the requisite vote of shareholders, upon receipt by the Bank of a copy of the minutes of the meeting of shareholders at which action was taken, certified by the Trust’s Secretary.
           14. Notices . Any notice or other instrument in writing authorized or required by this Agreement to be given to either party hereto will be sufficiently given if addressed to such party and mailed or delivered to it at its office at the address set forth below; namely:
  (a)   In the case of notices sent to the Trust to:
 
      GMO Trust
c/o Grantham, Mayo, Van Otterloo & Co.
40 Rowes Wharf
4th Floor
Boston, MA 02110
Attn: David A. Salem
 
  (b)   In the case of notices sent to the Bank to:
 
      Investors Bank & Trust Company
Financial Product Services
One Lincoln Plaza P.O. Box 1537

Page 18


 

      Boston, Massachusetts 02205-1537
 
    or at such other place as such party may from time to time designate in writing.
           15. Amendments . This Agreement may not be altered or amended, except by an instrument in writing, executed by both parties, and in the case of the Trust, such alteration or amendment will be authorized and approved by its Trustees.
           16. Parties . This Agreement will be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns; provided, however, that this Agreement will not be assignable by the Trust without the written consent of the Bank or by the Bank without the written consent of the Trust, authorized and approved by its Trustees; and provided further that termination proceedings pursuant to Section 13 hereof will not be deemed to be an assignment within the meaning of this provision.
           17. Governing Law . This Agreement and all performance hereunder will be governed by the laws of the Commonwealth of Massachusetts.
           18. Limitation of Liability . The term GMO Trust means and refers to the Trustees from time to time serving under the Agreement and Declaration of Trust of the Trust dated June 24, 1985, as the same may subsequently thereto have been, or subsequently hereto be, amended. It is expressly agreed that the obligations of the Trust hereunder shall not be binding upon any of the Trustees, shareholders, nominees, officers, agents or employees of the Trust, personally, but shall bind only the trust property of the Trust as provided in the Agreement and Declaration of Trust of the Trust. The execution and delivery of this Agreement have been authorized by the Trustees of the Trust and this Agreement has been signed by an authorized officer of the Trust, acting as such, and neither such authorization by such Trustees nor such execution and delivery by such officer shall be deemed to have been made by any of them, but shall bind only the trust property of the Trust as provided in the Agreement and Declaration of Trust.

Page 19


 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed in duplicate and their respective corporate seals to be affixed hereto as of the date first above written by their respective officers thereunto duly authorized.
         
    GMO Trust
 
       
 
  By:   /s/ R. Jeremy Grantham
 
       
ATTEST:
       
 
       
/s/ Esther Cash
 
       
 
       
    Grantham, Mayo, Van Otterloo & Co.
 
       
 
  By:   /s/ David A. Salem
 
       
 
       
ATTEST:
       
 
       
/s/ Esther Cash
 
       
 
       
    Investors Bank & Trust Company
 
       
 
  By:   /s/ [signature]
 
       
 
       
ATTEST:
       
 
       
/s/ [signature]
 
       

Page 20


 

Schedule A
Custody of Foreign Securities
          The following provisions govern the maintenance of the Fund’s foreign securities, and cash incidental to transactions in such securities, which pursuant to this Schedule A shall be held in the custody of certain foreign banking institutions and foreign securities depositories acting as sub-custodians in conformity with the requirements of Rule 17f-5 under the Investment Company Act of 1940 (the “ Act ”):
I. EUROCLEAR
          1. Appointment of Euroclear as Sub-Custodian . The Fund hereby authorizes and instructs the Bank to employ the securities clearance and depository facilities operated by Morgan Guaranty Trust Company of New York in Brussels, Belgium (“ Euroclear ”), to act as sub-custodian of the Fund pursuant to and governed by the Terms and Conditions Governing the Euroclear System (the “ Terms and Conditions ”).
          2. Assets to be Held . The Bank shall limit the securities and other assets maintained in Euroclear to those Euroclear eligible securities which are “foreign securities”, as defined in paragraph (c)(l) of Rule 17f-5 of the Act, and to cash and cash equivalents in such amounts as the Bank or the Fund may determine to be reasonably necessary to effect the Fund’s foreign securities transactions through Euroclear.
          3. Use of Euroclear . Except as may other wise be agreed upon in writing by the Bank and the Fund, the Fund authorizes the deposit in Euroclear of all foreign securities of the Fund eligible for deposit therein and to utilize such securities depository to the extent possible in connection with settlements of purchases and sales of securities and deliveries and returns of securities, until notified to the contrary pursuant to Section 9 hereunder.
          4. Segregation of Securities . The Bank shall identify on its books as belonging to the Fund the foreign securities of the Fund held in Euroclear and shall hold all securities of the Fund in an “Unencumbered Securities Account” with Euroclear.
          5. Reports by Bank . The Bank shall supply the Fund from time to time, as mutually agreed upon, statements in respect of the securities and other assets of the Fund held in Euroclear as shall be made available to the Bank by Euroclear.
          6. Transactions in Foreign Custody Account . Transactions with respect to the securities and other assets of the Fund held in Euroclear shall be effected pursuant to Proper Instructions from the Fund to the Bank in accordance with the Terms and Conditions.
          7. Terms and Conditions . The Fund acknowledges that the Bank, as a participant in Euroclear, is subject to the Terms and Conditions, a copy of which has been made available to the Fund. The Fund acknowledges that pursuant to such Terms and Conditions, Morgan Guaranty Brussels shall have the sole right to exercise or assert any and all rights or claims in respect of actions or omissions of, or the bankruptcy or insolvency of, any other depository, clearance system or custodian utilized by Euroclear in connection with the Fund’s securities and other assets.

Page 21


 

          8. Monitoring Responsibilities . The Bank shall furnish to the Fund information made available to it by Euroclear concerning the Euroclear system for use by the Fund in evaluating such system to ensure compliance with the requirements of Rule l7f-5 of the Act. The Bank shall promptly inform the Fund of any material changes in the circumstances surrounding the foreign custody arrangements provided by Euroclear as such information shall be made available to the Bank by Euroclear or otherwise.
          9. Termination of Euroclear . Upon receipt of Proper Instructions, the Fund may instruct the Bank to cease the employment of Euroclear for maintaining custody of the Fund’s assets, and the Bank shall so cease to employ Euroclear as soon as alternate custodial arrangements have been implemented.
II. CITIBANK.
          1. Appointment of Citibank as Sub-Custodian . The Fund hereby authorizes and instructs the Bank to employ Citibank, NA, a national bank organized and existing under the laws of the United States, having its principal office and place of business at 399 Park Avenue, New York, New York (“ Citibank ”) which has established a global custody network for the custody of foreign securities (the “ Citibank Network ”) as sub-custodian for the Fund’s securities and other assets maintained outside the United States pursuant to the Sub-Custodial Agreement by and between Citibank and the Bank (the “ Citibank Agreement ”) a copy of which has been provided to the Fund.
          2. Appointment of Foreign Sub-Custodians . The Fund hereby authorizes the Bank and Citibank to employ as sub-custodians for the Fund’s securities and other assets maintained outside the United States those eligible foreign custodians as such term is defined in Rule 17f-S of the Act (an “ Eligible Foreign Custodian ”) or the foreign branch offices of Citibank (a “ Branch ”) which are listed on Annex A hereto (the “ Selected Foreign Sub-Custodians ”) pursuant to agreements between Citibank and each of such Selected Foreign Sub-Custodians (the “ Sub-Custodial Agreement ”) as shall have been previously furnished to the Fund by the Bank. Upon receipt of certified resolutions of the Fund’s Board of Directors, the Bank and the Fund may agree to amend Annex A hereto from time to time to designate additional Eligible Foreign Sub-Custodians or Branches which are part of the Citibank Network to act as sub-custodians.
          3. Assets to be Held . The Bank shall limit the securities and other assets maintained through Citibank in the custody of the foreign sub-custodians to: (a) “foreign securities”, as defined in paragraph (c)(1) of Rule 17f-5 under the Act, and (b) cash and cash equivalents in such amounts as the Bank or the Fund may determine to be reasonably necessary to effect the Fund’s foreign securities transactions, subject to the provisions of Part I of this Schedule A, relating to Euroclear eligible securities, and Part III of this Schedule A, relating to securities to be held in Australia.
          4. Foreign Securities Depositories . Except as may other wise be agreed upon in writing by the Bank and the Fund, the Fund authorizes the deposit in a securities depository which is a Selected Foreign Sub-Custodian, all securities of the Fund held in the Citibank Network eligible for deposit therein and to utilize such securities depository to the extent possible in connection with settlements of purchases and sales of securities and deliveries and returns of securities.

Page 22


 

          5. Segregation of Securities . The Bank shall identify on its books as belonging to the Fund the foreign securities of the Fund held in the Citibank Network, and Citibank shall identify in a separate account, pursuant to the Citibank Agreement, all securities and moneys of the Fund.
          6. Agreements with Selected Foreign Sub-Custodians . Upon receiving notification from Citibank, the Bank shall promptly notify the Fund of any changes in the terms of the Sub-Custodial Agreements in effect with Citibank with respect to Selected Foreign Sub-Custodians.
          7. Reports by Bank . The Bank shall supply the Fund from time to time, as mutually agreed upon, statements in respect of the securities and other assets of the Fund held in the Citibank Network, including but not limited to the identification of entities having possession of the Fund’s securities and other assets and advices or notifications of any transfers of securities to or from each account maintained on behalf of the Fund, as shall be made available to the Bank by Citibank.
          8. Transactions in Foreign Custody Account . Transactions with respect to the securities and other assets of the Fund held in the Citibank Network shall be effected pursuant to Proper Instructions from the Fund to the Bank in accordance with the Citibank Agreement If at any time, at the request of the Fund, any securities of the Fund shall be registered in the name of the nominee-of the Selected Foreign Sub-Custodian, the Fund agrees to reimburse the Bank for any expenses to which it may become liable pursuant to the Citibank Agreement by reason of the registration of such securities in the name of such nominee.
          9. Liability of Citibank . The standard of care and the liability of Citibank for its actions and the actions of Selected Foreign Sub-Custodians in connection with the securities and other assets of the Fund held in the . Citibank Network is set forth in the Citibank Agreement.
          10. Monitoring Responsibilities . The Bank shall furnish to the Fund information made available to it by Citibank concerning the Selected Foreign Sub-Custodians for use by the Fund in evaluating such Selected Foreign Sub-Custodians to ensure compliance with the requirements of Rule 17f-5 of the Act. The Bank shall promptly inform the Fund of any material changes in the circumstances surrounding the foreign custody arrangements provided by Citibank as such information shall be made available to the Bank by Citibank.
          11. Upon receipt of Proper Instructions, the Fund may instruct the Bank to cease the employment of any one or more of such Selected Foreign Sub-Custodians for maintaining custody of the Fund’s assets, or to terminate Citibank as Sub-Custodian of the Fund, and the Bank shall so cease to employ such sub-custodian as soon as alternate custodial arrangements have been implemented.
III. NATIONAL AUSTRALIA BANK LIMITED.
          1. Appointment of National Australia Bank Limited as Sub-Custodian . The Fund hereby authorizes and instructs the Bank to employ National Australia Bank Limited, a banking institution organized under the laws of Australia N.A., meeting the requirements of an eligible foreign custodian as that term is defined in Rule 171-5 of the Act, having its principal office and place of business in Melbourne, Victoria, Australia (“ NAB ”) as sub-custodian for the Fund’s securities and other assets maintained in Australia and New Zealand pursuant to the

Page 23


 

Master Sub-custodian Agreement by and between NAB and the Bank (the “ NAB Agreement ”), a copy of which has been made available to the Fund.
          2. Assets to be Held . The Bank shall limit the securities and other assets maintained at NAB to: (a) “foreign securities”, as defined in paragraph (c)(1) of Rule 17f-5 under the Act, the principal trading market for which is in Australia or New Zealand and (b) cash and cash equivalents in such amounts as the Bank or the Fund may determine to be reasonably necessary to effect the Fund’s foreign securities transactions, subject to the provisions of Part I of this Schedule A, relating to Euroclear eligible securities.
          3. National Nominees Limited . All securities of the Fund held by NAB shall be registered in the name of its wholly-owned subsidiary, National Nominees Limited.
          4. Segregation of Securities . The Bank shall identify on its books as belonging to the Fund the foreign securities of the Fund held by NAB, and NAB shall identify in a separate account, pursuant to the NAB Agreement, all securities and moneys of the Fund.
          5. Reports by Bank . The Bank shall supply the Fund from time to time, as mutually agreed upon, statements in respect of the securities and other assets of the Fund held by NAB, including but not limited to advices or notifications of any transfers of securities to or from each account maintained on behalf of the Fund, as shall be made available to the Bank by NAB.
          6. Transactions in Foreign Custody Account . Transactions with respect to the securities and other assets of the Fund held by NAB shall be effected pursuant to Proper Instructions from the Fund to the Bank in accordance with the NAB Agreement
          7. Use of Austraclear . Upon receipt of certified resolutions of the Fund’s Board of Directors authorizing the use of Austraclear, a securities depository, all securities of the Fund held by NAB and eligible for deposit therein may be so deposited and held therein.
          8. Liability of NAB . The standard of care and the liability of NAB for its actions in connection with the securities and other assets of the Fund held by NAB is set forth in the NAB Agreement.
          9. Monitoring Responsibilities . The Bank shall furnish to the Fund information made available to it by NAB concerning NAB for use by the Fund in evaluating NAB and to ensure compliance with the requirements of Rule 17f-5 of the Act. The Bank shall promptly inform the Fund of any material changes in the circumstances surrounding the foreign custody arrangements provided by NAB as such information shall be made available to the Bank by NAB.
          10. Termination . Upon receipt of Proper Instructions, the Fund may instruct the Bank to cease the employment of NAB for maintaining custody of the Fund’s assets, and the Bank shall so cease to employ NAB as soon as alternate custodial arrangements have been implemented.

Page 24


 

[This page is intentionally left blank.]

 


 

[IBT LETTERHEAD]
May 30, 2003
GMO Trust
40 Rowes Wharf
Boston, MA 02110
Grantham, Mayo, Van Otterloo & Co. LLC
40 Rowes Wharf
Boston, MA 02110
Re: Amendment to the Custodian Agreement (the “Agreement”), dated August 1, 1991, by and among GMO Trust (the “Trust”), on behalf of certain series of the Trust (the “Funds”), Grantham, Mayo, Van Otterloo & Co. LLC (“GMO”) and Investors Bank & Trust Co. (the “Bank”), as amended.
Ladies and Gentlemen:
               Pursuant to Section 15 of the Agreement, this letter amends the Agreement as required by recently adopted amendments to Rule 17f-4 under the Investment Company Act of 1940, as amended (“Rule 17-4”), governing investment companies’ use of securities depositories. Capitalized terms used, but not otherwise defined herein, shall have the meanings ascribed to them in the Agreement. The terms “financial assets,” “securities entitlements,” “securities intermediary,” “securities depository,” and “intermediary custodian,” as used herein, shall have the same meaning as when such terms are used in Rule 17f-4 for purposes of Rule 17f-4.
               The Bank hereby agrees to the following as of the date hereof:
  (1)   In addition to, and not in lieu of, any standard of care set forth in the Agreement, the Bank shall be obligated to exercise due care in accordance with reasonable commercial standards when placing and maintaining financial assets corresponding to the Trust’s securities entitlements with a securities depository or an intermediary custodian;
 
  (2)   In addition to the Bank’s obligations under Section 11 of the Agreement, the Bank shall provide, promptly upon request by

1


 

      the Trust, such reports as are available regarding its internal accounting controls and financial strength;
 
  (3)   In addition to, and not in lieu of, any standard of care set forth in the Agreement that is applicable to an intermediary custodian appointed by the Bank pursuant to the terms of the Agreement, any such intermediary custodian shall be obligated, pursuant to the terms of its agreement or other arrangement with the Bank, at a minimum to exercise due care in accordance with reasonable commercial standards in discharging its duty as a securities intermediary to obtain and thereafter maintain financial assets, corresponding to the security entitlements of its entitlement holders (as defined in U.C.C. Sections 8-102(a)(7) (2002));
 
  (4)   Notwithstanding requirements to the contrary in Sections 6.2(a) through (c) of the Agreement, the Trustees of the Trust shall not be required to provide prior approval or annual reapproval of the Bank’s use of the Book-Entry System, a Depository, or a system maintained by the Bank for the holding of Book-Entry Paper, and the Trust hereby agrees that the Bank may so use such systems or depositories; and
 
  (5)   The clause “, specifically identified in a certified copy of a resolution of the Trustees of the Trust” in the last sentence of Section 2.6 of the Agreement is hereby deleted.
               This letter agreement shall constitute an amendment to the Agreement and, as such, a binding agreement among the Trust, on behalf of the Funds, the Manager, and the Bank in accordance with its terms. The terms of this letter agreement shall be effective as of March 28, 2003.

2


 

         
  Sincerely,

INVESTORS BANK & TRUST
COMPANY
 
 
  By:   /S/ Andrew M. Nesvet    
    Name:   Andrew M. Nesvet   
    Title:   Managing Director   
 
The foregoing is hereby
accepted and agreed.
GMO TRUST, on behalf of the Funds
         
     
By:   /S/ Elaine M. Hartnett      
  Name:   Elaine M. Hartnett     
  Title:   Vice President and Secretary     
 
GRANTHAM, MAYO, VAN OTTERLOO & CO. LLC
 
   
By:   /S/ Elaine M. Hartnett      
  Name:   Elaine M. Hartnett     
  Title:   Associate General Counsel     
 

3

Exhibit (h)(1)
Execution Copy
CONFORMING TRANSFER AGENCY
AND SERVICE AGREEMENT
          Conforming Transfer Agency and Service Agreement (“Conforming Agreement”) made as of this 23 rd day of August, 2011 by and between GMO Series Trust, (the “Series Trust”), a business trust established under the laws of the Commonwealth of Massachusetts, and State Street Bank and Trust Company (as successor by merger to Investors Bank & Trust Company)(“State Street”).
          WHEREAS, GMO Trust (the “Company”), Grantham, Mayo, Van Otterloo & Co. LLC (“GMO”) and State Street are party to the Transfer Agency and Service Agreement dated August 1, 1991, as amended, supplemented or otherwise modified from time to time (the “Agreement”) pursuant to which State Street agrees to provide certain services to the Company;
          WHEREAS, in connection with the creation of the Series Trust, the parties intend to apply the terms of the Agreement to the Series Trust without modifying the terms of the Agreement with respect to the Company;
          NOW, THEREFORE, in connection with the foregoing and in consideration of the mutual covenants herein set forth, the Series Trust and State Street agree as follows:
  1.   The terms of the Agreement shall apply, mutatis mutandis , to the Series Trust as if it were the Company and to each series of the Series Trust as if it were a series of the Company, provided that all obligations of GMO in the Agreement shall be the obligations of the Series Trust.
 
  2.   A list of the series of the Series Trust is set forth in Schedule A, which shall be amended from time to time in writing by mutual agreement of the Series Trust and State Street.
 
  3.   For the avoidance of doubt, the Series Trust and State Street shall be liable to the other to the extent and under the circumstances described in the Agreement. Further, with respect to Section 14, references to the ‘Manager’ shall be replaced by the ‘Series Trust’; provided, however that the obligations of each series of the Series Trust are binding solely upon the assets and liability of the relevant series. Section 14.06 of the Agreement shall not apply with respect to the Series Trust.
[signature page immediately follows]

1


 

     IN WITNESS WHEREOF; the parties hereto have caused this Conforming Agreement to be duly executed as of the day and year first written above.
         
GMO SERIES TRUST*    
 
       
By:
  /s/ JB Kittredge
 
   
Name:
  JB Kittredge    
Title:
  President and Chief Executive Officer    
 
*   GMO Series Trust is a Massachusetts business trust and a copy of the Agreement and Declaration of Trust of GMO Series Trust is on file with the Secretary of State of the Commonwealth of Massachusetts. Notice is hereby given that this Agreement is executed on behalf of the Trustees of the Series Trust as Trustees and not individually, and that the obligations of or arising out of this Agreement with respect to each series of the Series Trust are not binding upon any of the Trustees or shareholders individually or any other series, but are binding only upon the assets and property of that series.
         
STATE STREET BANK AND TRUST COMPANY    
 
       
By:
  /s/ Michael F. Rogers    
 
       
Name:
  Michael F. Rogers    
Title:
  Executive Vice President    

2


 

SCHEDULE A
LIST OF GMO SERIES TRUST FUNDS
1
GMO U.S. Core Equity Series Fund
 
1   As of August 23, 2011

3


 

[This page intentionally left blank.]

 


 

EXECUTION COPY
TRANSFER AGENCY AND SERVICE AGREEMENT
     AGREEMENT made as of this 1st day of August, 1991 by and among GMO TRUST, a business trust established under the laws of the Commonwealth of Massachusetts (the “Company”) on behalf of the GMO Core Fund, GMO SAF Core Fund, GMO Value Allocation Fund, GMO Growth Fund, GMO Short-Term Income Fund, GMO International Core Fund, GMO Japan Fund and any other series of the Trust currently existing or hereafter created, as shall be mutually agreed to by the parties hereto to be subject to this Agreement in accordance with Article 17 (each such series referred to herein as the “Fund” and collectively as the “Funds”), GRANTHAM, MAYO, VAN OTTERLOO & CO., a Massachusetts General Partnership, (the “Manager”) and INVESTORS BANK & TRUST COMPANY, a Massachusetts trust company (the “Bank”).
WITNESSETH:
     WHEREAS, the Company desires to appoint the Bank as its transfer agent, dividend disbursing agent and agent in connection with certain other activities, and the Bank desires to accept such appointment;
     WHEREAS, the Bank is duly registered as a transfer agent as provided in Section 17A(c) of the Securities Exchange Act of 1934, as amended;
     NOW, THEREFORE, in consideration of the mutual covenants herein set forth, the Company and the Bank agree as follows:
    ARTICLE 1. Terms of Appointment; Duties of the Bank .
     1.01 Subject to the terms and conditions set forth in this Agreement, the Company hereby, employs and appoints the Bank to act as, and the Bank agrees to act as transfer agent for the Company’s authorized and issued shares of beneficial interest (“Shares”), dividend disbursing agent and agent in connection with any accumulation, open-account or similar plans provided to the shareholders of the Company (“Shareholders”) and set out in the currently effective prospectus and statement of additional information of the Company (the “Prospectus”), including without limitation any periodic investment plan or periodic withdrawal program.

 


 

Page 2

     1.02 The Bank agrees that it will perform the following services:
          (a) In accordance with procedures established from time to time by agreement between the Company and the Bank, the Bank shall:
          (i) Receive for acceptance, orders for the purchase of Shares, and promptly deliver payment and appropriate documentation therefor to the Custodian of the Company appointed by the Trustees (the “Trustees”) of the Company (the “Custodian”);
          (ii) Pursuant to purchase orders, issue the appropriate number of Shares and hold such Shares in the appropriate Shareholder account;
          (iii) Receive for acceptance, redemption requests and redemption directions and deliver the appropriate documentation therefor to the Custodian;
          (iv) At the appropriate time as and when it receives monies paid to it by the Custodian with respect to any redemption, pay over or cause to be paid over in the appropriate manner such monies as instructed by the redeeming Shareholders;
          (v) Effect transfers of Shares by the registered owners thereof upon receipt of appropriate instructions;
          (vi) Prepare and transmit payments for dividends and distributions declared by a Fund; and
          (vii) Create and maintain all necessary records including those specified in Article 10 hereof, in accordance with all applicable laws, rules and regulations, including but not limited to records required by Section 31(a) of the Investment Company Act of 1940 (the “1940 Act”), and those records pertaining to the various functions performed by it hereunder. All records shall be available for inspection and use by the Company. Where applicable, such records shall be maintained by the Bank for the periods and in the places required by Rule 31a-2 under the 1940 Act.
          (viii) Make available during regular business hours all records and other data created and maintained pursuant to this Agreement for reasonable audit and inspection by


 

Page 3

the Company, or any person retained by the Company. Upon reasonable notice by the Company, the Bank shall make available during regular business hours its facilities and premises employed in connection with its performance of this Agreement for reasonable visitation by the Company, or any person retained by the Company;
          (ix) At the expense of the Company, the Bank shall maintain an adequate supply of blank share certificates for each Fund providing for the issuance of certificates to meet the Bank’s requirements therefor. Such share certificates shall be properly signed by facsimile. The Company agrees that, notwithstanding the death, resignation, or removal of any officer of the Company whose signature appears on such certificates, the Bank may continue to countersign certificates which bear such signatures until otherwise directed by the Company. Share certificates may be issued and accounted for entirely by the Bank and do not require any third party registrar or other endorsing party;
          (x) Issue replacement share certificates in lieu of certificates which have been lost, stolen or destroyed, without any further action by the Trustees or any officer of the Company, upon receipt by the Bank of properly executed affidavits and lost certificate bonds, in form satisfactory to the Bank, with the Company and the Bank as obligees under the bond. At the discretion of the Bank, and at its sole risk, the Bank may issue replacement certificates without requiring the affidavits and lost certificate bonds described above and the Bank agrees to indemnify the Company against any and all losses or claims which may arise by reason of the issuance of such new certificates in the place of the ones allegedly lost, stolen or destroyed;
          (xi) Record the issuance of Shares of the Company and maintain pursuant to SEC Rule 17Ad-10(e) a record of the total number of Shares of the Company which are authorized, based upon data provided to it by the Company, and issued and outstanding. The Bank shall also provide the Company on a regular basis with the total number of Shares which are authorized and issued and outstanding and shall have no obligation, when recording the issuance of Shares, to monitor the issuance of such Shares or to take cognizance of any laws relating to the issue or sale of such Shares, which functions shall be the sole responsibility of the Company.


 

Page 4

          (b) In addition to and not in lieu of the services set forth in the above paragraph (a) or in Schedule A hereto, if any, the Bank shall: (i) perform all of the customary services of a transfer agent, dividend disbursing agent and, as relevant, agent in connection with accumulation, open-account or similar plans (including without limitation any periodic investment plan or periodic withdrawal program); including but not limited to: maintaining all Shareholder accounts, preparing Shareholder meeting lists, mailing proxies, receiving and tabulating proxies, mailing Shareholder reports and prospectuses to current Shareholders, withholding taxes on all accounts, including non-resident alien accounts, preparing and filing U.S. Treasury Department Forms 1099 and other appropriate forms required with respect to dividends and distributions by federal authorities for all Shareholders, preparing and mailing confirmations forms and statements of account to Shareholders for all purchases and redemptions of Shares and other confirmable transactions in Shareholder accounts, responding to Shareholder telephone calls and Shareholder correspondence, preparing and mailing activity statements for Shareholders, and providing Shareholder account information and (ii) provide a system which will enable the Company to monitor the total number of Shares sold in each State. The Company shall (i) identify to the Bank in writing those transactions and assets to be treated as exempt from the blue sky reporting for each State and (ii) verify the establishment of transactions for each state on the system prior to activation and thereafter monitor the daily activity for each State. The responsibility of the Bank for a Fund’s blue sky State registration status is solely limited to the initial establishment of transactions subject to blue sky compliance by such Fund(s) and the reporting of such transactions to the Fund(s) as provided above.
          (c) Additionally, the Bank shall:
          (i) Utilize a system to identify all share transactions which involve purchase and redemption orders that are processed at a time other than the time of the computation of net asset value per share next computed after receipt of such orders, and shall compute the net effect upon the Fund(s) of such transactions so identified on a daily and cumulative basis.
          (ii) If upon any day the cumulative net effect of such transactions upon the Fund(s) is negative and exceed a dollar amount equivalent to 1/2 of 1 cent per share due to an error of the Bank, the Bank shall promptly make a payment to the Fund(s) in cash or through the use of a


 

Page 5

credit, in the manner described in paragraph (iv) below, in such amount as may be necessary to reduce the negative cumulative net effect to less than 1/2 of 1 cent per share.
          (iii) If on the last business day of any month the cumulative net effect upon the Fund(s) (adjusted by the amount of all prior payments and credits by the Bank and the Fund(s)) is negative, the Fund(s) shall be entitled to a reduction in the fee next payable under the Agreement by an equivalent amount, except as provided in paragraph (iv) below. If on the last business day in any month the cumulative net effect upon the Fund(s) (adjusted by the amount of all prior payments and credits by the Bank and the Fund(s)) is positive, the Bank shall be entitled to recover certain past payments and reductions in fees, and to credit against all future payments and fee reductions that may be required under the Agreement as herein described in paragraph (iv) below.
          (iv) At the end of each month, any positive cumulative net effect upon the Fund(s) shall be deemed to be a credit to the Bank which shall first be applied to permit the Bank to recover any prior cash payments and fee reductions made by it to the Fund(s) under paragraphs (ii) and (iii) above during the calendar year, by increasing the amount of the monthly fee under the Agreement next payable in an amount equal to prior payments and fee reductions made by the Bank during such calendar year, but not exceeding the sum of that month’s credit and credits arising in prior months during such calendar year to the extent such prior credits have not previously been utilized as contemplated by this paragraph. Any portion of a credit to the Bank not so used by it shall remain as a credit to be used as payment against the amount of any future negative cumulative net effects that would otherwise require a cash payment or fee reduction to be made to the Fund(s) pursuant to paragraphs (ii) or (iii) above (regardless of whether or not the credit or any portion thereof arose in the same calendar year as that in which the negative cumulative net effects or any portion thereof arose).
          (v) The Bank shall supply to the Fund(s) from time to time, as mutually agreed upon, reports summarizing the transactions identified pursuant to paragraph (i) above, and the daily and cumulative net effects of such transactions, and shall advise the Fund(s) at the end of each month of the net cumulative effect at such time. The


 

Page 6

Bank shall promptly advise the Fund(s) if at any time the cumulative net effects exceeds a dollar amount equivalent to 1/2 of 1 cent per share.
          (vi) In the event that this Agreement is terminated for whatever cause, or this provision 1.02(c) is terminated pursuant to paragraph (vii) below, the Fund shall promptly pay to the Bank an amount in cash equal to the amount by which the cumulative net effect upon the Fund(s) is positive or, if the cumulative net effect upon the Fund(s) is negative, the Bank shall promptly pay to the Fund(s) an amount in cash equal to the amount of such cumulative net effect.
          (vii) This provision 1.02(c) of the Agreement may be terminated by the Bank at any time without cause, effective as of the close of business on the date written notice (which may be by telex) is received by the Fund(s).
ARTICLE 2. Sale of Company Shares .
     2.01 Whenever the Company shall sell or cause to be sold any Shares of a Fund, the Company shall deliver or cause to be delivered to the Bank a document duly specifying: (i) the name of the Fund whose Shares were sold; (ii) the number of Shares sold, trade date, and price; (iii) the amount of money to be delivered to the Custodian for the sale of such Shares and specifically allocated to such Fund; and (iv) in the case of a new account, a new account application or sufficient information to establish an account.
     2.02 The Bank will, upon receipt by it of a check or other payment identified by it as an investment in Shares of one of the Funds and drawn or endorsed to the Bank as agent for, or identified as being for the account of, one of the Funds, promptly deposit such check or other payment to the appropriate account postings necessary to reflect the investment. The Bank will notify the Company, or its designee, and the Custodian of all purchases and related account adjustments.
     2.03 Under procedures as established by mutual agreement between the Company and the Bank, the Bank shall issue to the purchaser or his authorized agent such Shares, computed to the nearest three decimal points, as he is entitled to receive, based on the appropriate net asset value of the Funds Shares, determined in accordance with applicable Federal law or regulation. In issuing Shares to a purchaser or his authorized agent, the Bank shall be entitled to rely upon the latest


 

Page 7

directions, if any, previously received by the Bank from the purchaser or his authorized agent concerning the delivery of such Shares.
     2.04 The Bank shall not be required to issue any Shares of the Company where it has received a written instruction from the Company or written notification from any appropriate Federal or state authority that the sale of the Shares of the Fund(s) in question has been suspended or discontinued, and the Bank shall be entitled to rely upon such written instructions or written notification, provided however that this provision shall not imply any duty or obligation on the part of the Bank to monitor federal or state laws with regard to the sale of Shares.
     2.05 Upon the issuance of any Shares of any Fund(s) in accordance with the foregoing provisions of this Section, the Bank shall not be responsible for the payment of any original issue or other taxes required to be paid by the Company in connection with such issuance.
     2.06 The Bank may establish such additional rules and regulations governing the transfer or registration of Shares as it may deem advisable and consistent with such rules and regulations generally adopted by transfer agents.
ARTICLE 3.
     3.01 Returned Checks . In the event that any check or other order for the transfer of money is returned unpaid for any reason, the Bank will take such steps as the Bank may, in its discretion, deem appropriate to protect the Company from financial loss or as the Company or its designee may instruct. Provided that the standard procedures, as agreed upon from time to time, between the Company and the Bank, regarding purchases and redemptions of Shares, are adhered to by the Bank, the Bank shall not be liable for any loss suffered by a Fund as a result of returned or unpaid purchase or redemption transactions. Legal or other expenses incurred to collect amounts owed to a Fund as a consequence of returned or unpaid purchase or redemption transactions shall be paid by the Manager or, if not so paid promptly, then by the relevant Fund.
ARTICLE 4.
     4.01 Redemptions . Shares of any Fund may be redeemed in accordance with the procedures set forth in the Prospectus and the Bank will duly process all redemption requests.


 

Page 8

ARTICLE 5.
     5.01 Transfers and Exchanges . The Bank is authorized to review and process transfers of Shares of each Fund, exchanges between Funds on the records of the Funds maintained by the Bank, and exchanges between the Company and any other entity, in each case as may be permitted by the Prospectus. If Shares to be transferred are represented by outstanding certificates, the Bank will, upon surrender to it of the certificates in proper form for transfer, and upon cancellation thereof, countersign and issue new certificates for a like number of Shares and deliver the same. If the Shares to be transferred are not represented by outstanding certificates, the Bank will, upon an order therefor by or on behalf of the registered holder thereof in proper form, credit the same to the transferee on its books. If Shares are to be exchanged for Shares of another Fund, the Bank will process such exchange in the same manner as a redemption and sale of Shares, except that it may in its discretion waive requirements for information and documentation.
ARTICLE 6.
     6.01 Right to Seek Assurances . The Bank reserves the right to refuse to transfer or redeem Shares until it is satisfied that the requested transfer or redemption is legally authorized, and it shall incur no liability for the refusal, in good faith, to make transfer or redemptions which the Bank, in its judgment, deems improper or unauthorized, or until it is satisfied that there is no basis for any claims adverse to such transfer or redemption. The Bank may, in effecting transfers, rely upon the provisions of the Uniform Act for the Simplification of Fiduciary Security Transfers or the Uniform Commercial Code, as the same may be amended from time to time, which in the opinion of legal counsel for the Company or of its own legal counsel protect it in not requiring certain documents in connection with the transfer or redemption of Shares of any Fund, and the Bank shall be entitled to indemnification in accordance with Article 14 hereof for any act done or omitted by it in reliance upon such laws or opinions of counsel of the Company or of its own counsel.
ARTICLE 7. Distributions .
     7.01 The Company will promptly notify the Bank of the declaration of any dividend or distribution. The Company shall furnish to the Bank a resolution of the Trustees of the Company certified by the Secretary: (i) authorizing the declaration of dividends on a specified periodic basis and authorizing the Bank


 

Page 9

to rely on oral instructions or a Certificate specifying the date of the declaration of such dividend or distribution, the date of payment thereof, the record date as of which Shareholders entitled to payment shall be determined and the amount payable per share to Shareholders of record as of the date and the total amount payable to the Bank on the payment date; or (ii) setting forth the date of the declaration of any dividend or distribution by a Fund, the date of payment thereof, the record date as of which Shareholders entitled to payment shall be determined, and the amount payable per share to the Shareholders of record as of that date and the total amount payable to the Bank on the payment date.
     7.02 The Bank, on behalf of the Company, shall instruct the Custodian to place in a dividend disbursing account funds equal to the cash amount of any dividend or distribution to be paid out. The Bank will calculate, prepare and mail checks to (at the address as it appears on the records of the Bank), or (where appropriate) credit such dividend or distribution to the account of, Fund Shareholders, and maintain and safeguard all underlying records.
     7.03 The Bank will replace lost checks at its discretion and in conformity with regular business practices.
     7.04 The Bank will maintain all records necessary to reflect the crediting of dividends which are reinvested in Shares of the Company, including without limitation daily dividends.
     7.05 The Bank shall not be liable for any improper payments made in accordance with a resolution of the Trustees of the Company.
     7.06 If the Bank shall not receive from the Custodian sufficient cash to make payment to all Shareholders of the Company as of the record date, the Bank shall, upon notifying the Company, withhold payment to all Shareholders of record as of the record date until such sufficient cash is provided to the Bank.
ARTICLE 8.
     8.01 Other Duties . In addition to the duties expressly provided for herein, the Bank shall perform such other duties and functions and shall be paid such amounts therefore as may from time to time be agreed in writing.


 

Page 10

ARTICLE 9.
     9.01 Taxes . It is understood that the Bank shall file such appropriate information returns concerning the payment of dividends and capital gain distributions and tax withholding with the proper Federal, State and local authorities as are required by law to be filed by the Company and shall withhold such sums as are required to be withheld by applicable law.
ARTICLE 10. Books and Records .
     10.01 The Bank shall maintain records showing for each Shareholder’s account the following: (i) names, addresses and tax identification numbers; (ii) numbers of Shares held; (iii) historical information regarding the account of each Shareholder, including dividends paid and date and price of all transactions on a Shareholder’s account; (iv) any stop or restraining order placed against a Shareholder’s account; (v) information with respect to withholdings; (vi) any capital gain or dividend reinvestment order, plan application, dividend address and correspondence relating to the current maintenance of a Shareholder’s account; (vii) certificate numbers and denominations for any Shareholders holding certificates; (viii) any information required in order for the Bank to perform the calculations contemplated or required by this Agreement; and (ix) such other information and data as may be required by applicable law.
     10.02 Any records required to be maintained by Rule 31a-1 under the 1940 Act will be preserved for the periods prescribed in Rule 31a-2 under the 1940 Act. Such records may be inspected by the Company at reasonable times. The Bank may, at its option at any time, and shall forthwith upon the Company’s demand, turn over to the Company and cease to retain in the Bank’s files, records and documents created and maintained by the Bank in performance of its service or for its protection. At the end of the six-year retention period, such periods and documents will either be turned over to the Company, or destroyed in accordance with the Company’s authorization.
     10.03 Procedures applicable to the services to be performed hereunder may be established from time to time by agreement between the Fund(s) and the Bank. The Bank shall have the right to utilize any shareholder accounting and recordkeeping systems which, in its opinion, qualifies to perform any services to be performed hereunder.


 

Page 11

ARTICLE 11. Fees and Expenses .
     11.01 For performance by the Bank pursuant to this Agreement, the Manager agrees to pay the Bank an annual maintenance fee for each Shareholder account as set out in the initial fee schedule attached hereto. Such fees and out-of-pocket expenses and advances identified under Section 11.02 below may be changed from time to time subject to mutual written agreement between the Manager and the Bank.
     11.02 In addition to the fee paid under Section 11.01 above, the Manager agrees to reimburse the Bank for out-of-pocket expenses or advances incurred by the Bank for the items set out in the fee schedule attached hereto. In addition, any other expenses incurred by the Bank at the request or with the consent of the Fund(s) including, without limitation, any equipment or supplies specifically ordered by the Company or required to be purchased by the Company, will be reimbursed by the Manager.
     11.03 The Manager agrees to pay all fees and reimbursable expenses within five days following the mailing of the respective billing notice. Postage for mailing of dividends, proxies, Fund reports and other mailings to all shareholder accounts shall be advanced to the Bank by the Manager at least seven (7) days prior to the mailing date of such materials.
     11.04 Notwithstanding the foregoing, to the extent the Manager is not obligated pursuant to an agreement with the Company to pay the fees and expenses of the Bank hereunder, the Company shall be responsible for such obligations of the Manager set forth in this Article 11.
ARTICLE 12. Representations and Warranties of the Bank .
     The Bank represents and warrants to the Company that:
     12.01 It is a banking association duly organized and existing and in good standing under the laws of the United States of America.
     12.02 It is empowered under applicable laws and by its charter and By-laws to enter into and perform this Agreement.
     12.03 All requisite corporate proceedings have been taken to authorize it to enter into and perform this Agreement.


 

Page 12

     12.04 It has and will continue to have access to the necessary facilities, equipment and personnel to perform its duties and obligations under this Agreement.
ARTICLE 13. Representations and Warranties of the Company and the Manager .
     The Company represents and warrants to the Bank that:
     13.01 It is a business trust duly organized and existing and in good standing under the laws of the state of its organization as set forth in the preamble hereto.
     13.02 It is empowered under applicable laws and by its charter documents and By-Laws to enter into and perform this Agreement.
     13.03 All proceedings required by said charter documents and By-Laws have been taken to authorize it to enter into and perform this Agreement.
     13.04 It is an open-end, management investment company registered under the Investment Company Act of 1940.
     13.05 A registration statement on Form N-1A (including a prospectus and statement of additional information) under the Investment Company Act of 1940 is currently effective and will remain effective, and appropriate state securities law filings have been made and will continue to be made, with respect to all Shares of the Company being offered for sale.
     13.06 When Shares are hereafter issued in accordance with the terms of the Prospectus, such Shares shall be validly issued, fully paid and nonassessable by the Company.
     The Manager represents and warrants to the Bank that:
     13.07 It is a Massachusetts general partnership, empowered under applicable laws and by its agreement of partnership to enter into and perform this Agreement.
     13.08 All proceedings required by said agreement have been taken to authorize it to enter into and perform this Agreement, and the partner executing this Agreement on behalf of the partnership has full authority to do so on behalf of the partnership.


 

Page 13

ARTICLE 14. Indemnification .
     14.01 The Bank shall not be responsible for, and the Manager shall indemnify and hold the Bank harmless from and against, any and all losses, damages, costs, charges, counsel fees, payments, expenses and liability arising out of or attributable to:
          (a) All actions taken or omitted to be taken by the Bank or its agent or subcontractors in good faith in reliance on, or, use by the Bank or its agents or subcontractors of information, records and documents which (i) are received by the Bank or its agents or subcontractors and furnished to it by or on behalf of the Fund(s), (ii) have been prepared and/or maintained by the Fund(s) or any other person or firm on behalf of the Fund(s), or (iii) were received by the Bank or its agents or subcontractors from a prior transfer agent.
          (b) Any action taken or omitted to be taken in good faith by the Bank in connection with its appointment hereunder, in reliance upon any law, act, regulation or interpretation of the same even though the same may thereafter have been altered, changed, amended or repealed.
          (c) The Funds’ refusal or failure to comply with the terms of this Agreement, or which arise out of the Funds’ lack of good faith, negligence or willful misconduct or which arise out of the breach of any representation or warranty of the Fund(s) hereunder.
          (d) The reliance on, or the carrying out by the Bank or its agents or subcontractors of any instructions or requests, whether written or oral, of the Fund(s).
          (e) The offer or sale of Shares in violation of any requirement under the federal securities laws or regulations or the securities laws or regulations of any state that such Shares be registered in such state or in violation of any stop order or other determination or ruling by any federal agency or any state with respect to the offer or sale of such Shares in such state.
          (f) Indemnification under this Agreement shall not apply to actions or omissions of the Bank or its directors, officers, employees, agents or subcontractors in cases of its own negligence, willful misconduct, bad faith, or reckless disregard of its duties or their own duties hereunder.


 

Page 14

     14.02 The Bank shall indemnify and hold the Fund(s) harmless from and against any and all losses, damages, costs, charges, counsel fees, payments, expenses and liability arising out of or attributed to any action or failure, or omission to act by the Bank as a result of the Bank’s lack of good faith, negligence or willful misconduct.
     14.03 At any time the Bank may apply to any officer of the Company for instructions, and may consult with legal counsel with respect to any matter arising in connection with the services to be performed by the Bank under this Agreement, and the Bank and its agents or subcontractors shall not be liable and shall be indemnified by the Manager for any action taken or omitted by it in reliance upon such instructions or upon the opinion of such counsel. The Bank, its agents and subcontractors shall be protected and indemnified in acting upon any paper or document furnished by or on behalf of the Fund(s), reasonably believed to be genuine and to have been signed by the proper person or persons, or upon any instruction, information, data, records or documents provided the Bank or its agents or subcontractors by machine readable input, telex, CRT data entry or other similar means authorized by the Fund(s), and shall not be held to have notice of any change of authority of any person, until receipt of written notice thereof from the Fund(s). The Bank, its agents and subcontractors shall also be protected and indemnified in recognizing stock certificates which are reasonably believed to bear the proper manual or facsimile signatures of the officer of the Company, and one proper countersignature of any former transfer agent or registrar, or of a co-transfer agent or co-registrar.
     14.04 In the event either party is unable to perform its obligations under the terms of this Agreement because of acts of God, strikes, interruption of electrical power or other utilities, equipment or transmission failure or damage reasonably beyond its control, or other causes reasonably beyond its control, such party shall not be liable to the other for any damages resulting from such failure to perform or otherwise from such causes.
     14.05 No party to this Agreement shall be liable to any other party for consequential damages under any provision of this Agreement or for any act or failure to act hereunder.
     14.06 Notwithstanding anything herein to the contrary, in the event that the Bank is entitled to indemnification from the Manager pursuant to the terms hereof and the Bank is not promptly or fully indemnified, the Company agrees that the


 

Page 15

Company shall indemnify the Bank in accordance with the provisions hereof, and all references to the Manager in this Article 14 shall be deemed to refer to the Company.
     14.07 In order that the indemnification provision contained in this Article 14 shall apply, however, it is understood that if in any case the Manager or the Company may be asked to indemnify or save the Bank harmless, the Manager and the Company shall be fully and promptly advised of all pertinent facts concerning the situation in question, and it is further understood that the Bank will use all reasonable care to identify and notify the Manager and the Company promptly concerning any situation which presents or appears likely to present the probability of such claim for indemnification. The Manager or the Company, as the case may be, shall have the option to defend the Bank against any claim which may be the subject of this indemnification, and in the event that the Manager or the Company so elects it will so notify the Bank and thereupon the Manager or the Company as the case may be, shall take over the complete defense of the claim, and the Bank shall in such situations incur no further legal or other expenses in connection with such claim, provided however, if the defendants in any such action include both (i) the Manager or the Company and (ii) the Bank, and the Bank shall have reasonably concluded that there may be legal defenses available to it which are different from or additional to those available to the Manager or the Company, as the case may be, the Bank shall have the right to select separate counsel to assert such legal defenses and to otherwise participate in the defense of such action on behalf of the Bank with such cost to be borne by the party hereto ultimately liable with respect to such claim. The Bank shall in no case confess any claim or make any compromise in any case in which the Manager or the Company will be asked to indemnify the Bank except with the prior written consent of the Manager or the Company, as the case may be, which consent shall not be unreasonably withheld. The Manager or the Company, as the case may be, shall not settle any claim without the Bank’s prior written consent, provided however that the Bank shall not unreasonably withhold its consent.
ARTICLE 15. Covenants of the Company and the Bank .
     15.01 The Company shall promptly furnish to the Bank the following:
          (a) A certified copy of the resolution of the Trustees of the Company authorizing the appointment of the Bank and the execution and delivery of this Agreement.


 

Page 16

          (b) A copy of the charter documents and By-Laws of the Company and all amendments thereto.
          (c) Copies of each vote of the Trustees designating authorized persons to give instructions to the Bank.
          (d) Certificates as to any change in any officer or Trustee of the Company.
          (e) If applicable, a specimen of the certificate of Shares of each Fund of the Company in the form approved by the Trustees, with a certificate of the Secretary of the Company as to such approval.
          (f) Specimens of all new certificates for Shares, accompanied by the Trustees’ resolutions approving such forms.
          (g) All account application forms and other documents relating to shareholder accounts or relating to any plan, program or service offered by the Company.
          (h) A list of Shareholders of the Fund(s) with the name, address and tax identification number of each Shareholder, and the number of Shares of the Fund(s) held by each, certificate numbers and denominations (if any certificates have been issued), lists of any account against which stops have been placed, together with the reasons for said stops, and the number of Shares redeemed by the Fund(s).
          (i) An opinion of counsel for the Company with respect to the validity of the currently authorized Shares and the status of such Shares under the Securities Act of 1933, which may be copies of previously issued opinions, and an opinion of counsel for the Company with respect to newly authorized Shares with respect to the validity of such Shares and the status of such Shares under the Securities Act of 1933.
          (j) Copies of the Fund(s) registration statement on Form N-1A as currently in effect as of the date hereof and all post-effective amendments thereto filed subsequent to the date hereof.
          (k) Such other certificates, documents or opinions as may mutually be deemed necessary or appropriate for the Bank in the proper performance of its duties.
     15.02 The Bank hereby agrees to establish and maintain facilities and procedures reasonably acceptable to the Company


 

Page 17

for safekeeping of stock certificates, check forms and facsimile signature imprinting devices, if any; and for the preparation or use, and for keeping account of, such certificates, forms and devices.
     15.03 The Bank shall keep records relating to the services to be performed hereunder, in the form and manner as it may deem advisable. To the extent required by Section 31 of the Investment Company Act of 1940, as amended, and the Rules thereunder, the Bank agrees that all such records prepared or maintained by the Bank relating to the services to be performed by the Bank hereunder are the property of the Company and will be preserved, maintained and made available in accordance with such Section and Rules, and will be surrendered to the Company on and in accordance with its request.
     15.04 The Bank and the Company agree that all books, records, information and data pertaining to the business of the other party which are exchanged or received pursuant to the negotiation or the carrying out of this Agreement shall remain confidential, and shall not be voluntarily disclosed to any other person, except as may be required by law.
     15.05 In case of any requests or demands for the inspection of the Shareholder records of the Company, the Bank will endeavor to notify the Company and to secure instructions from an authorized officer of the Company as to such instruction. The Bank reserves the right, however, to exhibit the Shareholder records to any person whenever it is advised by its counsel that it may be held liable for the failure to exhibit the Shareholder records to such person.
ARTICLE 16. Term of Agreement .
     16.01 This Agreement shall become effective on the date hereof (the “Effective Date”) and shall continue in effect for twelve months from the Effective Date (the “Initial Term”) and from year to year thereafter with respect to each Fund, provided that subsequent to the Initial Term, this Agreement may be terminated by either the Company or the Bank at any time without payment of any penalty upon ninety (90) days written notice to the other. In the event such notice is given by the Company, it shall be accompanied by a resolution of the Trustees, certified by the Secretary, electing to terminate this Agreement and designating a successor transfer agent.
     16.02 Should the Company exercise its right to terminate, all out-of-pocket expenses associated with the


 

Page 18

movement of records and material will be borne by the Manager, except as set forth in Article 11.04 hereof. Additionally, the Bank reserves the right to charge for any other reasonable expenses associated with such termination.
ARTICLE 17. Additional Funds .
     17.01 In the event that the Company establishes one or more series of Shares in addition to the initial series listed by name in the preamble to this Agreement with respect to which it desires to have the Bank render services as transfer agent under the terms hereof, it shall so notify the Bank in writing, and if the Bank agrees in writing to provide such services, such series of Shares shall become a Fund hereunder.
ARTICLE 18. Assignment .
     18.01 Except as provided in Section 18.03 below, neither this Agreement nor any rights or obligations hereunder may be assigned by any party without the written consent of the other parties.
     18.02 This Agreement shall inure to the benefit of and be binding upon the parties and their respective permitted successors and assigns.
     18.03 The Bank, may without further consent on the part of the Company, subcontract for the performance of services to be provided hereunder to third parties, including any affiliate of the Bank, provided that the Bank shall remain liable hereunder for any acts or omissions of any subcontractor as if performed by the Bank.
ARTICLE 19. Amendment .
     19.01 This Agreement may be amended or modified by a written agreement executed by each of the parties.
ARTICLE 20. Massachusetts Law to Apply .
     20.01 This Agreement shall be construed and the provisions thereof interpreted under and in accordance with the laws of The Commonwealth of Massachusetts.
ARTICLE 21. Merger of Agreement .
     21.01 This Agreement constitutes the entire agreement between the parties hereto and supersedes any prior agreement with respect to the subject hereof whether oral or written.


 

Page 19

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed in their names and on their behalf under their seals by and through their duly authorized officers, as of the day and year first above written.
                 
        GMO TRUST    
 
               
 
      By:   /s/ R. Jeremy Grantham    
 
               
 
               
ATTEST:
               
 
               
/s/ Esther Cash
               
 
               
 
               
        GRANTHAM, MAYO, VAN OTTERLOO & CO.    
 
               
 
      By:   /s/ David A. Salem    
 
               
 
               
ATTEST:
               
 
               
/s/ Esther Cash
               
 
               
 
               
        INVESTORS BANK & TRUST COMPANY    
 
               
 
      By:   /s/ [signature]    
 
               
 
               
ATTEST:
               
 
               
/s/ [signature]
               
 
               


 

[This page intentionally left blank.]


 

     
(GMO LOGO)
  Grantham, Mayo, Van Otterloo & Co. LLC

40 Rowes Wharf o Boston, MA 02110
T: (617) 330-7500 o F: (617) 261-0134 o
www.gmo.com
June 1, 2010
State Street Bank and Trust Company
Attn: Transfer Agent
200 Clarendon Street
16th Floor
Boston, MA 02116
Re:     Fund of Funds Procedures
Ladies and Gentlemen:
     Pursuant to the Transfer Agency and Service Agreement, dated August 1, 1991, by and among GMO Trust (the “Trust”), on behalf of certain of its series of the Trust, Grantham, Mayo, Van Otterloo & Co. LLC (“GMO”) and State Street Bank and Trust Company (as successor by merger to Investors Bank & Trust Co.), as amended (the “Agreement”), State Street Bank and Trust Company (“State Street”) serves as transfer agent, dividend disbursing agent and agent for certain other activities for the Trust. The purpose of this letter is to instruct State Street to follow the procedures set forth below (the “Procedures”) so that certain conditions set forth by the staff of the Securities and Exchange Commission in a line of “no action” letters 2 may be met in connection with the investment by certain series of the Trust (each, a “Fund of Funds”) in shares issued by other series of the Trust (each, an “Underlying Fund”), and which shares are maintained in the name of the relevant Fund of Funds in the book-entry system of State Street pursuant to the Agreement.
Procedures
1. Upon ceasing to act as transfer agent for the Trust, State Street will deliver all shares of Underlying Funds owned by each Fund of Funds to the successor transfer agent, clearing agency, custodian, or safekeeper designated by the Trust.
2. In its capacity as transfer agent for each Underlying Fund, State Street will maintain a segregated account, that is, an account of record on State Street’s shareholder record keeping system, representing only shares held for each Fund of Funds.
 
2   See , e.g. , Franklin Investors Securities Trust (pub. avail. September 24, 1992).

 


 

Page 2
3. With respect to each Fund of Fund’s investments in shares of an Underlying Fund, State Street will send to the address of record for each Fund of Funds copies of all confirmations of any purchases, redemptions, or other transfers to or from the segregated account of the Fund of Funds.
4. Upon the reasonable request of GMO or the Trust, State Street will send to the Trust a copy of State Street’s most recent SAS 70 report (or equivalent assurance report) regarding State Street’s transfer agency system of internal accounting control and such other documentation on State Street’s system of internal accounting control as may be mutually agreed between State Street and GMO or the Trust.
5. Transaction orders submitted to State Street by GMO on behalf of any Fund of Funds in accordance with the Agreement and the following procedures will constitute valid, authorized, and appropriate instructions under the Agreement, upon which State Street may rely:
  (a)   Each business day, GMO shall aggregate all orders received by GMO Shareholder Services (“SHS”) in “good order” in accordance with the relevant Fund of Funds’ prospectus.
 
  (b)   A SHS representative previously identified by GMO to State Street in accordance with the Agreement as an “authorized person” of the Trust shall transmit an electronic file or fax containing all such orders.
 
  (c)   Each business day, State Street shall confirm to GMO in writing receipt of the file containing the orders and that the file is readable and complete.
Notice
     A copy of the Declaration of Trust, together with all amendments thereto, is on file with the Secretary of the Commonwealth of Massachusetts and notice is hereby given that this instrument is executed on behalf of the Trust by an officer of the Trust as an officer and not individually and that the obligations of this instrument are not binding upon any of the Trustees or officers of the Trust or shareholders of any series of the Trust individually but are binding only upon the assets and property of the Trust or the respective series.
* * * *
     The signature of a duly authorized officer of State Street at the end of this letter will constitute State Street’s acknowledgement that GMO provided the Procedures to State Street for State Street’s review and State Street’s willingness to treat the Procedures as mutually agreed upon procedures under the Agreement. These Procedures may be amended by the parties from time to time in a writing signed by both parties. The parties also agree that in the event any clause of the Agreement contradicts any provision of this letter, the provisions of the Agreement shall control.

 


 

Page 3
     This letter may be executed in one or more counterparts, each of which will be deemed an original, but all of which together shall constitute one and the same instrument.
             
    Sincerely,    
 
           
    GMO TRUST    
 
           
 
  By:   /s/ Jason Harrison    
 
           
 
  Name:   Jason Harrison    
 
  Title:   Clerk    
 
           
    GRANTHAM, MAYO    
    VAN OTTERLOO & Co. LLC    
 
           
 
  By:   /s/ JB Kittredge    
 
           
 
  Name:   JB Kittredge    
 
  Title:   General Counsel    
         
The foregoing is hereby accepted and agreed to as of the date written below.    
 
       
STATE STREET BANK AND TRUST COMPANY    
 
       
By:
  /s/ Joshua Lovell    
 
       
Name:
  Joshua Lovell    
Title:
  Senior Vice President    
 
       
Date:
  6/9/2010    
This Agreement is executed on behalf of Grantham, Mayo, Van Otterloo & Co. LLC (GMO) by a duly authorized officer or other agent solely in his or her capacity as an authorized signatory, pursuant to delegated authority from GMO, and not individually. The obligations of or arising out of this Agreement are not binding upon any officer or other agent, partner, member or director of GMO individually, but are binding only upon GMO and its assets. GMO’s certificate of organization is on file with the Secretary of State of The Commonwealth of Massachusetts.

 

Exhibit (h)(2)
ADMINISTRATION AGREEMENT
     This Administration Agreement is dated [          ], 2011 between GMO SERIES TRUST, a Massachusetts business trust (the “Trust”) on behalf of each of its series listed on Exhibit I hereto (each, a “Fund,” and collectively, the “Funds”), and GRANTHAM, MAYO, VAN OTTERLOO & CO. LLC, a Massachusetts limited liability company (the “Administrator”).
      WHEREAS , the Trust is registered with the Securities and Exchange Commission (the “SEC”) as an open-end management investment company under the Investment Company Act of 1940, as amended (the “1940 Act”);
      WHEREAS , the Trust is authorized to establish separate series and issue shares of beneficial interest (“Shares”) in each Fund;
      NOW, THEREFORE , in consideration of the premises and mutual covenants herein contained, the parties agree as follows:
1.   APPOINTMENT OF ADMINISTRATOR AND SERVICES TO BE RENDERED.
     (a)  Appointment . The Trust hereby appoints Grantham, Mayo, Van Otterloo & Co. LLC as the Administrator with respect to the Funds to provide or procure administrative support services to shareholders of Shares of each Fund for the period and on the terms set forth in this Agreement, as amended or supplemented from time to time. The Administrator accepts such appointment and agrees during such period to render or procure, as applicable, the services for the compensation herein provided. The Administrator will perform the services set forth below that are designated to it. The Administrator is responsible only for the services that it has specifically agreed to herein.
     (b)  Services Rendered . Services rendered by the Administrator will include, without limitation, (i) processing aggregated master account purchase and redemption orders, (ii) coordinating operation of the National Security Clearing Corporation’s Fund/SERV system with intermediary platforms, (iii) providing information about and processing dividend payments, (iv) assisting with distribution of shareholder communications such as proxies, shareholder reports, dividend and tax notices, (v) updating prospectuses, (vi) establishing and maintaining certain information about the Shares on the Administrator’s internet site, (vii) recordkeeping, (viii) providing reports to various regulatory agencies, (ix) providing reports to the Trustees of the Trust regarding the administrative support services provided to the intermediary platform, (x) administering contracts on behalf of Shares of each Fund, (xi) providing direct client service, maintenance and reporting to platform sponsors, retirement plans, and other recordholders of Shares, and otherwise maintaining the relationship with the recordholders, (xii) furnishing office space and equipment, providing bookkeeping and clerical services (excluding determination of net asset value, shareholder accounting services and the fund accounting services for the Fund being supplied by other service providers as the Fund or the Administrator may engage from time to time), and (xiii) providing individuals affiliated with the Administrator to serve as officers of the Trust and paying all salaries, fees and expenses of such officers and Trustees of the Trust who are affiliated with the Administrator. The Administrator may provide these services directly or may contract with third party service providers (“Third Party Servicers”) to provide any or all of these services.

 


 

     (c) The Administrator shall not be required to provide directly hereunder any of the foregoing services which may cause the Administrator to be engaged in the business of effecting transactions in securities for the account of others, or to induce or attempt to induce the purchase or sale of any security, but may procure such services on behalf of the Trust from certain Third Party Servicers or Plan Administrators.
     (d) The Administrator shall not be obligated under this Agreement to pay any expenses of or for the Trust or of or for the Fund not expressly assumed by the Administrator pursuant to this Agreement.
2.   OTHER AGREEMENTS, ETC.
     It is understood that any of the shareholders, Trustees, officers and employees of the Trust may be a partner, shareholder, director, officer or employee of, or be otherwise interested in, the Administrator, and in any person controlled by or under common control with the Administrator, and that the Administrator and any person controlled by or under common control with the Administrator may have an interest in the Trust. It is also understood that the Administrator and persons controlled by or under common control with the Administrator may have advisory, servicing, distribution or other contracts with other organizations and persons, and may have other interests and businesses.
3.   COMPENSATION TO BE PAID BY THE TRUST TO THE ADMINISTRATOR.
     The Shares of each Fund will pay to the Administrator as compensation for the Administrator’s services rendered and for the expenses borne by the Administrator with respect to such Class of Shares of such Fund pursuant to Section 1, a fee, computed and accrued daily, and paid monthly or at such other intervals as the Trustees shall determine, at the annual rate of such Class’ average daily net asset value set forth on the Fee Rate Schedule attached as Exhibit II hereto. Such fee shall be payable for each month (or other interval) within five (5) business days after the end of such month (or other interval). The Administrator may elect to pay all or any portion of such fee to any Third Party Servicers performing any services listed in Section 1 hereof for the Funds. No compensation paid by the Trust hereunder shall be for services primarily intended to result in the sale of Shares.
     Each Fund will also pay or reimburse the Administrator from time to time for all necessary and proper disbursements, expenses, and charges made or incurred by the Administrator in the performance of this Agreement, including any indemnities for any loss, liabilities or expense to the Administrator. The Administrator will also be entitled to reimbursement from the Trust for all reasonable expenses incurred in conjunction with the termination of this Agreement and any conversion or transfer work done in connection herewith.
     The Administrator may, from time to time, elect to undertake to waive all or a portion of the fee it is entitled to under this Agreement, or reimburse the Funds for certain fees and expenses incurred in connection with the Services.

-2-


 

     If the Administrator shall serve for less than the whole of a month (or other interval), the foregoing compensation shall be prorated.
4.   AMENDMENTS.
     This Contract shall not be amended unless such amendment is approved by the vote of a majority of the Trustees of the Trust.
5.   EFFECTIVE PERIOD AND TERMINATION OF THIS CONTRACT.
     This Contract shall become effective upon its execution, and shall remain in full force and effect continuously thereafter, except that either party hereto may at any time terminate this Contract (or this Contract’s application to one or more Funds) by not more than ninety days’ written notice delivered or mailed by registered mail, postage prepaid, to the other party.
     Termination of this Contract pursuant to this Section 5 shall be without the payment of any penalty.
6.   CERTAIN DEFINITIONS.
     For the purposes of this Contract, the terms “affiliated person”, “control” and “interested person” shall have their respective meanings defined in the 1940 Act, and the rules and regulations thereunder, subject, however, to such exemptions as may be granted by the SEC under the 1940 Act.
7.   NONLIABILITY OF ADMINISTRATOR AND INDEMNIFICATION
     (a) In the absence of willful misfeasance, bad faith or gross negligence on the part of the Administrator, or reckless disregard of its obligations and duties hereunder, the Administrator, its directors, officers, employees, and agents shall not be subject to any liability to the Trust, or to any shareholder of the Trust, for any act or omission in the course of, or connected with, rendering services hereunder.
     (b) The Trust will indemnify the Administrator, its directors, officers, employees, and agents against, and hold it and them harmless from, any and all losses, claims, damages, liabilities, or expenses (including legal fees and expenses) resulting from any claim, demand, action or suit (i) arising out of the actions or omissions of the Trust or (ii) not resulting from the willful misfeasance, bad faith, or gross negligence of the Administrator in the performance of its obligations and duties hereunder or by reason of its reckless disregard thereof.
     (c) The Administrator shall not be liable or accountable for any action taken or omitted by it in good faith in accordance with an instruction from the Trust. The Administrator shall not be liable for any act or omission taken or not taken in reliance upon any document,

-3-


 

certificate, or instrument that it reasonably believes to be signed or presented by the proper person or persons. The Administrator shall not be held to have notice of any change of authority of any officers, employees, or agents of the Trust until receipt of written notice thereof has been received from the Trust.
     (d) In the event the Administrator is unable to perform, or is delayed in performing, its obligations under the terms of this Agreement because of acts of God, strikes, legal constraint, government actions, war, emergency conditions, interruption of electrical power or other utilities, or other causes reasonably beyond its control, the Administrator shall not be liable to the Trust for any damages resulting from such failure to perform, delay in performance, or otherwise from such causes.
     (e) Notwithstanding anything to the contrary in this Agreement, the liability of the Administrator for any loss or damages directly or indirectly suffered by the Trust in connection with the performance by the Administrator of its obligations hereunder shall in no event exceed the fees paid by the Trust to the Administrator hereunder. In no event shall the Administrator be liable for special, incidental, or consequential damages, even if advised by the possibility of such damages.
8.   LIMITATION OF LIABILITY OF THE TRUSTEES AND SHAREHOLDERS.
A copy of the Agreement and Declaration of Trust of the Trust is on file with the Secretary of The Commonwealth of Massachusetts, and notice is hereby given that this instrument is executed on behalf of the Trustees of the Trust as Trustees and not individually and that the obligations of this instrument are not binding upon any of the Trustees or shareholders individually but are binding only upon the assets and property of the Fund.

-4-


 

     IN WITNESS WHEREOF, GMO SERIES TRUST and GRANTHAM, MAYO, VAN OTTERLOO & CO. LLC have each caused this instrument to be signed in duplicate on its behalf by its duly authorized representative, all as of the day and year first above written.
         
  GMO SERIES TRUST
 
 
  By      
    Name:      
    Title:      
 
  GRANTHAM, MAYO, VAN OTTERLOO
& CO. LLC
 
 
  By      
    Name:      
    Title:      
 

-5-


 

Exhibit I
GMO Series Trust
List of Series of the Trust Covered by the Administration Agreement
1.   GMO U.S. Core Equity Series Fund

 


 

Exhibit II
GMO Series Trust
Administration Fee Schedule
                 
Fund   Class     Administration Fee  
GMO U.S. Core Equity Series Fund
    R1       0.05 %

 

Exhibit (h)(3)
Execution Copy
CONFORMING ADMINISTRATION AGREEMENT
     Conforming Administration Agreement (the “Conforming Agreement”), made as of this 23 rd day of August, 2011, by and between Grantham, Mayo, Van Otterloo & Co. LLC (“GMO”) and State Street Bank and Trust Company (as successor by merger to Investors Bank & Trust Company) (“State Street Bank”).
     WHEREAS, State Street Bank and GMO are party to the Administration Agreement dated June 30, 2003 and the Rider dated February 28, 2007, each as amended, supplemented or otherwise modified from time to time (the “Agreement”) by which State Street Bank agrees to render certain administrative services to GMO Trust (the “Trust”);
     WHEREAS, in connection with the creation of the GMO Series Trust (the “Series Trust”), GMO has been retained by the Series Trust to furnish certain administrative services to the Series Trust pursuant to an administration agreement;
     WHEREAS, the parties intend to apply the terms of the Agreement to the Series Trust without modifying the terms of the Agreement with respect to GMO or the Trust;
     NOW, THEREFORE, in connection with the foregoing and in consideration of the mutual covenants herein set forth, the Series Trust, GMO and State Street Bank agree as follows:
  1.   The terms of the Agreement shall apply, mutatis mutandis, with respect to the Series Trust as if it were the Trust and with respect to each series of the Series Trust as if it were a series of the Trust.
 
  2.   A list of the series of the Series Trust is set forth in Schedule A, which shall be amended from time to time in writing by mutual agreement of the Series Trust and State Street Bank.
 
  3.   For the avoidance of doubt, GMO and State Street Bank shall continue be liable to the other to the extent and under the circumstances described in the Agreement.
 
  4.   The ‘Summary of Administration Functions — Appendix 1’ currently set forth in the Agreement shall be deleted in its entirety and replaced with the Summary of Administration Functions — Appendix 1’ attached hereto, which shall be amended from time to time in writing by mutual agreement of the Series Trust and State Street Bank.
[signature page immediately follows]

1


 

     IN WITNESS WHEREOF; the parties hereto have caused this Conforming Agreement to be duly executed as of the day and year first written above.
         
GRANTHAM, MAYO, VAN OTTERLOO & CO. LLC*    
 
       
By:
Name:
  /s/ JB Kittredge
 
JB Kittredge
   
Title:
  General Counsel    
 
*   This Amendment is executed on behalf of the Manager by a duly authorized officer or other agent, solely in his or her capacity as an authorized signatory, pursuant to delegated authority from the Manager, and not individually. The obligations of or arising out of this Amendment are not binding upon any officer or other agent, partner, member or director of the Manager directly, but are binding upon only the Manager and its assets. A Certificate of Organization of the Manager is on file with the Secretary of State of the Commonwealth of Massachusetts.
         
STATE STREET BANK AND TRUST COMPANY    
 
       
By:
Name:
  /s/ Michael F. Rogers
 
Michael F. Rogers
   
Title:
  Executive Vice President    

2


 

SCHEDULE A
LIST OF GMO SERIES TRUST FUNDS
1
GMO U.S. Core Equity Series Fund
 
1   As of August 23, 2011

3


 

Execution Copy
Appendix 1
State Street Bank and Trust Company as Successor by Merger to Investors Bank & Trust
Summary of Administration Functions
For Grantham, Mayo, Van Otterloo & Co. LLC
(GMO Series Trust Entities)
             
            Suggested Fund
Function   Investors Bank & Trust   GMO   Auditor or Counsel
 
MANAGEMENT REPORTING & OTHER TREASURY
FUNCTIONS
           
 
           
Monitor portfolio compliance in accordance with the current Prospectus, SAI and other regulatory or self-imposed guidelines
  Perform tests of certain specific portfolio activity designed from provisions of the Fund’s Prospectus and SAI, as outlined in the compliance testing matrices

Short Duration Collateral Fund and World Opportunity Overlay Fund are monitored weekly.
  Continuously monitor portfolio activity and Fund operations in conjunction with 1940 Act, Prospectus, SAI and any other applicable laws and regulations. Monitor and approve resolution of compliance issues.   C-Provide consultation as needed on compliance issues.
 
           
Frequency: Monthly
           
 
           
Prepare the Fund’s annual expense budget. Establish daily accruals.
  Prepare preliminary expense budget. Notify fund accounting agents of new accrual rates.   Provide asset level projections. Approve expense budget.    
 
           
Frequency: Annually
           
 
           
Monitor the Fund’s expense budget. Review the Fund’s multi-class expense differentials (when applicable)
  Monitor actual expenses, updating budgets/expense accruals. Review expense differentials among classes.   Provide asset level projections and vendor information as necessary. Review and approve budget revisions.    
 
           
Frequency: Monthly/Quarterly
           

4


 

             
            Suggested Fund
Function   Investors Bank & Trust   GMO   Auditor or Counsel
 
MANAGEMENT REPORTING & OTHER TREASURY FUNCTIONS (cont’d)
           
 
           
Receive and coordinate payment of fund expenses.
  Propose allocation of invoices among Funds and obtain approval to process payment. Coordinate and review payment of monthly management fee.   Approve invoices and allocations of payments. Send invoices to IBT in a timely manner.    
 
           
Frequency: As often as necessary
           
 
           
Review the Fund’s multi-class dividend calculation procedures (when applicable). Calculate period dividend rates, including applicable quarterly net income rates, spillback rates, excise requirement rates and unscheduled rates as required to be declared in accordance with management guidelines.
  Calculate amounts available for distribution. Calculate dividend rates for each class in accordance with approved methodology. Coordinate review by management and auditors. Notify custodians, fund accounting agents and transfer agent of authorized dividend rates.   Review and approve dividend calculation methodologies for each class. Approve distribution rates per share and aggregate amounts. Obtain Board approval when required.   A-Review and approve dividend calculation methodology for each class of shares. Provide consultation as requested. Calculate spillback distribution dollars on a Fund level.
 
           
Frequency: According to dividend policy
           
 
           
Prepare disinterested director/trustee and Vendors Form 1099-Misc
  Summarize amounts paid to directors/trustees during the calendar year. Prepared and mail Form 1099-Misc.   Provide social security numbers and current mailing address for trustees. Review and approve information provided for Form 1099-Misc.    
 
           
Frequency: Annually
           

5


 

             
            Suggested Fund
Function   Investors Bank & Trust   GMO   Auditor or Counsel
 
REGULATORY
           
 
           
Coordinate the preparation and printing shareholder reports.
  Draft financial statements and coordinate auditor and management review. Draft and manage production cycle. Coordinate printing, editing of report and Edgar conversion with outside printer and filing with SEC via Edgar.   Review and approve report. Prepare and coordinate production of MD&A   A-Review reports

A-Issue audit opinion on annual financial statements.
 
           
Frequency: Semi-annually/Quarterly
           
 
           
Coordinate the preparation and filing of form N-CSR and N-Q
  Draft Form N-CSR and Form
N-Q and certifications and coordinate management review. Coordinate Edgar conversion with outside printer and filing with the SEC via Edgar
  Review and approve Form
N-CSR and N-Q. Forward signed form N-CSR, N-Q and certifications to IBT prior to filing of report.
  C-Review Form N-CSR and N-Q
 
           
Frequency: Semi-annually/Quarterly
           
 
           
Prepare and file Form N-SAR
  Prepare form for filing. Obtain any necessary supporting documents. File with SEC via Edgar   Provide appropriate responses. Provide signature page   A-Provide annual audit internal control letter to accompany the annual filing. Provide annual multi-class report when applicable.
 
           
Frequency: Semi-annually/Quarterly
           
 
           
Assist in preparing amendments to Registration Statement
  Provide requested information to GMO and fund counsel (currently Ropes & Gray). Review document provided by fund counsel   Review and approve   C-Coordinate the preparation and filing of post-effective amendments. Coordinate with outside printers the Edgar conversion filing with the SEC and printing of prospectus. A/C —Provide consents as appropriate.
 
           
Frequency: As needed
           
 
           
Coordinate the preparation and filing of form N-PX
  Coordinate with proxy tabulator to receive electronic proxy voting files and forward to printer for Edgarization and SEC filing.   Review and approve    
 
           
Frequency: Annually
           

6


 

             
            Suggested Fund
Function   Investors Bank & Trust   GMO   Auditor or Counsel
 
REGULATORY (cont)
           
 
           
Coordinate the preparation and filing of Form 24F-2
  Accumulate capital stock information and draft Form
24F-2. Coordinate filing of approved From with SEC via Edgar.
  Review and approve filing   A-Review informally when requested
 
           
Frequency: Annually
           
 
           
Respond to regulatory audits
  Compile and provide documentation pursuant to audit requests. Assist client in resolution of audit inquiries   Coordinate with regulatory auditors to provide requested documentation and resolutions to inquiries.   C-Provide consultation when needed.
 
           
Frequency: As needed
           

7


 

             
            Suggested Fund
Function   Investors Bank & Trust   GMO   Auditor or Counsel
 
TAX AND ACCOUNTING
           
 
           
Coordinate the fiscal year end wash sales deferral, reversals and holding period reclass and realized swaps analysis with management, fund accounting and the independent public accountants.
  Coordinate with IBT and BBH fund accounting to obtain reports required for the wash sales and swaps analysis.   Make appropriate representations in conjunction with audit.   A-Perform audit and render opinion.         .
 
           
Frequency: Semi-annually
           
 
           
Perform & review asset diversification and gross income test to establish qualification as a RIC
  Perform & review preliminary asset diversification (if equal to or less than 80% at previous quarter end), final asset diversification and qualifying income tests at each tax quarter end and as may otherwise be necessary. Follow up on issues until qualification is resolved.   Continuously monitor portfolio activity in conjunction with IRS requirements. Review test results and take any necessary action. Approve tax positions taken.   C/A — Provide consultation as needed in establishing positions to be taken in tax treatment of particular issues.

A-Review quarter end tests on a current basis, as required.
 
           
Frequency: Quarterly
           
 
           
Calculate excise tax distributions
  Calculate required distributions to avoid imposition of excise tax. Coordinate with auditors to receive calculation of prior year over/under, PFIC adjustments and other open temporary tax differences from the previous fiscal year end.   Review and approve distribution rates per share and aggregate amounts   A-Provide consultation as requested. Provide certain information relating to tax adjustments. Provide dividend designations.
 
           
Frequency: Annually
           
 
           
Prepare Form 1099
  Obtain yearly distribution information. Calculate Form 1099 reclasses and related disclosures including the ICI Primary and Secondary tax reporting schedules. Coordinate with transfer agent (i.e. dividends received deductions, foreign tax credits, tax exempt income, income by jurisdiction.   Review and approve information provided for on Form 1099   A-Review Form 1099 reclasses and related disclosures.
 
           
Frequency: Annually
           

8


 

             
            Suggested Fund
Function   Investors Bank & Trust   GMO   Auditor or Counsel
 
TAX AND ACCOUNTING (cont)
           
 
           
Prepare Financial Statement tax disclosures
  Obtain applicable information from Auditors in order to report proper tax disclosures in the financial statements (tax costs quarterly, all other disclosures annually)   Review and approve information provided   Review annual disclosures
 
           
Frequency: Annually
           
 
           
Prepare TDF 90-22 Report of Foreign Bank and financial statement accounts for all applicable GMO Trust Funds
  Obtain required information, file form by June 30   Review and approve filing   N/A
 
           
Frequency: Annually
           

9


 

[This page intentionally left blank.]

 


 

ADMINISTRATION AGREEMENT
     THIS ADMINISTRATION AGREEMENT made as of June 30, 2003 by and between Grantham, Mayo, Van Otterloo & Co. LLC, a Massachusetts limited liability company (“GMO”), and INVESTORS BANK & TRUST COMPANY, a Massachusetts trust company (“Investors Bank”).
     WHEREAS, the GMO Trust, a business trust established under the laws of the Commonwealth of Massachusetts (the “Trust”), is registered as a management investment company under the Investment Company Act of 1940, as amended (the “1940 Act”), consisting of separate portfolios;
     WHEREAS, GMO acts as manager of the Trust, which includes responsibility for functions often entrusted to an administrator; and
     WHEREAS, GMO desires to retain Investors Bank to render certain administrative services with respect to the Trust and Investors Bank is willing to render such services.
     NOW, THEREFORE, in consideration of the mutual covenants herein set forth, it is agreed between the parties hereto as follows:
     1.  Appointment . GMO hereby appoints Investors Bank to act as administrator with respect to the Trust on the terms set forth in this Agreement. Investors Bank accepts such appointment and agrees to render the services herein set forth. GMO shall compensate Investors Bank for acting as Administrator to the Trust hereunder as may be agreed in writing between GMO and Investors Bank from time to time.
     2.  Delivery of Documents . GMO or the Trust has furnished Investors Bank with copies properly certified or authenticated of each of the following:
          (a) The Trust’s incorporating documents filed with the Commonwealth of Massachusetts and all amendments thereto (the “Articles”);
          (b) The Trust’s by-laws and all amendments thereto (the “By-Laws”);
          (c) The Trust’s agreements with all service providers which include any investment advisory agreements, sub-investment advisory agreements, custody agreements, distribution agreements and transfer agency agreements (collectively, the “Agreements”);
          (d) The Trust’s most recent Registration Statement (the “Registration Statement”) under the Securities Act of 1933 and under the 1940 Act and all amendments thereto; and
          (e) The Trust’s most recent prospectus and statement of additional information (the “Prospectus”); and
          (f) Such other certificates, documents or opinions as may mutually be deemed necessary or appropriate for Investors Bank in the proper performance of its duties hereunder.

 


 

          GMO will immediately furnish Investors Bank with copies of all amendments of or supplements to the foregoing. Furthermore, GMO will notify Investors Bank as soon as possible of any matter which may materially affect the performance by Investors Bank of its services under this Agreement.
     3.  Duties and Administrator . Subject to the supervision and direction of GMO, Investors Bank, as Administrator, will assist in conducting various aspects of the Trust’s administrative operations and undertakes to perform the services described in Appendix 1 hereto. Investors Bank may, from time to time, perform additional duties and functions that shall be set forth in an amendment to such Appendix 1 executed by both parties.
          In performing all services under this Agreement, Investors Bank shall act in conformity with the Trust’s Articles and By-Laws and the 1940 Act, as the same may be amended from time to time, and the investment objectives, investment policies and other practices and policies set forth in the Trust’s Registration Statement, as the same may be amended from time to time. Notwithstanding any item discussed herein, Investors Bank has no discretion over the Trust’s assets or choice of investments and cannot be held liable for any problem relating to such investments.
     4.  Duties of GMO .
          GMO agrees to make its legal counsel available to Investors Bank for instruction with respect to any matter of law arising in connection with Investors Bank’s duties hereunder, and GMO further agrees that Investors Bank shall be entitled to rely on such instruction without further investigation on the part of Investors Bank.
     5.  Fees and Expenses .
          (a) For the services rendered by Investors Bank hereunder, GMO will pay to Investors Bank such fees at such rate as shall be agreed upon in writing by the parties from time to time. GMO will also pay or reimburse Investors Bank from time to time for all necessary proper disbursements, expenses and charges made or incurred by Investors Bank in the performance of this Agreement (including any duties listed on any Schedule hereto, if any) including any indemnities for any loss, liabilities or expense to Investors Bank as provided herein. Investors Bank will also be entitled to reimbursement by GMO for all reasonable expenses incurred in conjunction with termination of this Agreement and any conversion or transfer work done in connection therewith, including, without limitation, data extracts and technology interfaces.
          (b) Fees and expenses will be calculated monthly. Fees and expenses owed to Investors Bank for any month shall be paid by GMO within five (5) business days of receipt by GMO of an invoice for such fees and expenses, provided that Investors Bank shall deliver an invoice to GMO for each month by no later than the third business day of the following month.
          (c) Investors Bank shall not be required to pay any expenses incurred by the Trust.

 


 

          (d) Notwithstanding anything to the contrary set forth herein or in any schedule or appendix hereto, Investors Bank shall not be responsible for, and shall be reimbursed for any out-of-pocket expenses incurred in connection with, any electronic data feeds or information flows that Investors Bank is required to put in place with any unaffiliated entity in order to provide the services required of Investors Bank pursuant to this Agreement, including any systems development work required based on requests by GMO.
     6.  Limitation of Liability .
          (a) Investors Bank, its directors, officers, employees and agents shall not be liable for any error of judgment or mistake of law or for any loss suffered by the Trust or GMO or any third party in connection with the performance of its obligations and duties under this Agreement, except a loss resulting from willful misfeasance, bad faith or negligence in the performance of such obligations and duties, or by reason of its reckless disregard thereof. GMO will indemnify Investors Bank, its directors, officers, employees and agents against and hold it and them harmless from any and all losses, claims, damages, liabilities or expenses (including legal fees and expenses) resulting from any claim, demand, action or suit (i) arising out of the actions or omissions of the Trust or GMO, (ii) arising out of the offer or sale of any securities of the Trust in violation of (x) any requirement under the federal securities laws or regulations, (y) any requirement under the securities laws or regulations of any state, or (z) any stop order or other determination or ruling by any federal or state agency with respect to the offer or sale of such securities; or (iii) not resulting from the willful misfeasance, bad faith or negligence of Investors Bank in the performance of such obligations and duties or by reason of its reckless disregard thereof.
          (b) Investors Bank may apply to GMO at any time for instructions and may consult counsel for GMO, or its own counsel, and with accountants and other experts with respect to any matter arising in connection with its duties hereunder, and Investors Bank shall not be liable or accountable for any action taken or omitted by it in good faith in accordance with such instruction, or with the opinion of such counsel, accountants, or other experts. Investors Bank shall notify GMO whenever it intends to rely on advice of independent counsel, accountants, or experts other than counsel for GMO, and shall describe the nature of the advice being sought. Investors Bank shall not be liable for any act or omission taken or not taken in reliance upon any document, certificate or instrument which it reasonably believes to be genuine and to be signed or presented by the proper person or persons. Investors Bank shall not be held to have notice of any change of authority of any officers, employees, or agents of the Trust or GMO until receipt of written notice thereof has been received from the Trust or GMO, as the case may be.
          (c) In the event Investors Bank is unable to perform, or is delayed in performing, its obligations under the terms of this Agreement because of acts of God, strikes, legal constraint, government actions, war, emergency conditions, interruption of electrical power or other utilities, or other causes reasonably beyond its control, Investors Bank shall not be liable to the Trust or GMO for any damages resulting from such failure to perform, delay in performance, or otherwise from such causes.

 


 

          (d) Notwithstanding anything to the contrary in this Agreement, the liability of Investors Bank for any loss or damages directly or indirectly suffered by the Trust or GMO in connection with the performance by Investors Bank of its obligations hereunder shall in no event exceed the fees paid by GMO to Investors Bank hereunder unless due to Investors Bank’s own fraud, gross negligence, or willful misfeasance. In no event shall Investors Bank be liable for special, incidental or consequential damages, even if advised of the possibility of such damages.
     7.  Termination of Agreement . The term of this Agreement shall be three years commencing upon the date first above written (the “Initial Term”), unless earlier terminated as provided herein. After the expiration of the Initial Term, the term of this Agreement shall continue in effect until terminated by either party upon ninety (90) days prior written notice to the other party.
     If, during the Initial Term, a majority of the officers of the Trust reasonably determines that the performance of Investors Bank has been materially lower than Investors Bank’s previous service levels, then GMO shall give written notice to Investors Bank of such determination and Investors Bank shall have ninety (90) days to correct such performance to the reasonable satisfaction of the officers. If the conditions of the preceding sentence are not met then GMO may terminate this Agreement on thirty (30) days written notice.
     Either party hereto may terminate this Agreement prior to the expiration of the Initial Term in the event the other party violates any material provision of this Agreement, provided that the non-violating party gives written notice of such violation to the violating party and the violating party does not cure such violation within 90 days of receipt of such notice. In the event the violating party does not cure such violation within 90 days, this Agreement may be terminated immediately.
     In addition, this Agreement may be terminated upon ninety (90) days prior written notice by GMO to Investors Bank in the event that at any time neither GMO nor any of its successors, assigns, or affiliates of any thereof is no longer serving as investment manager to any series of the Trust.
     Furthermore, in the event that GMO terminates this Agreement other than in a manner described in the foregoing three paragraphs, GMO shall make a one-time cash payment, calculated as provided below (the “Termination Payment”), to Investors Bank on the date that this Agreement terminates (constructively or otherwise) with respect to each series of the Trust, or the Trust’s successors, assigns, or transferees (the “Termination Date”).
     The Termination Payment shall be equal to the product of the then current monthly fee rate per series and fund of fund being paid hereunder as of the Termination Date multiplied by the number of months remaining during the then current Term of this Agreement (prior to its early termination).
     The parties acknowledge and agree that (i) it would be extremely difficult to determine the actual damages incurred by Investors Bank as a result of Investors Bank’s ceasing to provide services with respect to the Trust or its successors, assigns or transferees as set forth above, (ii) Investors Bank will have incurred and will incur considerable costs in anticipation of rendering

 


 

services through the then remaining Term which cannot be readily avoided if any of the events referred to above were to occur, and (iii) the Termination Payment is intended to adequately compensate Investors Bank for damages incurred and is not intended to constitute any form of penalty.
     The parties agree that any Termination Payment payable hereunder shall be in addition to and not in lieu of, and shall not be deemed a waiver of (i) any fees or reimbursements due to Investors Bank for services rendered through the Termination Date, including any costs associated with conversion, or (ii) any claim, right, remedy or privileges arising under this Agreement or applicable law.
     8.  Miscellaneous .
          (a) Any notice or other instrument authorized or required by this Agreement to be given in writing to the parties hereto shall be sufficiently given if addressed to that party and received by it at its office set forth below or at such other place as it may from time to time designate in writing.
     
To GMO:
  Grantham, Mayo, Van Otterloo & Co. LLC
 
  40 Rowes Wharf
 
  Boston, MA 02110
 
  Attention: Susan Randall Harbert
 
  With a copy to: General Counsel
 
   
To Investors Bank:
  Investors Bank & Trust Company
 
  200 Clarendon Street, P.O. Box 9130
 
  Boston, MA 02117-9130
 
  Attention: Carol Lowd, Client Management
 
  With a copy to: John E. Henry, General Counsel
          (b) This Agreement shall extend to and shall be binding upon the parties hereto and their respective successors and assigns; provided, however, that this Agreement shall not be assignable without the written consent of the other party.
          (c) This Agreement shall be construed in accordance with the laws of the Commonwealth of Massachusetts, without regard to its conflict of laws provisions.
          (d) This Agreement may be executed in any number of counterparts each of which shall be deemed to be an original and which collectively shall be deemed to constitute only one instrument.
          (e) The captions of this Agreement are included for convenience of reference only and in no way define or delimit any of the provisions hereof or otherwise affect their construction or effect.
     9.  Confidentiality . All books, records, information and data pertaining to the business of the other party which are exchanged or received pursuant to the negotiation or the carrying out of this Agreement shall remain confidential, and shall not be voluntarily disclosed to

 


 

any other person, except as may be required in the performance of duties hereunder or as otherwise required by law.
     10.  Use of Name . Neither party shall use the name of the other party or any of its affiliates or, with respect to GMO, the Trust, in any prospectus, sales literature or other material in a manner not approved by the other party prior thereto in writing; provided however, that approval shall not be required for any use of a party’s name which merely refers in accurate and factual terms Investors Bank’s appointment hereunder or which is required by the Securities and Exchange Commission or any state securities authority or any other appropriate regulatory, governmental or judicial authority; provided further, that in no event shall such approval be unreasonably withheld or delayed.
[Remainder of Page Intentionally Left Blank]

 


 

          IN WITNESS WHEREOF, the parties hereto have caused this instrument to be duly executed and delivered by their duly authorized officers as of the date first written above.
             
    GRANTHAM, MAYO, VAN OTTERLOO & CO. LLC    
 
           
 
  By:
Name:
  /s/ Susan Randall Harbert
 
Susan Randall Harbert
   
 
  Title:   Member, Grantham, Mayo, Van Otterloo & Co. LLC    
 
           
    INVESTORS BANK & TRUST COMPANY    
 
           
 
  By:
Name:
  /s/ Andrew M. Nesvet
 
Andrew M. Nesvet
   
 
  Title:   Managing Director    

 


 

Appendices
     
Appendix 1   Services

 


 

Appendix 1 — June 30, 2003
Investors Bank & Trust
Summary of Administration Functions
For Grantham, Mayo, Van Otterloo & Co. LLC
(GMO Trust Entities)
             
            Suggested Fund
Function   Investors Bank & Trust   GMO   Auditor or Counsel
 
MANAGEMENT REPORTING & OTHER TREASURY FUNCTIONS
           
 
           
Monitor portfolio compliance in accordance with the current Prospectus, SAI and other regulatory or self-imposed guidelines.
  Perform tests of certain specific portfolio activity designed from provisions of the Fund’s Prospectus and SAI, as outlined in the compliance testing matrices.

Short Duration Collateral Fund and World Opportunity Overlay Fund are monitored weekly.
  Continuously monitor portfolio activity and Fund operations in conjunction with 1940 Act, Prospectus, SAI and any other applicable laws and regulations. Monitor and approve resolution of compliance issues   C-Provide consultation as needed on compliance issues.
 
           
Frequency: Monthly
           
 
           
Prepare the Fund’s annual expense budget. Establish daily accruals.
  Prepare preliminary expense budget. Notify fund accounting agents of new accrual rates.   Provide asset level projections. Approve expense budget.    
 
           
Frequency: Annually
           
 
           
Monitor the Fund’s expense budget. Review the Fund’s multi-class expense differentials (when applicable).
  Monitor actual expenses, updating budgets/expense accruals. Review expense differentials among classes.   Provide asset level projections and vendor information as necessary. Review and approve budget revisions.    
 
           
Frequency: Monthly/Quarterly
           

1


 

             
            Suggested Fund
Function   Investors Bank & Trust   GMO   Auditor or Counsel
 
MANAGEMENT REPORTING & OTHER TREASURY FUNCTIONS (Con’t)
           
 
           
Receive and coordinate payment of fund expenses.
  Propose allocation of invoices among Funds and obtain approval to process payment. Coordinate and review payment of monthly management fee.   Approve invoices and allocations of payments. Send invoices to IBT in a timely manner.    
 
           
Frequency: As often as necessary
           
 
           
Review the Fund’s multi-class dividend calculation procedures (when applicable). Calculate periodic dividend rates, including applicable quarterly net income rates, spillback rates, excise requirement rates, and unscheduled rates as required to be declared in accordance with management guidelines.
  Calculate amounts available for distribution. Calculate dividend rates for each class in accordance with approved methodology. Coordinate review by management and auditors. Notify custodians, fund accounting agents, and transfer agent of authorized dividend rates.   Review and approve dividend calculation methodologies for each class. Approve distribution rates per share and aggregate amounts. Obtain Board approval when required.   A- Review and approve dividend calculation methodology for each class of shares. Provide consultation as requested. Calculate spillback distribution dollars on a Fund level
 
           
Frequency: According to dividend policy
           
 
           
Prepare disinterested director/trustee and Vendors Form 1099-Misc.
  Summarize amounts paid to directors/trustees during the calendar year. Prepare and mail Form 1099-Misc.   Provide social security numbers and current mailing address for trustees. Review and approve information provided for Form 1099-Misc.    
 
           
Frequency: Annually
           

2


 

             
            Suggested Fund
Function   Investors Bank & Trust   GMO   Auditor or Counsel
 
REGULATORY
           
 
           
Coordinate the preparation and printing shareholder reports.
  Draft financial statements and coordinate auditor and management review. Draft and manage production cycle. Coordinate printing, editing of report and Edgar conversion with outside printer and filing with the SEC via Edgar.   Review and approve report. Prepare and coordinate production of MD&A.   A — Review reports

A- Issue audit opinion on annual financial statements.
 
           
Frequency: Semi-annually / Quarterly
           
 
           
Coordinate the preparation and filing of form N-CSR and N-Q
  Draft Form N-CSR and Form  N-Q and certifications and coordinate management review. Coordinate Edgar conversion with outside printer and filing with the SEC via Edgar.   Review and approve Form N-CSR and N-Q. Forward signed form N-CSR, N-Q and certifications to IBT prior to filing of report.   C—Review Form N-CSR and N-Q
 
           
Frequency: Semi-annually / Quarterly
           
 
           
Prepare and file Form N-SAR
  Prepare form for filing. Obtain any necessary supporting documents. File with SEC via Edgar.   Provide appropriate responses. Provide signature page.   A-Provide annual audit internal control letter to accompany the annual filing. Provide annual multi-class report when applicable.
 
           
Frequency: Semi-annually/Quarterly
           
 
           
Assist in preparing amendments to Registration Statement.
  Provide requested information to GMO and fund counsel (currently Ropes & Gray). Review document provided by fund counsel.   Review and approve.   C-Coordinate the preparation and filing of post-effective amendments. Coordinate with outside printers the Edgar conversion, filing with the SEC and printing of prospectus.
A/C — Provide consents as appropriate.
 
           
Frequency: As needed
           
 
           
Coordinate the preparation and filing of form N-PX
  Coordinate with proxy tabulator to receive electronic proxy voting files and forward to printer for Edgarization and SEC filing.   Review and approve    
 
           
Frequency: Annually
           

3


 

             
            Suggested Fund
Function   Investors Bank & Trust   GMO   Auditor or Counsel
 
REGULATORY (Cont.)
           
 
           
Coordinate the preparation and filing of Form 24F-2.
  Accumulate capital stock information and draft Form
24F-2. Coordinate filing of approved Form with SEC via Edgar.
  Review and approve filing.   A — Review informally when requested.
 
           
Frequency: Annually
           
 
           
Respond to regulatory audits
  Compile and provide documentation pursuant to audit requests. Assist client in resolution of audit inquiries.   Coordinate with regulatory auditors to provide requested documentation and resolutions to inquiries.   C-Provide consultation as needed.
 
           
Frequency: As needed
           

4


 

             
            Suggested Fund
Function   Investors Bank & Trust   GMO   Auditor or Counsel
 
TAX AND ACCOUNTING
           
 
           
Coordinate the fiscal year end wash sales deferral, reversals and holding period reclass and realized swaps analysis with management, fund accounting and the independent public accountants.
  Coordinate with IBT and BBH fund accounting to obtain reports required for the wash sales and swaps analysis.   Make appropriate representations in conjunction with audit.   A- Perform audit and render opinion.
 
           
Frequency: Semi-Annually
           
 
           
Perform & review asset diversification and gross income test to establish qualification as a RIC.
  Perform & review preliminary asset diversification (if equal to or less than 80% at previous quarter end), final asset diversification, and qualifying income tests at each tax quarter end and as may otherwise be necessary. Follow-up on issues until qualification is resolved.   Continuously monitor portfolio activity in conjunction with IRS requirements. Review test results and take any necessary action. Approve tax positions taken.   C/A — Provide consultation as needed in establishing positions to be taken in tax treatment of particular issues. A-Review quarter end tests on a current basis, as required
 
           
Frequency: Quarterly
           
 
           
Calculate excise tax distributions
  Calculate required distributions to avoid imposition of excise tax. Coordinate with auditors to receive calculation of prior year over/under, PFIC adjustments and other open temporary tax differences from the previous fiscal year end.   Review and approve distribution rates per share and aggregate amounts.   A-Provide consultation as requested. Provide certain information relating to tax adjustments. Provide dividend designations.
 
           
Frequency: Annually
           
 
           
Prepare Form 1099.
  Obtain yearly distribution information. Calculate Form 1099 reclasses and related disclosures including the ICI Primary and Secondary tax reporting schedules. Coordinate with transfer agent (i.e. dividends received deductions, foreign tax credits, tax-exempt income, income by jurisdiction).   Review and approve information provided for on Form 1099.   A- Review Form 1099 reclasses and related disclosures.
 
           
Frequency: Annually
           

5


 

             
            Suggested Fund
Function   Investors Bank & Trust   GMO   Auditor or Counsel
 
TAX AND ACCOUNTING
           
 
           
Prepare Financial Statement tax disclosures
  Obtain applicable information from Auditors in order to report proper tax disclosures in the financial statements (tax cost quarterly, all other disclosures annually)   Review and approve information provided.   Review annual disclosures.
 
           
Frequency: Annually
           
 
           
Prepare TDF 90-22.1 Report of foreign Bank and financial statement accounts for all applicable GMO Trust Funds
  Obtain required information, file form by June 30.   Review and approve filing.   N/A
 
           
Frequency: Annually
           

6


 

[This page intentionally left blank.]

 


 

Rider to the Administration Agreement between Investors Bank & Trust Company
and Grantham, Mayo, Van Otterloo & Co. LLC Related to the February 28, 2007
Fiscal Year-End GMO Trust Tax Preparation
Investors Bank & Trust Company (“Investors Bank”) agrees to perform the following services for Grantham, Mayo, Van Otterloo & Co. LLC (“GMO”) relating to the February 28, 2007 year-end GMO Trust preparation of the tax provisions, tax disclosures in the annual reports, and preparation of applicable tax returns in consideration for $578,000 additional fees.
General :
Investors Bank will perform the necessary tax procedures, to prepare for each series of GMO Trust (each a “Fund” and, collectively, the “Funds”), listed on Attachment A hereto, an annual tax provision, all applicable tax disclosures for the annual report, and all federal and applicable state tax returns and attachments. The tax work will be performed in conformity with the applicable sections of the Internal Revenue Code (“IRC”) and Treasury Regulations (“TR”), as well as established procedures set-forth by and communicated to Investors Bank by GMO and/or the Funds. Investors Bank will prepare complete and reasonable supporting tax supporting work-papers and tax returns for the tax fiscal year ending February 28, 2007 (December 31, 2006 in the case of GMO Inflation Indexed Plus Bond Fund).
Tax Provision :
  1)   Investors Bank will input all current year (“cy”) book profit and loss amounts (“p&l”) as well as total cy distributions by book character (net income, short-term capital gain, long-term capital gain) into the tax provision (“TP” — see the definition of TP below) from sources available or provided to Investors Bank including the final Detailed Fund Statements (“DFS”) and “Market Value Trial Balance” (“TB”) as prepared by Brown Brothers Harriman & Co. (“BBH”) and other reports, as applicable, as well as agreeing these book amounts in the TP to the applicable amounts disclosed in the draft annual report, then final annual report (“AR”), such as net income, net realized gains/(losses), foreign withholding taxes for applicable funds making a foreign tax credit pass-through election under IRC Section 853, and total distributions made in fiscal 2007.
 
      Definition of Tax Provision : The tax provision is a schedule that computes the annual investment company taxable income and capital gains as well as undistributed investment company taxable income, including a separate break-out for short-term capital gains/(losses) for both annual and undistributed capital gain amounts, as of February 28, 2007. The schedule will start with final 2007 book income, expense and short-term and long-term capital gains/(losses), will include all necessary tax adjustments, will include distributions made in the year by book character (net income, short-term gain, and long-term gain distributions), and will

1


 

      end with undistributed net income, short-term capital gains, and long-term capital gains (“spillovers”).
 
  2)   Investors Bank will ensure all p&l numbers per the DFS and TB are reconciled to the corresponding subsidiary reports for all Funds whether held in custody at Investors Bank or BBH, provided that appropriate information is available to Investors Bank.
 
  3)   On or before February 15, 2007 , Investors Bank will request all the applicable reports from BBH to prepare the cy TP. In addition, Investors Bank will inventory all reports received by BBH within 24 hours of receipt to ensure the report package is complete. Investors Bank will notify BBH and GMO of any reports that appear to be missing within the 24 hour period. GMO will assure Investors Bank obtains reports needed from BBH if BBH is not providing the requested information to Investors Bank.
 
  4)   Investors Bank will obtain all cumulative carry-forward tax points from GMO and other sources, as applicable. If tax adjustments are required based on these carry-forward tax points, Investors Bank will prepare such adjustments and include them in the cy TP.
 
  5)   Investors Bank will reverse, where applicable, in the cy all prior year (“py”) temporary tax accruals/deferrals, such as IRC Section 1256 mark-to-market (“mtm”), swap accruals, post-October capital and/or foreign currency (“fx”) deferrals using the py amounts per the final py Form 1120-RIC (“federal tax return”) for such prior year.
 
  6)   Investors Bank will compute all necessary cy wash sale deferrals and reversals and calculate all necessary wash sale holding period reclasses, as necessary.
 
  7)   For Funds held in custody at BBH, Investors Bank will ensure reconciliation has been done to the net income on the DFS to the book numbers used on the tax provision to ensure all applicable p&l amounts are included on the cy TP.
 
  8)   Investors Bank will obtain a list from Investors Bank & Trust Transfer Agent (“TA”) of all contributions in-kind (“CIKs”) and redemption in-kind (“RIKs”) for 2007. Investors Bank will make all necessary security basis adjustments for the applicable CIKs made to both realized gain/losses on securities sold and to the security lots still held at February 28, 2007. For any RIK, Investors Bank will reverse all realized gains/losses related to RIKs from the book numbers and include as a tax adjustment on the cy TP as necessary. In addition, Investors Bank will adjust for tax as necessary, all wash sale reversals, REIT sales, and PFIC sales affected by the RIK as applicable.
 
  9)   In regards to any RIKs in fiscal 2007, Investors Bank will be responsible for reconciling the RIK proceeds to the TA records as well as GMO’s records of such

2


 

      RIKs to ensure the realized gain/(loss) associated with each RIK loss is proper and totals to the correct amount per the records.
 
  10)   For any security identified by GMO as a passive foreign investment company (“PFIC”) as of February 28, 2007 or a PFIC sold in the 2007 fiscal period, and by obtaining the final October 31, 2006 fiscal year-to-date (“FYTD”) PFIC analysis from GMO, Investors Bank will perform all necessary PFIC tax adjustments, including cy and py mtm inclusions/reversals, respectively, and all sales adjustments. GMO will be responsible to identify PFICs and provide a list of new PFICs or changes to any PFICs since October 31, 2006.
 
  11)   For all swaps held at February 28, 2007 and all swaps terminated in the period ending February 28, 2007, Investors Bank will compute all necessary tax adjustments and reclasses following policies communicated to Investors Bank by GMO, including but not limited to, accrual of net income on credit default swaps, reclassing IRC 988 gains/losses to ordinary income. In order to complete the swap analysis, GMO will provide term sheets to Investors Bank Tax as positions are opened and Investors Bank will review the terms of each swap contract. GMO will be available for any questions Investors Bank may have with regard to the tax treatment. Where necessary, GMO will engage an outside party to assist in determining the proper tax treatment in situations of new contract terms, changed terms from a py of an existing contract. As part of the swap analysis, Investors Bank will identify and properly accrue/amortize up front swap payments or other such fee payments made/received by the Funds as necessary.
 
  12)   Using a list of futures and option contracts exchanges from Investors Bank and BBH for the year ended February 28, 2007, Investors Bank will prepare all necessary futures and options tax reclass adjustments and other related applicable derivative tax adjustments on the cy TP, including, but not limited to IRC Section 1256 mtm and IRC Section 988 reclasses.
 
  13)   Using the DFS and related necessary subsidiary reports, Investors Bank will prepare all necessary IRC Section 988 reclass adjustments, including any related to swaps, options, futures, other derivatives, trade/settlement date payable receivable transactions, bond bifurcation.
 
  14)   Investors Bank will ensure all bond restructurings book-to-tax adjustments occurring in the year ended February 28, 2007 that GMO has approved and provided to Investors Bank have been included in the cy TP to the extent there are book-to-tax adjustments.
 
  15)   Investors Bank will ensure any applicable pay-down reclasses have been made to the cy TP for applicable pay-down bonds as per GMO’s pay-down tax treatment policy.

3


 

  16)   For any funds holding real estate investment trusts (“REITs”), Investors Bank will compute all return of capital (“roc”), long-term gain, short-term gain and other necessary reclass adjustments, including sales of REITs with py and cy carry forward roc adjustments, based on the policies already in place at Investors Bank set-forth by the Funds and communicated to Investors Bank. In addition, any necessary reclasses will be made by Investors Bank in accordance with Ire Section 857(b)(8)(A) applicable to REITs held and/or sold by the Funds.
 
  17)   For Funds holding other mutual funds (investment companies), Investors Bank will prepare all necessary adjustments, including, but not limited to, reclasses from any short-term capital gain distributions to ordinary income, any reclasses from short-term capital losses to long-term capital losses under IRS Section 852(b)( 4), any reclasses from dividend income to long-term capital gains, if applicable.
 
  18)   Any book -to-tax adjustments related to the accretion of discounts and amortization of premiums under the latest AICPA Audit Guide will be made by Investors Bank to the cy TP, including those related to the sale of applicable bonds in the cy.
 
  19)   For Funds that passed-through foreign tax credits ( “ftc”) for 2006 calendar year tax reporting, a list of which Investors Bank already has, Investors Bank will compute the applicable ftc gross-up and include the gross-up as well as a dividends-paid deduction on the cy TP for the same amount. Such foreign taxes and related foreign gross income amounts need to be adjusted for the countries communicated to Investors Bank by GMO that do not qualify for ftc pass-through and/or the foreign gross income pass-through (e.g. U.K, Malaysia, Singapore).
 
  20)   For Funds that pay capital gain taxes and other such fees treated as ordinary deductions for tax purposes as set-forth by the Funds’ policy for such fees and as maintained in separate accounts on the BBH TB, Investors Bank will make any necessary reclass adjustments from capital losses to ordinary losses. Also, any such capital gain taxes that GMO treats as qualified foreign tax credits (e.g. Indian capital gain taxes), Investors Bank will include in the ftc gross-up on the cy TP.
 
  21)   For any Funds with miscellaneous income/(loss) and/or realized capital gain/(loss) accounts, Investors Bank will take reasonable action to identify the appropriate tax treatment for such amounts. GMO will make all decisions in terms of tax treatment that is not apparent under the applicable IRS and/or TR.
 
  23)   22) For any Fund holding a partnership investment for U.S. federal income tax purposes as communicated to Investors Bank by GMO, Investors Bank will ensure the most recent Schedule K-l or equivalent schedule provided by GMO of final/estimated tax p&l amounts have been included in the partnership basis and that any p&l from the K-1s are included on the cy TP. Also, all partnership interest basis adjustments will be tracked cumulatively off-line on a lot-by-lot

4


 

      basis by Investors Bank and Investors Bank will notify GMO if any basis becomes zero or less to ensure the Fund is not being allocated excess losses from the partnership. If at the time the annual reports are being compiled only estimates are available, Investors Bank will true-up the calculation using final Schedule K-Is or equivalent schedules provided by GMO at that time. A cy post October capital and fx deferral computation will be prepared by Investors Bank, including an analysis under Notice 97-64. The final fiscal-year-to-date October 31, 2006 excise tax provision will be used for this analysis, as well as the cy annual TP. Any resulting deferrals or reclasses will be included on the cy TP by Investors Bank.
 
  24)   All py spillover amounts and cy distributions will be included on the cy TP by character. The py spillovers will be agreed by Investors Bank to the final federal tax returns provided to Investors Bank by GMO. The cy distributions will be agreed to the final DFS/TB and will be agreed in total to the AR.
 
  25)   Investors Bank will compute any tax return of capital distributions (“roc”) by applying the applicable accumulated earnings and profit IRC and TR Sections. Investors Bank will inform GMO of any such roc distributions and GMO will determine if such amounts are material for disclosure in the AR as a roc. GMO will provide prior year accumulated earning and profit calculations to Investors Bank.
 
  26)   Investors Bank will agree the total capital loss carry forward (“clco”) amount input into the cy TP to the final federal tax return. (GMO needs to provide b.o.y. to Investors Bank).
 
  27)   As it relates to reorganizations, Investors Bank will ensure any clco limitation under IRC Section 382 as computed by the Funds’ tax auditors and reviewed by GMO are included in the cy TP, including any unused but available clco from the py as well as including in the TP any BIG (built-in gains) or BIL (built-in losses) adjustments computed by the Fund’s tax auditors and reviewed by GMO related to cy sale activity.
 
  28)   Investors Bank will look at the py final TP provided by GMO for potential recurring adjustments to determine if such adjustments are required in the cy.
 
  29)   All sub-totals, totals, and mathematical calculations on the cy TP will be reviewed to ensure accuracy by Investors Bank.
 
  30)   Except as agreed upon by GMO staff for purposes of estimates, etc. Investors Bank will ensure each Fund’s cy TP has been reviewed and signed-off as ready for GMO and the Funds’ tax auditor review before it is delivered to either party. In addition, Investors Bank will provide to both GMO and the Funds’ tax auditors a complete tax package supporting the TP, including 1) a final, signed- off DFS/TB by the applicable Fund Accountant; 2) a wash sale deferral, reversal,

5


 

      and holding period report/analysis; 3) a PFIC analysis for each applicable fund; 4) support for all derivative tax adjustments; 5) support for any miscellaneous income/(loss) and/or realized capital gain (loss) DFS/TB accounts, and 6) support for any other tax adjustments not supported by the DFS/TB.
 
  31)   Investors Bank will respond to questions from GMO and/or Funds’ tax auditor regarding the TP within a 24 hour period after receiving comments. GMO will be responsible for receiving the comments/questions from the tax auditor and delivering them to Investors Bank. If Investors Bank believes the answer will not be ready in the specified time period, GMO and the Funds’ tax auditor will be informed before the 24 hour period lapses.
 
  32)   Investors Bank will inform GMO and the tax auditor of any delays expected from the agreed upon TP delivery dates immediately after the delay becomes known or estimated by Investors Bank.
 
  33)   Once the final AR are completed and mailed, Investors Bank will complete a final TP and deliver to GMO and the Funds’ tax auditor on an agreed upon date but in any case no later than June 15, 2007 . Any open points due to information required from GMO to complete the final TP will be the responsibility of GMO.
 
  34)   Before the spillovers are paid in early July of 2007 , Investors Bank will prepare a matrix that includes the total dollar and character (net income, short-term capital gain, and long-term capital gain) of each spillover amount as well as ending clco amounts for review by both GMO and the Funds’ tax auditor. This schedule will be delivered to GMO at the same time as the final TP mentioned above. GMO will be responsible for ensuring any information needed by Investors Bank to complete such matrix has been provided to Investors Bank.
 
  35)   After the Funds’ spillovers have been paid in early July 2007, Investors Bank will review the amounts paid by character to ensure the spillover has been satisfied using the applicable post ex-date DFS/TB from Investors Bank: and BBH. (GMO will be responsible for ensuring timely and accurate payment of distributions occur)
 
  36)   GMO Inflation Indexed Plus Bond Fund (IIXF) : For tax purposes, this Fund has a December 31, 2006 year-end. All the other Funds in the Trust currently have a tax year-end of February 28. For IIXF, Investors Bank will be responsible for preparing a tax provision based on the Fund’s December 31, 2006 first tax yearend (period May 31, 2006 through December 31, 2006). All delivery dates referenced above will be applicable for IIXF, including the preparation of the TP, the tax disclosures for the AR, and the delivery dates for the final TP, and the spillover matrix. All February 28, 2007 dates above shall be replaced with December 31, 2006 for IIXF.

6


 

Tax Disclosures in the Notes to the Financial Statements:
Investors Bank will prepare all the necessary tax disclosures for the Funds’ AR using the tax provision prepared above and any other necessary reports from Investors Bank/BBH Fund Accounting or GMO by performing the following procedures and others procedures as necessary:
  1)   Investors Bank will prepare a tax note disclosure analysis for the AR for each Fund based on the points below and other procedures as may be required. Such tax note disclosure analysis will be delivered to GMO and the Funds’ tax auditor on dates to be agreed upon between GMO, Investors Bank, and PwC but in no case not later than three days (72 hours) before such tax disclosures are due for inclusion into the draft AR. If Investors Bank does not believe this time frame will be met, Investors Bank will inform GMO and the Funds’ tax auditor as soon as Investors Bank is aware of the delay but in no case later than the beginning of such 3 day period.
 
  2)   Investors Bank will prepare an analysis under Statement of Position 93-2 (“roc-sop analysis”) that will include all permanent and temporary capital adjustments using the cy TP and py carry-forward amounts as of February 28, 2007. The roc-sop analysis will start with the py ending capital book balances per the final AR. GMO and/or PWC will provide Investors Bank with final prior year AR/TP.
 
  3)   Any py true-up adjustments made to the py final 1120-RIC but not to the py AR will be included by Investors Bank in the cy roc-sop analysis.
 
  4)   The roc-sop analysis will include a total of all permanent capital book-to-tax p&l adjustments made in the cy as well as all temporary cy and accumulated income/loss), capital gain/Loss), and security basis book-to-tax differences as of February 28, 2007.
 
  5)   The roc-sop analysis will determine the correct adjusted ending cy book capital balances that include all permanent cy tax adjustments.
 
  6)   The roc-sop analysis will prove-out the ending adjusted book balances by adding back the temporary tax adjustments to the cy ending tax spillovers. Any variances will be reconciled by Investors Bank.

7


 

  7)   Investors Bank will summarize the following required tax disclosure to the notes of the ap in the tax note disclosure analysis: 1) any foreign tax liabilities on unrealized gains (e.g. Indian capital gains taxes accrued); 2) any foreign capital gains taxes/fees paid in the cy (e.g. Indian capital gains taxes paid, Brazilian CPMF); 3) tax basis of any distributions paid in the year ended on February 28, 2007 including ordinary income (which includes any short-term capital gain distributions), long-term capital gain distributions, and return of capital distributions as per GMO’s roc instructions (the tax cost disclosure analysis will sum the net income and short-term capital distributions to derive the total ordinary income distributions made); and 4) will include ordinary income and long-term capital gain spillovers as of February 28, 2007 (the tax cost disclosure analysis will sum the net income and short-term capital gain distributions to derive the total ordinary spillover).
 
  8)   Investors Bank will prepare for any RIK that occurred in a Fund, the gross gains (not net gains) related to such RIK(s) and include on the tax note disclosure analysis.
 
  9)   The analysis will include the summary permanent adjustments, along with a description of the material permanent adjustments agreed upon by GMO, for inclusion in the notes to the cy AR. Materiality of such disclosures will be determined by GMO and discussed with Investors Bank prior to the release of the tax disclosures.
 
  10)   Investors Bank will prepare list describing all the material temporary tax adjustments approved by GMO for inclusion in the notes to the AR. Materiality of will be determined by GMO and discussed with Investors Bank.
 
  11)   The tax disclosure analysis will include the determination of tax cost and gross unrealized appreciation, gross unrealized deprecation, net unrealized appreciation (depreciation) on a tax basis by including all temporary tax adjustments that impact total book security cost. Investors Bank will tie-out the tax cost by adding the net unrealized tax appreciation (depreciation) to the tax cost and agree it to the total fair market value of the securities included in the Schedule of Investments included in the AR. Tax cost adjustments include, but are not limited to, PFIC mtm carry forward and QEF election basis adjustments, basis adjustments to partnership interests held, wash sale deferral carry forwards, REIT roc basis adjustments, if necessary, AICPA Guide bond accretion/amortization book-to-tax adjustments.
 
  12)   Investors Bank will prepare a summary of the clco by expiration date, adjusted for any permanent lost clco due to IRC 382 annual limitations prepared by the Fund’s tax auditor. For py clco layers, Investors Bank will agree such amounts, year of realization, and year of expiration, to the final py 1120-RIC. Investors Bank will ensure that the total clco per the tax disclosure summary agrees to the total clco per the cy TP.

8


 

  13)   If the Fund experienced a RIK in the cy, Investors Bank will prepare the total gross gains and gross losses related to such RIKs for inclusion in the notes to the cy AR.
 
  14)   Investors Bank will summarize any capital and/or fx post-October loss deferrals for inclusion in the notes to the cy AR.
 
  15)   Unaudited Tax Disclosures : Investors Bank will include or perform the following in regards to the unaudited tax disclosures on the tax note disclosure analysis: 1) Investors Bank will summarize the qualified dividend income (“QDI”) and dividend-received deduction (“DRD”) percentages used for 2006 tax reporting for inclusion in the unaudited section of the notes to the AR. If a Fund paid a dividend/distribution in the months of January and February of 2007, Investors Bank will re-compute, if necessary, the QDI and DRD percentages to be disclosed in the cy AR; 2) Investors Bank will compute for inclusion in the unaudited section of the cy AR, the qualified interest income (“QII”) for all Funds that paid net income and/or short-term capital gains in the fiscal year ended February 28, 2007 using GMO’s QII template; 3) Investors Bank will compute, using the ftc in the cy TP and by obtaining the corresponding gross foreign source income, for disclosure for the unaudited section of notes to the cy AR; and 4) Investors Bank, using the cy TP, will compute, taking into account any reclass distribution adjustments on the cy TP, the long-term capital gain paid designation disclosure for inclusion in the unaudited section of the notes to the AR.
 
  16)   All sub-totals, totals, and mathematical calculations on the tax note disclosure analysis will be reviewed for accuracy by Investors Bank.
 
  17)   Investors Bank will agree to deliver all tax disclosures for the AR to GMO and the Funds’ tax auditor on dates agreed to between GMO, Investors Bank, and the tax auditor.
 
  18)   Investors Bank will verify the mathematical accuracy of all totals and sub-totals related to tax disclosures in AR (e.g. net unrealized appreciation (depreciation), accumulated undistributed net income/loss + accumulated net realized gain (1oss) equals the paid-in capital adjustment).
 
  19)   Investors Bank will respond to questions from GMO, Investors Bank Reporting, and the tax auditor regarding the tax note disclosures within a 24 hour period by providing to GMO all responses related to GMO and PwC questions. GMO will provide such responses to the tax auditor. If Investors Bank believes the answer will not be ready in the specified time frame, GMO and the tax auditor will be informed by Investors Bank before the 24 hour period lapses.

9


 

  20)   Investors Bank will review all applicable tax disclosures made to the applicable draft AR and, in any event, the final draft before print, to the tax disclosure analysis. Any differences will be brought to Investors Bank Reporting and GMO’s attention immediately upon noting the difference(s). All such differences will be cleared by GMO before releasing the AR to print.
 
  21)   IIXF Tax Note Disclosures in AR : Investors Bank will prepare, a tax disclosure summary for the 2/28/07 IIXF AR, based on book-to-tax adjustments for the period May 31, 2006 through December 31, 2006. Investors Bank will review for any material tax adjustments that may have occurred between January 1, 2007 through February 28, 2007 for consideration of inclusion in the February 28, 2007 AR. GMO will determine if any such material adjustments need to be included in the tax disclosure in the February 28, 2007 AR.
Federal and State Tax Returns and Related Extensions :
Investors Bank will perform the following procedures, and others as necessary, to prepare for review by GMO and the Funds’ tax auditor, a complete and accurate federal and state tax return (if applicable) for each Fund:
  1)   Investors Bank, GMO, and the tax auditor will sign-off as final the cy TP before the any tax return is deemed final by Investors Bank and GMO.
 
  2)   Investors Bank will prepare Form 1120-RIC (“tax return”) and all related attachments to complete the tax return. Investors Bank will also be responsible for preparing additional federal tax forms that certain GMO Funds may require as reasonably requested by GMO, including, but not limited to, Form 8865, Form 5471, Form 926, Form 5472, Form 5452, Form 6781, Form 8621 (including the lot-level detailed PFIC holding and PFIC sales analysis and where the mtm election under IRC 1296 is made), Schedule PH. GMO will be responsible for providing any information not available or accessible to Investors Bank to complete these forms and schedules. GMO will be responsible for filing all tax returns and related schedules and attachments to the appropriate Internal Revenue Service Center (“IRSC”).
 
  3)   For questions on the tax return regarding shareholders’ ownership at February 28, 2007 (except for personal holding companies), Investors Bank will obtain the applicable ownership information from the TA. GMO will be responsible for providing Investors Bank all PHC related information for Schedule PH.
 
  4)   Investors Bank will be responsible for preparing Form 7004, the tax return extension, for all Funds. GMO expects to get delivery of all completed 7004s for review on or before March 15, 2007 . Regarding IIXF, Investors Bank will deliver to GMO for review Form 7004 on or before February 15, 2007 . GMO will be responsible for mailing Forms 7004 to the appropriate IRSC for all Funds.

10


 

  5)   For any Funds that underwent a liquidation/termination in 2007 (2006 for IIXF), Investors Bank will prepare for review by GMO Form 966 on or before 15 days after such liquidation notification has been has been provided to Investors Bank by GMO. GMO will be responsible for filing Form 966 with the applicable IRSC. GMO to provide a complete list of liquidations to Investors Bank Tax.
 
  6)   If a Fund underwent a reorganization under IRC Section 368 or a transfer of securities under IRC Section 351 requiring additional tax return disclosures, Investors Bank will prepare the necessary disclosures in the tax returns for such reorganizations/transfer as required under the applicable IRC and TR Sections. If Investors Bank does not have the necessary information or access to the necessary information to prepare such disclosure, GMO will provide the information to Investors Bank.
 
  7)   In regards to Schedule PH, GMO will provide Investors Bank all the necessary personal holding company information for the applicable Funds by July 16, 2007 . If GMO expects that this deadline will not be met, GMO will inform Investors Bank immediately upon determination that July 16, 2007 will not be feasible.
 
  8)   Investors Bank will ensure all book amounts in the tax returns agree to the final AR.
 
  9)   Investors Bank will agree all py book and tax amounts in the tax returns to the final py 1120-RIC and final py AR, respectively.
 
  10)   Investors Bank will ensure all applicable amounts in the tax returns agree to the corresponding amounts in the final cy TP.
 
  11)   Investors Bank will prepare either an initial informative MA Form 3 for any new Fund in fiscal 2007 and a final MA Form 3 for any Fund that liquidated or terminated in fiscal 2007.
 
  12)   Investors Bank will manually mathematically test all totals and sub-totals in any tax return to ensure they are proper.
 
  13)   Investors Bank will ensure all amounts in any tax return prepared by Investors Bank that appear more than once agree (e.g. gross assets, capital).
 
  14)   GMO expects to have all tax returns, including any MA state tax returns, delivered to GMO and the tax auditor on or before September 17, 2007 . If Investors Bank believes this due date will not be met, Investors Bank will inform GMO as soon as Investors Bank becomes aware of any delay or issue that would prevent Investors Bank from meeting this delivery due date and propose a revised delivery schedule by Fund. In no case, unless Investors Bank is waiting for GMO to provide information to complete a tax return/ supporting schedule or

11


 

      attachment, shall Investors Bank deliver any returns to GMO after October 15, 2007 .
 
  15)   All sub-totals, totals, and mathematical calculations in any tax return/related schedules and attachments prepared by Investors Bank will be reviewed for accuracy by Investors Bank.
 
  16)   Regarding IIXF, the initial Form 1120-RIC and the initial MA Form 3F will be delivered by Investors Bank for review by GMO and the Fund’s auditor on or before June 15, 2007 .
         
Agreed to by:    
 
       
Investors Bank & Trust Company    
 
       
By:
Name:
  /s/ Stephen DeSalvo
 
Stephen DeSalvo
   
Title:
  Managing Director    
 
       
3/6/07    
Date    
 
       
Grantham, Mayo, Van Otterloo & Co. LLC    
 
       
/s/ JB Kittredge    
     
JB Kittredge    
General Counsel    
 
       
3/7/07    
Date    

12

Exhibit (h)(4)
GRANTHAM, MAYO, VAN OTTERLOO & CO. LLC
Notification Of Undertaking To Reimburse
Certain Fund Expenses
     NOTIFICATION made October 1, 2011 by GRANTHAM, MAYO, VAN OTTERLOO & CO. LLC, a Massachusetts limited liability company (the “Adviser”), to GMO SERIES TRUST, a Massachusetts business trust (the “Trust”).
WITNESSETH:
     WHEREAS, the Adviser has organized the Trust to serve primarily as an investment vehicle for certain eligible retirement plans; and
     WHEREAS, the Adviser believes it would benefit from a high sales volume of shares of the Trust in that such a volume would maximize the Adviser’s fee as investment adviser to each series of the Trust constituting a separate investment portfolio set forth below (each a “Fund” and, collectively, the “Funds”); and
     WHEREAS, the Adviser has agreed to reimburse certain Funds for certain Fund expenses so as to reduce or eliminate certain costs otherwise borne by shareholders of the Funds and to enhance the returns generated by shareholders of the Funds.
     NOW, THEREFORE, the Adviser hereby notifies the Trust that the Adviser shall, as set forth below, reimburse a portion of the expenses of certain Funds listed below through the date designated by the Adviser in this Notification (the “Reimbursement Date”) (and any subsequent periods as may be designated by the Adviser by notice to the Trust).
     The Adviser will be obligated to reimburse a Fund for the portion of the Fund’s total annual operating expenses (excluding fees and expenses identified below (the “Excluded Fund Fees and Expenses”)) that exceed 0.00% of the Fund’s average daily net assets (the “Post-Reimbursement Expense Limitation”).
     As used in this Notification, Excluded Fund Fees and Expenses are: administration fees, 12b-1 fees, expenses indirectly incurred by investment in other Funds managed by the Adviser, fees and expenses of the independent trustees of the Trust and their independent counsel, fees and expenses for legal services the Adviser for the Trust has not undertaken to pay, compensation and expenses of Trust officers and agents who are not affiliated with the Adviser, brokerage commissions, securities lending fees and expenses, interest expense, transfer taxes, and other investment-related costs (including expenses associated with investments in any company that is an investment company (including an exchange-traded fund) or would be an investment company under the Investment Company Act of 1940, as amended (the “1940 Act”), but for the exceptions to the definition of investment company provided in Sections 3(c)(1) and

 


 

3(c)(7) of the 1940 Act), hedging transaction fees, and extraordinary, non-recurring and certain other unusual expenses (including taxes).
     The Reimbursement Date for each Fund listed in the table above is October 1, 2012, and may be extended by the Adviser at its discretion.
     In providing this Notification, the Adviser understands and acknowledges that the Trust intends to rely on this Notification, including in connection with the preparation and printing of the Trust’s prospectuses and its daily calculation of each Fund’s or class’s net asset value.
     Please be advised that all previous notifications by the Adviser with respect to fee waivers and/or expense limitations regarding any of the Funds shall hereafter be null and void and of no further force and effect.

-2-


 

     IN WITNESS WHEREOF, the Adviser has executed this Notification of Undertaking to Reimburse Certain Fund Expenses on the day and year first above written.
         
  GRANTHAM, MAYO, VAN OTTERLOO & CO. LLC
 
 
  By:      
  Name:  J.B. Kittredge   
  Title:  General Counsel   
 

-3-

Exhibit (i)
     
(ROPES & GRAY LOGO)
  ROPES & GRAY LLP
  PRUDENTIAL TOWER
  800 BOYLSTON STREET
  BOSTON, MA 02199-3600
  WWW.ROPESGRAY.COM
September 14, 2011
GMO Series Trust
40 Rowes Wharf
Boston, MA 02110
Re: GMO U.S. Core Equity Series Fund
Ladies and Gentlemen:
We are furnishing this opinion in connection with the proposed offer and sale by GMO Series Trust, a Massachusetts business trust (the “Trust”), of shares of beneficial interest (“Shares”) of GMO U.S. Core Equity Series Fund (the “Fund”) pursuant to the Trust’s Registration Statement on Form N-1A under the Securities Act of 1933, as amended (File No. 333-174627) and the Investment Company Act of 1940, as amended (File No. 811-22564) (the “Registration Statement”).
We are familiar with the actions taken by the Trustees of the Trust to authorize the issuance and sale to the public from time to time of authorized and unissued Shares of the Fund. We have examined or relied upon a copy of the Trust’s Amended and Restated Agreement and Declaration of Trust (the “Declaration of Trust”), as certified by the Clerk of the Trust; copies of resolutions adopted by written consent of the sole Trustee of the Trust on August 23, 2011, as certified by the Clerk of the Trust; copies of resolutions adopted at the meeting of the Trustees of the Trust held on August 23, 2011, as certified by the Clerk of the Trust; copies of resolutions adopted by written consent of the sole Trustee of the Trust on September 14, 2011, as certified by the Clerk of the Trust; and such other documents as we deem necessary for purposes of this opinion.
Based upon the foregoing, we are of the opinion that the issue and sale by the Trust of the authorized but unissued Shares of the Fund have been duly authorized under Massachusetts law. Upon the original issue and sale of any such authorized but unissued Shares of the Fund and upon receipt by the Trust of the authorized consideration therefor in an amount not less than the applicable net asset value, the Shares so issued will be validly issued, fully paid and nonassessable by the Trust.
The Trust is an entity of the type commonly known as a “Massachusetts business trust.” Under Massachusetts law, shareholders could, under certain circumstances, be held personally liable for the obligations of the Trust. However, the Declaration of Trust disclaims shareholder liability for acts or obligations of the Trust and requires that notice of such disclaimer be given in each

 


 

         
GMO Series Trust   -2-   September 14, 2011
note, bond, contract, instrument, certificate or undertaking made or issued on behalf of the Trust by the Trustees of the Trust, by any officer or officers of the Trust, or otherwise. The Declaration of Trust provides for indemnification out of the property of a particular series or class of a series of the Trust for all loss and expense of any shareholder of that series or class held personally liable for the obligations of that series or class solely by reason of his or her being or having been a shareholder of that series or class. Thus, the risk of a shareholder’s incurring financial loss on account of being a shareholder of a series or class is limited to circumstances in which the series or class itself would be unable to meet its obligations.
We consent to the filing of this opinion with and as part of the Registration Statement.
Very truly yours,
     
/s/ Ropes & Gray LLP
   
 
Ropes & Gray LLP
   
     
cc:
  J.B. Kittredge, Esq., Grantham, Mayo, Van Otterloo & Co. LLC
 
  Jason B. Harrison, Esq., Grantham, Mayo, Van Otterloo & Co. LLC

 

Exhibit (j)
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the use in this Registration Statement on Form N-1A of our report dated September 7, 2011, relating to the financial statement of GMO U.S. Core Equity Fund, which appear in such Registration Statement. We also consent to the references to us under the headings “Investment Advisory and Other Services — Independent Registered Public Accounting Firm” and “Disclosure of Portfolio Holdings — Ongoing Arrangements To Make Portfolio Holdings Available” in such Registration Statement.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
September 7, 2011

Exhibit (l)
__________ ___, 2011
GMO Series Trust
40 Rowes Wharf
Boston, Massachusetts 02110
Re: Subscription for Shares
Ladies and Gentlemen:
Grantham, Mayo, Van Otterloo & Co. LLC (“GMO”), in consideration of the formation of GMO Series Trust (the “Trust”) and its initial series, GMO U.S. Core Equity Series Fund (the “Fund”), has subscribed for 5,000 Class R1 shares of beneficial interest of the Fund (the “Shares”) and has paid the Fund $100,000 in exchange for the Shares ($20.00 per share).
The Shares subscribed for in this letter were issued prior to the effective date of the registration statement relating to the Shares under the Securities Act of 1933, as amended (the “Act”), and were paid for in cash.
In connection with your sale to us of the Shares, we understand that: (i) the Shares have not yet been registered under the Act; (ii) your sale of the Shares to us is in reliance on the sale’s being exempt under Section 4(2) of the Act as not involving any public offering; (iii) in part, your reliance on such exemption is predicated on our representation, which we hereby confirm, that we are acquiring the Shares for investment and for our own account as the sole beneficial owner hereof, and not with a view to or in connection with any resale or distribution of any or all of the Shares or of any interest therein or with the current intention to redeem the Shares; (iv) this letter and all of its provisions shall be binding upon the legal representatives, heirs, successors and assigns of GMO; and (v) this letter is executed on behalf of the Trust by an officer of the Trust as an officer and not individually, and the obligations imposed upon the Trust by this letter are not binding upon any of the Trust’s Trustees, officers or shareholders individually but are binding only upon the assets and property of the Trust. We hereby agree that we will not sell, assign or transfer the Shares or any interest therein except upon repurchase or redemption by the Fund unless and until the Shares have been registered under the Act, or you have received an opinion of your counsel indicating to your satisfaction that such sale, assignment or transfer will not violate the provisions of the Act, or any rules and regulations promulgated thereunder.
This letter is intended to take effect as an instrument under seal and shall be construed under the laws of The Commonwealth of Massachusetts.
Please indicate your agreement and acceptance of this subscription by signing below.

 


 

         
GRANTHAM, MAYO, VAN OTTERLOO & CO. LLC    
 
       
By:
       
Name:
 
 
   
Title:
       
 
       
Accepted and Agreed to on ___________ ___, 2011    
 
       
GMO SERIES TRUST,
on behalf of GMO U.S. Core Equity Series Fund
   
 
       
By:
       
Name:
 
 
   
Title:
       

 

Exhibit (p)(1)
GMO
CODE OF ETHICS

GMO AUSTRALASIA LLC
GMO AUSTRALIA LTD.
GMO SINGAPORE PTE LTD.
GMO SWITZERLAND GMBH
GMO U.K. LIMITED
GRANTHAM, MAYO, VAN OTTERLOO & CO. LLC
GMO RENEWABLE RESOURCES, LLC
GMO RENEWABLE RESOURCES (in New Zealand)
GMO RENEWABLE RESOURCES URUGUAY, SRL
Dated May 20, 2011

 


 

Table of Contents
         
Overview and Summary Charts
    1  
Overview Chart/Basic Rules and Exceptions
    1  
Overview Chart—By Instrument
    2  
 
       
1. PROHIBITED TRANSACTIONS
    3  
1.1 Securities Being Considered for Purchase or Sale
    3  
1.2 Options on Securities
    4  
1.3 Short Selling of Securities
    4  
1.4 Short-Term Trading
    5  
1.5 Short-Term Trading Strategies in GMO Long-Term Funds
    5  
1.6 Trading on Inside Information
    6  
1.7 Market Manipulation
    6  
1.8 Other Illegal and/or Impermissible Transactions
    6  
 
       
2. PRE-CLEARANCE REQUIREMENTS
    6  
2.1 Transactions in Certain Securities
    6  
2.2 Dividend Reinvestment, etc.
    7  
2.3 Discretionary Accounts
    7  
2.4 De Minimis Purchases and Sales of Certain Large Cap Securities
    7  
2.5 Transactions Pursuant to Limit Orders Previously Approved by Compliance Department
    8  
2.6 Transactions by Brokers to Satisfy Margin Calls
    8  
2.7 Non-GMO Employee Stock Investment Options
    8  
2.8 Donation of Securities to a Charity
    8  
2.9 GMO Hedge Funds
    8  
 
       
3. REPORTING REQUIREMENTS
    9  
3.1 Initial and Annual Disclosure of Personal Holdings
    9  
3.2 Quarterly Reporting Requirements
    9  
3.3 Exemptions for Transactions in Certain Securities
    10  
3.4 Additional Exemption From Quarterly Reports
    10  
3.5 Brokerage Confirmations
    10  
3.6 Procedures for Filing Reports
    11  
3.7 Reporting Violations
    11  
 i

 


 

         
4. ADMINISTRATION AND ENFORCEMENT OF CODE OF ETHICS
    11  
4.1 General Principles
    11  
4.2 Role of COIC; Delegation
    11  
4.3 CCO Role, Investigations
    12  
4.4 Sanctions
    12  
4.5 Administration of Pre-clearance
    12  
4.6 No Explanation Required for Refusals
    13  
4.7 Review of Denied Pre-Clearance Requests
    13  
 
       
5. MISCELLANEOUS
    13  
5.1 Copies of Code; Annual Affirmation
    13  
5.2 Review of Reports
    13  
5.3 Availability of Reports
    13  
5.4 Exceptions to the Code
    14  
5.5 Inquiries Regarding the Code
    14  
5.6 Amendments to Code
    14  
 
       
Exhibit A: Definitions
    15  
Appendix A-1 List of Restricted Exchange Traded Funds
    20  
Appendix A-2 List of Reportable 529 Plans
    21  
GMO UK Limited — Code of Ethics Supplement
    22  
GMO Australia Ltd. — Code of Ethics Supplement
    25  
GMO Renewable Resources (in New Zealand) — Code of Ethics Supplement
    27  
GMO Non-Access Director — Code of Ethics Supplement
    28  
 ii

 


 

GMO CODE OF ETHICS
as revised May 20, 2011
OVERVIEW AND SUMMARY CHARTS
GMO and its affiliates have adopted this Code of Ethics in order to reflect the values of the firm and to fulfill the firm’s regulatory obligations. Because the regulations are complex and technical, a number of terms are defined in Exhibit A and appear in the Code in bold .
The following chart provides an overview of some key rules under the Code and some common exceptions. This is only an overview and there are other rules and exceptions. Each Access Person is still responsible for reading and understanding this Code in its entirety.
     
Five Basic Rules   Common Exceptions
Basic Rule #1:
  Mutual Funds
Do not trade in advance of clients
  Most Exchange Traded Funds
 
  U.S. Government Securities
 
  Money Market Instruments
 
  Financial Futures
 
   
Basic Rule #2:
  Mutual Funds
Pre-Clear all trades
  Most Exchange Traded Funds
 
  529 Plans
 
  U.S. Government Securities
 
  Money Market Instruments
 
  Municipal Bonds
 
  Financial Futures
 
   
Basic Rule #3:
  Mutual Funds not advised/sub-advised by GMO (but not Exchange Traded
Funds)
Report all trades
  Most 529 Plans
 
  U.S. Government Securities
 
  Money Market Instruments
 
  Currencies/Currency forwards/Non-exchange traded options on currencies
 
  Futures on interest rates/currencies
 
   
Basic Rule # 4:
  Mutual Funds not advised/sub-advised by GMO
Don’t churn your account
  U.S. Government Securities
 
  Money Market Instruments
 
  Currencies/Currency forwards/Non-exchange traded options on currencies
 
  Municipal Bonds
 
  Financial Futures
 
   
Basic Rule #5:
  None
No violation of laws, for example:
No Transactions on inside information;
No market manipulation.

 


 

The following chart provides a different overview of the Code’s operation, organized by the type of security. As with the previous chart, this is, however, only an overview of some of the rules applicable to different kinds of securities. Every Access Person is still responsible for reading and understanding this Code in its entirety.
                     
        Prohibited if            
        Purchase or   Subject to        
        Sale Being   Quarterly and   Disgorge Short-    
        Considered for   Annual   Term Profit   Short Sales
    Preclearance   a GMO Client   Reporting   (<60 day   Generally
Type of Security   Required   Account   Requirements   Round Trip)   Prohibited 1
GMO Mutual Funds and GMO Sub-Advised Funds
  No   No   Yes 2   Yes, except SDCF, SDC Share, SDIF, Domestic Bond and WOOF   Yes
Non-GMO Mutual Funds
  No   No   No   No   Yes
Closed-End Funds
  Yes   Yes   Yes   Yes   Yes
Most Exchange Traded Funds 3 (does not include Closed-End Funds)
  No   No   Yes   No   No
Exempted Government Securities
  No   No   No   No   Yes
Money Market Instruments
  No   No   No   No   Yes
Currencies and related forward contracts
  No   No   No   No   No
Financial Futures (including
physical commodities)
  No   No   Generally Yes 4   No   No
 
1   Subject to limited exceptions (see Section 1.3), short selling is prohibited with respect to any investment held in any GMO Client Account.
 
2   Please note that Access Persons do not need to enter reporting details in StarCompliance for GMO Mutual Fund investments only. However, investments in GMO Sub-Advised Funds will need to be entered in StarCompliance.
 
3   See Appendix A-1 for a list of exceptions.
 
4   Futures on interest rates and currencies are exempt from the Code’s reporting requirements.

2


 

                     
        Prohibited if            
        Purchase or   Subject to        
        Sale Being   Quarterly and   Disgorge Short-    
        Considered for   Annual   Term Profit   Short Sales
    Preclearance   a GMO Client   Reporting   (<60 day   Generally
Type of Security   Required   Account   Requirements   Round Trip)   Prohibited 1
Put or Call Options (buying or writing)
  Generally Yes   Yes   Generally Yes   Generally Yes   N/A
Municipal Bonds
  No   Yes   Yes   No   Yes
IPOs
  Yes   Yes   Yes   Yes   Yes
Private Placements (including third
party private funds)
  Yes   Yes   Yes   Yes   Yes
Most 529 Plans 5
  No   Not Applicable   Generally No   N/A   N/A
MOST OTHER INVESTMENTS
  Yes   Yes   Yes   Yes   Yes
Gift Policy: GMO also has a “Gift Policy” which is a separate, stand-alone document.
Special Rules for Access Persons of Subsidiaries; Non-Access Directors . Employees, partners, consultants and all other Access Persons are subject to all provisions of this Code unless you are an Independent Trustee of GMO Trust or a Non-Access Director of GMO. If you are one of the following, you should also look at the related Code Supplement :
  4   Officers and Employees of GMO UK Limited;
 
  4   Officers and Employees of GMO Australia Limited;
 
  4   Officers and Employees of GMO Renewable Resources (in New Zealand); and
 
  4   Non-Access Directors of GMO;
1.   PROHIBITED TRANSACTIONS
Access Persons and members of their Immediate Family are prohibited from engaging in the following transactions:
  1.1   Securities Being Considered for Purchase or Sale .
          Except as provided below, any transaction in a Security being considered for purchase or sale by a GMO Client Account is prohibited. For this purpose, a Security is being considered for purchase or sale when a recommendation to purchase or sell the Security has been communicated or, with respect to the person making the recommendation, when such person seriously considers making the recommendation. The following Securities are not subject to this prohibition:
 
5   See Section 3.3 (“Exemptions for Transactions in Certain Securities”) and the definition of Reportable 529 Plan .

3


 

    Registered open-end investment companies (but not Restricted Exchange Traded Funds) ;
 
    Unrestricted Exchange Traded Funds (including short sales thereof);
 
    Financial Futures ; options on Financial Futures ; and short sales of Financial Futures .
 
    U.S. Government Securities and other Exempted Government Securities ;
 
    Money Market Investments ;
 
    Securities held or to be acquired by a Discretionary Account ; and
 
    Currencies, options on currencies, and forward contracts on currencies.
Note: The formulation of purchases and sale orders generally begins before the relevant trading desk is asked to execute the trade. GMO reserves the right to require the unwinding of personal trades that occur on or about the same time as client trades without proving that the Access Person or member or his or her Immediate Family had actual knowledge of the pending client trade.
     1.2 Options on Securities .
          Purchasing or selling options on a Security held (or being considered for purchase or sale) by any GMO Client Account is prohibited (other than options on Financial Futures or on foreign currencies). The following Securities are not subject to this prohibition:
    Securities held or to be acquired by a Discretionary Account .
     1.3 Short Selling of Securities .
          Short selling Securities held (or being considered for purchase or sale) in any GMO Client Account is prohibited. The following Securities are not subject to this prohibition:
    Short sales of Unrestricted Exchange Traded Funds ; and
 
    Short sales of Financial Futures and options on Financial Futures .
 
    Securities held or to be acquired by a Discretionary Account .
Note: Forward contracts on currencies are not considered a short sale of either currency for purposes of this Code.

4


 

     1.4 Short-Term Trading .
          Except as provided below, purchasing and selling the same or equivalent Securities within 60 calendar days is prohibited. (For the sake of clarity, except as otherwise noted, this prohibition applies to short-term profiting through the use of derivatives, either alone (e.g., exercising an option within 60 days of purchasing the option) or in combination with other Securities Transactions (e.g., selling the underlying Security within 60 days of purchasing a call on such Security) ). The following Securities are not subject to this prohibition:
    Registered open-end investment companies (other than GMO Long-Term Funds and GMO Sub-Advised Funds )
 
    U.S. Government Securities and other Exempted Government Securities ;
 
    Exchange Traded Funds (whether or not they are registered open-end investment companies)
 
    Money Market Instruments ;
 
    Currencies and related forward contracts;
 
    Financial Futures and short sales of Financial Futures ;
 
    Physical commodity contracts and options on physical commodity contracts;
 
    Securities acquired through the exercise of rights issued by an issuer to all holders of a class of its Securities , to the extent the rights were acquired in the issue;
 
    Securities acquired through Non-GMO Employee Stock Investment Options ;
 
    Transactions resulting from stop-loss orders (note that this does not apply to limit orders).
 
    Municipal bonds; and
 
    Securities held in a Discretionary Account .
     1.5 Short-Term Trading Strategies in GMO Long-Term Funds .
          Transactions in any GMO Long-Term Fund that, when taken together, constitute a short-term trading strategy that is inconsistent with the interests of the Fund’s long-term investors, are prohibited. In addition (and in addition to the prohibition in Section 1.4), making three “round-trip” transactions (purchase and

5


 

subsequent redemption) over a 12-month period in the same GMO Long-Term Fund is prohibited.
     1.6 Trading on Inside Information .
          Any transaction in a Security while in possession of material nonpublic information regarding the Security or the issuer of the Security is prohibited.
     1.7 Market Manipulation .
          Transactions intended to raise, lower, or maintain the price of any Security or to create a false appearance of active trading are prohibited.
     1.8 Other Illegal and/or Impermissible Transactions .
          All Access Persons and all members of their Immediate Family are required to comply with all applicable Federal Securities Laws . In addition to the prohibitions in Sections 1.6 (Trading on Inside Information) and 1.7 (Market Manipulation), Securities Transactions not in compliance with applicable Federal Securities Laws , or any other transactions deemed by the CCO to involve a conflict of interest, possible diversion of corporate opportunity, or an appearance of impropriety, are prohibited.
2. PRE-CLEARANCE REQUIREMENTS
Access Persons and members of their Immediate Family are prohibited from engaging in any Securities Transaction without prior approval of the Compliance Department unless otherwise provided below. Once obtained, pre-clearance is valid only for the day on which it is granted and the following three business days (or the following 30 calendar days in the case of a Private Placement ). Limit orders and stop-loss orders relating to Securities must be pre-cleared prior to establishment and prior to any modifications, including cancellations.
There is no exemption from pre-clearance for IPOs or Private Placements , even where such transactions are effected through Discretionary Accounts . See Sections 4.5.1 and 4.5.2 on how to process a request for pre-clearance.
Please refer to the “StarCompliance User Guide” found within StarCompliance for information regarding how to request pre-clearance or how to appeal denied pre-clearance requests.
The following Securities Transactions are exempt from the pre-clearance requirement:
     2.1 Transactions in Certain Securities .
           Securities Transactions involving the following instruments may be subject to the substantive prohibitions in Section 1, but they are exempt from the pre-clearance requirement:

6


 

    Securities issued by any registered open-end investment company (including GMO Affiliated Funds , but excluding Restricted Exchange Traded Funds ).
 
    Unrestricted Exchange Traded Funds (including short sales thereof);
 
    U.S. Government Securities and other Exempted Government Securities .
 
    Money Market Instruments .
 
    Currencies and related forward contracts.
 
    Options on currencies.
 
    Financial Futures ; options on Financial Futures ; and short sales of Financial Futures .
 
    Physical commodities (e.g., gold).
 
    Municipal bonds.
 
    529 Plans.
 
    Any transaction in other Securities as may from time to time be designated in writing by the CCO (as directed by the COIC) on the ground that the risk of abuse is minimal or non-existent.
     2.2 Dividend Reinvestment, etc .
           Securities Transactions involving acquisition of Securities acquired through stock dividends, dividend reinvestments, stock splits, reverse stock splits, mergers, consolidations, spin-offs, the exercise of rights issued by an issuer to all holders of the same class of Securities , or other similar corporate reorganizations or distributions generally applicable to all holders of the same class of Securities.
     2.3 Discretionary Accounts .
           Securities Transactions through Discretionary Accounts in Securities other than IPOs and Private Placements.
     2.4 De Minimis Purchases and Sales of Certain Large Cap Securities .
          Purchases or sales of less than $25,000 of common stock, depository receipts, or preferred stock where the size of the relevant issue is greater than $5 billion as of the date of such purchases or sales are exempt from pre-clearance. This exemption from pre-clearance may be utilized once per security within multiple accounts during a 4-day pre-clearance period (i.e., the day pre-clearance

7


 

is granted and the following three business days) so long as the total across all accounts is less than $25,000.
     2.5 Transactions Pursuant to Limit Orders or Stop-Loss Orders Previously Approved by Compliance Department .
          Transactions effected pursuant to limit orders or stop-loss orders already approved by the Compliance Department are exempt from pre-clearance, provided that the Access Person provides the Compliance Department with an attestation from the relevant broker stating that the broker will act solely in accordance with that limit order or stop-loss order, with no influence exercised or information supplied by the Access Person or anyone else acting on his or her behalf.
     2.6 Transactions by Brokers to Satisfy Margin Calls .
          Liquidations of Securities by a broker to satisfy margin calls are not subject to pre-clearance, provided that the Access Person provides to the Compliance Department a letter or other documentation from the brokerage firm confirming that the liquidation was effected to satisfy applicable margin requirements, and was not requested by the Access Person .
     2.7 Non-GMO Employee Stock Investment Options .
           The receipt of stock or options in connection with an Immediate Family member’s employment are exempt from pre-clearance provided that the Compliance Department receives an initial attestation from the Immediate Family member’s employer confirming that the securities were acquired through a non-GMO compensation program. This attestation can be documentation detailing the program, such as terms and entitlements, or, to the extent such documentation is not available, an attestation from the employer. This exemption is inclusive of exercising a cash-settled option or the acquisition of stock by exercising an option acquired in connection with an Immediate Family member’s employment. The receipt of stock and options is still subject to reporting requirements under the Code.
     2.8 Donation of Securities to a Charity .
          Donations of Securities to charities are not subject to pre-clearance.
     2.9 GMO Hedge Funds
          Investments in GMO hedge funds, while subject to pre-clearance, are automatically pre-cleared when the subscription is accepted by GMO.

8


 

3. REPORTING REQUIREMENTS
     3.1 Initial and Annual Disclosure of Personal Holdings .
          No later than 10 calendar days after initial designation as an Access Person and thereafter on an annual basis (currently expected of all Access Persons by January 30 of each year), each Access Person must report to the Compliance Department all of the following (subject to the exceptions in Section 3.3):
3.1.1. The title, type, number of shares and principal amount of each Security (including as applicable any exchange ticker symbol or CUSIP number) in which that Access Person has any Beneficial Interest (including Securities held in Discretionary Accounts );
3.1.2. The name of any broker, dealer or bank with whom the Access Person maintains a Reportable Account ; and
3.1.3. The date that the report is submitted by the Access Person .
          Both initial reports and annual reports must be based on information current as of a date not more than 30 days before the report is submitted.
     3.2 Quarterly Reporting Requirements .
          Each Access Person must file a quarterly report with the Compliance Department no later than 30 calendar days following the end of each calendar quarter. The quarterly report shall include the following information regarding each transaction during the quarter in any Security in which the Access Person had any Beneficial Interest (subject to the exceptions in Sections 3.3 and 3.4):
3.2.1. The date of the transaction, the title, the interest rate and maturity date (if applicable), the number of shares and the principal amount of each Security (including as applicable any exchange ticker symbol or CUSIP number) involved;
3.2.2. The nature of the transaction (i.e., purchase, sale or any other type of acquisition or disposition);
3.2.3. The price of the Security at which the transaction was effected; 3.2.4. The name of the broker, dealer or bank with or through which the transaction was effected;
3.2.5. A certification that, with respect to each transaction effected during the quarter, the Access Person neither had confidential information nor was aware of any pending consideration of possible transactions or pending transactions in the relevant security by GMO on behalf of a GMO client; and
3.2.6. The date that the report is submitted by the Access Person .

9


 

          In addition, with respect to any Reportable Account established during such quarter by the Access Person , the quarterly report must also include the name of the broker, dealer or bank with whom the Access Person established the account.
           No quarterly report is required to list transactions that are automatic dividend reinvestments.
     3.3 Exemptions for Transactions in Certain Securities .
          Transactions in the following instruments may be subject to the substantive prohibitions in Section 1 and/or the pre-clearance requirements in Section 2, but are exempt from the Reporting Requirements in Sections 3.1 (Initial/Annual Report) and 3.2 (Quarterly Reports):
    Securities issued by any registered open-end investment company (other than a GMO Affiliated Fund or an Exchange Traded Fund .)
 
    U.S. Government Securities and other Exempted Government Securities .
 
    Money Market Instruments .
 
    Futures on interest rates, futures on currencies, and non-exchange-traded options on currencies and currency futures (including short sales of any of the foregoing). (NOTE: Not all Financial Futures are covered by this exemption.)
 
    Currencies and related forward contracts.
 
    529 Plans (other than Reportable 529 Plans )
     3.4 Additional Exemption From Quarterly Reports .
          Transactions in the following are exempt from the quarterly transaction reporting requirement in Section 3.2 (but the results of these transactions must still be included in the annual report required by Section 3.1):
    Securities acquired through stock dividends, dividend reinvestments, stock splits, reverse stock splits, mergers, consolidations, spin-offs, the exercise of rights issued by an issuer to all holders of the same class of Securities , or other similar corporate reorganizations or distributions generally applicable to all holders of the same class of Securities .
     3.5 Brokerage Confirmations .
          With respect to each Reportable Account , each Access Person must require the applicable broker, dealer or bank to forward to the Compliance Department copies of

10


 

confirmations of account transactions. The Compliance Department has forms that can be used for this purpose.
     3.6 Procedures for Filing Reports .
          Please refer to the “StarCompliance User Guide” found within StarCompliance for information regarding how to submit the reports and other information required by this Code.
     3.7 Reporting Violations .
          Any violations of the Code shall be reported promptly to the CCO .
4. ADMINISTRATION AND ENFORCEMENT OF CODE OF ETHICS
     4.1 General Principles .
          The administration of this Code shall be guided by the general principle that, as an investment adviser, all GMO Advisory Entities (and all Access Persons ) are fiduciaries with respect to the assets managed on behalf of various clients. Consequently, GMO holds all Access Persons responsible for:
Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; and
Compliance with applicable laws and governmental rules and regulations, including the requirement in Section 206(4) of the Advisers Act that GMO shall not engage in any act, practice, or course of business that is fraudulent, deceptive or manipulative.
     4.2 Role of COIC; Delegation .
          The COIC is responsible for overseeing the application of this Code, and has the authority to interpret this Code in the event of any ambiguities. The COIC may also recommend changes to the Code to the board of managing directors of GMO or a designated committee thereof (the “GMO Board”) and may authorize any changes in procedures recommended by the CCO. No member of the COIC or the CCO may review his or her own transactions. The COIC may delegate some or all of its authority to the CCO , whether as explicitly set forth in this Code or by specific resolution of the COIC . The CCO may, in turn, delegate any or all of his or her responsibilities hereunder to members of the Compliance Department ; provided, however, that in the event that the Compliance Department is notified of any violation of this Code, the Compliance Department shall promptly notify the CCO .
          The COIC will consider appropriate actions, if any, as described in Section 4.4 of this Code. The COIC may determine to delay the imposition of any sanctions pending review by the GMO Board and/or the Board of Trustees of GMO Trust.
11

 


 

     4.3 CCO Role, Investigations .
          The CCO shall recommend to the COIC such changes to procedures, if any, as the CCO may determine in his or her reasonable judgment may be necessary or appropriate to enable the detection of violations of this Code. The CCO is hereby delegated the authority to use those procedures and the reports made under this Code to investigate and detect any violations and/or potential violations of the Code . The CCO will report all violations to the COIC and shall also report such potential violations as the CCO may deem appropriate.
     4.4 Sanctions .
          If an Access Person (or a member of his or her Immediate Family ) has committed a violation of the Code, the COIC or CCO may take such actions against the Access Person as the COIC or CCO deems appropriate, including a letter of caution or warning, reversal of relevant trade(s) in question, forfeiture of any profit derived thereon, suspension of personal trading rights, suspension of employment (with or without compensation), fine, civil referral to the SEC , criminal referral, and/or termination of the employment of the violator for cause. All findings and actions taken by the COIC or CCO with respect to violations of this Code will be reported by the CCO to the Trustees of GMO Trust and by the COIC to GMO’s Board.
          The COIC may delegate to the CCO the authority to assess monetary penalties in amounts determined by the COIC from time to time (such amounts not to exceed $10,000).
     4.5 Administration of Pre-clearance
          Requests for pre-clearance will be handled in the first instance by the CCO , who shall operate in accordance with the following:
4.5.1. Blackout Policy . In general, pre-clearance requests to buy or sell a Security (or to sell the Security short) will be denied if the Security (a) was purchased or sold by any GMO Client Account within 3 calendar days prior to the date of the request or (b) in the reasonable judgment of the CCO is being considered for purchase or sale by any GMO Client Account within 7 calendar days after the date of the request. Pre-clearance requests to sell a Security short or to buy or write an option will be denied if the underlying Security is owned by any GMO Client Account . The CCO will consult with appropriate representatives of the Investment Division(s) for purposes of determining whether a Security is being considered for purchase or sale.
4.5.2. IPOs. Pre-clearance requests to purchase Securities in an IPO will generally be denied by the CCO , subject to the following exceptions: (i) new offerings of a registered open-end investment company or (ii) any initial offering that an Access Person can demonstrate in the pre-clearance process is available and accessible to the general investing public through on-line or other means.
12

 


 

4.5.3. Private Placements . Pre-clearance requests to purchase Securities in a Private Placement will be processed in a manner prescribed from time to time by the CCO . At the date of adoption of this Code of Ethics, those procedures require the Access Person to complete and submit a questionnaire at least 10 calendar days before the date of requested approval.
     4.6 No Explanation Required for Refusals .
          The COIC and/or the CCO may refuse to authorize a pre-clearance request for a reason that is confidential. Neither the COIC nor the CCO is required to provide an explanation for refusing to authorize any transaction.
     4.7 Review of Denied Pre-Clearance Requests .
          Upon written request by any Access Person , the COIC shall review any request for pre-clearance that is denied by the Compliance Department . The COIC may override a pre-clearance denial if, in its absolute discretion, it believes the proposed activity is not fraudulent or manipulative, and not inconsistent with GMO’s fiduciary standards.
     5. MISCELLANEOUS.
     5.1 Copies of Code; Annual Affirmation .
          Each Access Person will be provided with a copy of the Code and any amendments to the Code. Each Access Person will be required to acknowledge in writing receipt of the Code and any amendments to the Code.
          At least once annually, each Access Person must affirm in writing (which may be by electronic means) that the Access Person has received, has read, understands, and has complied with the Code and any amendments thereto.
     5.2 Review of Reports .
          The CCO shall review and maintain each Access Person’s reports filed pursuant to Section 3.
     5.3 Availability of Reports .
          All information supplied pursuant to this Code will generally be maintained in a secure and confidential manner, but may, without notice to the relevant Access Person , be made available for inspection by the directors, trustees or equivalent persons of each GMO Entity employing the Access Person , the directors, trustees or senior management of the GMO Trust or other GMO Client , the COIC , the Compliance Department, the CCO , GMO Trust’s Chief Compliance Officer, the Access Person’s department manager (or designee), any party to which any investigation is referred by any of the foregoing, the SEC , any state securities commission, any attorney or agent of the foregoing or of the GMO Trust, and any other person as may be approved by the COIC .
13

 


 

     5.4 Exceptions to the Code .
          The COIC may in unusual or unforeseen circumstances grant exceptions to the requirements of the Code if the COIC finds that the proposed conduct involves negligible opportunity and/or motive for abuse. All such exceptions must be in writing and must be reported by the CCO to the Boards of Trustees of the GMO Trust at their next regularly scheduled meeting after the exception is granted. Exceptions granted prior to the date of this Code and identified by the CCO as being of continued relevance and validity are grandfathered.
     5.5 Inquiries Regarding the Code .
           Access Persons should direct all inquiries regarding this Code (or any other compliance-related matter) to the CCO . However, it is the personal responsibility of every Access Person to understand this Code and to comply with it (and for his or her Immediate Family to understand and comply with it).
     5.6 Amendments to Code .
          The Boards of Trustees of GMO Trust, including a majority of the Trustees who are not “interested persons” under the 1940 Act, and the board of directors of every GMO Sub-Advised Fund must approve any material amendment to the Code within six months of such change.
* * * * * * * * * *
Special Note for Certain Officers of GMO Trust: In addition to the requirements set forth in this Code, the Principal Executive Officer and Principal Financial Officer of GMO Trust are also subject to the GMO Trust Code of Ethics for Principal Executive Officer and Principal Financial Officer.
Special Note for Independent Trustees : Independent Trustees of GMO Trust are subject to a separate code of ethics, and are exempt from all requirements under this Code.
Adopted by the GMO Board of Directors on May 19, 2011 .
To be effective May 20, 2011 or such later date as may be determined by the CCO .
14

 


 

Exhibit A: Definitions
Access Person ” means, except as specifically noted otherwise:
(1)   every employee or on-site consultant of any GMO Advisory Entity ; every partner, member (excluding Class I-A, Special Class I-As, and Capital Members of GMO), trustee, director or officer (or other person occupying a similar status or performing similar functions) of GMO Trust or any GMO Advisory Entity ; and every other person who provides investment advice on behalf of a GMO Advisory Entity and that is subject to the supervision and control of a GMO Advisory Entity ;
 
(2)   every general partner, member (excluding Class I-A, Special Class I-As, and Capital Members of GMO), trustee, director, officer, employee or on-site consultant of GMO Trust or any GMO Advisory Entity (or any company in a control relationship to any GMO Mutual Fund or GMO Advisory Entity ) who, in connection with his or her regular functions or duties, makes, participates in, or obtains information regarding, the purchase or sale of a Security by a GMO Mutual Fund , or whose functions relate to the making of any recommendations with respect to such purchases or sales;
 
(3)   every natural person in a control relationship to a GMO Mutual Fund or GMO Advisory Entity who obtains information concerning recommendations made to a GMO Mutual Fund with regard to the purchase or sale of Securities by the GMO Mutual Fund ; and
 
(4)   such other persons as the Compliance Department shall designate;
provided , however , that Independent Trustees are not Access Persons for purposes of this Code and provided further that the Compliance Department may except certain persons who are on-site consultants based on various factors, which may include length of contract, physical location, and computer system access.
Beneficial Interest ” means the opportunity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, to profit, or share in any profit derived from, a transaction in the subject Securities . An Access Person is deemed to have a Beneficial Interest in Securities owned by members of his or her Immediate Family . Common examples of Beneficial Interest include joint accounts, spousal accounts (including Non-GMO Employee Stock Investment Options ), UTMA accounts, partnerships, trusts and controlling interests in corporations. Any uncertainty as to whether an Access Person has a Beneficial Interest in a Security should be brought to the attention of the Compliance Department . Such questions will be resolved in accordance with, and this definition shall be interpreted in a manner consistent with, the definition of “beneficial owner” set forth in Rules 16a-1(a)(2) and (5) promulgated under the Securities Exchange Act of 1934.
Client ” means any GMO Client Account .
Closed-End Funds ” means any fund with a fixed number of shares and which does not issue and redeem shares on a continuous basis. While Closed-End Funds are often listed and trade on stock exchanges, they are not “ Exchange Traded Funds ” as defined below.
15

 


 

Compliance Department ” means the Compliance Department of Grantham, Mayo, Van Otterloo & Co. LLC. Communications required under this Code to be directed to the Compliance Department should in the first instance be directed to the CCO .
CCO ” means the Chief Compliance Officer of Grantham, Mayo, Van Otterloo & Co. LLC (currently, John McGinty).
COIC ” means the GMO Conflicts of Interest Committee (currently, Bevis Longstreth (Chairman), Domenic Esposito and J.B. Kittredge).
Discretionary Account ” is an account that satisfies all of the following criteria: (1) the Access Person has no authority to make investment decisions with respect to the assets in the account and (2) the Access Person has arranged for quarterly certification from the third party manager stating that the relevant owner ( Access Person or Immediate Family Member ) has not influenced the discretionary manager’s decisions during the period in question and (3) the account is confirmed in advance by the Compliance Department to be a Discretionary Account .
Exchange Traded Funds ” are registered open-end investment companies, unit investment trusts or depository receipts that trade on a national securities exchange and that hold portfolios of Securities that closely track the performance and dividend yield of specific indexes, either broad market, sector or international. Examples of ETFs include iShares, NASDAQ 100 Index Shares (QQQQ), HOLDRs Trusts, and S&P Depository Receipts (SPY). For avoidance of doubt, Exchange Traded Funds do not include Closed-End Funds, even if the Closed-End Funds are traded on a national securities exchange.
Exempted Government Securities ” means direct obligations of the governments of the United States, New Zealand, Australia, and the United Kingdom.
Federal Securities Laws means the Securities Act of 1933, Securities Act of 1934, Sarbanes-Oxley Act of 2002, 1940 Act, Investment Advisers Act of 1940, Title V of Gramm-Leach-Bliley Act, any rules adopted by the SEC under any of these statutes, the Bank Secrecy Act as it applies to investment companies and investment advisers, and any rules adopted thereunder by the SEC or the Department of the Treasury.
Financial Futures means futures contracts on any of the following: (i) indexes of stocks, bonds or currencies (but excluding single stock futures); (ii) interest rates; (iii) currencies; or (iv) commodities.
GMO Advisory Entity ” means Grantham, Mayo, Van Otterloo & Co. LLC, GMO Australasia LLC, GMO Australia Ltd., GMO Singapore PTE Ltd., GMO Switzerland GMBH, GMO U.K. Limited, GMO Renewable Resources, LLC, GMO Renewable Resources (in New Zealand) or GMO Renewable Resources Uruguay, SRL.
GMO Affiliated Fund ” means any GMO Mutual Fund or GMO Sub-Advised Fund or Wells Fargo Advantage Asset Allocation Fund.
16

 


 

GMO Client Account ” means any investments managed for a client by a GMO Advisory Entity , including GMO Affiliated Funds , private investment accounts, ERISA pools and unregistered pooled investment vehicles.
GMO Entity ” means GMO Trust and each GMO Advisory Entity .
GMO Long-Term Fund ” means a GMO Affiliated Fund that seeks to limit frequent trading of its shares, as disclosed in its prospectus as amended from time to time. As of December 16, 2009, the GMO Long-Term Funds are all GMO Affiliated Funds other than the following:
  §   GMO Asset Allocation Bond Fund
 
  §   GMO Asset Allocation International Bond Fund
 
  §   GMO Debt Opportunities Fund
 
  §   GMO Domestic Bond Fund
 
  §   GMO Flexible Equities Fund
 
  §   GMO High Quality Short-Duration Bond Fund
 
  §   GMO Short-Duration Collateral Fund
 
  §   GMO Short-Duration Collateral Share Fund
 
  §   GMO Short-Duration Investment Fund
 
  §   GMO Special Situations Fund
 
  §   GMO U.S. Treasury Fund
 
  §   GMO World Opportunity Overlay Fund
 
  §   GMO World Opportunity Overlay Share Fund
GMO Mutual Fund ” means any series of GMO Trust.
GMO Sub-Advised Fund ” means a registered investment company for which a GMO Advisory Entity serves as a sub-adviser.
Immediate Family ” of an Access Person means any spouse, domestic partner, child, stepchild, grandchild, parent, stepparent, grandparent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law of an Access Person who resides in the same household. Immediate Family includes adoptive relationships and any other relationship (whether or not recognized by law) which the Compliance Department determines could lead to the possible conflicts of interest or appearances of impropriety which this Code is intended to prevent. The Compliance Department may from time to time circulate such expanded definitions of this term as it deems appropriate.
Independent Trustee ” means any trustee of GMO Trust who is not an “interested person” (as defined in Section 2(a)(19) of the 1940 Act) of GMO Trust.
Investment Division ” means any of the following functional investment divisions of GMO: International Active, U.S. Quantitative, International Quantitative, Emerging Quantitative, Fixed Income, Forestry, Asset Allocation, U.K. Equities, Australian Equities, Global Tactical and any other discrete investment division dedicated to a discrete asset class and/or style of investing.
17

 


 

IPO means an offering of securities registered under the Securities Act of 1933, the issuer of which, immediately before the registration, was not subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934.
Money Market Instruments ” means money market instruments or their equivalents, including bankers’ acceptances, bank certificates of deposit, commercial paper and high quality short-term debt instruments, including repurchase agreements.
Mutual Funds ” means registered open-end investment companies (and does not include closed-end investment companies).
Non-Access Director ” means any person who is a director of GMO who (1) is not an officer or employee of a GMO Entity ; (2) has been designated as a Non-Access Director by the CCO (or a designee); (3) is subject to any requirements of GMO’s “Procedures Regarding Certain Outside Directors”; and (4) meets each of the following conditions:
  (1)   he or she does not have access to nonpublic information regarding any Client ’s purchase or sale of securities (other than shares of GMO Affiliated Funds ), or nonpublic information regarding the portfolio holdings of any GMO Affiliated Fund ;
 
  (2)   he or she is not involved in making securities recommendations to Clients , and does not have access to such recommendations that are nonpublic; and
 
  (3)   he or she, in connection with his or her regular functions or duties, does not make, participate in, or obtain information regarding the purchase or sale of a Security by a GMO Affiliated Fund , and his or her functions do not relate to the making of any recommendations with respect to such purchases or sales.
A list of Non-Access Directors may be found on Appendix A of the Procedures Regarding Certain Outside Directors.
Non-GMO Employee Stock Investment Options ” means a compensation program offered through the employer of an Access Person ’s spouse.
Private Placement ” means an offering that is exempt from registration under the Securities Act of 1933 pursuant to Section 4(2) or Section 4(6) of such Act or pursuant to Rule 504, Rule 505 or Rule 506 under such Act.
Reportable 529 Plan means any 529 Plan for which GMO (or a control affiliate) manages the investments or strategies underlying the 529 Plan or for which GMO (or a control affiliate) manages, distributes, markets or underwrites the 529 Plan. While not an exclusive list and while Access Persons are ultimately responsible for determining whether a 529 Plan is a Reportable 529 Plan , Appendix A-2 to this Code includes a list of Reportable 529 Plans as of the date of this Code.
Reportable Account ” means, with respect to any Access Person , an account in which the Access Person has a Beneficial Interest and in which any Securities are held.
18

 


 

Restricted Exchange Traded Fund means any Exchange Traded Fund determined by the CCO , in consultation with GMO’s trading desks, to: (i) be likely to be used by a trading desk; and (ii) possess attributes (e.g., limited liquidity or limited number of underlying securities) suggesting that contemporaneous trading by Access Persons could result in a benefit to an Access Person or a detriment to any GMO client. A complete list of Restricted Exchange Traded Funds is set forth in Appendix A-1 to this Code.
SEC ” means the Securities and Exchange Commission.
Security ” means any security (as defined in Section 2(a)(36) of the 1940 Act) as well as any derivative instrument (including swaps), financial commodity or other investment instrument that is traded in any public or private market. The definition in the 1940 Act is very broad and includes notes, bonds, debentures, participations in any profit sharing agreement, collateral-trust certificates, investment contracts, undivided interests in oil, gas or other mineral rights, any put, call, straddle, option or privilege on any security or on any group or index of securities, any put, call, straddle, option, or privilege entered into on a national securities exchange relating to a foreign currency “or, in general, any interest or instrument commonly known as a security.”
Securities Transaction ” means a transaction (including both purchases and sales) in a Security in which the Access Person or a member of his or her Immediate Family has or acquires a Beneficial Interest . For avoidance of doubt, a donation of Securities to a charity is considered a Securities Transaction . In addition, certain investments may involve multiple Securities Transactions for purposes of this Code (e.g., purchase of option, followed by exercise of option).
StarCompliance ” means a web-based, automated, fully managed personal trading solution, accessible from GMO computer terminals via http://starcompliance.
Unrestricted Exchange Traded Fund means any Exchange Traded Fund not designated as a Restricted Exchange Traded Fund .
U.S. Government Securities ” means direct obligations of the Government of the United States.
19

 


 

Appendix A-1
This Appendix A-1 is maintained on the GMO Legal Department intranet website. Please consult the website for the most current list of Restricted Exchange Traded Funds.
20

 


 

Appendix A-2
This Appendix A-2 is maintained on the GMO Legal Department intranet website. Please consult the website for the most current list of Reportable 529 Plans.
21

 


 

GMO U.K. Limited Code of Ethics Supplement
(Last Amended February 23, 2011)
In order to comply with the FSA’s personal account dealing rules and to allow for certain UK specific investment practices, this supplement (the “UK Supplement”) has been issued to all GMO UK staff as a supplement to the GMO Code of Ethics (“Code”). In the event of a conflict between the Code and the UK Supplement, the UK Supplement shall govern.
1.   Application of the Code to Covered Accounts
 
    The Code and the UK Supplement apply to all GMO UK employees, on-site consultants and “Covered Accounts”. A “Covered Account” includes the employee’s spouse and minor children and any person to whom the employee, in his or her personal capacity, gives share recommendations including, a relative, co-habitee, business partner or friend. GMO presumes that an employee exercises control or influence over a spouse’s or minor child’s personal account transactions and therefore any such transactions must comply with the Code. All transactions by a Covered Account must be reported by the employee concerned.
 
2.   Special Rules for Certain Investments and Investment Practices
    UK Gilts: Transactions in UK Gilts are not subject to pre-clearance but must be reported quarterly.
 
    PEP’s and ISA’s: Any proposed transaction for a PEP or ISA account must be pre-cleared unless an available exemption exists.
 
    De Minimis Purchases and Sales of FTSE 100 stocks: Employees may purchase or sell up to a maximum of £15,000 of any FTSE 100 stock once, within a three business day period without obtaining pre-clearance. All such transactions are subject to quarterly reporting.
 
    Investment Trusts: Purchases and sales of investment trusts which hold predominantly UK equities are not subject to pre-clearance but are subject to quarterly reporting. Pre-clearance will be required for transactions in investment trusts holding non-UK stocks as such trusts may be purchased for client accounts from time to time.
 
    Contracts for Differences (CFDs) and Spread Bets: CFDs and spread bets are not subject to the short-term trading prohibition set forth in Section 1.4 of the Code, PROVIDED that the security underlying the CFD or spread bet would itself be exempted from the prohibition.
3.   Exemptions for Unit Trusts, etc. The prohibitions in Section 1 of the Code and the pre-clearance requirements in Section 2 of the Code do not extend to any transaction by you in an authorised unit trust, a regulated collective investment scheme or a life assurance policy (including a pension).
22

 


 

4. Counseling and procuring
If the Code precludes you from entering into any transaction, you cannot:
  (a)   advise or cause any other person to enter into such a transaction; or
 
  (b)   communicate any information or opinion to any other person,
    if you know, or have reason to believe, that the other person will as a result enter into such a transaction or cause or advise someone else to do so.
 
    This does not apply to actions that you take in the course of your employment with us. For example, the fact that you are yourself prohibited from dealing in a certain stock as a result of one of the provisions above does not necessarily mean that you are precluded from dealing for the client’s account, subject to the insider dealing legislation summarised in 8 below.
 
5.   Summary of insider dealing legislation
 
    The UK insider dealing provisions contained in part V of the Criminal Justice Act 1993 (the “Act”) are complex, and if you would like fuller details or are in any doubt whether a particular transaction would be prohibited, you should consult the Compliance Department .
 
    The Act applies to all securities traded on a regulated market (which currently includes all EC stock exchanges, LIFFE, OMLX and NASDAQ) and to warrants and derivatives (including index options and futures) relating to these securities even if these warrants and derivatives are only “over the counter” or otherwise not publicly traded.
 
    In broad terms, and subject to the exemptions provided by the Act, the Act makes it a criminal offence, with a maximum penalty of seven years imprisonment and an unlimited fine, for an individual who has non-public information to deal in price-affected securities (including warrants or derivatives relating to them) on a regulated market; or deal with or through a professional intermediary; or by acting himself as a professional intermediary. Securities are “price-affected” if the inside information, if made public, would be likely to have a significant effect on the price of the securities. This applies to all companies’ securities affected by the information, whether directly or indirectly (for example, competitors of a company about to bring out a new product).
 
    The Act applies whether you deal as part of your employment or on your own account. It also applies to information which you obtain directly or indirectly from an insider whether or not in the course of your employment (for example, by social contacts).
  (1)   If you are precluded from dealing, normally you are also prohibited from dealing on behalf of the firm or a client (except perhaps on an unsolicited basis);
23

 


 

  (2)   Procuring or encouraging another person to deal in the price-affected securities (whether or not the other person knows they are price affected); and
 
  (3)   Passing the inside information to another person other than in the proper performance of your employment.
    It is possible for a transaction which involves insider dealing to constitute an offence otherwise than under the insider dealing provisions of the Criminal Justice Act. In particular, under section 118 of the Financial Services and Markets Act 2000 a person who “dishonestly conceals any material facts” is guilty of an offence if he does so for the purpose of inducing, or is reckless as to whether it may induce, another person (whether or not the person from whom the facts are concealed) to buy or sell an investment, or to refrain from buying or selling and investment. This offence could well be committed by a person who conceals price sensitive information from a counterparty to induce him to deal, if the concealment is dishonest.
 
6.   Compliance Contacts
 
    For queries in relation to this GMO U.K. Limited Code of Ethics Supplement please refer to:
 
    Rishika Jay Prakash, Compliance Officer
24

 


 

GMO Australia Limited Code of Ethics Supplement
(Last Amended October 1, 2010)
The following policies and procedures are in addition to, and where relevant supersede the policies and procedures detailed in the GMO Code of Ethics (the “Code”).
Authorisation
Authorisation must be sought by all staff members prior to trading via the StarCompliance system.
Exemption from Authorisation Requirement
Authorisation for purchasing securities in an unrestricted public offer is not required.
GMOA Trading
Securities that are held in the GMOA trusts or individually managed portfolios:
  may not be traded by staff during the 3 working days before and after re-balancing* by GMOA.
  and are not being traded as part of the re-balancing* by GMOA may be traded during this 6 working day period subject to pre-authorisation.
Staff may trade securities at any other time subject to the pre-authorisation.
*   Re-balancing includes normal monthly trading and any other trading as a result of cash flows.
Special Rules for Certain Investments
Australian Registered Managed Investment Schemes and Superannuation Funds: Australian Registered Managed Investment Schemes are publicly offered pooled investment products registered and regulated by the Australian Securities and Investment Commission (“ASIC”). Superannuation Funds are pooled superannuation investment products registered and regulated by the Australian Prudential Regulation authority (“APRA”). Purchases and Sales of these publicly offered products are not subject to pre-clearance or reporting requirements under the Code.
Exception for those Australian Registered Managed Investment Schemes and Superannuation Funds sub-advised or managed by GMOA: Purchases and sales of these schemes are not subject to pre-clearance but are subject to the reporting requirement of the Code. As of February 2, 2010, such schemes include but are not limited to:
    BT Investments — Australia Value Shares Value 1 and Multi-Manager Options
 
    Colonial First State — First Choice Investment Options (Australian Small Companies Option)
 
    ipac investment management limited: Diversified Investment Strategies
25

 


 

    International Share Strategy No.’s 3 & 4
 
    Diversified Investment Strategies — Australia Share Stategy No 1
Exception for other types of pooled investments sub-advised or managed by GMOA: Purchases and sales of these schemes are not subject to pre-clearance but are subject to the reporting requirement of the Code. As of February 2, 2010, such schemes include but are not limited to:
    Partners Group Alternative Strategies PCC Limited — Red Epsilon Cell: An open-ended protected cell investment company established under the laws of Guernsey.
 
    Global Funds Trust Company — GMO Global Tactical Fund F: a unit trust esablished under the laws of the Cayman Islands.
The above list may change regularly. It is best in all circumstances to confer with Legal & Compliance Asia-Pacific prior to making any investments in order to ensure the above list is current.
26

 


 

GMO Renewable Resources (in New Zealand) Code of Ethics Supplement
(Last Amended September 8, 2009)
The following policies and procedures are in addition to, and where relevant supersede the policies and procedures detailed in the GMO Code of Ethics (the “Code”).
De Minimis Purchases and Sales of Certain Securities of Issuers in the NZSX 50 Index
Purchases or sales by Access Persons of less than NZ$40,000 of common stock, depository receipts, or preferred stock of issuers who are not timber or timber-related and are listed in the New Zealand Stock Exchange Top 50 Companies (NZSX 50 Index) as of the date of such purchases or sales are not subject to pre-clearance requirement. This exemption from pre-clearance may be utilized once per security within multiple accounts during a pre-clearance period so long as the total across all accounts is less than NZ$40,000;
The NZSX 50 index contains the top fifty securities ranked by tradable equity quoted on the New Zealand Stock Exchange.
27

 


 

GMO Non-Access Directors Code of Ethics Supplement
      Non-Access Directors of GMO are exempt from all requirements under the GMO Code except for the following:
      Non-Access Directors are subject to the Code’s restrictions relating to Inside Information (see Section 1.6), Market Manipulation (see Section 1.7), and Short-Term Trading Strategies in GMO Long-Term Funds (see Section 1.5);
      Non-Access Directors are subject to any personal trading restrictions and periodic reporting requirements set forth in GMO’s “Procedures for Certain Outside Directors,” as may be in effect from time to time; and
      Non-Access Directors are subject to the GMO Gift Policy (which is set forth in a separate stand-alone policy), except that Non-Access Directors shall not be restricted from receiving, nor required to report, gifts received from current or former clients or business associates, notwithstanding that such persons may also be clients or prospective clients of GMO.
28

 

Exhibit (p)(2)
GMO SERIES TRUST
CODE OF ETHICS
Adopted: August 23, 2011
          The Board of Trustees (the “Board”) of GMO Series Trust (the “Trust”) has adopted this Code of Ethics (the “Code”) applicable to Access Persons of the Trust. Capitalized terms used but not otherwise defined herein shall have the meanings set forth in Section VI.C of this Code.
I.   General Requirements
  A.   Reporting . Except as provided in Section II, each Access Person of the Trust must satisfy the reporting requirements set forth in Rule 17j-1(d) under the Investment Company Act of 1940, as amended (the “1940 Act”). Access Persons may satisfy this obligation by filing such reports with the Chief Compliance Officer of the Trust (the “Trust CCO”) within the time periods prescribed by Rule 17j-1(d).
 
  B.   Pre-approval of Investments in IPOs and Limited Offerings . Except as provided in Section II, Investment Personnel of the Trust must obtain pre-approval from the Trust CCO before directly or indirectly acquiring Beneficial Ownership in any securities in an Initial Public Offering or in a Limited Offering.
II.   Special Rules Applicable to Certain Access Persons
  A.   GMO Access Persons . Access Persons and Investment Personnel of the Trust who are also “access persons” under the code of ethics applicable to Grantham, Mayo, Van Otterloo & Co. LLC (“GMO”) and its affiliates (the “GMO Code”) shall be subject only to the applicable provisions of the GMO Code and are exempt from all provisions of this Code.
 
  B.   Independent Trustees . Trustees of the Trust who are not “interested persons” of the Trust (as defined in Section 2(a)(19) of the 1940 Act) (“Independent Trustees”) are subject to a separate code of ethics and are exempt from all provisions of this Code and the GMO Code.
 
  C.   Non-Access Directors . “Non-Access Directors” (as defined in the GMO Code) of GMO, if any, shall be subject only to the applicable provisions of the GMO Code and are exempt from all provisions of this Code.
III.   Administration of Code. The Trust’s CCO shall be responsible for administering this Code, including: (i) reviewing reporting forms and pre-clearance requests required to be submitted hereunder; and (ii) reviewing possible violations of this Code and imposing any related sanctions. To the extent that all Access Persons and Investment Personnel of the Trust are also “access persons” under either the GMO Code or the Independent Trustee Code of Ethics and, consequently, no reports or pre-clearance requests are required to be submitted hereunder, the Trust’s CCO shall have no further duties with respect to the administration of this Code.

 


 

IV.   Special Rules Applicable to the Trust CCO
 
    The following special rules applicable to the Trust CCO shall apply:
  A.   Investigations of Possible Code Violations . The GMO Compliance Department is responsible for investigating any suspected violations of this Code by the Trust CCO and shall report any suspected violation to the Chairman of the Board. The Chairman of the Board is responsible for reviewing the results of any investigation of any such reported or suspected violations of this Code. Any such violations of this Code will be reported to the Board at or prior to its next regularly scheduled meeting.
 
  B.   Sanctions . If the Chairman of the Board determines that the Trust CCO has committed a violation of this Code, the Chairman of the Board may impose sanctions and take other actions as he deems appropriate, including a letter of caution or warning, suspension of personal trading rights, suspension of employment (with or without compensation), fine, civil referral to the SEC, criminal referral, and termination of the employment for cause.
V.   Code Approval; Amendments
  A.   Amendments to Trust Code . The Board, including a majority of the Independent Trustees, must approve this Code and any amendments thereto based upon a determination that it contains provisions reasonably necessary to prevent Access Persons of the Trust from engaging in conduct prohibited by Rule 17j-1(b) under the 1940 Act.
 
  B.   Amendments to the GMO Code . GMO shall provide the Trust CCO with copies of all amendments to the GMO Code promptly upon adoption. The Board, including a majority of the Independent Trustees, must approve any material amendment to the GMO Code within six months of such change. GMO shall not amend the GMO Code to eliminate the reporting and pre-approval requirements set forth in Rule 17j-1.
VI.   Miscellaneous
  A.   Records. The Trust shall maintain the following records :
  (1)   A copy of this Code and any other code which is, or at any time within the past five years has been, in effect shall be preserved in an easily accessible place;
 
  (2)   A record of any violation of this Code and of any action taken as a result of such violation shall be preserved in an easily accessible place for a period of not less than five years following the end of the fiscal year in which the violation occurs;

-2-


 

  (3)   A copy of each report made by an Access Person pursuant to this Code shall be preserved for a period of not less than five years from the end of the fiscal year in which it is made, the first two years in an easily accessible place; and
 
  (4)   A list of all persons who are, or within the past five years have been, required to make reports pursuant to this Code shall be maintained in an easily accessible place.
      To the extent any record required to be kept by this section is also required to be kept by GMO pursuant to the GMO Code, GMO shall maintain such record on behalf of both GMO and the Trust.
 
  B.   Confidentiality . All reports of securities transactions and any other information filed pursuant to this Code shall be treated as confidential, but are subject to disclosure in accordance with the provisions of the GMO Code.
 
  C.   Definitions . The terms “Access Person”, “Investment Personnel”, “Beneficial Ownership”, “Initial Public Offering” and “Limited Offering”, where used but not otherwise defined herein, shall have the meanings ascribed to such terms in Rule 17j-1 under the 1940 Act.

-3-


 

[This page intentionally left blank.]

 


 

GMO TRUST
CODE OF ETHICS
Dated September 5, 2008
          The Board of Trustees (the “Board”) of GMO Trust (the “Trust”) has adopted this Code of Ethics (the “Code”) applicable to Access Persons of the Trust. Capitalized terms used but not otherwise defined herein shall have the meanings set forth in Section VI.C of this Code.
I.   General Requirements
  A.   Reporting . Except as provided in Section II, each Access Person of the Trust must satisfy the reporting requirements set forth in Rule 17j-1(d) under the Investment Company Act of 1940, as amended (the “1940 Act”). Access Persons may satisfy this obligation by filing such reports with the Chief Compliance Officer of the Trust (the “Trust CCO”) within the time periods prescribed by Rule 17j-1(d).
 
  B.   Pre-approval of Investments in IPOs and Limited Offerings . Except as provided in Section II, Investment Personnel of the Trust must obtain pre-approval from the Trust CCO before directly or indirectly acquiring Beneficial Ownership in any securities in an Initial Public Offering or in a Limited Offering.
II.   Special Rules Applicable to Certain Access Persons
  A.   GMO Access Persons . Access Persons and Investment Personnel of the Trust who are also “access persons” under the code of ethics applicable to Grantham, Mayo, Van Otterloo & Co. LLC (“GMO”) and its affiliates (the “GMO Code”) shall be subject only to the applicable provisions of the GMO Code and are exempt from all provisions of this Code.
 
  B.   Independent Trustees . Trustees of the Trust who are not “interested persons” of the Trust (as defined in Section 2(a)(19) of the 1940 Act) (“Independent Trustees”) are subject to a separate code of ethics and are exempt from all provisions of this Code and the GMO Code.
 
  C.   Non-Access Directors . “Non-Access Directors” (as defined in the GMO Code) of GMO, if any, shall be subject only to the applicable provisions of the GMO Code and are exempt from all provisions of this Code.
III.   Administration of Code . The Trust’s CCO shall be responsible for administering this Code, including: (i) reviewing reporting forms and pre-clearance requests required to be submitted hereunder; and (ii) reviewing possible violations of this Code and imposing any related sanctions. To the extent that all Access Persons and Investment Personnel of the Trust are also “access persons” under either the GMO Code or the Independent Trustee Code of Ethics and, consequently, no reports or pre-clearance requests are required to be submitted hereunder, the Trust’s CCO shall have no further duties with respect to the administration of this Code.

 


 

IV.   Special Rules Applicable to the Trust CCO
 
    The following special rules applicable to the Trust CCO shall apply:
  A.   Investigations of Possible Code Violations . The GMO Compliance Department is responsible for investigating any suspected violations of this Code by the Trust CCO and shall report any suspected violation to the Chairman of the Board. The Chairman of the Board is responsible for reviewing the results of any investigation of any such reported or suspected violations of this Code. Any such violations of this Code will be reported to the Board at or prior to its next regularly scheduled meeting.
 
  B.   Sanctions . If the Chairman of the Board determines that the Trust CCO has committed a violation of this Code, the Chairman of the Board may impose sanctions and take other actions as he deems appropriate, including a letter of caution or warning, suspension of personal trading rights, suspension of employment (with or without compensation), fine, civil referral to the SEC, criminal referral, and termination of the employment for cause.
V.   Code Approval; Amendments
  A.   Amendments to Trust Code . The Board, including a majority of the Independent Trustees, must approve this Code and any amendments thereto based upon a determination that it contains provisions reasonably necessary to prevent Access Persons of the Trust from engaging in conduct prohibited by Rule 17j-1(b) under the 1940 Act.
 
  B.   Amendments to the GMO Code . GMO shall provide the Trust CCO with copies of all amendments to the GMO Code promptly upon adoption. The Board, including a majority of the Independent Trustees, must approve any material amendment to the GMO Code within six months of such change. GMO shall not amend the GMO Code to eliminate the reporting and pre-approval requirements set forth in Rule 17j-1.
VI.   Miscellaneous
  A.   Records . The Trust shall maintain the following records:
  (1)   A copy of this Code and any other code which is, or at any time within the past five years has been, in effect shall be preserved in an easily accessible place;
 
  (2)   A record of any violation of this Code and of any action taken as a result of such violation shall be preserved in an easily accessible place for a period of not less than five years following the end of the fiscal year in which the violation occurs;

-2-


 

  (3)   A copy of each report made by an Access Person pursuant to this Code shall be preserved for a period of not less than five years from the end of the fiscal year in which it is made, the first two years in an easily accessible place; and
 
  (4)   A list of all persons who are, or within the past five years have been, required to make reports pursuant to this Code shall be maintained in an easily accessible place.
      To the extent any record required to be kept by this section is also required to be kept by GMO pursuant to the GMO Code, GMO shall maintain such record on behalf of both GMO and the Trust.
 
  B.   Confidentiality . All reports of securities transactions and any other information filed pursuant to this Code shall be treated as confidential, but are subject to disclosure in accordance with the provisions of the GMO Code.
 
  C.   Definitions . The terms “Access Person”, “Investment Personnel”, “Beneficial Ownership”, “Initial Public Offering” and “Limited Offering”, where used but not otherwise defined herein, shall have the meanings ascribed to such terms in Rule 17j-1 under the 1940 Act.

-3-

Exhibit (p)(3)
CODE OF ETHICS
FOR THE INDEPENDENT TRUSTEES
OF GMO SERIES TRUST
Effective: August 23, 2011
OVERVIEW
          The Board of Trustees (the “Board”) of GMO Series Trust (the “Trust”) has adopted this code of ethics (the “Code”) applicable to Trustees who are not “interested persons” of each series of the Trust (each such series a “Fund” and, collectively, the “Funds”), as defined in Section 2(a)(19) of the Investment Company Act of 1940 (the “1940 Act”) (the “Independent Trustees”).
          This Code is separate and distinct from other codes of ethics that the Board has approved applicable to GMO Series Trust or Grantham, Mayo, Van Otterloo & Co. LLC, the Funds’ investment adviser (the “Adviser”), and their officers, directors, and employees.
          This Code is administered by the Chief Compliance Officer of the Trust (the “CCO”).
SECTION I: SCOPE AND GENERAL PURPOSE
A. Personal Investment Activities. It is unlawful for an Independent Trustee in connection with his or her purchase or sale (directly or indirectly) of a Security Held or to be Acquired by a Fund (as defined in Appendix C hereto), to:
    employ any device, scheme or artifice to defraud a Fund;
 
    to make any untrue statement of material fact to a Fund or omit to state a material fact necessary in order to make the statements made to a Fund, in light of the circumstances under which they are made, not misleading;
 
    to engage in any act, practice or course of business that operates or would operate as a fraud or deceit on a Fund; or
 
    to engage in any manipulative practice with respect to a Fund.
B. Transactions in the Funds. Independent Trustees are subject to such restrictions on transactions with the funds as may be in effect from time to time, including being prohibited from engaging in market timing or other short term trading strategies in any Fund. Additionally, all Independent Trustees are specifically prohibited from redeeming a portion or all of a purchase in a Fund made within the past 60 calendar days. Additionally, more than three “round-trip” transactions (purchase and subsequent redemption) in the same Fund over a 12 month

 


 

period are prohibited. For purposes of the foregoing prohibitions, reinvestments of distributions are not considered purchase transactions.
C. Insider Trading. It is unlawful for an Independent Trustee to use material, non-public information in violation of the federal securities laws (“insider trading”). The Funds’ policy on insider trading applicable to an Independent Trustee is set forth on Appendix A hereto.
          If an Independent Trustee becomes aware of any potential violation of this Code, he or she shall report such matter to the CCO as soon as reasonably practicable.
SECTION II: PERSONAL TRADING REPORTING OBLIGATIONS
          Except as provided below, an Independent Trustee is ordinarily not required to report his or her personal securities transactions or identify his or her brokerage accounts to a Fund or its representatives under this Code.
           An Independent Trustee is required to deliver to the CCO a transaction report containing the information set forth in Appendix B if the Independent Trustee knew or, in the ordinary course of fulfilling his or her official duties as an Independent Trustee, should have known, that during the fifteen-day period immediately before or after a transaction by such Independent Trustee in a Covered Security (as defined in Appendix C, and including securities both directly and indirectly beneficially owned by such Independent Trustee) (i) a Fund purchased or sold such Covered Security or (ii) a Fund or the Adviser considered purchasing or selling such Covered Security.
SECTION III: ADMINISTRATION AND ENFORCEMENT
A. Review of Reports
          The CCO and the Governance Committee of the Board shall review any reports delivered by an Independent Trustee pursuant to this Code at the next regularly scheduled meeting of the Committee or sooner if deemed necessary by the CCO and the Chair of the Committee.
B. Investigations of Potential Violations
          The CCO shall report all potential violations of the Code by Independent Trustees to the Governance Committee. The Governance Committee of the Trust, with the assistance of the CCO, shall investigate any potential violation of the provisions of this Code. After completion of such investigation, the Governance Committee shall determine whether a violation has occurred and, if so, make a recommendation to the Board as to any action to be taken in response thereto. The CCO and/or the Board shall notify the President or Chief Legal Officer of all violations and the action to be taken in response thereto. Any member of the Governance Committee who is alleged to have been involved in a violation shall be excluded from any such investigation and vote as to whether a violation has occurred or with respect to any action to be taken.

- 2 -


 

C. Recordkeeping
          The Funds must maintain the following records and make these records available to the Securities and Exchange Commission at any time and from time to time for reasonable periodic, special or other examination:
    A copy of this Code as currently in effect, or at any time within the past five years was in effect, must be maintained in an easily accessible place.
 
    A record of any violation of this Code, and of any action taken as a result of the violation, must be maintained in an easily accessible place for at least five years after the end of the fiscal year in which the violation occurs.
 
    A copy of each report made by an Independent Trustee under the Code and each report required under Section III.E below must be maintained for at least five years after the end of the fiscal year in which the report is made, the first two years in an easily accessible place.
 
    A record of all Independent Trustees, currently or within the past five years, who are subject to the Code, and of individual(s) responsible for reviewing reports made under the Code, must be maintained in an easily accessible place.
The foregoing shall be maintained in a secure and confidential manner by the CCO on behalf of the Funds.
D. Amendments
          Any amendment to this Code must be approved by a majority of the Trustees of the Board, including a majority of the Independent Trustees.
E. Annual Report
          On at least an annual basis, (i) the CCO, in consultation with the Governance Committee shall provide the Board with a written report that describes issues that arose under this Code since the prior such report, including information relating to material violations of this Code and any actions taken, procedures adopted or sanctions imposed as a result of such violations, and (ii) the CCO shall provide the Board with a certification that the Funds have adopted procedures reasonably necessary to prevent the Independent Trustees from violating the Code.
F. Certification
          Each Independent Trustee must sign a certification (substantially in the form of Appendix D hereto) within seven (7) days of the effective date of this Code or, thereafter, within seven (7) days of becoming an Independent Trustee, which certification acknowledges that the Independent Trustee: (i) has received a copy of this Code and any amendments hereto, (ii) has read and understands all the provisions of this Code, and (iii) agrees to comply with the provisions of this Code.

- 3 -


 

APPENDIX A
Insider Trading
While the law concerning insider trading is not static or clearly defined, the federal securities laws are generally understood to prohibit:
1.   Trading by an insider, while in possession of material, non-public information;
 
2.   Trading by a non-insider, while in possession of material, non-public information, where the information either was disclosed to the non-insider in violation of an insider’s duty to keep it confidential or was misappropriated;
 
3.   An insider communicating material, non-public information to others;
 
4.   A non-insider communicating material, non-public information to others where the information either was disclosed to the non-insider in violation of an insider’s duty to keep it confidential or was misappropriated; and
 
5.   Trading while in possession of material, non-public information regarding a tender offer.
It is the Funds’ policy that:
1.   No Independent Trustee may trade in any security (including any equity or fixed income instruments), either personally or on behalf of others, while in possession of material, non-public information relating to the issuer of that security;
 
2.   No Independent Trustee may communicate material, non-public information to any other person;
 
3.   No Independent Trustee in possession of material, non-public information may recommend trading a security in an issuer to which the information relates, or otherwise recommend the purchase or sale of any such security; and
 
4.   No Independent Trustee shall trade in violation of federal securities laws in a security subject to a tender offer while in possession of material, non-public information relating to the tender offer or the issuer of the security.
The foregoing should be understood as a brief synopsis of a complex legal subject matter and shall not be deemed to prohibit conduct that is otherwise lawful and consistent with a Trustee’s fiduciary duty.
Any questions regarding the Funds’ insider trading policy should be addressed to the Independent Trustees’ legal counsel.

A-1


 

APPENDIX B
Transaction Report
Only required for Transactions in Covered Securities purchased or sold, or considered for purchase or sale, by a Fund within 15 days of the Trustee’s transaction:
    Date of the transaction:                                                                                     
 
    Security Name:                                                                                     
 
    Security Ticker/Symbol:                                                                                     
 
    The interest rate and maturity date (if applicable):                                                                                      
 
    Number of shares/principal amount of each Covered Security involved:                                                                                      
 
    The nature of the transaction (i.e., purchase, sale or any other type of acquisition or disposition):
 
    The price of the Covered Security at which the transaction was effected:                                                                                     
 
    The name of the broker, dealer or bank with or through which the transaction was effected:                                                               
 
    Transaction Report Date (No later than thirty (30) days after the end of a calendar quarter in which the reportable transaction occurred.) :                                                                                     

B-1


 

APPENDIX C
Definition of “Covered Security” and “Security Held or to be Acquired by a Fund”
  A.   “Covered Security” means any “security,” as defined in Section 2(a)(36) of the Investment Company Act of 1940, as amended, except:
  i)   Direct obligations of the U.S. Government;
 
  ii)   Bankers’ acceptances, bank certificates of deposit, commercial paper and high quality short-term debt instruments, including repurchase agreements; and
 
  iii)   Shares issued by U.S. registered open-end funds (other than funds advised by the Adviser or any fund whose investment adviser or principal underwriter controls the Adviser, is controlled by the Adviser, or is under common control with the Adviser).
  B.   “Security Held or to be Acquired by a Fund” means:
  i)   Any Covered Security which, within the most recent 15 days:
  o   Is or has been held by a Fund; or
 
  o   Is being or has been considered by a Fund or its investment adviser for purchase by a Fund; and
  ii)   Any option to purchase or sell, and any security convertible into or exchangeable for, a Covered Security described in B(i) above.

C-1


 

APPENDIX D
Certificate of Acknowledgement
1.   I hereby acknowledge receipt of the Code of Ethics of the Independent Trustees of the Trust, effective ________________ (the “Code”).
 
2.   I hereby certify that I have read, understand and am in full compliance with the Code and that I agree to abide by its requirements and procedures.
 
3.   I hereby acknowledge that failure to comply fully with the Code may subject me to disciplinary action.
 
4.   I hereby acknowledge that I have been informed of my reporting obligations pursuant to the Code.
Date
Signature
Printed Name

D-1

Exhibit 1
GMO SERIES TRUST
CERTIFICATE OF CLERK
          I, Jason Harrison, hereby certify that I am the duly elected and acting Clerk of GMO Series Trust, a Massachusetts business trust (the “Trust”), and do hereby further certify as follows:
          1. Attached hereto as Exhibit A is a true and correct copy of resolutions from the action by written consent of the sole Trustee of the Trust (the “Trustee”) executed on May 31, 2011. The resolutions were duly adopted by the Trustee with the same force and effect as if they had been approved and adopted at a duly convened meeting of the Board of Trustees of the Trust. Such resolutions have not been modified or rescinded since their adoption and are in full force and effect as of the date hereof.
          IN WITNESS WHEREOF, I have hereunto set my hand this 15 th day of September, 2011.
         
     
  By:   /s/ Jason Harrison    
    Name:   Jason Harrison   
    Title:   Clerk   
 

 


 

Exhibit A
Resolutions of the Trustee — May 31, 2011
     
 
  Authorization of Power of Attorney
 
   
VOTED :
  That each of Sheppard N. Burnett and Jason Harrison be, and each of them acting singly hereby is, authorized to sign for J.B. Kittredge, in his name and in the capacity of President and Chief Executive Officer, on behalf of the Trust, the Trust’s Registration Statement on Form N-1A filed with the Securities and Exchange Commission and any and all amendments thereto, pursuant to a power of attorney executed by Mr. Kittredge.

 

Exhibit 2
POWER OF ATTORNEY
     I, the undersigned trustee of GMO Series Trust, a Massachusetts business trust, hereby constitute and appoint each of Sheppard N. Burnett and Jason Harrison, singly, my true and lawful attorney, with full power to him to sign for me, and in my name and in the capacity indicated below, the Registration Statement of GMO Series Trust filed with the Securities and Exchange Commission on Form N-1A and any and all amendments thereto (including pre- and post-effective amendments), hereby ratifying and confirming my signature as it may be signed by my said attorney on said Registration Statement and any and all amendments thereto.
     Witness my hand and common seal on the date set forth below.
          (Seal)
         
Signature   Title   Date
 
       
/s/ Maria D. Furman
 
Maria D. Furman
  Trustee    August 24, 2011